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Abstract 
The chemokine CCL2 activates its cognate receptor CCR2 to orchestrate monocyte 
trafficking towards infected, inflamed, and injured tissues during immune responses and 
the development of inflammatory disease.  However, despite research into this area being 
plentiful, CCR2 antagonists have lacked clinical efficacy.  A possible explanation for this 
may be that other chemoattractants such as extracellular nucleotides steer monocyte 
trafficking and compensate for a loss in CCR2 function.  This study therefore intended to 
(i) determine the mechanisms involved in CCL2/CCR2-mediated monocyte signalling and 
function and (ii), examine the requirement of purinoceptor signalling for CCL2/CCR2-
mediated monocyte signalling and function.  Human monocytic THP-1 cells and PBMCs 
were employed as models to assess CCR2 activation indirectly by intracellular Ca2+ 
release, cell migration, and cell adhesion to vascular endothelium.  Techniques such as 
lentivirus-mediated gene-knockdown, RT-PCR, and HPLC complemented these studies.  
A pharmacological approach indicated a requirement of CCR2, Ca2+, Gαi/o-type G-
proteins, PI3K, PLC, IP3Rs, RyRs, SERCA, DAGL, DAGK, and PKC for CCL2-mediated 
monocyte signalling and/or function.  Initial observations from apyrase studies indicated 
an involvement of extracellular nucleotides in CCL2/CCR2-mediated monocyte signalling 
and function.  Pharmacological experiments also indicated that although P1, P2X1, P2X4, 
P2X7, P2Y1, P2Y11, P2Y12, and P2Y13 purinoceptors were unlikely to play a major role,   
P2Y6 and CCR2 engaged in crosstalk.  Cross-desensitisation experiments and studies on 
P2RY6-knockdown THP-1 cells supported this finding and indicated that a blockade of 
P2Y6 signalling was likely to affect the capacity of monocytes to migrate and adhere in 
response to CCL2.  Moreover, these findings indicated that P2Y6 and CCR2 crosstalk in 
monocytes was likely to involve ATP release.  The findings in this thesis suggest that the 
CCL2/CCR2 axis is important for monocyte signalling and function and that P2Y6 engages 
in crosstalk with CCR2.  Taken together, these findings may prove relevant in the search 
for future therapies for monocyte-associated inflammatory diseases. 
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Chapter 1: Introduction 
1.1 The immune system 
The immune system is a continuously evolving system that protects human health by 
acting against a constant onslaught of challenges made by pathogens, tumour cells, and 
dead cells.  The immune system consists of two branches, the innate immune response 
and the antigen-specific adaptive response, both diverging via a sophisticated network of 
cellular and chemical effectors (Parkin and Cohen, 2001).  The innate branch of the 
immune system is fixed in germ-line deoxyribonucleic acid (DNA) and consists of various 
immune cells (e.g. neutrophils, macrophages, and monocytes) and effectors (e.g. 
complements, cytokines and chemokines) which act collectively to provide a rapid 
response without the need to adapt to a changing environment.  In contrast, the adaptive 
branch comprises of cells such as T-lymphocytes (thymus-derived), B-lymphocytes (bone-
marrow-derived), and dendritic cells.  Together, these provide a slow but specific 
response that increases in speed upon re-exposure due to an ability to remember and 
learn from past-experiences (Koenderman et al., 2014).  Despite the intrinsic differences 
between the two branches, the cellular custodians of both systems rely on an ability to 
sense warning signals from specific molecules through the activation of surface pattern 
recognition receptors (PRRs) that alert them to intruding organisms or cellular damage 
(Bianchi, 2007).  Warning signals detected by PRRs include pathogen/microbial-
associated molecular patterns (PAMPs/MAMPs) associated with microbial challenge, and 
damage-associated molecular-patterns (DAMPs) associated with cellular damage or 
death. 
1.2 Monocytes 
1.2.1 Human and mouse monocyte heterogeneity 
Monocytes represent a population of immune cells that are crucial for driving the innate 
immune response (Ingersoll et al., 2011).  Monocytes and their progeny (macrophages 
and dendritic cells), participate in a wide range of protective activities including the 
removal of intruding organisms and cell debris, tissue healing, and the initiation of 
adaptive immune responses (Ingersoll et al., 2011).  Although monocytes are a 
heterogeneous cell population, they are characterised by their expression of specific 
PRRs.  This concept was first introduced by Passlick et al. (1989) and Geissmann et al. 
(2003) who observed that human monocytes differed in their expression of cluster of 
differentiation 14 (CD14; lipopolysaccharide receptor), cluster of differentiation 16 (CD16; 
low affinity FcγIII receptor), and the chemokine receptors CX3C-motif receptor-1 
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(CX3CR1), and CC-motif receptor 2 (CCR2).  Based on the information provided in these 
studies, human monocyte subsets have been divided into classical (CD14++/CD16-), 
intermediate (CD14++/CD16+), and non-classical (CD14+/CD16++) monocytes (Table 1.1) 
(Weber et al., 2000; Geissmann et al., 2003; Ziegler-Heitbrock 2007; Yona and Jung, 
2010). 
Mouse monocyte subsets can be distinguished by differential expression of lymphocyte 
6C (Ly6C/Gr1; pro-inflammatory antigen) and cluster of differentiation 43 (CD43; 
leukosialin), but also differ in their expression of CX3CR1, CCR2, and cluster of 
differentiation 62L (CD62L; L-selectin) (Geissmann et al., 2003).  Mouse monocytes are 
therefore grouped into classical (Ly6Chigh), intermediate (Ly6Cmiddle), and non-classical 
(Ly6Clow) subsets  (Table 1.1) (Geissmann et al., 2003; Sunderkötter et al., 2004; 
Geissmann et al., 2010; Ziegler-Heitbrock et al., 2010; Yang et al., 2014).  Data from gene 
array studies suggests that mouse subsets closely resemble human subsets (Geissmann 
et al., 2003; Ingersoll et al., 2010; Cros et al., 2010).    
Table 1.1 Human and mouse monocyte subsets 
Species Subset 
% of 
MNC 
Markers 
Possible 
roles 
Human Classical 80-95 CD14++ CD16- CCR2high CX3CR1
low Phagocytosis 
 Intermediate 2-11 
CD14++ CD16+ CCR2mid CX3CR1
high 
CCR5+ 
Pro-
inflammatory 
 Non-classical 2-8 CD14+ CD16++ CCR2low CX3CR1
high Patrolling 
Mouse Classical 40-45 
CD11b+ CD115+ CD43low CD62L+ 
Ly6Chigh CCR2high CX3CR1
low 
Phagocytosis 
and Pro-
inflammatory 
 Intermediate 5-32 
CD11b+ CD115+ CD43high CD62L 
Ly6Cmiddle CCR2high CX3CR1
low 
Pro-
inflammatory 
 Non-classical 26-50 
CD11b+ CD115+ CD43high CD62L- 
Ly6Clow CCR2low CX3CR1
high 
Patrolling and 
Tissue repair 
MNC = mononuclear cell.  Human intermediate monocytes also express chemokine (CC-
motif) receptor 5 (CCR5).  Murine monocytes also express cluster of differentiation 115 
(CD115; colony stimulating factor receptor 1 (CSF-1R)) and cluster of differentiation 11b 
(CD11b; integrin αM) (Geissmann et al., 2003; Sunderkötter et al., 2004; Ziegler-
Heitbrock., 2010; Yang et al., 2014). 
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1.2.2 Monocyte origins 
Our current understanding of the origins of human monocytes has been predicted 
predominantly from data on mouse monocytes.  From these data, we now know that 
haematopoietic stem cells (HSCs) in the bone marrow differentiate into monocytes via a 
series of committed steps (Figure 1.1) (Akashi et al., 2000).  HSCs give rise to myeloid 
and lymphoid-committed precursors (MP and LP).  While LPs primarily give rise to 
lymphoid cells, MPs generate monocyte/macrophage and dendritic cell precursors 
(MDPs) that are responsible for generating common dendritic cell precursors (CDP), some 
macrophage subsets, and monocytes (Fogg et al., 2006).  Generation of monocytes from 
MDPs requires the growth factor colony-stimulating factor/CSF1-R (Dai et al., 2002).  
Following their generation, classical monocytes egress from the bone marrow into the 
bloodstream in a CCR2-dependent manner (Kuziel et al., 1997; Serbina and Pamer, 2006; 
Tsou et al., 2007).  The mechanisms involved in the egression of non-classical monocytes 
however, remain uncertain.  Although the exact mechanisms are unknown, monocytes 
also emigrate from reservoirs in the spleen and lung (Van Furth and Sluiter, 1986; Swirski 
et al., 2009). 
 
Figure 1.1 Differentiation of monocytes in the bone marrow 
HSCs generate monocytes through MDPs.  During inflammation, classical monocytes 
generate macrophages and dendritic cells; however, in the absence of inflammation, 
classical monocytes return to the bone marrow where they generate intermediate and 
non-classical monocytes.  Adapted from Geissmann et al. (2010). 
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1.2.3 Monocyte functions 
Monocytes roles are orchestrated by their expression of various innate scavenging and 
sensing receptors PRRs (Lauvau et al., 2014).  Some of the main roles undertaken by 
monocytes are discussed below. 
1.2.3.1 Recruitment during infection and inflammation  
1.2.3.1.1 Bone marrow egression 
Classical human monocytes are key players in initiating innate immune responses during 
pathogen challenge (Lauvau et al., 2014).  While the exact functions of human classical 
monocytes are yet to be defined, studies on their mouse (Ly6Chigh) counterparts suggest 
that bacterial infection or inflammation drives the rapid egression of these cells from the 
bone marrow in a CCR2-dependent manner (Serbina and Pamer, 2006; Tsou et al., 2007; 
Shi et al., 2011).  For example, during Listeria monocytogenes (LM) infection, increased 
levels of the CCR2 ligand CCL2 are released by bone marrow mesenchymal stromal cells 
(MSCs) and their progeny in a bid to drive monocytes towards endothelial cells, and from 
there, into the bloodstream (Serbina and Pamer 2006; Serbina et al., 2008; Shi et al., 
2011).  Evidence from other studies also suggests that another CCR2 ligand, CCL7, is 
equally involved in this process (Jia et al., 2008). 
1.2.3.1.2 Sensing of warning signals 
Monocytes rely on a wide array of sensing machineries such as PRRs for the efficient 
detection of PAMPs or DAMPs associated with cellular damage or death.  One example of 
an important PRR pathway is the Toll-like receptor-myeloid differentiation primary 
response gene (88) (TLR-MyD88) pathway.  Early studies by Serbina et al. (2003a) were 
the first to propose an involvement of TLR-MyD88 in monocyte activation following LM 
infection.  In their studies, the authors observed that LM-infected mouse macrophages 
activated classical (Ly6Chigh) monocytes by secreting CCL2 in a TLR-MyD88-dependent 
manner.  Other monocyte cytosolic sensing machineries include, dead box polypeptide 41 
(DDX41) and stimulator of interferon (IFN) genes (STING), both of which are involved in 
producing interferon gamma (IFN-γ) and inflammasome complexes for the production of 
interleukin 1-beta (IL-1β) (Lauvau et al., 2014). 
1.2.3.1.3 Trafficking and adhesion 
Following sensing of warning signals, monocytes rely on trafficking and adhesion 
molecules to promote their localisation into injured or infected tissues.  Crucial to their 
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trafficking are ligands for CCR2 (Section 1.5.3), CX3CR1, CC-motif receptor 1 (CCR1), 
and CCR5 (Serbina and Pamer, 2006; Auffray et al., 2009; Lauvau et al., 2014).   
Monocyte localisation at sites involves the leukocyte-adhesion cascade (Ley et al., 2007), 
a pathway by which various selectins, arrest chemokines, and integrins mediate monocyte 
capture, rolling, and transmigration into the endothelium (Figure 1.2).  The initial rolling of 
monocytes along the endothelium involves selectins, such as L-selectin and P-selectin, 
very late antigen 4 (VLA4; α4β1-integrin) which is expressed by monocytes and facilitates 
their rolling by engaging with endothelial vascular cell-adhesion molecule-1 (VCAM-1) 
(Berlin et al., 1995).  Endothelial cells also induce the expression of intercellular adhesion 
molecule-1 (ICAM-1) near the foci of infection, which may be important for localising 
monocyte adhesion (Shi et al., 2010).  
Monocyte rolling is followed by their arrest (tethering), a process involving “arrest 
chemokines”, integrins, and adhesion molecules (Campbell et al., 1998).  The slow rolling 
of monocytes on the endothelium facilitates their arrest/adhesion and subsequent 
diapedesis (Figure 1.2).  A specific example of an arrest chemokine is CCL5, which 
platelets deposit onto the inflamed endothelium (Von Hundelshausen et al., 2001).  The 
binding of chemokines to glycosaminoglycans (GAGs) located on the endothelial surface 
are also required for monocyte arrest (Johnson et al., 2005).  Arrest chemokines also 
facilitate monocyte adhesion by altering the affinity of integrins for adhesion molecules 
from a low-affinity conformation to a high-affinity conformation (Chan et al., 2001).  
Monocyte adhesion may also involve pathways mediated by the enzyme phospholipase C 
and formyl peptide receptors which are required by integrins to assume a high-affinity 
conformation (Hyduk et al., 2007; Wantha et al., 2013). 
1.2.3.1.4 Transmigration/Diapedesis 
Monocyte transmigration into the endothelium is a rapid process facilitated by adhesion 
molecules such as ICAM-1 and VCAM-1 (Figure 1.2).  Studies by Schenkel et al. (2004) 
have suggested that human peripheral blood monocytes move from areas of firm 
adhesion to the nearest preferred junction where they transmigrate.  In the absence of 
adhesion molecules, monocytes are unable to polarise or adhere to the vascular 
endothelium, suggesting that adhesion molecules are critical for monocyte transmigration 
(Schenkel et al., 2004). 
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Figure 1.2 The leukocyte adhesion cascade 
The leukocyte adhesion cascade describes the capture, rolling, activation, arrest, and 
transmigration of leukocytes.  Adapted from Ley et al. (2007). 
1.2.3.1.5 Phagocytosis 
Monocytes are efficient phagocytes and produce reactive oxygen species, nitrogen 
species, and phagolysosomal enzymes in response to bacterial, fungal, parasitic, and viral 
infections (Serbina et al., 2008).  For example, during infection with LM, monocytes are 
recruited by infected macrophages and differentiate in a CCR2/TLR-MyD88-dependent 
manner into TNFα and inducible nitric oxide synthase (iNOS) – producing dendritic cells 
(TipDCs) (Randolph et al., 1999; Serbina et al., 2003a, 2003b).  Monocyte differentiation 
into TipDCs is also facilitated by the synthesis of TNFα and interferon gamma (IFN-γ) by 
bacteria and recruited natural killer (NK) cells (Pamer, 2004).  Following their generation, 
TipDCs carry phagocytosed particles towards the T-cell area of draining lymph nodes for 
clearance (Randolph et al., 1999; Serbina et al., 2003a, 2003b).  Additional studies have 
suggested that mouse Ly6Chigh monocytes also contribute to the priming of cluster of 
differentiation 4 (CD4) T-cells during Mycobacterium tuberculosis (Mtb) infection 
(Samstein et al. 2013).  The authors discovered that Ly6Chigh monocytes carried antigens 
towards the lymph nodes and transferred these to classical DCs (cDCs) which then 
presented these to antigen-specific CD4 T-cells, activating them for Mtb clearance.   
1.2.3.2   Precursors for mononuclear phagocytes 
Classical (CD14++/CD16-) monocytes are best known for their role as a direct source of 
tissue macrophages and antigen-presenting dendritic cells (DCs) (Figure 1.1) (Geissmann 
et al., 2010).  The mononuclear phagocyte-system (MPS) is composed of monocytes, 
macrophages, and DCs, and assumes that commitment of cells to a myeloid lineage is 
pre-determined in the bone marrow (Van Furth et al., 1972).  The MPS also assumes that 
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monocytes with their short half-life of 20 hours are a transient reservoir for tissue-resident 
macrophages and DCs since these are terminally differentiated and unable to self-
proliferate (Van Furth et al., 1972; Geissmann et al., 2010).   
However, the MPS has come under much scrutiny since the discovery of 
monocyte/macrophage and dendritic cell precursors (MDPs) which are directly 
responsible for generating monocytes, common dendritic cell precursors (CDP), and some 
macrophage subsets (Figure 1.1) (Fogg et al., 2006).  This suggests that DCs and 
macrophages do not rely solely on monocyte input for replenishment.  Indeed, newer 
experimental approaches have established that most steady-state macrophages and DCs 
originate and self-proliferate independent of monocyte input (Hashimoto et al., 2013; Yona 
et al., 2013).  The importance of the MPS has been further questioned following the 
discovery that tissue-resident macrophages pushed to the M2- (alternative-state) of 
activation by helminth infection or interleukin-4 (IL-4), can self-proliferate without 
monocyte input (Jenkins et al., 2011).  These findings are important since they suggest 
that a local proliferation of M2 macrophages may be important for fulfilling M2-associated 
functions such as wound healing, T-helper type 2 (Th2) lymphocyte responses and the 
resolution of inflammation (Martinez and Gordon, 2014). 
1.2.3.3 Patrolling 
Peripheral blood monocytes act as a reservoir of effectors and scavengers that are 
activated when required.  Studies in mice have revealed that non-classical (Ly6Clow) 
monocytes participate in immune homeostasis by patrolling blood vessels to monitor 
PAMPs (Auffray et al., 2007).  Through their studies, the authors found that Ly6Clow 
monocytes displayed a “crawling-” or “patrolling-” type behaviour along the endothelial 
lumen independent of the direction of blood-flow, a process facilitated by their high 
expression of CX3CR1 and the integrin, lymphocyte function-associated antigen-1 (LFA-
1).  Upon infection with LM, Ly6Clow monocytes respond rapidly by migrating into infected 
tissues and releasing pro-inflammatory mediators such as TNFα, IL-1β, and chemokines 
for the recruitment of other cells (Auffray et al., 2007).  Studies by Cros et al. (2010) have 
demonstrated that human non-classical (CD14+/CD16++) monocytes also display a similar 
behaviour.  Further studies (Carlin et al., 2013) have suggested that non-classical 
monocytes also play a housekeeping role for vasculature and through toll-like receptor-7 
(TLR7), recruit neutrophils for repairing endothelial integrity following damage. 
1.2.4 Involvement in sterile inflammation 
While inflammation is beneficial for restoring organism homeostasis, it can also become 
detrimental if prolonged or excessive.  Studies on mouse and human monocyte subsets 
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have revealed that excessive monocyte infiltration into tissues in the absence of infection 
leads to sterile inflammation, a major marker in the onset and progression of chronic 
inflammatory diseases such as atherosclerosis, rheumatoid arthritis, and stroke (Table 
1.2) (Yang et al., 2014). 
Table 1.2 Frequencies of monocytes in human pathologies 
Pathology CD16- CD16+ 
Rheumatoid arthritis No change ↑2.2% 
Coronary arterial disease  ↑2.2 to 8% 
Atherosclerosis 8% ↓ ↑8% 
Haemophagocytic syndrome  ↑31% 
Crohn’s disease  ↑5.7% 
Cancer  ↑13.3% 
Stroke  ↑3% 
Tuberculosis ↓10% ↑9% 
Sepsis No change to ↓9.5% ↑11.5 to 12% 
Adapted from Yang et al. (2014) 
Although monocyte frequencies in human pathologies seem to be dependent on their 
expression of CD16, monocyte signalling and function during both innate immune 
responses and sterile inflammation is also regulated by G-protein-coupled receptors. 
1.3 G-protein-coupled receptors (GPCRs) 
1.3.1 General overview 
GPCRs are a large family of receptor proteins responsible for mediating extracellular to 
intracellular signals within a broad range of physiological settings.  Comprised of over 
1000 genes, GPCRs represent a key therapeutic target for the pharmaceutical industry 
with almost half of all approved drugs targeting this class of proteins (Garland, 2013).  
Members of this group are subdivided into six families based on their sequence homology: 
A (rhodopsin-like), B (secretin-like), C (glutamate/pheromone), F (frizzled), adhesion, and 
others, with family members sharing up to 25% sequence homology (Pierce et al., 2002).  
The rhodopsin-like (class A) family is the largest group of GPCRs and includes receptors 
for light (rhodopsin), chemokine receptors, and P1 and P2Y purinoceptors (Pierce et al., 
2002; Abbracchio et al., 2006; Von Kϋgelgen, 2006; Fredholm et al., 2011; Bachelerie et 
al., 2014). 
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1.3.2 GPCR structure 
Our current understanding of the structure of GPCRs comes primarily from high-resolution 
crystallography structures of rhodopsin and the β2-adrenergic receptor (Schertler et al., 
1993; Palczewski et al., 2000; Rasmussen et al., 2011).  Together with the recently 
published high-resolution crystal structures of the human P2Y1 and P2Y12 purinoceptors 
(Zhang et al., 2014; Zhang et al., 2015), these have provided the molecular models from 
which most GPCR structures and protein dynamics have been elucidated. 
In general, all GPCRs are characterised by a signature seven-transmembrane (7TM) α-
helix configuration, three extracellular loops (ECL1 to ECL3), three intracellular loops 
(ICL1 to ICL3), an extracellular N-terminal tail, and an intracellular C-terminal tail (Figure 
1.3).  Functionally, the extracellular domain controls ligand access, the 7TM region forms 
the main structural core and transduces any extracellular information to the intracellular 
domain via conformational changes, and the intracellular domain directs cellular signalling 
and physiological events by interacting with cytosolic effectors (Kobilka, 2007). 
Figure 1.3 G-protein-coupled receptor  
GPCRs generally comprise of a 7TM helical structure with an extracellular N-terminal 
domain (ammonia-NH3), and an intracellular C-terminal domain (carboxylic acid–COOH).  
The 7TM helical structures are connected by three extracellular loops (ECL1–ECL3) and 
three intracellular loops (ICL1–ICL3).  Classical GPCR signalling involves a transduction 
of extracellular signals to an intracellular heterotrimeric G-protein comprising of α, β, and γ 
subunits.  Adapted from Bridges and Lindsley (2008). 
1.3.3 G-protein cycle 
Classical GPCR activation involves a ligand-induced conformational change through the 
stabilisation of effector molecules such as heterotrimeric G-proteins comprising of α, β, 
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and γ subunits (Pierce et al., 2002) (Figure 1.3).  The α subunit binds to guanine 
triphosphate (GTP) and guanine diphosphate (GDP), while β and γ associate in an 
obligatory Gβγ dimer (Evanko et al., 2001).   
The simplest kinetic model proposed for GPCR activation is the two-state model (Figure 
1.4).  This proposes that a receptor exists in equilibrium between two states, the low-
affinity state (R), and the high-affinity state (R*) (Leff, 1995).  Full agonists bind R*, 
inverse agonists to R, and partial agonists to R and R* (Leff, 1995).  In the low-affinity (R) 
state where Gαβγ has a low affinity for the GPCR, Gα remains tightly bound to Gβγ and 
aids in plasma membrane localisation while preventing the spontaneous release of GDP 
by acting as a guanine-nucleotide dissociation inhibitor (GDI) (Brandt and Ross, 1985).  In 
the high-affinity (R*) state, the ligand-bound GPCR acts as a guanine-nucleotide 
exchange factor (GEF), and through its C-terminus, binds to the GDP-bound Gαβγ 
causing GDP to be replaced by GTP (Leifert et al., 2005).  This causes Gα and Gβγ to 
separate, leaving them free to activate downstream effectors.  Signalling by Gα and Gβγ 
terminates upon hydrolysis of GTP by GTPase, which leads to a re-association of GTP-
bound Gα to Gβγ (Bridges and Lindsley, 2008). 
Figure 1.4 G-protein cycle 
Upon activation, GDP dissociates from Gα and is replaced by GTP, leading to a 
dissociation of Gαβγ and effector activation by Gα and Gβγ.  The G-protein cycle is 
terminated by GTPase leading to a re-association of Gαβγ.  Adapted from Bridges and 
Lindsley (2008). 
32 
 
1.3.4 Heterotrimeric G-protein effectors 
The downstream signalling cascades driven by GPCRs depend on the isoforms of Gα, 
Gβ, and Gγ activated.  In humans, there are 15 Gα, 5 Gβ, and 12 Gγ genes that encode 
for Gα, Gβ, and Gγ subunits (Wettschureck and Offermanns, 2005).  Heterotrimeric G-
proteins are generally referred to by their Gα subunits and are classed into four main 
families based on their sequence homology and their sensitivity to Bordetella Pertussis 
(PTx), a bacterial toxin able to ribosylate adenosine 5’-diphosphate (ADP) of the GDP-
bound heterotrimer (Table 1.3) (Katada, 2012). 
Table 1.3 Heterotrimeric Gα-proteins and their effectors 
Gα-protein class Main Effector(s) PTx sensitive? 
Gαs 
(Gαs, GαsXL, Gαolf) 
Activation of adenylate cyclase No 
Gαi/o 
(Gαi1, Gαi2, Gαi3, Gαo, Gαz, Gαgust, 
Gαt-r, Gαt-c) 
Inhibition of adenylate cyclase/ 
Activation of phospholipase Cβ 
Yes 
Gαq/11 
(Gαq, Gα11, Gα14, Gα15/16) 
Activation of phospholipase Cβ No 
Gα12/13 
(Gα12, Gα13) 
Activation of Rho GTPases No 
Adapted from Wettschureck and Offermanns (2005) 
1.3.4.1 Main effectors of Gα and Gβγ subunits 
1.3.4.1.1 Adenylate cyclase (AC) 
The AC enzymes (E.C. 4.6.1.1) are a well-established effector of Gα subunits of the Gαs 
and Gαi/o class of G-proteins, but are also modulated by Gβγ (when activated by Gαs), 
calcium ions (Ca2+), and protein kinases (Hanoune and Defer, 2001).   
ACs are important for controlling the synthesis of cyclic adenosine 3′,5′-monophosphate 
(cAMP), a prototypical signalling molecule involved in regulating protein kinase A, 
phosphodiesterases, cyclic nucleotide-gated ion channels, and small G-protein regulating 
exchange proteins activated by cAMP (EPACs) (Gancedo, 2013).  In mammals, ten AC 
genes (AC1-10) have been cloned and characterised, AC1-9 encode for transmembrane 
ACs (tmACs) mainly regulated by GPCRs, and AC10 encodes for a soluble AC (sAC) 
mainly activated by adenosine 5’-triphosphate (ATP) and Ca2+ (Sunahara and Taussig, 
2002).   
33 
 
Structurally, mammalian ACs comprise of two homologous catalytic domains (C1 and C2) 
forming a heterodimer.  While C1 comprises of only a small amount of catalytic residues, 
C2 comprises of a complementary set of residues that are essential for AC activity 
(Krupinski et al., 1989).  Although all tmAC structures comprise of bound Gαs subunits and 
are activated directly by Gαs, tmACs 1, 5, and 6 can also be inhibited by Gαi/o-type G-
proteins (Sunahara and Taussig, 2002).   
1.3.4.1.2 Phospholipase C (PLC) 
The PLC enzymes (EC 3.1.4.3) are a family of soluble cytosolic enzymes responsible for 
the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) for the generation of  
inositol 1,4,5-trisphosphate (IP3) and the signalling lipid diacylglycerol (DAG) (Figure 1.5).  
The PLC family is comprised of thirteen members grouped into six different classes (β, γ, 
δ, ε, ζ, and η) depending on their structure and regulatory mechanisms (Fukami et al., 
2010).  Of these, only PLCβ, PLCε and PLCη are activated directly by heterotrimeric G-
proteins, and are a well-established effector of Gα subunits of the Gαq/11 class of G-
proteins and Gβγ subunits of the Gαi/o class of G-proteins (Blank et al., 1992; Boyer et al., 
1992; Smrcka et al., 1993; Kadamur and Ross, 2013). 
Structurally, PLC isoenzymes comprise of subtype-specific domains and conserved core 
domains, which include a pleckstrin homology (PH) domain located in the N-terminal 
domain, a series of EF hands, a catalytic triose phosphate isomerase (TIM) barrel, and a 
C-terminal C2 domain (Bunney and Katan, 2011).  Evidence from fluorescence resonance 
energy transfer (FRET) assays suggests that PLC activation by the Gβγ dimer involves a 
direct binding of Gβγ to the PH domain during activation (Wang et al., 1999).   
As mentioned above, the principle substrate of PLC is PIP2.  As a signalling molecule, 
PIP2 acts a membrane anchor for proteins (Falkenburger et al., 2010).  PIP2 is also 
utilised as a substrate for the synthesis of phosphatidylinositol 3,4,5-trisphosphate (PIP3), 
a signalling lipid involved in controlling many cellular processes (Cantley, 2002).  Although 
PIP2 is important for cellular signalling, the formation of IP3 and DAG from PIP2 is 
essential for mammalian cell signalling and function.  IP3 is required for the release of 
intracellular Ca2+ from internal Ca2+ stores such as the endoplasmic reticulum (ER) (Figure 
1.5) (Berridge, 1983; Streb et al., 1983).  This process, which occurs through the 
activation of IP3 receptors (IP3Rs), is crucial for the regulation of metabolic and regulatory 
processes such as cell differentiation, proliferation, exocytosis, and tissue contraction 
(Berridge, 2009).  The signalling lipid DAG is a signalling molecule in its own right but also 
serves as a precursor for other signalling lipids (Baldanzi, 2014).  Signalling cascades 
regulated by DAG occur typically through the activation of target proteins such as protein 
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kinase C, Munc13s, protein kinase D, Ras guanyl nucleotide-releasing proteins 
(RasGRP), and chimaerins (Baldanzi, 2014).   
1.3.4.1.3 Phosphoinositide-3-kinases (PI3Ks) 
The Gβγ subunit can also directly activate PI3Ks (Figure 1.5) (Krugmann et al., 1999; 
Brock et al., 2003).  The PI3Ks are subdivided into three classes (Type IA, IB, and II) 
based on their substrate requirements and mechanism of action (Katso et al., 2001).  Of 
these, only PI3Kγ (p110γ) a Type IB class of PI3Ks, is activated by GPCRs (Krugmann et 
al., 1999; Brock et al., 2003).  Activation of PI3Ks by Gβγ is important for modulating 
signalling pathways involved in cell growth, survival, and migration (Foster et al., 2003).  
The requirement of PI3K for efficient immune cell chemotaxis and polarity is also widely 
accepted.  For example, neutrophils and macrophages require PI3K activation at the 
leading edge for cell polarisation and chemotaxis (Li et al., 2000; Hirsch et al., 2000; 
Wang et al., 2002).   
 
Figure 1.5 Classical GPCR pathways 
Upon activation, Gα and Gβγ activate different downstream effectors.  Modulation of AC is 
achieved by Gα subunits of the Gαs and Gαi/o-type G-proteins (and Gβγ when activated by 
Gαs).  PLC is activated by Gα subunits of the Gαq/11-type G-proteins and Gβγ subunits of 
the Gαi/o-type G-proteins.  Rho GTPase is activated by Gα subunits of the Gα12/13 (and 
Gαq/11)-type G-proteins.  Gβγ dimers are also involved in activating PI3K.  PLC activation 
is important for Ca2+ release from internal Ca2+ stores. 
35 
 
1.3.5 Regulation of GPCR signalling 
Although it is widely accepted that GTPases regulate GPCR activation (Figure 1.4), in 
recent years, it has become apparent that other mechanisms play a similar role.  The 
purpose of these mechanisms discussed below is to protect GPCRs from over-activation, 
thereby allowing subsequent GPCR-mediated responses to remain close to the ambient 
stimulation level. 
1.3.5.1 Receptor expression and trafficking 
The expression of a GPCR on the cell surface is influenced by how efficiently it is 
assembled in the ER, packaged in the Golgi complex, and delivered to the plasma 
membrane (Dong et al., 2007).  The primary location for receptor production is the ER.  
Here, receptors must be correctly synthesised, folded and matured before they can be 
packaged into coat protein complex II (COPII) transport vesicles and trafficked to the ER-
Golgi intermediate complex (ERGIC), the Golgi complex, and to the trans-Golgi network 
(TGN) for final assembly and maturation prior to trafficking to the plasma membrane 
(Dong et al., 2007).  The individual steps taken by a GPCR from the ER to the plasma 
membrane are determined by specific GPCR membrane-proximal C-terminal and 
extracellular N-terminal amino acid motifs (Duvernay et al., 2005).  These determine the 
concentration of components for delivery to the Golgi complex, their rate of delivery, and 
their packaging in COPII vesicles (Duvernay et al., 2005; Dong et al., 2007).   
While motifs can also prevent the export of incorrectly assembled GPCRs, accessory 
(chaperone) proteins within the ER and at the cell surface also fulfil this role (Margeta-
Mitrovic et al., 2000; Ellgaard and Helenius, 2001).  Chaperone proteins such as calnexin 
and calreticulin bind to carbohydrate chains of GPCR intermediates and stabilise correct 
conformations whilst preventing their misfolding (Williams, 2006).  Correct conformations 
are passed from one chaperone to another until the correct and final conformation is 
achieved.  In the same manner, chaperones can also prevent the export of incorrect 
conformations and promote their degradation by the cytoplasmic ubiquitin–proteasome 
system (UPS) (Meusser et al., 2005). 
1.3.5.2 Receptor desensitisation 
Repeat or prolonged exposure of a GPCR to a ligand can lead to a dampened response 
due to receptor desensitisation, a mechanism by which GPCRs restore themselves to full 
functional capacity.  At the receptor level, GPCRs can be desensitised through 
homologous or agonist-specific desensitisation by the G-protein-coupled receptor kinase 
(GRK)–β-arrestin system (Pitcher et al., 1998).  Comprised of a family of seven GRK 
isoenzymes (GRK1–GRK7) and four arrestin isoforms (arrestin1-4), the GRK-β-arrestin 
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system selectively targets the active (R*) ligand-bound state of the receptor (Pitcher et al., 
1998; Claing et al., 2002).  GRKs specifically phosphorylate the serine and threonine 
residues in GPCR C-terminal domains thereby preventing ligand interaction.  While this is 
alone capable of desensitising GPCRs, GRK phosphorylation also leads to the 
recruitment of arrestins that further desensitise GPCRs by displacing heterotrimeric G-
proteins (Claing et al., 2002). 
GPCRs are also desensitised through negative-feedback signals generated by GPCR-
activated kinases (Gainetdinov et al., 2004).  For example, PKA and protein PKC can alter 
the responsiveness of multiple GPCRs by uncoupling these from heterotrimeric G-proteins 
or by causing GPCRs to switch from one G-protein to another (Daaka et al., 1997). 
The recent identification of regulators of G-protein signalling (RGS) proteins has also 
enhanced our understanding of GPCR desensitisation.  Approximately 25 RGS proteins 
exist, with individual members grouped into four classes (R4, R7, R12 and RZ) based on 
their sequence homology (Ross and Wilkie, 2000).  RGS proteins act as GTPase 
activating proteins (GAPs), accelerating the hydrolysis of GTP-bound Gα of Gαq/11 and 
Gαi/o-type G-proteins.  As a result, receptor signalling is dampened or completely 
inactivated (Ross and Wilkie, 2000). 
1.3.5.3 Receptor internalisation/endocytosis 
Prolonged or repeat ligand exposure can also cause GPCRs to draw away from the cell 
surface (Chuang and Costa, 1979).  While receptor internalisation can occur by a number 
of different mechanisms (Pierce et al., 2002), a well-studied example is via clathrin-coated 
pits, a process dependent on arrestins and dynamin, and reliant on the GRK-β-arrestin 
system (Ferguson et al., 1996).  During this process, arrestins such as β-arrestin and 
arrestin-3 are recruited by GRK-dependent phosphorylation.  These bind to the heavy 
chain and β2-adaptin subunit of clathrin, thereby forming a stable interaction with a 
clathrin-coated pit (Goodman et al., 1996).  As a result, the GTPase dynamin 
oligomerises, leading to the production of a helical extension at the neck of the pit, which 
facilitates the withdrawal of GPCRs from the cell surface (Claing et al., 2002).  Receptors 
are either internalised into endosomes and dephosphorylated, resensitised and recycled 
rapidly back to the cell surface, recycled slowly (4 hours) in larger endosomes, or 
degraded (down-regulated) (Ferguson et al., 2001). 
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1.4 Calcium (Ca2+) signalling 
1.4.1 General overview 
Ca2+ is a highly versatile and ubiquitous second messenger that is released in response to 
GPCR activation.  It is involved in regulating a diverse number of cellular processes such 
as cell differentiation, migration, death, and neurotransmission (Berridge et al., 2000).  
Cellular processes regulated by Ca2+ are initiated by a simple rise in cytosolic levels of 
Ca2+ ([Ca2+]i) from 100 nM to roughly 1 µM in response to external stimuli such as 
neurotransmitters, hormones, and agonists (Berridge et al., 2000; Patel and Docampo, 
2010).  However, in order to control the occurrence and magnitude of physiological events 
dependent on a rise in [Ca2+]i, its release and influx must be regulated in a time-
dependent manner.  The system responsible for ensuring this is a sophisticated cell-
specific calcium-signalling toolkit that is comprised of a complex network of Ca2+ channels, 
organelles, Ca2+ pumps and signalling components that constantly evolve depending on 
the circumstances under which they are required (Berridge et al., 2000).   
 
Figure 1.6 Overview of Ca2+ signalling  
Stimuli generate signals that activate ON mechanisms to trigger increases in [Ca2+]i by 
either releasing Ca2+ from stores or allowing Ca2+ influx.  Following its release, Ca2+ levels 
are rapidly bought down to cytosolic levels by OFF mechanisms.  Adapted from Berridge 
et al. (2000). 
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1.4.2 ON mechanisms 
Cytosolic Ca2+ is increased by “ON mechanisms” to enable the relaying of essential 
information required for inducing downstream signalling events (Berridge et al., 2000; 
Bootman et al., 2001).  ON mechanisms allow Ca2+ signals to be generated either by 
allowing Ca2+ influx from the extracellular space, or by allowing Ca2+ to be released from 
internal stores (Bootman et al., 2001; Berridge, 2002).  Mechanisms allowing Ca2+ influx 
include the receptor-operated (ROCC), voltage-operated (VOCC), and store-operated 
(SOCC) Ca2+ channels located in the plasma membrane.  Internal stores containing high 
concentrations of Ca2+ include the endoplasmic reticulum (ER), sarcoendoplasmic 
reticulum (SR, muscle cells), mitochondria, and acidic organelles such as 
acidocalcisomes, lysosomes, and the Golgi apparatus (Bootman et al., 2001; Berridge, 
2002; Patel and Docampo, 2010). 
1.4.2.1 Channel-mediated Ca2+ influx and release 
A diverse set of plasma membrane and intracellular ROCCs modulate increases in 
cytosolic Ca2+ following external stimuli.  Examples of plasma membrane ROCCs include 
the nicotinic acetylcholine receptor and the P2X purinoceptors (North, 2002; Albuquerque 
et al., 2009).  Other cell surface ROCCs such as GPCRs and protein tyrosine kinase-
linked receptors (PTRKs) can raise cytosolic Ca2+ either by promoting Ca2+ release 
through the activation of PLC (Section 1.3.4.2.1), or by allowing Ca2+ influx via TRPC and 
SOCCs; the latter an indirect consequence of store-depletion  (Hofmann, et al., 1999).  
The Ca2+-induced-Ca2+-release (CICR) receptors IP3R and RyR (Section 1.4.2.2) are also 
ROCCs, and promote the release of Ca2+ from internal stores such as the ER (Vetter, 
2012).  
Membrane depolarisation in response to electrical excitation can also lead to Ca2+ entry 
through cell surface VOCCs such as Cav1 (L-type), Cav2 (N-, P/Q- and R-type), and Cav3 
(T-type) channels (Catterall, 2000; Clapham, 2007).  Of these channels, the L-type 
channels are the most well studied, and are expressed by excitable cells and non-
excitable cells such as immune cells where they regulate Ca2+ signalling, cell activation 
and survival (Suzuki et al., 2010).  VOCCs allow Ca2+ levels to be increased directly by 
allowing Ca2+ influx, but also indirectly by triggering CICR through IP3R and RyR (Berridge 
et al., 2000). 
The SOCCs are auto-regulatory plasma membrane channels that open in response to 
internal store depletion.  Their simple aim is to raise [Ca2+]i via store-operated calcium 
entry (SOCE; also known as capacitative calcium entry) so that excess cytosolic Ca2+ can 
be sequestered by Ca2+ pumps and exchangers to allow a refilling of internal Ca2+ stores 
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(Putney, 2001; Parekh and Putney, 2005).  A well-studied example is the Ca2+-release 
activated Ca2+ channel (CRAC), which is activated entirely by ER Ca2+ depletion (Feske, 
2010).   
1.4.2.2 Store-mediated Ca2+ release 
Internal stores (intracellular organelles) such as the ER represent a major source of Ca2+ 
from which many cell types generate Ca2+ signals.  As mentioned previously, Ca2+ release 
from the ER primarily involves the activation of IP3Rs by IP3, a product formed from the 
hydrolysis of PIP2 by PLC (Berridge, 1993, 2009).  Further increases in [Ca
2+]i via the ER 
are achieved through CICR (Berridge, 2002). 
Mitochondria, which are essential for aerobic metabolism and cell survival, are a second 
type of organelle important for regulating [Ca2+]I (Murchison and Griffith, 2000).  Ca
2+ 
release and uptake by mitochondria involves a sodium (Na+)-dependent Ca2+ exchanger 
(mNCX) (Carafoli et al., 1974; Murchison and Griffith, 2000).  Mitochondria are also key 
players in apoptosis, where excessive levels of Ca2+ sequestered by mitochondria lead to 
the opening of permeability transition pores (PTP), forcing mitochondria to release Ca2+ 
and pro-apoptotic factors such as oxygen species and cytochrome C into the cytoplasm 
(Hajnόczky et al., 2003). 
Ca2+ can also be stored and released from acidic organelles.  Acidocalcisomes are a 
family of organelles represented by examples such as basophilic granules and platelet 
dense granules (Docampo and Moreno, 2011).  These are rich in Ca2+ and serve several 
functions including the storage of cations, osmoregulation, and maintenance of cellular pH 
(Patel and Docampo, 2010; Docampo and Moreno, 2011).  Lysosomes are a second type 
of organelle and are primarily involved in degrading and recycling extracellular particles 
and apoptotic bodies delivered by endocytic and autophagic routes (Patel and Docampo, 
2010).  As Ca2+-storing organelles, lysosomes can release Ca2+ into the cytosol upon 
exposure to the cathespin-C substrate, glycyl-L-phenylalanine-naphthylamide (GPN) 
(Berg et al., 1994).  The second messenger nicotinic acid–adenine dinucleotide 
phosphate (NAADP) is also known to mobilise Ca2+ from lysosomes and other organelles 
through a modulation of transient receptor potential cation channel, mucolipin subfamily 
(TRPML) channels and two-pore channels (Zhang et al., 2009; Patel et al., 2010). 
The Golgi apparatus (GA) and its associated secretory organelles represent a centralised 
sorting and processing station concerned with ensuring that proteins synthesised by the 
ER are correctly glycosylated and packaged into carrier proteins prior to dispatch to their 
final destinations (Jackson, 2009).  However, it is now apparent that the GA, like the ER, 
is a bona fide IP3-sensitive Ca
2+ store (Pinton et al., 1998).  In addition to its sensitivity to 
IP3, the GA is also NAADP-sensitive (Mitchell et al., 2003).  Ca
2+ released by the GA is 
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required for generating cytosolic Ca2+ signals and for ensuring the efficient function of 
enzymes and components involved in protein processing and packaging (Vanoevelen et 
al., 2005). 
1.4.2.3 Ca2+-binding proteins/Ca2+ buffers 
Translation of Ca2+ signals into cellular responses involves the participation of Ca2+-
binding proteins (CBP), a diverse group of proteins that regulate [Ca2+]i either by 
transporting Ca2+ across membranes for participation in cellular functions during ON 
reactions, or by acting as Ca2+ sensors and buffers during OFF reactions (Berridge et al., 
2003).  The CBPs are low-affinity/high-capacity binders of Ca2+ and can exist either as 
mobile proteins found in the cytosol or extracellular space (e.g. calmodulin), or non-mobile 
proteins found in membranes (e.g. calreticulin) (Yáñez et al., 2012). 
1.4.3 OFF mechanisms 
Following completion of its signalling functions, Ca2+ is rapidly removed from the cytosol in 
order to prevent Ca2+ overload, which can cause cell necrosis and apoptosis (Berridge, et 
al., 2000, 2003; Hajnόczky et al., 2003).  The calcium signalling toolkit has equipped itself 
with a number of sophisticated OFF mechanisms that work collectively to return [Ca2+]i to 
resting levels (100 nM).  Components of this system include various Ca2+ pumps, 
exchangers, and buffers (latter discussed in Section 1.4.2.3) that facilitate Ca2+ extrusion 
or sequestration. 
1.4.3.1 Ca2+ pumps and exchangers 
The calcium-signalling toolkit consists of a number of pumps that remove Ca2+ from the 
cytosol either by extruding it from the cell, or by sequestering it into intracellular 
organelles.  The contribution of individual pumps depends on the [Ca2+]i, where lower 
concentrations of Ca2+ are cleared by higher affinity systems, and higher concentrations 
are cleared by lower-affinity mechanisms. 
The plasma membrane Ca2+-ATPases (PMCAs) and the Na+/Ca2+ exchanger (NCX) 
remove excess Ca2+ by extruding it from the cell (Brini and Carafoli, 2011).  The PMCAs 
are encoded by four genes (PMCA1 to PMCA4) and are considered high-affinity, low-
capacity P-type ATPases since they utilise ATP to produce an aspartyl-phosphate 
intermediate (Guerini et al., 2005; Brini and Carafoli, 2011).  PMCAs exist in two 
conformational states, an E1 state that binds to Ca2+ in the cytosol with a high-affinity, and 
a low-affinity E2 state that releases Ca2+ from the cell (Guerini et al., 2005).  PMCAs co-
ordinate Ca2+ extrusion with the low-affinity, high-capacity NCX pumps (Marchand et al., 
2012).  Encoded by three genes (NCX1 to NCX3), the NCX pumps are fully reversible 
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pumps which remove Ca2+ from the cytosol using the electrochemical gradient of three 
sodium (Na+) ions to remove a single Ca2+ ion (Brini and Carafoli, 2011).   
Intracellular organelles also sequester excess cytosolic Ca2+.  Sequestration into the ER 
and NAADP-sensitive lysosomes is through the high-affinity sarco/endoplasmic reticulum 
Ca2+ ATPase (SERCA) pump, a P-type ATPase (Periasamy and Kalyanasundaram, 
2007).  However, unlike other Ca2+ pumps, SERCA is also important for replenishing the 
ER following Ca2+ depletion (Clapham, 2007).  To date, three major isoforms of SERCA 
have been identified (SERCA1 (a-b), SERCA2 (a-d) and SERCA3 (a-f)), which are 
encoded by the genes ATP2A1, ATP2A2 and ATP2A3 (Periasamy and 
Kalyanasundaram, 2007).   
Sequestration of cytosolic Ca2+ by mitochondrion is important for regulating cell processes 
such as metabolism, respiration, and oxidative phosphorylation (Murchison and Griffith, 
2000).  However, mitochondrial uptake is also important during Ca2+ overload (Hajnόczky 
et al., 2003).  Mitochondrial Ca2+ uptake depends largely on its close proximity to the ER 
and the activation of voltage dependent anion channels (VDAC) that facilitate Ca2+ 
diffusion through the outer mitochondrial membrane (OMM) (Raffaello et al., 2012).  
Diffusion of Ca2+ through the inner mitochondrial membrane (IMM) is driven by the 
mitochondrial Ca2+ uniporter (MCU), a low-affinity, high-capacity transmembrane protein 
activated when cytosolic Ca2+ levels are in excess of levels regulated by other 
mechanisms (Kirichok et al., 2004; De Stefani et al., 2011).  Ca2+ uptake by the uniporter 
is driven by an electrochemical gradient generated by the respiratory chain (Kirichok et al., 
2004; De Stefani et al., 2011). 
1.5 Chemokines 
1.5.1 General overview 
The chemokines are a family of low molecular weight (~70 amino acid) chemotactic 
peptides that stimulate the release of intracellular Ca2+ from internal stores as a 
prerequisite to their primary role, which is to direct the polarisation and migration of 
monocytes and other immune cells (Rollins, 1997).  By directing cellular migration, 
chemokines play a crucial role not only in embryonic development and host defence, but 
also in the development of inflammatory diseases (Raman et al., 2011).  Chemokines can 
be broadly classified as being either homeostatic, (involved in cell trafficking, e.g. 
chemokine (CC-motif) ligand 21 (CCL21)), inflammatory (synthesised in response to 
inflammatory insult, e.g. chemokine (CXC-motif) ligand 8 (CXCL8)), or both (e.g. CCL2). 
To date, around 50 chemokines have been identified, with almost all members secreted 
from the cell upon synthesis (Bachelerie et al., 2014).  Chemokines are grouped into four 
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classes (C, CC, CXC and CX3C) based on the number and location of their conserved 
cysteine residues which can either be adjacent or separated by amino acids (Figure 1.6) 
(Zlotnik and Yoshie, 2000).  The current system replaces the previous system where 
chemokines were given multiple names.  For example, CCL2 has many synonyms 
including, monocyte-chemoattractant protein-1 (MCP-1) and small inducible cytokine A2 
(SCYA2) (Zlotnik and Yoshie, 2000).   
All chemokines exhibit a highly variable sequence homology but in general, have a 
conserved tertiary structure consisting of a disordered 6-10aa N-terminal region followed 
by a long loop (N loop) that ends in a 310 helix, a three-stranded β-sheet, and a C-
terminal α-helical domain (Allen et al., 2007).   
Figure 1.7 Chemokine families 
CXC chemokines have one amino acid separated by two adjacent conserved cysteine 
residues, the CC chemokines have two adjacent conserved cysteine residues, the C 
chemokines have one conserved cysteine residue, and the CX3C chemokine CX3CL1 
(fraktalkine), has three amino acids separated by four conserved cysteine residues 
(Townson and Liptak, 2003). 
1.5.2 Chemokine receptors and ligand pairings 
Chemokines exert their effects through the activation of receptors.  However, due to their 
promiscuous nature, chemokines often activate multiple receptors.  To date, 24 
mammalian chemokine receptors have been cloned, of which six are atypical G-protein-
independent, arrestin-dependent receptors (Figure 1.7) (Bachelerie et al., 2014).  While 
the majority of chemokines exert their effects through the activation of class-A GPCRs 
coupled to Gαi/o-type G-proteins (Section 1.3), members of the CXC and CC families can 
also activate atypical receptors.  Studies on human embryonic kidney 293 (HEK293) and 
300-19 pre-B cells transfected with Gαi/o, Gαs, or Gαq/11, have shown that Gαi/o and Gβγ 
are required for chemotaxis (Arai et al., 1997; Neptune and Bourne et al., 1997).   
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Figure 1.8 Chemokine receptors and their ligands 
Adapted from Bachelerie et al. (2014). 
1.6 Chemokine (CC-motif) receptor 2 (CCR2) 
1.6.1 General overview and structure 
The human CCR2 receptor (cluster of differentiation 192/CD192) is a chemokine receptor 
belonging to the class-A family of GPCRs (Section 1.3).  The CCR2 receptor is important 
for immune cell recruitment and is expressed by a wide variety of cells including 
monocytes, T lymphocytes, and endothelial cells (Loetscher et al., 1996; Sozzani et al., 
1997; Weber et al., 1999). 
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The human CCR2 receptor consists of two isoforms, CCR2A (360 amino acids (aa)) and 
CCR2B (374 aa) encoded by the CCR2A and CCR2B genes respectively, which are 
located on the short arm of chromosome 3 (3p21) (Charo et al., 1994; Yamagami et al., 
1994; Samson et al., 1996).  Both isoforms are produced from an alternatively spliced C-
terminus, where the 47 aa C-terminus of CCR2B is located in the same exon as the 7TM 
regions of the receptor, while the 61 aa C-terminus of CCR2A lies in a downstream exon 
(Charo et al., 1994; Wong et al., 1997).  These differences appear to determine the 
surface expression and activation of both isoforms in vitro and in vivo (Wong et al., 1997; 
Sanders et al., 2000; Cho et al., 2007).  Early studies by Wong et al. (1997) showed that 
CCR2A-transfected HEK293 cells (embryonic kidney) released intracellular Ca2+ less 
readily than CCR2B-transfected cells due to a lower surface expression caused by a C-
termini retention signal.  Other more recent studies (Sanders et al., 2000) have shown that 
CCR2A-transfected Jurkat (T-lymphocyte) cells require 5-fold more CCL2 than CCR2B 
transfectants for chemotaxis. 
Figure 1.8 shows the recently modelled crystal structure of the human CCR2 receptor 
(Kothandan et al., 2012).  While most GPCR structures are based on the bovine 
rhodopsin and human β2-adrenergic receptors, the crystal structure of CCR2 is modelled 
on the closer homolog, chemokine (CXC motif) receptor 4 (CXCR4).  The N-terminal 
region of CCR2 is critical for defining ligand specificity and binding affinity, where studies 
by Monteclaro and Charo (1996) have shown that replacing this region with the N-terminal 
region from CCR1 leads to a lower CCL2 binding affinity. 
Figure 1.9 Crystal structure of the human CCR2 receptor 
Representation of the crystal structure of CCR2.  The 7TM helical domains are shown in 
red, the extracellular/intracellular loops in green, and β-sheet in yellow (Kothandan et al., 
2012). 
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1.6.2 Homo- and heterodimerisation 
Similar to other GPCRs, CCR2 may form homo- or heterodimers.  The binding of CCL2 to 
CCR2 favours homodimerisation (Rodríguez-Frade et al., 1999), which may be important 
for functional responses such as chemotaxis.  The CCR2 receptor can also form 
heterodimers with other chemokine receptors such as CCR5 and CXCR4 (Bachelerie et 
al., 2014).  The CCR2-CCR5 heterodimer is a well-studied example, and favours 
signalling via Gαq/11 rather than Gαi/o (Mellado et al., 2001).  Moreover, the ligands for 
these receptors seem to operate synergistically, inducing intracellular Ca2+ release at 
concentrations 10- to 100-fold lower than either chemokine alone (Mellado et al., 2001).  
The formation of CCR2 heterodimers may also be important for receptor activation and 
cell function.  In studies reported by El-Asmar et al. (2005), it was seen that CCR2 and 
CCR5 ligands cross-competed for receptors, where CCR2 ligands blocked the binding of 
CCR5 ligands, and CCR5 ligands blocked the binding of CCR2 ligands. 
1.6.3 Ligands 
The human CCR2 receptor is a high-affinity receptor for chemokines of the monocyte-
chemoattractant protein (MCP) family and is activated by CCL2 (MCP-1), CCL7 (MCP-2), 
CCL8 (MCP-8), CCL11 (eotaxin-1), and CCL13 (MCP-4) (Bachelerie et al., 2014).  The 
preferred endogenous ligand for CCR2 however, is CCL2 (Bachelerie et al., 2014).  The 
N-terminal regions of ligands are crucial for efficient CCR2 activation.  For example, a 
deletion or truncation of residues in the N-terminal region of CCL2 generates a ligand that 
is still able to bind to CCR2, but is either inactive, or behaves as an antagonist (Jarnagin 
et al., 1999). 
The formation of heterodimers between ligands may also be relevant for CCR2 activation.  
For example, reports in literature suggest that CCL2 can form strong heterodimers with 
CCL8 at the expense of CCL2 homodimers (Crown et al., 2006).  Weaker heterodimers 
between CCL2 and other CCR2 ligands (CCL2-CCL13, CCL2-CCL11), can also be 
formed (Crown et al., 2006). 
1.6.4 Signalling and involvement in monocyte function 
The CCR2 receptor signals via the activation of Gαi/o-type G-proteins (Section 1.3).  
Activation of CCR2 leads to an inhibition of AC by Gα, and an activation of PLC and PI3K 
by Gβγ (Bizzarri et al., 1995; Myers et al., 1995; Turner et al., 1998).   
Chemotactic signals involve an interaction between CCR2 and FROUNT, a clathrin 
heavy-chain repeat homology protein that forms clusters at the cell front and facilitates the 
formation of F-actin-rich protrusions (lamellipodia) required for cell polarisation prior to 
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chemotaxis (Terashima et al., 2005).  Low-level activation of CCR2 is crucial for the 
homeostatic migration of monocyte subsets.  As mentioned previously (Section 1.2.1), 
CCR2 is expressed by human and mouse monocytes, particularly by classical and 
intermediate subsets (Table 1.1) (Geissmann et al., 2003).  Activation of the CCR2 
receptor is required for classical monocyte egression from the bone marrow during 
Listeria monocytogenes (LM) infection (Kurihara et al., 1997; Serbina and Pamer, 2006).  
Monocytes from mice lacking CCR2 are retained in the bone marrow, making mice more 
susceptible to LM (Kurihara et al., 1997; Serbina and Pamer, 2006).  CCR2-dependent 
monocyte recruitment is also essential for host defence against Mycobacterium 
tuberculosis, Toxoplasma gondii, and Cryptococcus neoformans (Serbina et al., 2008), 
thus highlighting the importance of CCR2 for efficient clearance against bacterial, 
protozoal, and fungal pathogens. 
In non-classical monocyte subsets, expression of CCR2 is either low or absent, whereas 
expression of CX3CR1 is high (Geissmann et al., 2010).  However, despite lacking CCR2, 
non-classical monocytes are also affected by a deficiency in CCR2 due to their 
dependence on classical monocytes for replenishment (Yona et al., 2013). 
Other studies reported by Chan et al. (2001) have shown that CCR2 activation induces a 
conformational change in VLA-4 (α4β1-integrin), increasing its affinity for VCAM-1.  This 
finding suggests that the CCL2/CCR2 axis is important for monocyte transmigration, a 
hypothesis that seems plausible given that several lines of evidence indicate that CCR2 
signalling is important for monocyte transmigration during sterile inflammation such as that 
seen during the development of atherosclerosis (Gu et al., 1998; Boring et al., 1998; 
Tacke et al., 2007). 
1.6.5 Involvement in human monocyte pathologies  
Pre-clinical studies on mouse (Ly6Chigh) classical monocytes (counterparts of human 
(CD14++/CD16-) classical monocytes), have suggested that CCR2-dependent monocyte 
trafficking underlies many monocyte-associate pathologies.  Murine models of monocyte-
associated conditions such as atherosclerosis, multiple sclerosis, and neuropathic pain 
have shown that a blockade or suppression of CCR2 reduces the severity of these 
pathologies through a reduced infiltration of monocytes and their progeny (Boring et al., 
1998; Gu et al., 1998; Izikson et al., 2000; Abbadie et al., 2003).  Motivated by these 
studies, pharmaceutical companies have sought to develop a number of antagonists 
targeting CCR2 (Table 1.4).  However, despite much investment, progress has been 
hampered by a lack of clinical efficacy in humans (Bachelerie et al., 2014).   
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Table 1.4 CCR2 antagonists in clinical development (2014) 
Drug Company Indication Phase/Status 
INCB8696 Incyte MS, Lupus No longer reported 
INCB3284 Incyte RA, Diabetes No longer reported 
CCX915 ChemoCentryx MS Terminated 
CCX140 ChemoCentryx Diabetic nephropathy II 
MK-0812 Merck MS, RA No efficacy 
PF-4136309 Pfizer Pain No longer reported 
BMS-741672 BMS Diabetic nephropathy II 
JNJ-17166864 Johnson & Johnson Allergic Rhinitis No efficacy 
MLN 1202 Millennium RA No efficacy 
  Atherosclerosis, MS II 
MS = multiple sclerosis, RA = rheumatoid arthritis.  Phase I = safety testing in normal 
human volunteers.  Phase II = drug efficacy trials in a small patient group.  Adapted from 
Bachelerie et al. (2014). 
Although the CCL2/CCR2 axis is an important signalling pathways for monocytes, it is fast 
becoming clear that other Ca2+-mobilising chemoattractants such as extracellular 
nucleotides (purinoceptor signalling), are also important for steering monocyte migration.  
Section 1.7 below moves on to discuss the purinoceptor signalling pathway and its 
involvement in monocyte signalling and function. 
1.7 Purinoceptor Signalling 
1.7.1 General overview 
Geoffrey Burnstock first coined the term “purinergic” in 1971 after putting forward the 
hypothesis that purine nucleotides such as adenosine 5’-triphosphate (ATP) and 
adenosine 5’-diphosphate (ADP) were potent neurotransmitters involved in non-
adrenergic/non-cholinergic (NANC) nerves supplying the gut (Burnstock et al., 1970, 
Burnstock, 1972).  While this proposal was initially met with opposition, it was finally 
accepted, and now describes a widespread intercellular signalling system by which ATP 
and related nucleotides and nucleosides participate in short-term signalling in 
neurotransmission, neuromodulation, and secretion, and long-term signalling in cell 
differentiation, proliferation and death (Burnstock, 2012). 
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1.7.2  Purinoceptors 
The purinoceptor signalling system comprises of a network of at least nineteen 
purinoceptors subdivided into three distinct families termed P1, P2X, and P2Y. 
1.7.2.1 P1 
The adenosine P1 purinoceptors are a family of class-A GPCRs (Section 1.2).  Four P1 
purinoceptors (A1, A2A, A2B, and A3) have been cloned and characterised (Fredholm et al., 
2001, 2011).  Although the preferred endogenous ligand of P1 purinoceptors is the 
nucleoside, adenosine, A1 and A3 are also activated by inosine, a product formed from the 
deamination of adenosine by the enzyme adenosine deaminase (ADA) (Jin et al., 1997; 
Fredholm et al., 2001, 2011).   
P1 receptors share between 31-46% sequence homology (Piirainen et al., 2011) with 
greatest homology seen between A2A and A2B (46%).  Although P1 purinoceptors are 
monomeric, these can self-associate to form homomers (A1-A1, A2A-A2A), or form 
heteromers with adenosine purinoceptors (A1-A2A), non-adenosine purinoceptors (A1-
P2Y1, A1-P2Y2), and non-purinoceptors (dopamine D1) (Fredholm et al., 2011).   
P1 receptors display distinct coupling to secondary effectors and have the ability to couple 
to multiple G-proteins (Table 1.5) (Fredholm et al., 2001, 2011).  Through these 
interactions, A1 and A3 receptors drive the inhibition of AC and the activation of PLC, while 
A2A and A2B drive the activation of AC and PLC (Fredholm et al., 2001; Burnstock, 2012).  
1.7.2.2 P2X 
The P2X purinoceptors are a family of homo- or heterotrimeric ATP-gated ion channels 
with permeability to sodium (Na+) ions, potassium (K+) ions, calcium (Ca2+) ions, and in 
exceptional circumstances, chloride (Cl-) ions (Khakh et al., 2001; North, 2002; Egan and 
Khakh, 2004).  Seven subunits are encoded in the human genome (P2X1 - P2X7), and 
these form functional ion channels as homotrimers (homomultimers) which must bind to 
three molecules of ATP in order to open (Hattori and Gouaux, 2012).  P2X1, P2X2, and 
P2X4 can also combine with other P2X receptor subunits to form heterotrimers with 
kinetic properties distinct from homotrimers (Khakh et al., 2001). 
Each P2X subunit comprises of two hydrophobic transmembrane-spanning regions (TM1 
and TM2) separated by a large extracellular loop (ectodomain) containing ten-conserved 
cysteine residues (Figure 1.9) (Valera et al., 1994).  While TM1 is associated with channel 
gating, TM2 lines the ion pore in the membrane.  The ectodomain allows the formation of 
disulphide bridges and forms the ATP-binding domain.  Each P2X subunit also comprises 
of an intracellular (cytosolic) amino (NH2) and carboxyl (COOH) termini.  The NH2 terminal 
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contains a consensus site for phosphorylation by PKC, and may be involved in modulating 
P2X receptor currents (Ennion et al., 2000; Ennion and Evans, 2002).  The COOH 
terminus diverges greatly between P2X subunits but the remaining sequence shares 40–
55% pairwise identity (North, 2002). 
Following activation, the channel pore opens allowing cations to flow.  Receptors such as 
P2X2, P2X4, and P2X7 may also undergo a second permeability state, allowing the flow 
of larger cations or dyes (Surprenant et al., 1996; Khakh et al., 1999).  The recent 
determination of the crystal structure of zebrafish P2X4 and the location of its ATP binding 
sites has led to the suggestion that ATP molecules sequentially activate homotrimers, 
where a binding of the first ATP molecule induces a conformational change that influences 
the binding of further ATP molecules (Hattori and Gouaux, 2012; Browne and North, 
2013). 
Like GPCRs, P2X receptors become desensitised by prolonged agonist exposure, 
resulting in a closure of the receptor pore.  Depending on their sensitivity to 
desensitisation, P2X receptors are either fast- (P2X1 and P2X3), or slow-desensitising 
(P2X2, P2X4, P2X5, and P2X7) (Khakh et al., 2001; Jarvis and Khakh, 2009). 
Figure 1.10 Structure of functional P2X purinoceptors 
P2X receptors are comprised of three subunits.  P2X receptor from (a) above, and (b), 
parallel to the membrane.  Homomers exhibit a dolphin-like shape and are arranged 
around a 3-fold symmetrical axis.  (c) P2X transmembrane topology shown, where TM1 
and TM2 are separated by an ectodomain containing two disulfide-bonded loops (S–S) 
and three N-linked glycosyl chains (triangles).  Also shown are the intracellular N and C-
termini.  Adapted from Brake et al. (1994) and Browne (2012). 
1.7.2.3 P2Y 
The P2Y receptors are a family of class-A GPCRs (Section 1.3).  Eight P2Y receptors 
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) are recognised, and a number 
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of purine and pyrimidine nucleotides activate these (Table 1.5) (Abbracchio et al., 2006).  
P2Y receptors share 21-48% sequence homology, with greatest similarity observed 
between P2Y12 and P2Y13.  A comparison of the structural and functional features of P2Y 
receptors has revealed that two distinct groups exist: the first group comprises of P2Y1, 
P2Y2, P2Y4, P2Y6, and P2Y11, and the second group comprises of P2Y12, P2Y13, and 
P2Y14 (Abbracchio et al., 2006; Von Kϋgelgen, 2006).  Members of the first group 
principally signal through Gαq/11 to activate PLC, whereas members of the second group 
signal through Gαi/o to inhibit AC (Table 1.6) (Abbracchio et al., 2006).   
1.7.2.4 Ligands for purinoceptors 
Extracellular purine and pyrimidine nucleotides and nucleosides are naturally-occurring 
molecules that regulate a wide range of cellular processes through purinoceptors (Figure 
1.10) (Table 1.5) (Burnstock, 2012).  Purinoceptors are also be modulated by nucleotide 
and nucleoside derivatives (Burnstock, 2012). 
 
Figure 1.11 Structures of some naturally-occuring purinoceptor ligands 
Central to all nucleotides and nucleosides is a pentose sugar (ribose) attached to a purine 
(adenine or uridine) base by its 1'-carbon atom.  Attached to the pentose sugar are two or 
three phosphate groups.  Source: http://www.chemspider.com/ (accessed 23rd Dec 2014). 
1.7.2.5 Distribution in immune cells and monocytes 
In general, all cells possess purinoceptors of some type, with many cells expressing 
multiple purinoceptors.  In immune cells, purinoceptor expression is seen in leukemic cell 
lines and primary cells of monocyte, macrophage, neutrophil, B- and T-lymphocyte, and 
dendritic cell origin (Bours et al., 2006).  Monocytes express multiple purinoceptors (Table 
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1.5), with expression levels often dependent on their maturation stage (Muller et al., 
1993). 
Table 1.5 Human purinoceptors 
Receptor Type Natural ligands Principle effector Monocytes? 
A1 GPCR Adenosine, Inosine Gαi/o (↓AC) Yes 
A2A GPCR Adenosine Gαs and Gαq/11 (↑ AC, ↑PLC) Yes 
A2B GPCR Adenosine Gαs and Gαq/11 (↑ AC, ↑PLC) Yes 
A3 GPCR Adenosine, Inosine Gαi/o and Gαq/11 (↓ AC, ↑ PLC) Yes 
P2X1 LGIC ATP Cation influx Yes 
P2X2 LGIC ATP Cation influx Unknown 
P2X3 LGIC ATP Cation influx Unknown 
P2X4 LGIC ATP Cation influx Yes 
P2X5 LGIC ATP Cation influx Unknown 
P2X6 LGIC ATP Cation influx Unknown 
P2X7 LGIC ATP Cation influx Yes 
P2Y1 GPCR ADP, ATP, Ap4A Gαq/11 and Gαi/o (↑ PLC) Yes 
P2Y2 GPCR ATP, UTP 
Gαq/11, Gαi/o, and Gα12/13 
(↓ AC, ↑ PLC, ↑Rho GTPase) 
Yes 
P2Y4 GPCR UTP Gαq/11 and Gαi/o (↓ AC, ↑ PLC) Yes 
P2Y6 GPCR 
UDP, UTP, ADP, 
ATP 
Gαq/11 (↑PLC) Yes 
P2Y11 GPCR ATP, ADP (UTP?) Gαq/11 and Gαs (↑ AC, ↑PLC) Yes 
P2Y12 GPCR ADP, ATP Gαi/o (↓ AC) Yes 
P2Y13 GPCR ADP, ATP Gαi/o (↓ AC, ↑ PLC?) Yes 
P2Y14 GPCR UDP, UDP-glucose Gαi/o and Gαq/11 (↓ AC, ↑ PLC) Unknown 
LGIC = ligand-gated ion channel, Rho GTPase = Rho guanosine triphosphatase (Merrill et 
al., 1997; Jin et al., 1998; Broussas et al., 1999., Gu et al., 2000; Fredholm et al., 2001; 
Khakh et al., 2001; Zhang et al., 2002; Thiele et al., 2004; Wang et al., 2004; Kaufmann et 
al., 2005; Klein et al., 2009; Lazarowski et al., 2011; Burnstock, 2012). 
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1.7.5 ATP release 
Cellular events leading to purinoceptor activation often involve a release of extracellular 
nucleotides such as ATP from intracellular compartments.  Following the discovery that 
non-neuronal cells express functional purinoceptors, elucidating the mechanisms by which 
cells release ATP has become a major interest for the research community (Bodin and 
Burnstock, 2001).  While early studies proposed that cells leaked ATP only during 
mechanical stress (Forrester, 1972), it is now apparent that resting and stimulated cells 
release ATP in a non-lytic manner (Lazarowski et al., 2011).  However, under stressful 
situations such as apoptosis, ATP is released by cells as a “find-me” signal for phagocytes 
(Elliott et al., 2009).  Under these circumstances, the pore-forming P2X7 receptor and 
connexion/pannexin hemichannels are thought to be the primary modes of ATP release 
(Bao et al., 2004; Eltzschig et al., 2006; Suadicani et al., 2006).  In contrast, the release of 
constitutive ATP by resting cells may be an important mechanism by which cells 
determine their “set-points”, or basal activation levels for regulating homeostatic 
responses such as blood flow, ion transport, and host immunity (Corriden and Insel, 
2010).  ATP release following the activation of non-purinergic GPCRs is also important for 
cell homeostasis.  For example, neutrophils contain a high concentration of cytosolic ATP 
(5 mM) and can liberate up to 25 µM ATP at the leading edge upon FPR activation in 
order to activate P2Y2 and A3 purinoceptors required for chemotaxis (Chen et al., 2006; 
Eltzschig et al., 2006; Corriden et al., 2007). 
1.7.6 Ecto-nucleotidases 
The ecto-nucleotidases are a family of extracellular plasma membrane enzymes that 
rapidly hydrolyse extracellular nucleotides in order to control their availability at 
purinoceptors (Table 1.6) (Yegutkin, 2008; Zimmermann et al., 2012).  Using this 
approach, ecto-nucleotidases can prevent purinoceptor desensitisation by terminating 
their activation while facilitating the activation of other purinoceptors by generating ligands 
(Zimmermann et al., 2012).  Although ecto-nucleotidases are the major enzymes involved 
in this process, a number of other enzymes including the nucleotide-hydrolysing secreted 
exo-enzymes and the nucleotide-phosphorylating ecto-kinases also regulating nucleotide 
release and availability (Kukulski et al., 2011). 
 
 
 
 
53 
 
Table 1.6 Major ecto-nucleotidase families 
Ecto-nucleotidase EC number 
Main 
substrate(s) 
Specificity 
Ecto-nucleoside triphosphate 
diphosphohydrolase (E-NTPDase) 
3.6.1.5 NTP, NDP 
Nucleotide-
specific 
Ecto-5′-nucleotidase 
(cluster of differentiation 73/CD73/eN) 
3.1.3.5 NMP 
Nucleotide-
specific 
Ecto-nucleotide 
pyrophosphatase/phosphodiesterase 
(E-NPP) 
3.6.1.9/ 
3.1.4.1 
NTP Non- specific 
Alkaline phosphatase (AP) 3.1.3.1 NTP, NDP, NMP Non-specific 
Adapted from Yegutkin (2008). 
1.7.7 Involvement in monocyte function 
The expression of purinoceptors by monocytes (Table 1.5) suggests that multiple 
purinoceptor subtypes are involved in regulating physiological responses of monocytes, 
such as trafficking and function (Burnstock and Boeynaems, 2014).   
Evidence for the involvement of P1 receptors is abundant, where studies have shown that 
individual receptors differentially modulate monocyte function (Haskό et al., 2007; Haskό 
and Pacher, 2012).  Studies in the literature examining the effects of P1 purinoceptors on 
monocyte adhesion to endothelium have shown that while A2A receptors promote IL-18-
induced monocyte adhesion, A1 and A3 receptors attenuate adhesion (Takahashi et al., 
2007).  However, in general, P1 purinoceptors play a restorative and protective role in 
monocytes.  For example, A2A and A2B are known to reduce the production of pro-
inflammatory mediators such as TNFα, CCL3, and nitric oxide (Le Vraux et al., 1993; 
Haskό et al., 1996; Szabo et al., 1998; Hasko et al., 2007).  The A3 receptor is considered 
the main receptor involved in inhibiting lipopolysaccharide (LPS)-induced TNFα production 
in monocytic cells (Sajjadi et al., 1996). 
Early studies by Cowen et al. (1989) were one of the first to suggest an association 
between P2 purinoceptors and intracellular Ca2+ release from monocytes.  This finding 
was taken further by Altieri et al. (1990) who found that nucleotide-evoked Ca2+ release in 
monocytes regulated the affinity of the integrin complement receptor, macrophage-1 
antigen (integrin αMβ2).  Other groups, including Kaufmann et al. (2005) and Elliott et al. 
(2009), have discovered that extracellular nucleotides promote monocyte chemotaxis 
through P2 purinoceptors, thus indicating that these are likely to influence monocyte 
trafficking in vivo in response to other chemoattractants.  A number of other studies 
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(Grahames et al., 1999; Warny et al., 2001; Cox et al., 2005; Ben Yebdri et al., 2009; 
Higgins et al., 2014) have also demonstrated that P2 purinoceptors such as P2Y2, P2Y6, 
and P2X7, regulate the release of pro-inflammatory mediators such as TNFα, CCL2, and 
IL-1β from human monocytes and monocytic cells. 
1.7.8 Involvement in human monocyte pathologies  
It has become increasingly clear that aberrant purinoceptor signalling of monocytes and 
their progeny is associated with pathologies such as atherosclerosis, thrombosis, 
diabetes, and neuropathic pain (Fabre et al., 1999; Balasubramanian et al., 2010; Guns et 
al., 2010; Ulmann et al., 2010).  Purinoceptor signalling therefore represents an attractive 
therapeutic area, with biopharmaceutical companies seeking to develop selective 
purinoceptor agonists and antagonists, antibodies, ecto-nucleotidase inhibitors, ecto-
nucleotidases, and modulators of nucleotide transport (Table 1.7, Table 1.8 and Table 
1.9) (Brass et al., 2012; Jacobson et al., 2012; Kaczmarek-Hájek et al., 2012).  However, 
despite continued efforts, few examples of therapeutically useful compounds or 
approaches exist.  While this may reflect the fact that our understanding of purinoceptor 
signalling is still at an early stage, a second possible explanation for this may be that 
purinoceptors display a broad expression pattern and are therefore difficult to target.  
Moreover, purinoceptors are regulated by ecto-nucleotidases and are likely to be co-
activated with other purinoceptors and non-purinoceptors.  Thus, developing novel 
therapies targeting purinoceptor signalling in monocyte-associated pathologies remains a 
challenge for the biopharmaceuticals industry. 
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Table 1.7 P1 ligands in clinical development (2012) 
Drug Action Company Indication Phase/Status 
Adenosine A1 agonist Astellas Tachycardia Approved 
INO-8875 A1 agonist Inotek Glaucoma I-II 
Capadenoson A1 agonist Bayer-Schering Atrial fibrillation II 
Regadenoson A2A agonist 
Dana-Farber 
Cancer Institute 
Sickle cell I 
IB-MECA A3 agonist Can-Fite 
RA, psoriasis, 
dry eye, glaucoma 
II/III 
Cl-IB-MECA A3 agonist Can-Fite 
Carcinoma, 
hepatitis C 
II 
Caffeine AR antagonist Univ. of Texas 
Sleep apnea, cancer 
pain, PD 
II/III 
Theophylline AR antagonist - Asthma, COPD Approved 
Istradefylline A2A antagonist Kyowa Hakko PD III 
KW-6356 A2A antagonist Kyowa Hakko PD III 
Preladenant A2A antagonist Schering PD III 
Tozadenant A2A antagonist Biotie PD IIB 
ST-1535 A2A antagonist Sigma-Tau PD I 
V81444 A2A antagonist Vernalis PD I 
DT1133 A2A antagonist Domain PD Pre-clinical 
CVT-6883 A2B antagonist Gilead Inflammation I 
AR = adenosine receptor, RA = rheumatoid arthritis, PD = Parkinson’s Disease, COPD = 
Chronic Obstructive Pulmonary Disease.  Phase I = safety testing in normal human 
volunteers.  Phase II = drug efficacy trials in a small patient group.  Phase III = drug 
efficacy trials in a large patient group (Jacobson et al., 2012). 
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Table 1.8 P2X ligands in clinical development (2012) 
Drug Action Company Indication Phase/Status 
AF-219 P2X3 antagonist Afferent 
Chronic cough, 
pain, 
II 
CE-224535 P2X7 antagonist Pfizer RA Terminated 
EVT-401 P2X7 antagonist Evotec Inflammation II 
AZD9056 P2X7 antagonist AstraZeneca RA Terminated 
GSK1482160 P2X7 antagonist GlaxoSmithKline Pain Terminated 
RA = rheumatoid arthritis.  Phase II = drug efficacy trials in a small patient group 
(Kaczmarek-Hájek et al., 2012). 
Table 1.9 P2Y ligands in clinical development (2012) 
Drug Action Company Indication Phase/Status 
Diquafosol P2Y2 agonist Santen Dry eye disease Approved 
Suramin P2Y2 antagonist Bayer 
Anti-
helminthic/protozoal 
Approved 
Clopidogrel P2Y12 antagonist BMS/Sanofi ACS, atherosclerosis Approved 
Prasugrel P2Y12 antagonist 
Lilly/Daiichi 
Sankyo 
ACS, angioplasty Approved 
Ticagrelor P2Y12 antagonist AstraZeneca ACS Approved 
Cangrelor P2Y12 antagonist 
The Medicines 
Co. 
Coronary artery 
bypass 
III 
Elinogrel P2Y12 antagonist Portola/Novartis ACS II 
ACR = acute coronary syndrome.  Phase II = drug efficacy trials in a small patient group.  
Phase III = drug efficacy trials in a larger patient group (Jacobson et al., 2012). 
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1.8 Aims and project outline 
It is apparent from the literature presented in this chapter that monocytes play pivotal roles 
in health and disease.  The CCL2/CCR2 axis is an important signalling pathway involved 
in orchestrating monocyte function and is associated with a growing number of monocyte-
associated pathologies.  However, despite research into this area being plentiful, 
biopharmaceutical companies have struggled to translate the effects of CCR2 antagonists 
seen in murine models, into efficacious therapies for humans.  The lack of progress made 
in this area may result from a lot of useful information surrounding the CCL2/CCR2 axis 
being missing.  For example, the contributions of other CCR2 ligands, chemokine 
receptors, and other chemotactic pathways that steer monocyte function are still to be 
determined.  Recently, the chemotactic effects of extracellular nucleotides have been 
described, which result in an increased infiltration of monocytes and their progeny during 
immune responses and monocyte-associated pathologies (Kaufmann et al., 2005; Elliott 
et al., 2009; Guns et al., 2010; Riegel et al., 2011; Tsuda et al., 2013; Stachon et al., 
2014).  It is possible, therefore, that the capacity of cells to traffic in response to the 
CCL2/CCR2 axis is influenced by extracellular nucleotides, arising from crosstalk between 
these signalling pathways.  While many studies have shown that purinoceptor activation 
evokes CCL2 release from monocytic cells and monocyte progeny (Cox et al., 2005; 
Stokes and Surprenant, 2007; Morioka et al., 2013; Garcia et al., 2014; Higgins et al., 
2014; Shieh et al., 2014), the exact mechanisms by which these pathways crosstalk, is 
still an open question.  Thus, in order to address this gap in knowledge, this thesis 
principally investigated the requirement of purinoceptor signalling for CCL2/CCR2-
mediated monocyte signalling and function using human monocytic THP-1 cells and 
peripheral blood mononuclear cells (PBMCs) as in vitro models, the latter being a primary 
source of monocytes. 
Chapter 3 investigated the expression of mRNA transcripts for monocyte/myeloid cell 
markers, CC chemokines, CC chemokine receptors, and potential purinoceptors involved 
in modulating CCL2/CCR2 signalling in THP-1 cells and human monocytes. 
Chapter 4 looked at the mechanisms involved in CCL2/CCR2-mediated signalling and 
function of monocytes using THP-1 cells and PBMCs as in vitro models.  The research 
presented here looks specifically at the involvement of individual signalling components 
on CCL2/CCR2 activation as measured by intracellular Ca2+ release, cell migration, and 
adhesion to vascular endothelium. 
Chapter 5 examined the requirement of extracellular nucleotides and purinoceptors for 
efficient CCL2/CCR2-mediated monocyte signalling and function using THP-1 cells and 
human PBMCs as models.  Similarly, to the previous chapter, great importance was given 
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to CCL2/CCR2 activation as measured by intracellular Ca2+ release, cell migration, and 
adhesion to vascular endothelium. 
The data generated from these experiments led to my project focussing on the P2Y6 
purinoceptor.  Chapter 6 investigated the requirement of P2Y6 for CCL2/CCR2-mediated 
monocyte signalling and function, using the THP-1 cell line and human PBMCs as 
models.  As with Chapter 4, the research presented here gives importance to CCL2/CCR2 
activation as measured by intracellular Ca2+ release, cell migration, and adhesion to 
vascular endothelium.  The research presented in this chapter also looks at the 
involvement of the CCL2/CCR2 axis in extracellular nucleotide release from THP-1 cells. 
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Chapter 2: Materials and Methods 
2.1 Materials and reagents 
All general salts and reagents were purchased from Sigma-Aldrich or Thermo Scientific 
unless otherwise stated.  All buffers were prepared in deionised water unless otherwise 
stated.   
Tables below provide a complete list of ligands, antagonists, and cell signalling 
modulators.   
Table 2.1 Chemoattractants and extracellular nucleotides 
Ligand Purity Supplier Vehicle 
Final 
concentration 
CCL2 98% LT DI 1-500 ng/ml 
CCL5 95% LT DI 1-50 ng/ml 
fMLP ≥97% SA DMSO 0.1-10 µM 
ATP ≥99% SA DI 1-100 µM 
ADP ≥95% SA DI 1-100 µM 
AMP ≥99% SA DI 1-100 µM 
Adenosine ≥99% SA DI 100 µM 
UTP ≥96% SA DI 1-100 µM 
UDP >98% Abcam DI 1-100 µM 
UMP ≥99% SA DI 100 µM 
Uridine ≥99% SA DI 100 µM 
UDP-glucose >98% Abcam DI 30 µM 
β-NAD ≥99% SA DI 1 mM 
BzATP >95% Tocris DI 50 µM 
α,β-MeATP >98% Tocris DI 10-100 µM 
DI = deionised water, DMSO = dimethyl sulfoxide, LT = Life Technologies, SA = Sigma-
Aldrich 
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Table 2.2 Purinoceptor agonists 
Compound Function Supplier Vehicle Final concentration 
MRS-2365 P2Y1 agonist Tocris DI 100 nM 
DI = deionised water 
Table 2.3 Chemokine receptor and purinoceptor antagonists  
Compound Main target receptor Supplier Vehicle 
Final 
concentration 
BMS-CCR2-22 CCR2 Tocris DMSO 30 pM-100 nM 
CGS-15943 P1 Tocris DMSO 2.5 µM 
Suramin P2 Tocris DI 100 µM 
PPADS P2 Tocris DI 100 µM 
Ro-0437626 P2X1 Tocris DMSO 10-100 µM 
5-BDBD P2X4 Tocris DMSO 1-5 µM 
A-438079 P2X7 Abcam DMSO 1-10 µM 
MRS-2179 P2Y1 Abcam DI 10 µM 
MRS-2578 P2Y6 Tocris DMSO 10nM - 10 µM 
NF3-40 P2Y11 Tocris DMSO 10 µM 
AR-C-66096 P2Y12 Tocris DI 1 µM 
MRS-2211 P2Y13 Abcam DI 10 µM 
DI = deionised water, DMSO = dimethyl sulfoxide 
Table 2.4 Nucleotide/nucleoside metabolising enzymes  
Enzyme 
EC 
number 
Function Supplier Vehicle 
Final 
concentration 
Apyrase - high 
NTPase/high NDPase 
3.1.6.5 
Ecto-
nucleotidase 
SA DI 
0.01-4 
units/ml 
Apyrase - high 
NTPase/low NDPase 
3.1.6.5 
Ecto-
nucleotidase 
SA DI 
0.1-4 
units/ml 
Adenosine deaminase 3.5.4.4 
Deaminates 
adenosine 
SA DI 2 units/ml 
DI = deionised water, SA = Sigma-Aldrich 
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Table 2.5 Inhibitors and modulators 
Compound/Tool Function Supplier Vehicle 
Final 
concentration 
ARL-67156 
Ecto-nucleotidase 
inhibitor 
Tocris DI 100 µM 
POM-1 
Ecto-nucleotidase 
inhibitor 
Santa-Cruz 
Biotech 
DI 1-100 µM 
Bordetella pertussis toxin Gαi inhibitor Tocris 
Distilled 
water 
100 ng/ml 
Gallein Gβγ inhibitor Tocris DMSO 10-100 µM 
Xestospongin-C IP3R Abcam DMSO 5 µM 
Dantrolene RyR Tocris DMSO 20 µM 
LY-294002 PI3K inhibitor Tocris DMSO 5-50 µM 
U-73122 PLC inhibitor Tocris DMSO 0.25-5 µM 
R-59022 DAGK inhibitor Tocris DMSO 10-30 µM 
RHC-80267 DAGL inhibitor Abcam DMSO 1-50 µM 
GF-109203X PKC inhibitor Tocris DMSO 1 µM 
Thapsigargin SERCA inhibitor Tocris DMSO 300 nM-5 µM 
Gly-Phe-β-naphthylamide 
(GPN) 
Cathepsin-C 
substrate 
Santa-Cruz 
Biotech 
DMSO 0.2 mM 
SKF-96365 SOCE inhibitor Tocris DI 100 µM 
BAPTA-AM Ca2+ chelator Tocris DMSO 100 µM 
Abbreviations: DI-deionised water, DMSO-dimethyl sulfoxide 
2.2 Cell culture 
2.2.1 Description of cell lines and passage 
2.2.1.1 THP-1 cells 
THP-1 cells are a human cell line isolated from a patient with acute monocytic leukaemia 
(Tsuchiya et al., 1980).  Cells were obtained from the European Collection of Cell Cultures 
(ECACC) and cultured in Roswell Park Memorial Institute (RPMI)-1640 medium 
containing 0.3 g/L L-Glutamine.  This was supplemented with 10% (v/v) heat-inactivated 
foetal calf serum (FCS; PAA Laboratories) and 1% (v/v) penicillin-streptomycin solution 
containing 50 units/ml of penicillin and 50 µg/ml of streptomycin (Life Technologies). 
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P2Y6 knockdown (P2Y6-KD) THP-1 cells were prepared by infecting THP-1 cells with 
lentiviral pLKO.1-puro shRNA constructs targeting the human P2Y6 receptor.  THP-1 cells 
with non-target control vectors were also prepared.  Cells were selected for stable 
expression and cultured in THP-1 cell culture medium supplemented with puromycin at a 
final concentration of 1 µg/ml (InvivoGen). 
THP-1 cells were cultured in suspension, in vented T75 flasks (Nunc) at 37ºC in a 
humidified 5% CO2 incubator (Nuaire).  Routine cell passage was performed by counting 
cells using a haemocytometer (Sigma-Aldrich) and then diluting cells to the required 
density using fresh media warmed to 37ºC.  Cells were maintained below 7x105 cells/ml to 
prevent cells from differentiating to THP-1-macrophages.  To promote consistent results in 
experiments, cells were used at densities between 2x105-4x105 cells/ml.  
For cryopreservation, 1x106 cells were resuspended into 1 ml THP-1 cell culture medium 
supplemented with 10% (v/v) glycerol.  Cells were added to cryovials (Nunc) and stored in 
a Mr Frosty™ freezing container (Thermo Scientific) for storage at -80 ºC overnight before 
indefinite storage in liquid nitrogen (-196 ºC).  To thaw, cells were removed from liquid 
nitrogen and swirled gently in a beaker of warm water before adding 5-10 ml of THP-1 
culture medium to dilute the cryopreservant.  Cells were centrifuged at 805 x g for 7 
minutes at room temperature to allow sedimentation and removal of the supernatant.  The 
cell pellet was finally resuspended in 5 ml of THP-1 culture medium and transferred to a 
vented T25 flask for incubation at 37ºC in a humidified 5% CO2 incubator. 
2.2.1.2 1321N1 cells 
Human 1321N1 cells are an astrocytoma cell line isolated as a sub-clone from the 
1181N1 line, a line isolated from the parent line U-118 MG (Pontén and Macintyre, 1968).  
These cells are not known to respond to classical purinoceptor ligands (Communi et al., 
1996).  1321N1 cells were kindly donated by Professor Jens George Leipziger (Aarhus 
University) and were cultured in Dulbecco’s Modified Eagle Medium containing L-
Glutamine (0.6 g/L) (DMEM) supplemented with 10% (v/v) heat inactivated FCS and 1% 
(v/v) penicillin-streptomycin solution containing 50 units/ml of penicillin and 50 µg/ml of 
streptomycin. 
Human 1321N1 cells stably expressing the P2Y6 receptor were also a kind gift from 
Professor Jens George Leipziger.  Cells were transfected as described by Communi et al., 
(1996) with recombinant pcDNA3 plasmid encoding human P2Y6 and were selected with 
1321N1 cell culture medium as described above supplemented with 400 mg/ml G418 
(InvivoGen).  Cells stably expressing the P2Y6 receptor were maintained in this medium. 
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Human 1321N1 cells are adherent and were cultured in vented T75 flasks at 37ºC in a 
humidified 5% CO2 incubator.  When cells had reached 70-80% confluency, cell 
monolayers were rinsed with 5 ml Dulbecco’s Phosphate Buffered Saline (dPBS).  
Adherent cells were removed by adding 3 ml TrypLE Express solution (Life Technologies) 
to the flask and incubating for 5 minutes at 37ºC.  Following gentle agitation to dislodge 
adherent cells, the enzymatic reaction was terminated by addition of 10 ml 1321N1 cell 
culture medium.  Cells were centrifuged at 805 x g for 7 minutes at room temperature and 
the supernatant was discarded.  The cell pellet was resuspended in 10 ml of 1321N1 
culture medium and used or re-seeded into fresh T75 flasks for culture. 
Cryopreservation of cells was performed as described for THP-1 cells (Section 2.2.1.2), 
substituting THP-1 cell culture medium for 1321N1 culture medium supplemented with 
10% (v/v) DMSO.   
2.2.1.3 HUVEC cells 
Human umbilical cord endothelial cells (HUVECs) are primary endothelial cells harvested 
from human umbilical vein using a technique first described by Jaffe et al., (1973).  
HUVEC cells form a useful tool for investigating the role of the endothelium cell wall in 
leukocyte adhesion.  Early passage (1-2) cells from a population of pooled donors (5x105 
cells) were purchased from Caltag Medsystems and cultured in Endothelium Cell Growth 
Medium (ECGM; PromoCell). 
HUVEC cells are adherent and were cultured in vented T75 flasks at 37ºC in a humidified 
5% CO2 incubator.  When cells had reached 60-80% confluency, cell monolayers were 
rinsed with 5 ml dPBS.  Adherent cells were removed by adding 3 ml TrypLE Express 
solution to the flask and incubating for 2-3 minutes at room temperature.  Following gentle 
agitation to dislodge adherent cells, the enzymatic reaction was terminated by addition of 
10 ml of ECGM.  Cells were centrifuged at 220 x g for 5 minutes at room temperature and 
the supernatant was discarded.  The cell pellet was resuspended in 10 ml of ECGM and 
counted for use in experiments.   
Cryopreservation of cells was performed by resuspending 5x105 cells in 1 ml of ECGM 
supplemented with 10% (v/v) DMSO.  Cells were added to cryovials as described for 
THP-1 cells and stored in a Mr. Frosty™ freezing container at -80 ºC prior to indefinite 
storage in liquid nitrogen (-196 ºC).  To thaw, cells were removed from liquid nitrogen and 
swirled gently in a beaker of warm water.  Thawed cells were added to two vented T75 
flasks, each containing 15 ml of warmed ECGM.  Flasks were incubated at 37ºC in a 
humidified 5% CO2 incubator for 24 hours before replacing the media and returning the 
flasks to the incubator.  The ECGM was replaced every 48 hours until flasks were 
confluent.  Cells were not used beyond 1-2 passages (15 population doublings). 
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2.2.1.4 HEK293T cells 
HEK293 cells are created by transforming normal human embryonic kidney cells with 
adenovirus-type 5 DNA (Graham et al., 1977).  HEK293T are HEK293 cells transfected 
with a gene encoding the SV40 large T-antigen and a neomycin resistance gene 
(DuBridge et al., 1987).  These cells are capable of replicating vectors containing the 
SV40 origin of replication.  Cells were obtained from ECACC and cultured in DMEM 
containing L-Glutamine (0.6 g/L) supplemented 10% (v/v) heat-inactivated FCS and 1% 
(v/v) penicillin-streptomycin solution containing 50 units/ml of penicillin and 50 µg/ml of 
streptomycin. 
HEK293T cells are adherent and were cultured in vented T75 flasks at 37ºC in a 
humidified 5% CO2 incubator.  HEK293T cells were passaged and cryopreserved in a 
similar manner to 1321N1 cells (Section 2.2.1.2), replacing 1321N1 culture medium for 
HEK293T culture medium. 
2.3 Primary Cell Isolation 
2.3.1 Collection of human peripheral blood and isolation of PBMCs 
Human peripheral blood was collected from healthy volunteers and was approved by the 
University of East Anglia (UEA) Faculty of Medicine and Health Sciences Research Ethics 
Committee under the ethical proposal “Inflammation and Cardiovascular Disease” 
submitted by Dr Samuel J. Fountain.  Samples were collected and treated in accordance 
to guidelines provided under the Human Tissue Act (2004). 
Blood from was collected in 4% (w/v) sodium citrate solution.  For each 10 ml blood 
collected, 1 ml of anti-coagulant was used.  Accuspin tubes (Sigma-Aldrich) were 
prepared by adding 13 ml of Histopaque-1077 density gradient media to each tube and 
centrifuging at 800 x g for 1 minute at room temperature.  The collected blood was diluted 
with an equal volume of dPBS and poured into Accuspin tubes before centrifuging at 1000 
x g for 10 minutes at room temperature.  Following centrifugation, the opaque interface 
containing mononuclear cells was carefully pipetted transferred into a fresh centrifuge 
tube.  The cells were washed with an equal volume of dPBS and then sedimented at 250 
x g for 10 minutes at room temperature.  Following removal of the supernatant, cells were 
washed twice with dPBS.  The resultant PBMC pellet was resuspended in 2-5 ml of the 
appropriate physiological buffer before counting the number of PBMCs using a 
haemocytometer. 
 
 
65 
 
2.3.2 Isolation of monocytes and monocyte-depleted PBMCs 
PBMCs were resuspended in 5 ml salt-buffered solution (SBS) (containing 130 mM 
sodium chloride, 5 mM potassium chloride, 1.2 mM magnesium chloride, 1.5 mM calcium 
chloride, 8 mM D-(+)-Glucose and 10 mM hydroxyethyl piperazineethanesulfonic acid 
(HEPES); pH 7.2).  Cells were added to wells of a sterile 24-well plate (Nunc) and 
incubated at 37ºC in a humidified 5% CO2 incubator for 2 hours.  Following incubation, 
unadhered cells were removed and transferred to fresh wells of a sterile 24-well plate, and 
reincubated for a further 2 hours.  Adhered monocytes were washed twice with dPBS and 
then treated with TRI reagent for RNA extraction.  Monocyte-depleted PBMC fractions 
were sedimented at 805 x g for 5 minutes at room temperature.  The supernatant was 
discarded, and cells were lysed with TRI reagent for RNA extraction. 
2.4 Reverse transcription-polymerase chain reaction (RT-PCR) 
2.4.1 Total RNA extraction  
RT-PCR was employed to investigate gene expression in human THP-1 cells, peripheral 
blood monocytes, monocyte-depleted PBMCs, brain RNA, and retina RNA (paramacular).  
Cellular samples and THP-1 cells (1x106 cells) were centrifuged at 805 x g for 7 minutes 
at room temperature to allow sedimentation and disposal of the supernatant.  Cellular 
disruption was achieved by addition of 1 ml TRI reagent; a single-step RNA isolation 
reagent modified from Chomczynski and Sacchi (1987).  Following addition, cells were 
vortexed for 1 minute to allow cellular disruption before transferring to a 1.5 ml nuclease-
free microcentrifuge tube (Eppendorf).  To facilitate visualisation of the cell pellet and to 
increase the recovery of nucleic acids, 200 µg/ml glycogen (Fermentas) was added and 
briefly vortexed.  In addition, 100 µl of 1-bromo-3-chloropropane (BCP) (for each ml of TRI 
reagent) was added to this to allow separation of the homogenate into aqueous and 
organic phases.  Samples were briefly vortexed and allowed to stand at room temperature 
for 15 minutes before centrifuging at 20,000 x g for 15 minutes at 4ºC.  Centrifugation 
resulted in 3 phases being established: a lower red organic phase, a cloudy interphase 
containing denatured proteins and genomic DNA, and an upper aqueous clear phase 
containing RNA.  The upper aqueous phase was transferred to a fresh 1.5 ml 
microcentrifuge tube.  To this, an equal volume of ice-cold isopropanol was added and 
samples were briefly vortexed and incubated on ice for 15 minutes.  Precipitation of the 
RNA from the aqueous phase was achieved by sedimentation of the sample at 20,000 x g 
for 20 minutes at 4ºC.  The supernatant was discarded, leaving a visible RNA pellet that 
was washed in 1 ml ice-cold 75% (v/v) ethanol.  The sample was centrifuged at 20,000 x g 
for 5 minutes at 4ºC, before removing the ethanol and air-drying the pellet for 5-10 
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minutes at room temperature.  Rehydration of the RNA was achieved by addition of 10 µl 
of nuclease-free water followed by heating at 55ºC for 5 minutes. 
2.4.2 Total RNA quantification 
The RNA concentration in each sample was determined using a BioPhotometer Plus 
UV/Vis photometer (Eppendorf).  Samples were prepared by diluting 1 in 50 with 
nuclease-free water in a UVette (Eppendorf).  The absorbance was read at A260 (nm) 
and A280 (nm), with the former being the absorbance at which nucleotides are maximally 
absorbed.  The concentration of RNA in a sample was quantified using the Lambert-Beer 
law: 
A = ƐCl 
Where, A is the absorbance at A260 (nm), Ɛ the molar extinction coefficient for RNA 
(0.025 (µg/ml) cm-1), C the concentration of RNA, and l the path length of the 
spectrophotometer cuvette.  The absorbance at A280 (nm) was read in order to identify 
the A260/A280 ratio that was used to assess the purity of RNA in the sample where 
values of 2.0 signified a sample of RNA free of contaminating DNA and proteins. 
2.4.3 First strand complementary DNA synthesis 
RNA isolated as described in Section 2.4.1 was reverse transcribed into complementary 
DNA (cDNA).  Human brain RNA (Ambion) at a concentration of 1 mg/ml served as a 
positive control for gene expression.  Reactions for isolated RNA samples were prepared 
in duplicate, with one reaction containing reverse transcriptase (RT) to produce cDNA 
from the target RNA sequence, and a second reaction omitting RT (no RT) which was 
used to confirm that any PCR amplicon was derived from the synthesised cDNA and not 
genomic DNA.  Reactions without RT were not prepared for human brain RNA.  For each 
reaction, 1 µg of total RNA was added to a thin-walled 0.2 ml nuclease-free 
microcentrifuge tube (Thermo Scientific) containing 1 µl (100 pmol) of 100 µM Oligo (dT)18 
(deoxythymidylic 18-mer oligonucleotide) primer (Fermentas), and 1 µl (0.05 mM) of 10 
mM dNTP (deoxyribonucleotide triphosphate) mix (Fermentas).  Reactions were made up 
to a volume of 14.5 µl with nuclease-free water and mixed by flicking the tube before 
briefly centrifuging.  Reactions were incubated at 65ºC for 5 minutes to allow the RNA to 
denature followed by incubation on ice to allow the primer to anneal to the RNA.  
Reactions for the transcription of RNA to cDNA were prepared by adding 4 µl of 5x RT 
buffer (Fermentas) to each sample.  To limit any degradation of RNA, 0.5 µl (0.5 U) of 
Ribolock RNase inhibitor (Fermentas) was also added to samples.  Reverse transcriptase 
(1 µl; 200U) was added to RT samples to enable transcription of RNA, and 1 µl of 
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nuclease-free water (Thermo Scientific) was added to “no RT” samples.  All samples were 
gently flicked before briefly centrifuging.  To allow transcription to occur, reactions were 
incubated at 50ºC for 30 minutes followed by inactivation of the enzyme at 85ºC for 5 
minutes.  Complementary DNA samples were stored at -20ºC until required. 
2.4.4 Primer design and preparation 
Primer sequences were designed using the National Centre for Biotechnology Information 
(NCBI) primer designing tool.  Primers were designed to meet the following criteria: 
1) Located on the coding DNA sequence (CDS) of the gene of interest. 
2) Limited cross homology with other genes. 
3) Targets all variants of selected gene. 
4) Optimal length of 18-22 base pairs (bp). 
5) A theoretical melting temperature (Tm) of 60ºC. 
6) A GC rich 3’ end to promote binding. 
7) Product size above or equal to 200 bp where possible. 
All primers were supplied lyophilised from Sigma-Aldrich.  Primers were reconstituted to 
100 µM in nuclease-free water and kept at -20ºC for long-term storage.  From these, 10 
µM working stocks were prepared in nuclease-free water and stored at -20ºC until use. 
Table 2.6 Primer sequences for ACTB (actin, beta) and monocyte markers 
Gene Accession Sequence Direction Size (bp) 
ACTB 
NM_001101.
3 
CACAGAGCCTCGCCTTTGCC 
CGATGCCGTGCTCGATGGGG 
Sense (5’-3’) 
Antisense (3’-5’) 
282 
CD14 NM_000591 
AAGCCACAGGACTTGCACTT 
GCGAACGACAGATTGAGGGA 
Sense (5’-3’) 
Antisense (3’-5’) 
445 
CD16 NM_000569 
TAGTTTCAGCTGGCATGCGG 
GTGGAGAGGTTTGTCTGGCA 
Sense (5’-3’) 
Antisense (3’-5’) 
247 
CD33 NM_001772 
ATCCTCATCCCTGGCACTCT 
TCCAGCGAACTTCACCTGAC 
Sense (5’-3’) 
Antisense (3’-5’) 
216 
CD93 NM_012072 
TGACCTGTGCCTCTCGAAAC 
CATGGTGCAAGAGACCCCAT 
Sense (5’-3’) 
Antisense (3’-5’) 
515 
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Table 2.7 Primer sequences for CC chemokines and receptors 
 
 
Gene Accession Sequence Direction 
Size 
(bp) 
CCL2 NM_002982.3 
GATGCAATCAATGCCCCAGTC 
CTTCGGAGTTTGGGTTTGCT 
Sense (5’-3’) 
Antisense (3’-5’) 
219 
CCL3 NM_002983.2 
CTGCAACCAGTTCTCTGCATC 
CGCTGACATATTTCTGGACCC 
Sense (5’-3’) 
Antisense (3’-5’) 
209 
CCL4 NM_002984.2 
CTGTCCTGTCTCTCCTCATGC 
AGCACAGACTTGCTTGCTTC 
Sense (5’-3’) 
Antisense (3’-5’) 
209 
CCL5 NM_002985.2 
GCATCTGCCTCCCCATATTCC 
AGAGTTGATGTACTCCCGAACC 
Sense (5’-3’) 
Antisense (3’-5’) 
201 
CCR1 NM_001295.2 
GCCTACGAGAGTGGAAGCTG 
TTCCGGAACCTCTCACCAAC 
Sense (5’-3’) 
Antisense (3’-5’) 
358 
CCR2A 
NM_00112304
1.2 
GGACCAAGCCACGCAGGTGAC 
TCCTGGACCTCCACACACTGG 
Sense (5’-3’) 
Antisense (3’-5’) 
160 
CCR2B 
NM_00112339
6.1 
GGCATAGGGCAGTGAGAGTC 
GCTTGGTGATGTGCTTTCGG 
Sense (5’-3’) 
Antisense (3’-5’) 
267 
CCR3 NM_001837.3 
TTGTCCATGCTGTGTTTGCC 
AAAAATGAGCCGGATGGCCT 
Sense (5’-3’) 
Antisense (3’-5’) 
323 
CCR4 NM_005508.4 
ATGATCTTTGCCGTGGTGGT 
ATGATCCATGGTGGACTGCG 
Sense (5’-3’) 
Antisense (3’-5’) 
336 
CCR5 NM_000579.3 
ACAGGGCTGTGAGGCTTATC 
CATTTGCAGAAGCGTTTGGC 
Sense (5’-3’) 
Antisense (3’-5’) 
277 
CCR6 NM_004367.5 
CAGCGATGTCTGTGAACCCA 
AATTTGCAGCCGTCACAAGC 
Sense (5’-3’) 
Antisense (3’-5’) 
263 
CCR7 NM_001838.3 
CAAGTCCTGGGTCTTCGGTG 
CCAGGACCACCCCATTGTAG 
Sense (5’-3’) 
Antisense (3’-5’) 
497 
CCR8 NM_005201.3 
GCCGTGTATGCCCTAAAGGT 
GGCATAAGTCAGCTGTTGGC 
Sense (5’-3’) 
Antisense (3’-5’) 
432 
CCR9 NM_006641.3 
GGCAATTGCTGACCTCCTCT 
CGAAGGGAAGGAAGAACCCC 
Sense (5’-3’) 
Antisense (3’-5’) 
413 
CCR10 NM_016602.2 
TTGCTACAAGGCCGATGTCC 
TGGAAGGAGGCCGAGTAGAG 
Sense (5’-3’) 
Antisense (3’-5’) 
285 
CCRL2 NM_003965.4 
TCTTCCTTCTGATGTGGGCG 
TTCCCTCGATGTGCCTTGTG 
Sense (5’-3’) 
Antisense (3’-5’) 
272 
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Table 2.8 Primer sequences for P1 purinoceptors 
Gene Accession Sequence Direction 
Size 
(bp) 
ADORA NM_000674 
GTGCGAGTTCGAGAAGGTCA 
GGATGCGGAAGGCATAGACA 
Sense (5’-3’) 
Antisense (3’-5’) 
374 
ADORA2A NM_000675 
CTACCGTATCCGCGAGTTCC 
GCTAAGGAGCTCCACGTCTG 
Sense (5’-3’) 
Antisense (3’-5’) 
295 
ADORA2B NM_000676.2 
CAGAACCCTGGGATGGAACC 
CAGCACAGGGCAAAAATCCC 
Sense (5’-3’) 
Antisense (3’-5’) 
277 
ADORA3 NM_001081976 
CTGGTGCCGAGGCTATTTCC 
CCTTGCGGACAACTTTGGGA 
Sense (5’-3’) 
Antisense (3’-5’) 
302 
 
Table 2.9 Primer sequences for P2X purinoceptors 
Gene Accession Sequence Direction 
Size 
(bp) 
P2RX1 NM_002558.2 
GCTTTCCACGCTTCAAGGTC 
GAGGTGACGGTAGTTGGTCC 
Sense (5’-3’) 
Antisense (3’-5’) 
341 
P2RX2 NM_170682.2 
GCACAGACGGGTACCTGAAG 
GGAGTACTTGGGGTTGCACT 
Sense (5’-3’) 
Antisense (3’-5’) 
200 
P2RX3 NM_002559 
TGTATCAGACAGCCAGTGCG 
CGGATGCCAAAAGCCTTCAG 
Sense (5’-3’) 
Antisense (3’-5’) 
564 
P2RX4 NM_001256796 
AGCAACGGAGTCTCAACAGG 
TGGAAACTGTGTCCTGCGTT 
Sense (5’-3’) 
Antisense (3’-5’) 
311 
P2RX5 NM_002561.3 
GCAATGTGATGGACGTCAAGG 
GTACCCGGAGGAGACAGACT 
Sense (5’-3’) 
Antisense (3’-5’) 
263 
P2RX6 NM_005446.3 
GACTTCGTGAAGCCACCTCA 
TTGTGGTTCATAGCGGCAGT 
Sense (5’-3’) 
Antisense (3’-5’) 
405 
P2RX7 NM_002562.5 
CGGTTGTGTCCCGAGTATCC 
AATGCCCATTATTCCGCCCT 
Sense (5’-3’) 
Antisense (3’-5’) 
414 
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Table 2.10 Primer sequences for P2Y purinoceptors 
Gene Accession Sequence Direction 
Size 
(bp) 
P2RY1 NM_002563 
GTTCAATTTGGCTCTGGCCG 
TTTTGTTTTTGCGGACCCCG 
Sense (5’-3’) 
Antisense (3’-5’) 
326 
P2RY2 NM_002564.2 
CCGCACCCTCTACTACTCCT 
TCAGTTCTGTCGGATCTGCG 
Sense (5’-3’) 
Antisense (3’-5’) 
243 
P2RY4 NM_002565 
CCCCAACCCTATGGCTCTTC 
TGGTCAAACTCTTCAGGCCG 
Sense (5’-3’) 
Antisense (3’-5’) 
427 
P2RY6 NM_176798 
GCTCTCACTGTCATCGGCTT 
TCTGCCATTTGGCTGTGAGT 
Sense (5’-3’) 
Antisense (3’-5’) 
391 
P2RY11 NM_002566 
CATGGCAGCCAACGTCTCG 
CAGGCTATACGCTCTGTAGGC 
Sense (5’-3’) 
Antisense (3’-5’) 
622 
P2RY12 NM_022788 
ACTGGGAACAGGACCACTGA 
CAGAATTGGGGCACTTCAGC 
Sense (5’-3’) 
Antisense (3’-5’) 
698 
P2RY13 NM_176894 
TTCCCAGCCCTCTACACAGT 
GGCCCCTTTAAGGAAGCACA 
Sense (5’-3’) 
Antisense (3’-5’) 
461 
P2RY14 NM_001081455 
CGGAAGTGGCACAAAGCATC 
CCCTAAACGGCTGGCATAGA 
Sense (5’-3’) 
Antisense (3’-5’) 
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2.4.5 Polymerase chain reaction (PCR) 
Prepared cDNA samples were used as a template for amplification in PCR using primers 
detailed in Section 2.4.4.  Retinal cDNA kindly gifted by Dr Julie Sanderson (School of 
Pharmacy, UEA), was also tested.  Primers were prepared as described (Section 2.4.4) 
and included β-actin (Table 2.6); a housekeeping gene that served as a positive control 
for PCR reactions.  Reactions for each primer were prepared in duplicate in thin-walled 
0.2 ml nuclease-free microcentrifuge tubes.  To each reaction, 1 µl of cDNA (either RT or 
no RT), 1 µl (200 nM) of forward primer, 1 µl (200 nM) of reverse primer, and 25 µl of 
ReadyMix™ Taq PCR Reaction Mix were added.  Reactions were made up to a final 
volume of 50 µl with nuclease-free water and mixed by flicking the tube before briefly 
centrifuging to allow sedimentation.  To allow selective amplification, samples were 
thermally cycled, allowing an initial denaturation of the DNA helix at 94ºC for 1 minute, 
followed by 35 cycles of denaturation at 94ºC for 30 seconds, an annealing of the primers 
to the DNA template at 55ºC for 30 seconds and finally, an extension of the cDNA strand 
by addition of dNTPs at 72ºC for 1 minute.  A final extension at 72ºC for 5 minutes was 
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performed to ensure that any remaining single-stranded DNA was fully extended.  
Samples amplified at this stage were stored at -20ºC until further use. 
2.4.6 Agarose gel electrophoresis 
Agarose gel electrophoresis is an analytical procedure that utilises an electromotive force 
to separate DNA molecules based on size and charge.  Agarose gel (Melford 
Laboratories) was prepared as a 2% (w/v) solution in 1x Tris-acetate-EDTA buffer (TAE; 
Thermo Scientific) and heated in a microwave until clear.  To this, 4 µl of ethidium bromide 
solution was added such that the final concentration was 0.4 µg/ml.  This is an 
intercalating dye that allows visualisation of DNA under ultra-violet (UV) light.  The gel was 
poured into a cast and allowed to set at room temperature for 30 minutes, before being 
transferred to an electrophoresis chamber containing 1x TAE.  Samples were prepared by 
mixing 10 µl of PCR reactions with 5 µl gel loading dye (New England Biolabs), and 
adding to wells of the gel.  A 100 base-pair (bp) DNA ladder (New England Biolabs) was 
used as a reference molecular weight marker and was prepared by mixing 4 µl of marker 
with 10 µl gel loading dye (New England Biolabs).  To allow separation of DNA, 
electrophoresis was performed at 95V (volts) for 45 minutes.  Gel visualisation was 
performed under UV light using a ChemiDoc™ XRS visualiser (Bio-Rad). 
2.5 Generation of P2Y6-knockdown THP-1 cells 
Gene silencing strategies were employed to generate P2Y6-knockdown THP-1 cells.  The 
method of choice was the delivery of short-hairpin ribonucleic acid (shRNA) sequences 
carried by the lentiviral pLKO.1 puro (puromycin-resistant) vector (Moffat et al., 2006; 
Figure 2.1) as this method enables the generation of long-term stable knockdown lines.  
The pLKO.1 vector was used together with the second-generation psPAX2 and pMD2.G 
plasmids.  The psPAX2 plasmid encodes for the HIV-1 proteins Gag (structural) and Pol 
(polymerase) and the accessory proteins, Tat and Rev that are involved in driving the 
activation of viral transcription and the subsequent migration of genomic RNA from the 
nucleus (Zufferey et al., 1997).  In comparison, the pMD2.G helper/envelope plasmid 
encodes for glycoproteins of vesicular stomatitis virus (VSV-G) that stabilise the viral 
particles and allow the vector to be pantropic by binding to ubiquitous phospholipid 
regions of the plasma membrane (Burns et al., 1993). 
 
72 
 
 
Figure 2.1 pLKO.1 puro shRNA vector 
Map of the lentiviral pLKO.1-puro vector.  The pLKO.1 puro vector is 7032 bp long and 
includes a U6 promoter that drives RNA polymerase transcription for the generation of 
shRNA transcripts.  Then pLKO.1 puro vector shown here includes a 60 bp shRNA 
sequence cloned using AgeI and EcoRI restriction sites.  Image source: 
http://www.addgene.org/tools/protocols/plko/#A (accessed 7th Jan 2014) 
2.5.1 Preparation of plasmid DNA for transfection 
Bacterial glycerol stocks for pLKO.1 puro vectors carrying shRNA sequences targeting 
P2RY6 were selected from the RNA interference (RNAi) consortium (TRC) and purchased 
from the MISSION™ shRNA library (Sigma-Aldrich).  
Table 2.11 shRNA sequences for P2RY6 
TRC Number Clone ID shRNA sequence 
14073 
NM_176797.1-
1249s1c1 
CCGGGCAGCCTTCATATTTGCCATTCTCGAG
AATGGCAAATATGAAGGCTGCTTTTT 
14075 
NM_176797.1-
806s1c1 
CCGGCCACTATATGCCCTATGGCATCTCGAG
ATGCCATAGGGCATATAGTGGTTTTT 
 
Bacterial stocks for psPAX2 and pMD2.G were purchased from Addgene.  Vectors and 
plasmids were streaked onto Luria Bertani agar plates (LB; containing 35 g of LB agar in 1 
L of distilled water and sterilised by autoclaving) supplemented with 100 µg/ml ampicillin.  
Plates were incubated overnight at 37ºC.  A single colony from each plate was transferred 
to 10 ml of LB broth (containing 20 g of LB broth in 1 L of distilled water and sterilised by 
autoclaving), supplemented with 100 µg/ml ampicillin.  Colonies were allowed to shake at 
200 revolutions per minute (rpm) overnight in a 37ºC shaking incubator (New Brunswick 
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Scientific).  The following morning, colonies were centrifuged at 652 x g for 20 minutes at 
4ºC and the supernatant was disposed.  Plasmid DNA was extracted using an E.Z.N.A 
Plasmid Mini Kit II (Omega Bio-Tek) as per manufacturer instructions.  Quantification of 
DNA in samples was achieved as described in Section 2.4.2, using the Lambert-Beer law 
and a molar extinction coefficient of (0.020 (µg/ml) cm-1) for DNA.  The purity of the 
sample was assessed using the A260/A280 ratio, which is typically 1.8 for DNA.  To check 
for plasmid DNA quality and recombination, agarose gel electrophoresis as described in 
section 2.4.6 was performed using a 0.8% (w/v) agarose gel prepared with 0.4 µg/ml 
ethidium bromide.  Gel visualisation was performed under ultraviolet (UV) light to verify 
DNA forms (Figure 2.2). 
 
Figure 2.2 Detection of plasmid DNA 
Plasmid DNA run on a 0.8% (w/v) gel with 0.4 µg/ml ethidium bromide and visualised 
under UV light.  Gel shows nicked and supercoiled DNA forms for pLKO.1 puro P2RY6 
shRNA sequences (clones 14073 and 14075).  Also shown are DNA forms for psPAX2 
and pMD2.G plasmids. 
2.5.2 Lentivirus production in HEK293T 
Lentivirus production was performed in HEK293T cells (Section 2.2.1.4).  For each 
pLKO.1 puro shRNA plasmid to be transfected, 7.5x105 HEK293T cells were required.  
Cells were counted and harvested by centrifuging at 805 x g for 7 minutes at room 
temperature.  The supernatant was discarded and the remaining cell pellet was 
resuspended in 4.5 ml HEK293T cell culture medium without penicillin-streptomycin 
solution, and added to a sterile 5 cm cell culture dish (Thermo Scientific).  The cells were 
allowed to adhere overnight at 37ºC in a humidified 5% CO2 incubator.  On the following 
day, 200 µl of serum-free OPTIMEM media (Life Technologies) was added to two sterile 
nicked 
supercoil 
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1.5 ml micro-centrifuge tubes designated mix 1 and mix 2.  To mix 2, 20 µl of 
lipofectamine-2000 transfection reagent (Life Technologies) was added.  To mix 1, the 
following concentrations of plasmid DNA and lentivirus vectors were added: 1 μg pLKO.1 
P2RY6 DNA, 0.75 μg psPAX2 packaging DNA, and 0.25 μg pMD2.G envelope DNA.  
Both mixes were allowed to incubate at room temperature for 30 minutes before adding 
mix 2 to mix 1.  The transfection mixture was added drop-wise to HEK293T cells and 
incubated at 37ºC in a humidified 5% CO2 incubator for 12-15 hours.  Following 
incubation, the transfection reagent was removed and replaced with 4.5 ml of HEK293T 
medium containing 1% penicillin-streptomycin solution before re-incubating cells at 37ºC 
in a humidified 5% CO2 incubator for 24 hours.  On the subsequent day, the media (virus) 
was harvested and transferred to a 15 ml centrifuge tube (Corning) for storage at 4ºC.  A 
further 4.5 ml of HEK293T medium was added to the dish before cells were once again 
incubated for 24 hours at 37ºC in a humidified 5% CO2 incubator.  Following incubation, 
the media (virus) was re-harvested and the HEK293T cells were disposed.  The harvested 
virus was sterile-filtered through a 0.45 µm filter disc and aliquoted into 1.5 ml micro-
centrifuge tubes for long-term storage at -80ºC. 
2.5.3 Generation of P2Y6-KD cells using lentiviral transduction particles 
Lentiviral particles incorporating P2RY6 pLKO.1-puro shRNA sequences were purchased 
from the MISSION™ shRNA library.  These are listed in Table 2.19. 
Table 2.12 Lentivirus P2RY6 shRNA sequences  
TRC Number Clone ID shRNA sequence 
14075 
NM_176797.1-
806s1c1 
CCGGCCACTATATGCCCTATGGCATCTCGA
GATGCCATAGGGCATATAGTGGTTTTT 
14076 
NM_176797.1-
377s1c1 
CCGGCATCTGTGTCATTACCCAGATCTCGA
GATCTGGGTAATGACACAGATGTTTTT 
14077 
NM_176797.1-
1142s1c1 
CCGGCCTCTTCTACTTCACCCAGAACTCGA
GTTCTGGGTGAAGTAGAAGAGGTTTTT 
357968 
NM_176797.1-
1244s21c1 
CCGGCCTGGGCAGCCTTCATATTTGCTCGA
GCAAATATGAAGGCTGCCCAGGTTTTTG 
358038 
NM_176797.1-
547s21c1 
CCGGTGGTCCGCTTCCTCTTCTATGCTCGA
GCATAGAAGAGGAAGCGGACCATTTTTG 
 
Using the reported transducing units (TU) of each virus, the volume of lentiviral particles 
required to achieve a multiplicity of infection of 10 (MOI 10) was calculated for a THP-1 
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cell number of 5x104 cells.  This volume of lentivirus was used to transduce THP-1 cells 
as described in Section 2.5.5. 
2.5.4 Puromycin kill curve 
A puromycin kill curve was constructed to determine the concentration of puromycin 
required to kill THP-1 cells.  Puromycin (InvivoGen) was tested in duplicate at final 
concentrations of 0, 1, 5, and 10 µg/ml over a 10-day period.  For each test well, 5x104 
cells were required.  On day 0, cells were counted and harvested by centrifuging at 805 x 
g for 7 minutes at room temperature.  The supernatant was discarded and cells were 
resuspended in THP-1 culture medium (Section 2.2.1.1) such that the final cell density 
was 5x104 cells/ml.  To each well of a sterile 24-well tissue culture plate, 1 ml of THP-1 
cells were added.  Puromycin or sterile water was next added to wells and plates were 
incubated at 37ºC in a humidified 5% CO2 incubator.  Cell viability was tested on day 0, 2, 
4, 6, 8, and 10, using Thiazolyl Blue Tetrazolium Bromide (MTT), a colorimetric reagent 
measuring mitochondrial function through the ability of cells to convert MTT into formazan 
crystals (Mosmann, 1983).  For this, 1 ml of cells from each treatment were transferred to 
1.5 ml microcentrifuge tubes and centrifuged at 2000 x g for 3 minutes at room 
temperature.  The supernatant was discarded, and cells were washed thrice with 1 ml of 
THP-1 cell culture medium.  After the 3rd wash, cells were resuspended in 1 ml THP-1 cell 
culture medium.  Media alone samples (1 ml THP-1 culture medium) were prepared at this 
stage.  Following the addition of 100 µl of 10 mg/ml MTT solution (prepared in distilled 
water), tubes were incubated at 37ºC in a humidified 5% CO2 incubator for 2 hours.  All 
tubes were then centrifuged at 2000 x g for 3 minutes at room temperature before 
discarding the supernatant.  DMSO (0.5 ml) was added to each tube and incubated for 15 
minutes at 37ºC.  Sample absorbance was determined by transferring 200 µl of each 
sample to a UVette and reading the absorbance at A595 (nm) using a BioPhotometer Plus 
UV/Vis photometer.  Cell viability was quantified by taking the absorbance of media alone 
samples and subtracting this from individual samples.  Based on this data, the optimal 
puromycin regime for killing THP-1 cells was 1 µg/ml for 5 days. 
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Figure 2.3 THP-1 cell puromycin kill curve 
THP-1 cells were incubated with 0 (vehicle), 1, 5 or 10 µg/ml puromycin and monitored for 
cell viability over 10 days using the MTT assay.  Results expressed as mean absorbance 
at A595 (nm) ± SEM for n=2 replicates. 
2.5.5 THP-1 cell transduction and puromycin selection 
For each prepared virus, pLKO.1-puro non-target shRNA transduction particles and 
control cells (no virus), 5x104 THP-1 cells were required.  Cells were centrifuged at 805 x 
g for 7 minutes at room temperature before disposing the supernatant.  Fresh THP-1 cell 
culture medium was added to yield a cell density of 5x104 cells/ml, and 1 ml of this was 
added to each well of a sterile 24-well tissue culture plate.  The following treatments were 
added: control well (no treatment), scrambled well (5 µl of non-target shRNA transduction 
particles), P2RY6 wells (100 µl of virus generated as per Section 2.5.2, or volumes of 
MISSION™ transduction particles giving MOI 10 as per Section 2.5.3).  To each well, 1 µl 
of 8 mg/ml of hexadimethrine bromide was added to promote transduction.  Plates were 
incubated at 37ºC in a humidified 5% CO2 incubator for 72 hours.  To select for cells 
stably incorporating the viral genome, THP-1 cells were treated for 5 days with 1 µg/ml 
puromycin (Section 2.5.4).  After 5 days, cells were removed from wells and centrifuged at 
805 x g for 7 minutes at room temperature.  The supernatant was disposed, and cells 
were washed once with 5 ml of THP-1 cell culture medium before transferring cells to 
vented T25 flasks containing 5 ml of fresh THP-1 cell culture medium supplemented with 
1 µg/ml puromycin. 
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2.5.6 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed to test the level of gene expression in P2RY6-knockdown and 
scrambled THP-1 cells.  This technique uses the rate of amplification of specific target 
sequences in a sample to estimate the level of gene expression in the original cDNA 
template (Higuchi et al., 1992).  qRT-PCR was performed using the fluorescent dye SYBR 
Green (SG; λEx = 494nm, λEm = 521nm) which preferentially binds to double-stranded DNA 
(Dragan et al., 2012).  cDNA for all cell lines were prepared as in Section 2.4.  Samples 
were diluted to 10 ng using nuclease-free water in thin-walled 0.2 ml nuclease-free 
microcentrifuge tubes.  Samples were then added in triplicate (10 µl) for each gene tested, 
to wells of a 96-well MicroAmp® fast optical plate (Applied Biosystems).  All cDNA 
samples were also tested in triplicate for β-actin.  Negative control wells were prepared for 
each gene tested by adding 10 µl of nuclease free-water to separate wells.  A reaction mix 
was then prepared for each gene tested (primers as Section 2.4.4), combining the 
following for each well in a total volume of 15 µl: 12.5 µl of SG PCR master mix (Applied 
Biosystems), 0.5 µl forward primer, 0.5 µl reverse primer, and 1.5 µl nuclease-free water.  
Following addition of 15 µl of the reaction mix to wells, the plate was sealed with an optical 
adhesive cover (Applied Biosystems) and centrifuged briefly at 400 x g.  Plates were 
loaded onto a 7500 fast real-time PCR machine (Applied Biosystems) and run for 20 
seconds at 50ºC, 10 minutes at 95ºC, followed by 40 cycles of 15 seconds at 95°C and 1 
min at 60°C and a dissociation step to assess for primer dimers and target specificity.  
Using the associated 7500 software, the threshold cycle (Ct) value was obtained for each 
set of samples.  This is the cycle number required for fluorescence to give a signal over 
background at the point at which amplification is linear.  Values were corrected against β-
actin and analysed using the ∆∆Ct method to calculate the relative quantification (RQ) 
values (2-∆∆Ct) which measures the fold-change in gene expression relative to control cells.  
A significant shift in gene expression was given by an RQ value of 0.5. 
2.6 Calcium mobilisation 
Detection of intracellular Ca2+ signals were undertaken using fluorescent Ca2+ indicators 
that altered in their fluorescence when bound to free Ca2+.  The fluorescent dyes used 
were Fluo-4 AM and Fura-2 AM (Life Technologies) (Figure 2.4a and c).  Fluo-4 AM was 
used with THP-1 cells and PBMCs, and Fura-2 AM with 1321N1 astrocytoma cells.   
The membrane impermeable carboxylate groups of both indicators are esterified into an 
acetoxymethyl (AM) ester that renders the dyes lipophilic making them cell permeant, 
non-fluorescent, and insensitive to ions.  Once inside the cell, the AM moiety is hydrolysed 
by esterases resulting in the release of an ion-sensitive and impermeable fluorescent 
indicator that remains trapped inside the cell (Tsien, 1981).   
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The Ca2+ indicator Fluo-4 AM is a di-fluoro analogue of Fluo-3, a Ca2+ indicator developed 
from the Ca2+ chelator, BAPTA (Gee et al., 2000) (Figure 2.4a).  As a single-emission 
wavelength dye excited by visible light, Fluo-4 AM exhibits a fluorescence spectra of λex = 
494nm and λem = 515nm, and increases over 100-fold in fluorescence when bound to Ca
2+ 
at λex = 488nm (Gee et al., 2000) (Figure 2.4b).  At 22ºC, Fluo-4 AM exhibits a Kd for Ca
2+ 
of 345 nM, and is capable of detecting Ca2+ concentrations between 100 nM-1 µM (Gee et 
al., 2000).   
The Ca2+ indicator dye Fura-2 AM is a dual excitation/single emission ratiometric dye 
which obtains its Ca2+-binding abilities from the presence a tetracarboxylic acid moiety 
derived from the Ca2+ chelator, EGTA (ethylene glycol tetraacetic acid) (Grynkiewicz et al., 
1985) (Figure 2.4c).  Excited by UV-light, the excitation spectra of Fura-2 AM shifts in 
peak fluorescence from λex = 362nm in Ca
2+-free states, to λex = 335nm in Ca
2+-bound 
states, thus displaying a 2-fold increase in fluorescence (Grynkiewicz et al., 1985).  Under 
both states, the emission spectra remains fixed at λem = 510nm.  The Kd value of Fura-2 
AM for Ca2+ shifts from 135 nM at 20ºC in the absence of magnesium ions (Mg2+), to 224 
nM at 37ºC in the presence of 1 mM Mg2+ (Grynkiewicz et al., 1985). 
 
Figure 2.4 Structure and fluorescence spectra of Fluo-4 AM and Fura-2 AM 
Structure of (A) Fluo-4 AM and (C) Fluo-3 AM.  Fluorescence emission spectra of (C) 
Fluo-4 AM (blue lines) and Fluo-3 AM (red lines), and (D) Fura-2 AM.  Fluorescence 
emission intensity plotted against wavelength (nm) for increasing concentrations of free 
Ca2+ at λex = 488 nm (Fluo-4 AM), and λem = 510 nm (Fura-2 AM).  Image source: Johnson 
(2010). 
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2.6.1 Intracellular Ca2+ measurements (with extracellular Ca2+) 
Cells were counted and harvested as paired replicates.  For each replicate, 2x106 THP-1 
cells or 30x106 PBMCs were required.  For PTx studies, THP-1 cells were seeded in 
vented T75 flasks and incubated with PTx for 4 hours at 37ºC in a humidified 5% CO2 
incubator.  For all other studies, cells were harvested and centrifuged at 805 x g for 7 
minutes at room temperature before discarding the supernatant.  The resultant cell pellet 
was resuspended in Ca2+ loading buffer (130 mM sodium chloride, 5 mM potassium 
chloride, 1.2 mM magnesium chloride, 1.5 mM calcium chloride, 8 mM D-(+)-Glucose, 10 
mM hydroxyethyl piperazineethanesulfonic acid (HEPES) and 0.01% (w/v) pluronic acid; 
pH 7.2), such that the final cell density was 1x106 cells/ml.  To this, fluo-4 AM was added 
such that the final concentration was 2 µM for THP-1 cells and 4 µM for PBMCs.  Cells 
were incubated in the dark for 1 hour at 37ºC followed by 30 minutes at room 
temperature.  For each replicate, 2 ml of cells were transferred to a microcentrifuge tube 
and centrifuged at 805 x g for 3 minutes at room temperature.  The supernatant was 
discarded and cells were resuspended in 2 ml SBS (Section 2.3.2) and transferred to a 
quartz cuvette (10 mm light path) containing a magnetic stirrer to continuously agitate the 
cells.  Fluorescence signals were detected with an F-2000 spectrofluorometer (Hitachi) set 
to record measurements at 1 second intervals at λex = 494 nm and λem = 516 nm.  Signals 
were allowed to equilibrate for 5 minutes before measurements.  A baseline measurement 
of 3 minutes was taken before the addition of cell treatments.  Cells were pre-incubated 
with the relevant vehicle or treatment for 10-30 minutes before the addition of ligands.  
Maximum fluorescent signals (Fmax) were generated by the addition of 40 µM Digitonin (5 
mg/ml stock prepared in deionised water heated to 95ºC for 5 minutes).  Calcium 
responses were quantified by expressing responses as a percentage of Fmax. 
2.6.2 Intracellular Ca2+ measurements (without extracellular Ca2+) 
THP-1 cells were counted, harvested, centrifuged, and loaded with 2 µM fluo-4 AM as 
described above (Section 2.6.2).  Following centrifugation of 2 ml cells in microcentrifuge 
tubes as also described above, cells were resuspended in 2 ml SBS from which calcium 
chloride was removed and replaced with the calcium chelator, ethylene glycol tetraacetic 
acid (EGTA) (130 mM sodium chloride, 5 mM potassium chloride, 1.2 mM magnesium 
chloride, 1 mM EGTA), 8 mM D-(+)-Glucose and 10 mM hydroxyethyl 
piperazineethanesulfonic acid (HEPES); pH 7.2).  Measurements were performed as 
described above however; 1.5 mM CaCl2 was added to cells just prior to addition of 40 µM 
Digitonin to raise extracellular levels of Ca2+ (“add-back” response). 
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2.6.3 Intracellular Ca2+ measurements on Fura-2 AM-loaded 1321N1 cells 
Human astrocytoma 1321N1 cells were diluted with 1321N1 cell culture media to 2x105 
cells/ml and added to wells (200 µl) of a sterile black 96-well, clear-bottomed plate 
(Corning) such that each well contained 4x104 cells.  Outer wells were not used and 
instead contained 300 µl of 1321N1 cell culture medium.  Plates were incubated at 37ºC 
in a humidified 5% CO2 incubator overnight to allow cells to form a confluent monolayer.  
On the following day, the media was carefully aspirated and replaced with 200 µl of 2 µM 
Fura-2 AM prepared in calcium loading buffer, prior to incubating plates in the dark for 1 
hour at 37ºC.  After loading, the wells were washed once with 200 µl SBS buffer (Section 
2.3.2) before the addition of 200 µl SBS to wells for nucleotide studies, or 180 µl SBS for 
MRS-2578 studies.  For nucleotide studies with P2Y6-stable cells, half-log, 9-point 
concentration curves were prepared in triplicate in SBS at 5x the final concentration.  
Experiments with parental 1321N1 cells involved adding nucleotides at final 
concentrations of 10 µM and 100 µM.  Antagonist studies with MRS-2578 involved 
preparing full-log 8-point concentration curves of MRS-2578 in 10% DMSO at 10x the 
required final concentration.  Cells were incubated with MRS-2578 or vehicle for 30 
minutes.  For all experiments, nucleotides were added by a FlexStation microplate reader 
(Molecular Devices) set to deliver 50 µl from 96-well u-bottomed plates (Thermo 
Scientific).  Measurements were taken at λem = 510 nm, λex = 340 nm and λex = 380 nm.  
Fluorescence at λex = 340 nm and λex = 380 nm were used to calculate the change in 
intracellular calcium (F-ratio) following subtraction of the baseline response. 
2.7 Transwell chemotaxis assay 
Chemotaxis assays were performed in sterile 24-well tissue culture plates using Transwell 
inserts (Corning) with “track etched” polyethylene terephthalate (PET) membranes with 3 
µm pores.  For each transwell, 1x106 THP-1 cells or PBMCs were required.  For studies 
with PTx or BAPTA-AM, harvested cells were seeded in vented T75 flasks and pre-
incubated with PTx (4 hours), BAPTA-AM (30 minutes) or vehicle.  Harvested cells were 
centrifuged at 805 x g for 7 minutes at room temperature to allow sedimentation of cells 
and disposal of the supernatant.  The resultant cell pellet was washed twice in chemotaxis 
medium (RPMI 1640 media containing 0.3 g/L L-Glutamine and 1% (v/v) penicillin-
streptomycin solution containing 50 units/ml of penicillin and 50 µg/ml of streptomycin).  
After washing, the cell pellet was resuspended in fresh chemotaxis medium such that the 
cell yield was 1x106 cells per 100 µl.  Chemotaxis medium or chemoattractants (prepared 
in chemotaxis medium) (500 µl), were added to wells of the culture plate, and transwell 
inserts were placed into these (Figure 2.5).  Cells (100 µl) were added to inserts, followed 
by the immediate addition of treatments.  Plates were then incubated at 37ºC in a 
humidified 5% CO2 incubator for 2 hours.  Following incubation, cells were aspirated and 
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inserts were washed twice in ice-cold dPBS.  After washing, inserts were placed in ice-
cold methanol for 10 minutes to fix the cells.  The methanol was aspirated and inserts 
were finally stained for 10 minutes with 0.5% (w/v) crystal violet solution (in 25% (v/v) 
methanol).  After staining, cells in the inner membrane of inserts were removed using 
cotton swabs.  Inserts were finally washed twice in deionised water and allowed to dry for 
24 hours.  The migration of cells was assessed by taking images of cells attached to the 
outer membrane of inserts using a CKX41 microscope set at 20x objective and ImageJ 
software.  Cellular migration was expressed as a chemotactic ratio and calculated by 
dividing the number of cells that migrated towards treatment over the number of cells that 
migrated towards vehicle. 
 
Figure 2.5 Cell chemotaxis 
Transwell inserts are placed into wells of a culture plate containing chemotactic agents.  
Cells (THP-1 or PBMCs) are added to inserts prior to addition of compounds.  Cells are 
allowed to migrate for 2 hours at 37C before removing and washing inserts.  Migrated 
cells are fixed with methanol prior to staining with crystal violet solution.  Transwell 
membrane pores and migrated cells attached to the outer membrane shown  
2.8 HUVEC adhesion assay 
HUVEC adhesion assays were developed using the non-fluorescent membrane-
permeable probe Calcein AM (Santa Cruz Biotechnology) using a method first described 
by Akeson and Woods (1993).  Like other fluorescent probes, the carboxylate groups of 
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Calcein AM are esterified into an AM ester that renders the dye lipophilic and cell 
permeant.  Upon entering cells, the AM group is cleaved by esterases to yield the 
membrane-impermeable dye, Calcein (λem = 496 nm, λex = 516 nm).  This method serves 
as a useful tool for detecting the adherence of THP-1 cells to HUVEC monolayers 
(Akeson and Woods, 1993). 
Experiments were performed in sterile 96-well black clear-bottomed tissue culture plates.  
HUVECs were centrifuged at 220 x g for 5 minutes at room temperature before discarding 
the supernatant.  Cells were counted and diluted in Endothelium Cell Growth Medium to 
obtain a cell yield of 1x105 cells/ml.  For each treatment, 4-6 replicates were required, 
adding 200 µl of cells such that each well contained 1x104 cells.  Plates were incubated at 
37ºC in a humidified 5% CO2 for 48 hours to allow cells to form a confluent monolayer.  
On the day of experimentation, cells were washed once with 200 µl SBS and treated with 
either vehicle or TNFα (10 ng/ml final concentration, Life Technologies) for 5 hours in a 
37ºC humidified 5% CO2 incubator.  During this incubation, THP-1 cells were counted and 
harvested, removing 2x105 cells for test wells.  Cells were centrifuged at 805 x g for 7 
minutes at room temperature and following disposal of the supernatant, were suspended 
to 1x106 cells/ml in calcium loading buffer (Section 2.6.1) containing calcein AM (final 
concentration of 5 µM).  Cells were incubated in the dark for 1 hour at 37ºC to allow 
loading of the dye.  Following loading, THP-1 cells were centrifuged at 805 x g for 7 
minutes at room temperature, and the supernatant was discarded.  Cells were 
resuspended in SBS buffer to yield 1x106 cells/ml and transferred to 1.5 ml 
microcentrifuge tubes.  Following the addition of treatments, cells were incubated at 37ºC 
in a humidified 5% CO2 incubator for 45 minutes.  After incubation, cells were centrifuged 
at 805 x g for 3 minutes and washed once with SBS before resuspending with SBS to 
yield 1x106 cells/ml.  At this stage, HUVEC plates were removed from the incubator and 
aspirated before washing once with 200 µl SBS.  To each well of HUVEC cells, 200 µl of 
THP-1 cells were added, and plates were incubated at 37ºC in a humidified 5% CO2 
incubator for 1 hour.  Following incubation, wells were aspirated and washed twice with 
200 µl SBS buffer before adding 200 µl of SBS to each well.  The fluorescence was 
measured using a FlexStation microplate reader set to λem = 496 nm and λex = 516 nm.  
Fluorescence values from vehicle wells were subtracted from all treatments.  Unless 
otherwise stated, THP-1 cell adhesion was represented as a percentage of cells treated 
with CCL2 alone (% control). 
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2.9 ATP/β-hexosaminidase release studies 
2.9.1 Extracellular nucleotide detection by ion-pair reverse-phase HPLC 
For ATP release studies, 2x106 THP-1 cells were harvested for each time-point tested.  
Cells were centrifuged at 805 x g for 7 minutes at room temperature, and the supernatant 
was discarded.  SBS was added to this such that the cell yield was 1x106 cells/ml.  THP-1 
cells (2x106) were next added to a quartz cuvette containing a magnetic stirrer, and cells 
were allowed to equilibrate for 10 minutes at room temperature.  To this, vehicle or CCL2 
(50 ng/ml) were added.  Sampling was performed at 0, 1, or 2 minutes post-challenge, 
transferring 200 µl of cells to a 1.5 ml microcentrifuge tube and immediately centrifuging at 
4°C, 20,000 x g for 1 minute.  Clarified samples (150 µl) were transferred to a 300 µl 
microsampling vial (Chromacol).  For nucleotide detection, 35 µl of sample was injected 
through a 3 µm particle size SUPERCOSIL LC-18-T column (Sigma-Aldrich) equilibrated 
with 10 column volumes of buffer B (organic phase - consisting of 39 mM dipotassium 
phosphate, 26 mM monopotassium phosphate and 25% (v/v) methanol, pH 6.0), and 30 
column volumes of buffer A (mobile phase - consisting of 39 mM dipotassium phosphate, 
26 mM monopotassium phosphate and 4 mM tetrabutylammonium hydrogen sulphate; pH 
6.0).  Buffers were injected at a flow rate of 1 ml per minute.  Clarified samples were 
injected after two blank injections with SBS.  Sample retention times were compared with 
nucleotide standards (Table 2.13 and Appendix Figures A1 and A2).  Nucleotide and 
nucleoside levels were quantified by taking peak height values given by LC-Solutions 
Software (Shimadzu).  The total run time for each sample was 51 minutes and included an 
11 minute wash to rinse the column. 
Table 2.13 Nucleotide retention times 
Nucleotide Approximate retention time (minutes) 
ATP 29 
ADP 20 
AMP 9 
Adenosine 13.5 
UTP 19 
UDP 6.5 
UMP 3.5 
Uridine 4.5 
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2.9.2 ATP detection by luciferase-luciferin 
ATP levels in THP-1 supernatants were also quantified using an ATP Bioluminescence 
Assay kit HS II (Roche).  THP-1 cells (4x106) were harvested and centrifuged at 805 x g 
for 7 minutes at room temperature prior to discarding the supernatant.  The cell pellet was 
resuspended in SBS such that the cell yield was 1x106 cells/ml.  Cells (2x106) were added 
to a quartz cuvette containing a magnetic stirrer and were allowed to equilibrate for 10 
minutes at room temperature.  Cells were challenged with vehicle or CCL2 (50 ng/ml), and 
sampled every 2 minutes by removing 60 µl of cells to a 1.5 ml homopolymer 
microcentrifuge tube (Axygen) and immediately centrifuging at 4°C, 20,000 x g for 1 
minute.  Clarified samples were mixed 1:1 with room temperature luciferase reagent and 
measured for luminescence using a Modulus Luminometer (Turner BioSystems) set to a 7 
second integration time.  Figure 2.5 shows a log-log plot of ATP concentration against 
bioluminescence from which sample concentrations were estimated. 
Figure 2.6 Log-log plot of standard curve data for ATP 
2.10 β-hexosaminidase release 
For β-hexosaminidase release experiments, THP-1 cells were counted and harvested, 
removing 4x104 cells for each well, with each treatment tested in duplicate.  Cells were 
centrifuged at 805 x g for 7 minutes at room temperature before removing the supernatant 
and washing cells once with SBS (Section 2.3.2).  Following washing, cells were 
resuspended in SBS such that the cell yield was 2.1x106 cells/ml.  Experiments were 
performed in sterile clear flat-bottomed 96-well tissue culture plates (Corning).  To each 
well, 190 µl of THP-1 cells were added, followed by 10 µl of treatments.  Triton X-100 at a 
final concentration of 1% (v/v) was used as a positive control in each experiment.  Plates 
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were then incubated for 20 minutes at 37ºC in a humidified 5% CO2 incubator.  Following 
incubation, plates were centrifuged at 300 x g for 5 minutes at room temperature before 
transferring 25 µl from each well to wells of a fresh 96-well tissue culture plate.  To wells, 
25 µl of 4 mM 4-Nitrophenyl N-acetyl-β-D-glucosaminide (pNAG) prepared fresh in citrate 
buffer (0.05 M citric acid, 0.05 M sodium citrate, pH 4.5) was added.  Plates were 
incubated for 1 hour at 37ºC to allow any released β-hexosaminidase to cleave pNAG to 
yield 4-nitrophenol (Borooah et al., 1961).  Reactions were quenched with 50 µl 0.1 M 
sodium bicarbonate buffer (0.1M sodium carbonate, 0.1M sodium bicarbonate) and 
absorbance values were read at A405 (nm) on a FlexStation microplate reader.  
Absorbance values for treatment wells were background subtracted with values from 
vehicle-alone wells, and normalised to signals generated by 1% (v/v) Triton X-100. 
2.11 Nucleotide hydrolysis studies 
2.11.1 Apyrase studies 
SBS buffer (Section 2.3.2) was added to a quartz cuvette containing a magnetic stirrer.  
To this, ATP, ADP, UTP or UDP prepared in SBS were added such that the final 
concentration of each nucleotide was 100 µM.  The spontaneous hydrolysis of each 
nucleotide was initially tested by adding vehicle (de-ionised water) to the cuvette and 
sampling (150 µl) at 0 and 30 minutes.  For apyrase studies, apyrase (high NTPase/high 
NDPase) was added to the cuvette such that the final concentration was 2 units/ml.  At 30 
minutes post-apyrase, 150 µl of sample was transferred to a 300 µl microsampling vial 
and assessed for nucleotide levels using reverse-phase ion-pair HPLC as described in 
Section 2.9.1.  Nucleotide and nucleoside levels were quantified by taking peak height 
values given by LC-Solutions Software (Shimadzu). 
2.11.2 THP-1 cell studies 
THP-1 cells were counted and harvested to yield 2x106 cells for each test replicate.  Cells 
were centrifuged at 805 x g for 7 minutes at room temperature and the supernatant was 
disposed.  SBS buffer was added to this such that the cell yield was 1.11x106 cells/ml.  
THP-1 cells (2x106 cells) were then transferred to a quartz cuvette and agitated using a 
magnetic stirrer.  To this, 200 µl of nucleotide was added such that the final concentration 
was 100 µM.  Sampling was performed at 0 and 30 minutes, removing 200 µl of sample to 
a 1.5 ml microcentrifuge tube and immediately centrifuging at 20,000 x g, 4ºC for 1 
minute.  Clarified samples (150 µl) were transferred to a 300 µl microsampling vial and 
assessed for nucleotide levels as described above in Section 2.11.1. 
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2.12 THP-1 cell viability assays 
2.12.1 Trypan blue exclusion assay 
THP-1 cell viability was tested after exposing cells to compounds for 2.5 hours as this 
represented the maximum exposure of BAPTA-AM in chemotaxis studies.  Cells were 
counted and harvested, removing 3x106 cells for each compound tested.  Harvested cells 
were centrifuged at 805 x g for 7 minutes at room temperature and the supernatant was 
disposed.  SBS buffer (Section 2.3.2) was then added such that the cell yield was 
1x106/100 µl SBS.  To each well of a sterile 96-well clear flat-bottomed plate, 100 µl of 
cells, compounds (in triplicate), or vehicle (in triplicate) were added.  Following addition, 
the plate was incubated for 2.5 hours in a 37ºC humidified 5% CO2 incubator.  After 2.5 
hours the plate was removed from the incubator and 50 µl of cells were removed and 
diluted with 450 µl SBS buffer (1 in 10 dilution).  This was diluted further by mixing 20 µl of 
sample with 80 µl of 0.4% (w/v) Trypan Blue solution.  Viable cells displaying a clear 
cytoplasm were counted using a haemocytometer.  Cell viability was represented as a 
percentage of viable cells treated with vehicle. 
2.12.2 Lactate dehydrogenase (LDH) assay 
THP-1 cell viability was also tested using a LDH kit (Cayman Chemicals) which works on 
the principle that the cytosolic enzyme, LDH, is released into cell supernatants by necrotic 
cells.  LDH detection is performed indirectly via a two-step enzymatic reaction that yields 
formazan; a coloured dye detectable at A490-520nm.  Cell viability was tested following a 
2.5 hour compound incubation as this represented the maximum exposure of BAPTA-AM 
in chemotaxis studies.  All compounds were tested in singlicate under acellular and 
cellular conditions.  Cells were counted and harvested, removing 1x105 cells for each 
treatment well.  Harvested cells were centrifuged at 805 x g for 7 minutes at room 
temperature, and the supernatant was discarded.  SBS buffer (Section 2.3.2) was added 
to this such that the cell yield was 1x105 cells/120 µl SBS.  Cells or SBS buffer (120 µl) 
were then added to alternate wells of a sterile 96-well clear flat-bottomed plate.  
Compounds or vehicle (1% DMSO or water) were next added in singlicate to cellular and 
acellular wells.  Digitonin (40 µM) and Triton X-100 (0.1% (v/v)) were also added to 
cellular and acellular wells as positive controls.  Following the addition of treatments, the 
plate was incubated at 37ºC in a humidified 5% CO2 incubator for 2.5 hours.  At the end of 
this period, the plate was centrifuged at 400 x g for 5 minutes at room temperature.  
Clarified samples (100 µl) were transferred to a fresh 96-well clear flat-bottomed plate, 
performing the remainder of the assay as per manufacturer’s instructions, and reading the 
absorbance at A490 (nm) on a FlexStation microplate reader.  The absorbance values for 
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acellular controls were subtracted from treatments, which were represented as a 
percentage of absorbance given by 0.1% (v/v) Triton X-100 (% control). 
2.13 Statistical analysis 
All data were analysed using Origin Pro 9.0 software (Origin Lab Corporation, USA) or 
Excel (Microsoft Corporation, USA).  Data is represented as mean±SEM (standard error 
of the mean), with n given as the number of experiments or the number of replicates.  
Statistical comparisons between paired data were performed by means of Students paired 
t-tests, while experiments involving more than two treatment groups were compared by a 
one-way ANOVA with Bonferroni’s multiple comparison.  Statistical significance at the 5% 
(p<0.05) and 1% levels (p<0.01) has been indicated by the asterisks * and ** respectively.  
Concentration-response curves were fitted with the Hill equation,  
Min + ((Max - Min) * x
s
 / (EC50
s
  +  x
s
)) 
where, Min and Max are the minimum and maximal values of the response, x is the 
concentration, s the slope, and the EC50 (or IC50) value is the concentration of ligand or 
antagonist corresponding to a half-maximal response.  The EC20 and EC10 values of 
ligands were also generated using the Hill equation.  Decay rates ((tau), second) for 
Ca2+ transients were estimated by fitting a first order exponential model (with offset) using 
the following formula: 
y0 + Ampl * Exp
 -x/t
1 
Where y0 is the y-axis offset, Ampl is the amplitude, Exp is the exponential, x is the x-axis 
value, and t1 is the decay constant. 
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Chapter 3: Comparison of mRNA 
expression of monocyte markers, CC 
chemokines, CC chemokine receptors 
and purinoceptors in THP-1 cells and 
human monocytes 
3.1 Introduction 
Monocytes are a heterogeneous population of immune effector cells that originate from 
common monocyte/macrophage and dendritic cell precursors located in the bone marrow 
(Akashi et al., 2000).  Once formed, mature classical monocytes egress from the bone 
marrow in a CCR2-dependent manner and enter the blood stream (Serbina and Pamer, 
2006; Tsou et al., 2007; Shi et al., 2011).  Here they participate in a wide range of 
protective activities that include the clearance of pathogens/cell debris, patrolling of blood 
vessels, and acting as precursors for other mononuclear phagocytes (Van Furth et al., 
1972; Serbina et al., 2008; Cros et al., 2010; Lauvau et al., 2014).   
Monocyte fates are pre-determined by their expression of PRRs and scavenging 
receptors, which affect their ability to detect chemical cues in their local microenvironment.  
While monocytes were initially characterised by their cellular density and size (Van Furth 
et al., 1972), later technical advancements led to monocytes being classified by their 
expression of CD14, CD16, and the chemokine receptors CX3CR1 and CCR2 (Passlick et 
al., 1989; Weber et al., 2000; Geissmann et al., 2003; Ziegler-Heitbrock 2007; Yona and 
Jung, 2009).  Based on this evidence, human monocyte subsets have been divided into 
classical (CD14++/CD16-), intermediate (CD14++/CD16+), and non-classical 
(CD14+/CD16++) monocytes. 
Although freshly isolated human monocytes represent a useful tool for studying monocyte 
function ex vivo, the use of these cells remains technically challenging due to the low 
availability of human samples, low cell yields, limited cell survival, and high degree of 
variability due to their heterogeneous nature.  The human monocytic THP-1 cell line is a 
well-established in vitro model for investigating monocyte function (Qin, 2012).  Isolated 
from a young male patient with acute monocytic leukaemia (Tsuchiya et al., 1980), THP-1 
cells represent a homogeneous cell population that share a similar cell morphology and 
molecular marker expression as human monocytes (Auwerx, 1991). 
Although THP-1 cells are a useful tool for assessing broad-range monocyte functions, the 
full experimental capabilities of this cell line are not fully understood.  For example, it is not 
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known whether THP-1 cells and human monocytes display a similar pattern of expression 
of CC chemokines, CC chemokine receptors, or purinoceptors. 
3.2 Aims 
To determine whether THP-1 cells represented a suitable model for investigating 
monocyte signalling and function, RT-PCR was employed to compare the expression of 
mRNA transcripts for monocyte and myeloid genes between THP-1 cells and human 
peripheral blood monocytes.  To address the principle objectives of this thesis, it was also 
necessary to examine and compare the expression of mRNA for CC chemokines, CC 
chemokine receptors, and purinoceptors between THP-1 cells and monocytes.  To 
confirm specificity and functionality, all primers were also tested using commercial human 
brain RNA.   
3.3 Results 
3.3.1 RT-PCR analysis of monocyte and myeloid markers  
Initial studies examined and compared the expression of β-actin and monocyte/myeloid 
markers in THP-1 cells and human monocytes.  The markers tested were CD14, CD16, 
and the less well-known markers, cluster of differentiation 33 (CD33/Siglec-33), and 
cluster of differentiation 93 (CD93/C1qRP) (Nepomuceno et al., 1997; Lock et al., 2004).  
To address this aim, the specificity and functionality of all primers were first tested in 
human brain.  Following the validation of primers, the expression of mRNA transcripts for 
these markers in THP-1 cells and human monocytes, were examined.  Table 3.1 and 
Figure 3.1 give a summary of the results obtained for this study. 
Table 3.1 Detection of mRNA for β-actin (ACTB) and monocyte/myeloid markers 
in human brain, THP-1 cells, and human monocytes 
Gene Human brain THP-1 cells Human monocytes 
ACTB + + + 
CD14 + + + 
CD16 (+) - + 
CD33 + + (+) 
CD93 + + + 
A + sign indicates that the gene is detected, a (+) sign indicates that the gene is detected 
but is represented by a faint band, and a – sign indicates that the gene is not detected. 
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As can be seen from Table 3.1 and Figure 3.1a, mRNA transcripts for β-actin and all of 
the cell markers were detected in human brain.  These results, while supporting the use of 
these primers for further studies, also suggest that mRNA for these markers are naturally 
present in human brain.  Table 3.1 and Figures 3.1b and 3.1c also show the detection of 
these genes in THP-1 cells and human monocytes.  As shown, THP-1 cells were found to 
express mRNA for all the markers tested, apart from CD16.  Although this indicates that 
THP-1 cells lack CD16 similar to classical (CD14++/CD16-) monocytes, it is also possible 
that levels of CD16 mRNA in THP-1 cells fell below the limits of detection.  In comparison, 
human monocytes were found to express mRNA transcripts for β-actin and all of the cell 
markers tested, including CD14 and CD16 (Table 3.1 and Figure 3.1c).  While this 
suggests that RT-PCR may be unable to discriminate between CD16- and CD16+ 
monocyte populations, it is also possible that the sample tested represents a monocyte 
population comprising of all three subsets.  Interestingly, although THP-1 cells and human 
monocytes showed differential mRNA expression for CD16, mRNA transcripts for CD33 
and CD93 were detected in both cell types, suggesting that both are of myeloid origin. 
Taken together, these results suggest that THP-1 cells express several monocyte/myeloid 
cell markers but lack CD16 similar to classical (CD14++/CD16-) monocytes.  Furthermore, 
human monocytes express a similar pattern of cell markers, but also express CD16.  This 
indicates that the monocyte sample employed by this study may represent a 
heterogeneous monocyte population. 
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Figure 3.1 Detection of mRNA for β-actin (ACTB) and monocyte/myeloid markers 
in human brain, THP-1 cells, and human monocytes 
Detection of housekeeping gene ACTB and cell markers in (A) human brain, (B) THP-1 
cells, and (C) human monocytes using RT-PCR and agarose gel electrophoresis.  
Expression was detected at 282 bp (ACTB), 445 bp (CD14), 247 bp (CD16), 216 bp 
(CD33) and 515 bp (CD93).  RT and no RT constitute first strand cDNA synthesis 
reactions with and without reverse transcriptase, respectively. 
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3.3.2 RT-PCR analysis of CC chemokines 
Despite the fact that over 25 human CC chemokines have been identified to date 
(Zweemer et al., 2014), only a small handful of studies have examined the expression of 
CC chemokines in resting THP-1 cells and human monocytes (Colotta et al., 1992; Lu et 
al., 2004; Stubbs et al., 2010).  Although further research is required in this area, in recent 
years there has been an increased interest in understanding how chemokine expression 
is modulated within inflammatory disease (Bruegel et al., 2006; Schildberger et al., 2013).  
While it is understandable that this is crucial for determining the involvement of 
chemokines in disease, knowing whether CC chemokines are expressed by resting cells 
is important since it allows a greater understanding of the homeostatic roles played by 
these peptides.   
Hence, the next aim of this chapter was to compare the expression of mRNA for a number 
of CC chemokines, between THP-1 cells and human monocytes.  As described 
previously, commercial human brain RNA was employed to test primer specificity and 
functionality.  Table 3.2 and Figure 3.2 display a summary of the results of this study. 
Table 3.2 Detection of mRNA for CC chemokines in human brain, THP-1 cells, 
and human monocytes 
Gene Human brain THP-1 cells Human monocytes 
CCL2 + + + 
CCL3 + + + 
CCL4 (+) (+) + 
CCL5 (+) + + 
A + sign indicates that the gene is detected, a (+) sign indicates that the gene is detected 
but is represented by a faint band, and a – sign indicates that the gene is not detected. 
As shown in Table 3.2 and Figure 3.2, mRNA transcripts for all four CC chemokines 
tested were detected in human brain, producing a PCR amplicon of the predicted size.  As 
also shown, mRNA for all four CC chemokines, including CCL2, were also detected in 
THP-1 cells and human monocytes, suggesting that both cell types constitutively 
expressed genes encoding for these chemokines.   
Taken together, these results suggest that THP-1 cells and human peripheral blood 
monocytes display an overlapping expression pattern among genes encoding for CCL2, 
CCL3, CCL4, and CCL5. 
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Figure 3.2 Detection of mRNA for CC chemokines in human brain, THP-1 cells, 
and human monocytes 
Detection of CC chemokines in (A) human brain, (B) THP-1 cells, and (C) human 
monocytes using RT-PCR and agarose gel electrophoresis.  Primers were designed to 
amplify all splice variants of the selected gene.  Expression was detected at 219 bp 
(CCL2), 209 bp (CCL3), 209 bp (CCL4) and 201 bp (CCL5).  RT and no RT constitute first 
strand cDNA synthesis reactions with and without reverse transcriptase, respectively. 
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3.3.3 RT-PCR analysis of CC chemokine receptors 
To date, ten CC chemokine receptors have been cloned and characterised, and are 
consecutively encoded by the genes CCR1 to CCR10 (Bachelerie et al., 2014).  Although 
a number of groups (Neote et al., 1993; Yamagami et al., 1994; Combadiere et al., 1996; 
Weber et al., 2000; Gouwy et al., 2014) have reported the expression of several CC 
chemokine receptors in THP-1 cells and human monocytes, a full and complete 
assessment has been lacking.  Thus, in order to address this gap in knowledge, the next 
study investigated the expression of mRNA transcripts for CC chemokine receptors in 
THP-1 cells and human peripheral blood monocytes.  To address this aim, the specificity 
and functionality of all CC chemokine primers were first tested in human brain.  CCR3 
primers were further tested in human monocyte-depleted PBMCs.  Following their 
validation, primers were used to test for the expression of mRNA transcripts for CC 
chemokine receptors in THP-1 cells and human monocytes.  All primers, except those for 
CCR2 were designed to amplify all splice variants of the selected gene.  CCR2 primers 
were designed to individually target CCR2A and CCR2B (Charo et al., 1994).  The current 
study also examined the expression of mRNA for CCRL2 (chemokine (C-C motif) 
receptor-like 2), a receptor initially identified as CCR11 (Fan et al., 1998), but now 
remains unclassified (Bachelerie et al., 2014).  The results of this study are summarised in 
Table 3.3 and shown in Figure 3.3 (human brain and monocyte-depleted PBMCs), Figure 
3.4 (THP-1 cells), and Figure 3.5 (human monocytes). 
As shown in Table 3.3 (and Figure 3.3), mRNA for all CC chemokine receptors except 
CCR3 were detected in human brain.  To rule out the possibility of poor primer design or 
specificity, CCR3 primers were also tested in monocyte-depleted PBMCs as these are 
known to be a source of CCR3-expressing T-helper 2 (Th2) lymphocytes (Gerber et al., 
1997).  As shown in Figure 3.3, CCR3 mRNA was detected in this sample.  While this 
suggests that CCR3 is likely to be expressed at the mRNA level by some cell types in 
PBMCs, a lack of expression in human brain is interesting and may indicate that CCR3 is 
not expressed by human brain, or that levels of CCR3 mRNA in brain fall below the limits 
of detection. 
Table 3.3, Figure 3.4, and Figure 3.5 show the expression of mRNA for CC chemokine 
receptors in THP-1 cells and human monocytes.  As shown, THP-1 cells were found to 
express mRNA transcripts for all CC chemokine receptors except CCR3 while human 
monocytes were found to express mRNA transcripts for all receptors, including CCR3.  It 
is also interesting that both cell types express mRNA for CCR2A and CCR2B.  As shown 
by Figure 3.4, in THP-1 cells CCR10 primers produced a second PCR amplicon of ~500 
base pairs in addition to an amplicon for the CCR10 receptor.  A similar PCR amplicon 
was also observed in human monocytes (Figure 3.5), but not in brain (Figure 3.3).  An 
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analysis of these primers using a basic local alignment search tool (BLAST) was unable to 
identify this product.   
Taken together, the results presented here suggest that with the exception of the CCR3 
receptor, THP-1 cells and human monocytes exhibit an overlapping expression pattern of 
genes encoding for CC chemokine receptors.  Furthermore, these results suggest that 
both cell types express genes encoding for CCR2A and CCR2B. 
Table 3.3 Detection of mRNA for CC chemokine receptors in human brain, THP-
1 cells, and human monocytes 
Gene Human brain THP-1 cells Human monocytes 
CCR1 + + + 
CCR2A (+) (+) (+) 
CCR2B + + + 
CCR3 - - + 
CCR4 (+) + + 
CCR5 + + + 
CCR6 + + + 
CCR7 + (+) + 
CCR8 + (+) (+) 
CCR9 (+) + + 
CCR10 (+) (+) (+) 
CCRL2 + + + 
A + sign indicates that the gene is detected, a (+) sign indicates that the gene is detected 
but is represented by a faint band, and a – sign indicates that the gene is not detected. 
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Figure 3.3 Detection of mRNA for CC chemokine receptors in human brain and 
human monocyte-depleted PBMCs 
Detection of CC chemokine receptors in (A) human brain and (B) monocyte-depleted 
PBMCs using RT-PCR and agarose gel electrophoresis.  Primers amplify all splice 
variants of the selected gene.  Expression was detected at 358 bp (CCR1), 160 bp 
(CCR2A), 267 bp (CCR2B), 323 bp (CCR3), 336 bp (CCR4), 277 bp (CCR5), 263 bp 
(CCR6), 497 bp (CCR7), 432 bp (CCR8), 413 bp (CCR9), 285 bp (CCR10) and 272 bp 
(CCRL2).  RT and no RT constitute first strand cDNA synthesis reactions with and without 
reverse transcriptase, respectively. 
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Figure 3.4 Detection of mRNA for CC chemokine receptors in THP-1 cells 
Detection of CC chemokine receptors in THP-1 cells using RT-PCR and agarose gel 
electrophoresis.  Primers amplify all splice variants of the selected gene.  Expression was 
detected at 358 bp (CCR1), 160 bp (CCR2A), 267 bp (CCR2B), 323 bp (CCR3), 336 bp 
(CCR4), 277 bp (CCR5), 263 bp (CCR6), 497 bp (CCR7), 432 bp (CCR8), 413 bp 
(CCR9), 285 bp (CCR10) and 272 bp (CCRL2).  RT and no RT constitute first strand 
cDNA synthesis reactions with and without reverse transcriptase, respectively. 
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Figure 3.5 Detection of mRNA for CC chemokine receptors in human monocytes 
Detection of CC chemokine receptors in monocytes using RT-PCR and agarose gel 
electrophoresis.  Primers amplify all splice variants of the selected gene.  Expression was 
detected at 358 bp (CCR1), 160 bp (CCR2A), 267 bp (CCR2B), 323 bp (CCR3), 336 bp 
(CCR4), 277 bp (CCR5), 263 bp (CCR6), 497 bp (CCR7), 432 bp (CCR8), 413 bp 
(CCR9), 285 bp (CCR10) and 272 bp (CCRL2).  RT and no RT constitute reactions with 
and without reverse transcriptase. 
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3.3.4 RT-PCR analysis of P1 purinoceptors  
The next aim was to investigate the gene expression of purinoceptors in THP-1 cells and 
human monocytes.  The purpose of this study was firstly to identify the purinoceptors 
expressed by THP-1 cells and human monocytes, and secondly, to compare the 
expression patterns between both cell types.  To simplify this aim, the findings of this 
study have been divided into sections for P1, P2X, and P2Y receptors.  The current 
section focuses on P1 purinoceptors.   
The human P1 purinoceptors are A1, A2A, A2B, and A3, and are encoded by the genes 
ADORA1, ADORA2A, ADORA2B, and ADORA3, respectively (Fredholm et al., 2001; 
Fredholm et al., 2011).  Studies in literature indicate that the expression pattern of P1 
purinoceptors in monocytes and THP-1 cells differ.  While monocytes are known to 
express genes for all four P1 purinoceptors (Merrill et al., 1997; Broussas et al., 1999; 
Thiele et al., 2004), THP-1 cells have only been examined for their expression of A2A and 
A2B (Munro et al., 1998; Khoa et al., 2001; Bshesh et al., 2002).  The expression of other 
P1 purinoceptors (A1 and A3) in THP-1 cells is therefore, uncertain.  This study therefore 
set out to confirm the findings of published studies and compare the expression of mRNA 
for P1 purinoceptors between THP-1 cells and human monocytes.  As with previous 
studies, an initial assessment of the selectivity and functionality of primers was performed 
using human brain RNA.  The results of this study are presented in Table 3.4 and Figure 
3.6. 
Table 3.4 Detection of mRNA for P1 purinoceptors in human brain, THP-1 cells, 
and human monocytes 
Gene Human brain THP-1 cells Human monocytes 
ADORA1 + + (+) 
ADORA2A + (+) + 
ADORA2B + + + 
ADORA3 (+) + (+) 
A + sign indicates that the gene is detected, a (+) sign indicates that the gene is detected 
but is represented by a faint band, and a – sign indicates that the gene is not detected. 
As summarised in Table 3.4, mRNA for all P1 receptors were detected in human brain, 
THP-1 cells, and human monocytes.  Although a detection of mRNA transcripts for A2A 
and A2B in THP-1 cells is consistent with previous studies (Munro et al., 1998; Khoa et al., 
2001; Bshesh et al., 2002), it is interesting that mRNA for A1 and A3 were also detected in 
these cells, which may represent a novel finding.  As can also be seen (Table 3.4 and 
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Figure 3.6), human monocytes were also found to express mRNA transcripts for all P1 
purinoceptors, a finding which agrees with prior work  (Merrill et al., 1997; Broussas et al., 
1999; Thiele et al., 2004). 
Taken together, the results of this study suggest that both cell types exhibit an overlapping 
expression profile among genes encoding for P1 purinoceptors. 
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Figure 3.6 Detection of mRNA for P1 purinoceptors in human brain, THP-1 cells, 
and human monocytes 
Detection of P1 (ADORA) purinoceptors in (A) human brain, (B) THP-1 cells and (C), 
human monocytes using RT-PCR and agarose gel electrophoresis.  Primers amplify all 
splice variants of the selected gene.  Expression was detected at 374 bp (ADORA1), 295 
bp (ADORA2A), 277 bp (ADORA2B) and 302 bp (ADORA3).  RT and no RT constitute 
first strand cDNA synthesis reactions with and without reverse transcriptase, respectively. 
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3.3.5 RT-PCR analysis of P2X purinoceptors  
To date, seven mammalian P2X receptors have been cloned and characterised, and are 
encoded by the genes P2RX1 through to P2RX7 (Khakh et al., 2001).  Although P2X1, 
P2X4, and P2X7 are known to be expressed in human monocytes and THP-1 cells 
(Humphreys and Dubyak, 1998; Gu et al., 2000; Into et al., 2002; Wang et al., 2004; 
Kaufmann et al., 2005; Li and Fountain, 2011), much uncertainty still exists about the 
expression of other P2X receptors in these cells.  This study therefore sought to 
investigate the expression of genes encoding for P2X receptors in THP-1 cells and human 
monocytes at the mRNA level.  As with previous studies in this chapter, primer specificity 
and functionality was first tested using human brain RNA.  As will be discussed later, 
primers for P2RX2 and P2RX3 were also tested on human retina.   
The results of this study are presented in Table 3.5, Figure 3.7 (brain and retina), Figure 
3.8 (THP-1 cells), and Figure 3.9 (monocytes). 
Table 3.5 Detection of mRNA for P2X purinoceptors in human brain, THP-1 
cells, and human monocytes 
Gene Human brain THP-1 cells Human monocytes 
P2RX1 + + + 
P2RX2 - - - 
P2RX3 - - - 
P2RX4 + + + 
P2RX5 + + + 
P2RX6 (+) + - 
P2RX7 + + + 
A + sign indicates that the gene is detected, a (+) sign indicates that the gene is detected 
but is represented by a faint band, and a – sign indicates that the gene is not detected. 
As shown in the Table 3.5 and Figure 3.7, mRNA transcripts for all P2X receptors except 
P2X2 and P2X3 were detected in human brain.  To rule out the possibility of poor primer 
design or specificity, primers for these receptors were also tested in human retina 
(paramacular) samples isolated as described by Niyadurupola et al., (2011).  As shown 
(Figure 3.7), mRNA for P2X2 and P2X3 were detected in this sample, therefore confirming 
the specificity and functionality of these primers.  Table 3.5 also summarises the 
expression of P2X receptors in THP-1 cells and human monocytes.  THP-1 cells (Figure 
3.8) were found to express mRNA for all P2X receptors except P2X2 and P2X3, therefore 
exhibiting a similar pattern of expression as human brain.  In THP-1 cells (Figure 3.8), it 
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was also seen that P2RX6 primers produced a second PCR amplicon of a lower 
molecular weight in addition to a PCR amplicon for P2RX6.  A similar PCR amplicon was 
also detected in human brain (Figure 3.7).  Although an analysis of these primers using 
BLAST was unable to identify this product, it may be that this is a second variant of 
P2RX6.  As also shown (Table 3.5 and Figure 3.9), mRNA for all P2X receptors, except 
P2X2, P2X3, and P2X6, were detected in human monocytes.  These results suggest that 
with the exception of mRNA for P2X6, human monocytes and THP-1 cells exhibit an 
overlapping expression pattern among genes encoding for P2X receptors.  In human 
monocytes (Figure 3.9), it can also be seen that primers for P2X4, P2X5, and P2X7 all 
produced secondary PCR amplicons in addition to a PCR amplicon of the predicted size.  
Although a BLAST analysis was unable to confirm the identity of these amplicons, these 
may refer to other splice variants of these genes.  Interestingly, these additional PCR 
amplicons were not detected in human brain or THP-1 cells. 
Taken together, the results of this study suggest that with the exception of mRNA for 
P2X6, THP-1 cells and human monocytes exhibit an overlapping expression pattern 
among genes encoding for P2X receptors.  Furthermore, the results of this study indicate 
a number of novel findings with respect to the expression of P2X receptors in both cell 
types. 
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Figure 3.7 Detection of mRNA transcripts for P2X purinoceptors in human brain 
and retina 
Detection of P2X purinoceptors in (A) human brain and (B) human retina (paramacular 
region), using RT-PCR and agarose gel electrophoresis.  Primers amplify all splice 
variants of the selected gene.  Expression was detected at 341 bp (P2RX1), 200 bp 
(P2RX2), 564 bp (P2RX3), 311 bp (P2RX4), 263 bp (P2RX5), 405 bp (P2RX6), and 414 
bp (P2RX7).  RT and no RT constitute first strand cDNA synthesis reactions with and 
without reverse transcriptase, respectively.  
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Figure 3.8 Detection of mRNA transcripts for P2X purinoceptors in THP-1 cells 
Detection of P2X purinoceptors in THP-1 cells using RT-PCR and agarose gel 
electrophoresis.  Primers amplify all splice variants of the selected gene.  Expression was 
detected at 341 bp (P2RX1), 200 bp (P2RX2), 564 bp (P2RX3), 311 bp (P2RX4), 263 bp 
(P2RX5), 405 bp (P2RX6), and 414 bp (P2RX7).  RT and no RT constitute first strand 
cDNA synthesis reactions with and without reverse transcriptase, respectively. 
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Figure 3.9 Detection of mRNA for P2X purinoceptors in human monocytes 
Detection of P2X purinoceptors in human monocytes using RT-PCR and agarose gel 
electrophoresis.  Primers amplify all splice variants of the selected gene.  Expression was 
detected at 341 bp (P2RX1), 200 bp (P2RX2), 564 bp (P2RX3), 311 bp (P2RX4), 263 bp 
(P2RX5), 405 bp (P2RX6), and 414 bp (P2RX7).  RT and no RT constitute first strand 
cDNA synthesis reactions with and without reverse transcriptase, respectively.  
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3.3.6 RT-PCR analysis of P2Y purinoceptors 
To date, eight mammalian P2Y receptors have been cloned and characterised, and are 
encoded by the genes P2RY1, P2RY2, P2RY4, P2RY6, P2RY11, P2RY12, P2RY13, and 
P2RY14.  The missing gene numbers represent either non-mammalian receptors or other 
GPCRs that exhibit a similar sequence homology to P2Y receptors, but cannot be 
activated by extracellular nucleotides (Abbracchio et al., 2006).   
A considerable amount of literature has been published on the expression of P2Y 
receptors in human monocytes and THP-1 cells.  These studies have shown that human 
monocytes express P2Y1-13, (Jin et al., 1998; Zhang et al., 2002; Wang et al., 2004; 
Kaufmann et al., 2005; Klein et al., 2009), and THP-1 cells express P2Y1, P2Y2, P2Y6, and 
P2Y11 (Clifford et al., 1997; Moore et al., 2001; Ben Yebdri et al., 2009).  However, while 
this suggests that both cell types differ in their expression of P2Y purinoceptors, the 
results reported by these studies are not consistent.  Moreover, the expression of P2Y14 in 
these cells is unknown.  Thus, the aim of this study was to determine the gene expression 
of all P2Y purinoceptors in THP-1 cells and human monocytes.  As mentioned previously, 
all primer pairs were tested for specificity and functionality in human brain.  The results of 
this study are presented in Table 3.6, Figure 3.10 (brain and THP-1 cells) and Figure 3.11 
(monocytes). 
Table 3.6 Detection of mRNA for P2Y purinoceptors in human brain, THP-1 
cells, and human monocytes 
Gene Human brain THP-1 cells Human monocytes 
P2RY1 + + + 
P2RY2 + + + 
P2RY4 + + + 
P2RY6 + + + 
P2RY11 (+) (+) + 
P2RY12 + (+) + 
P2RY13 + (+) + 
P2RY14 + + + 
A + sign indicates that the gene is detected, a (+) sign indicates that the gene is detected 
but is represented by a faint band, and a – sign indicates that the gene is not detected. 
As summarised in the Table 3.6 and Figure 3.10, mRNA transcripts for all P2Y receptors, 
including P2Y14 were detected in human brain.  As also shown (Table 3.6, Figure 3.10 and 
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Figure 3.11), mRNA for all P2Y receptors were also detected in THP-1 cells and human 
monocytes.  These results suggest that THP-1 cells and human monocytes express all 
P2Y receptors, but also exhibit an overlapping expression pattern among genes encoding 
for these receptors.  In THP-1 cells (Figure 3.10), it was also seen that primers for P2RY6 
also produced a second PCR amplicon of a lower molecular weight in addition to an 
amplicon of the predicted size.  Interestingly, a second PCR amplicon was not seen in 
human brain or monocytes.  Although a BLAST analysis was unable to identify this 
product, it is possible that this amplicon is a splice variant of P2RY6. 
In summary, the results of this study have demonstrated for the first time that THP-1 cells 
and human monocytes exhibit an overlapping expression pattern among genes encoding 
for P2Y receptors.  Moreover, both cell types also express mRNA for the human P2Y14 
receptor, which is also a novel finding. 
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Figure 3.10 Detection of mRNA for P2Y purinoceptors in human brain and THP-1 
cells 
Detection of P2Y purinoceptors in (A) human brain, and (B) THP-1 cells using RT-PCR 
and agarose gel electrophoresis.  Primers amplify all splice variants of the selected gene.  
Expression was detected at 326 bp (P2RY1), 243 bp (P2RY2), 427 bp (P2RY4), 391 bp 
(P2RY6), 622 bp (P2RY11), 698 bp (P2RY12), 461 bp (P2RY13), and 371 bp (P2RY14).  
RT and no RT constitute first strand cDNA synthesis reactions with and without reverse 
transcriptase, respectively. 
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Figure 3.11 Detection of mRNA for P2Y purinoceptors in human monocytes 
Detection of P2Y purinoceptors in human monocytes using RT-PCR and agarose gel 
electrophoresis.  Primers amplify all splice variants of the selected gene.  Expression was 
detected at 326 bp (P2RY1), 243 bp (P2RY2), 427 bp (P2RY4), 391 bp (P2RY6), 622 bp 
(P2RY11), 698 bp (P2RY12), 461 bp (P2RY13), and 371 bp (P2RY14).  RT and no RT 
constitute first strand cDNA synthesis reactions with and without reverse transcriptase, 
respectively. 
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3.4 Summary 
The principle aim of this chapter was to compare the gene expression of 
monocyte/myeloid cell markers, CC chemokines, CC chemokine receptors and 
purinoceptors between monocytic THP-1 cells and human peripheral blood monocytes.  
The purpose of these studies was also to examine the suitability of THP-1 cells as a 
model for investigating the role of the CCL2/CCR2 axis in monocytes and its modulation 
by extracellular nucleotides.  The individual aims of this chapter were addressed by 
employing non-quantitative RT-PCR to detect mRNA transcripts.  While mRNA for CD14, 
CD33, and CD93 were detected in both cell types, mRNA for CD16 was not detected in 
THP-1 cells, but was found in heterogeneous monocytes.  Although these results 
suggested that THP-1 cells and human monocytes displayed an overlapping expression 
pattern for most monocyte/myeloid markers, they also indicated that THP-1 cells lacked 
mRNA for CD16, similar to classical (CD14++/CD16-) monocytes.  The results of CC 
chemokines studies suggested that both cell types expressed mRNA for CCL2, CCL3, 
CCL4, and CCL5.  Interestingly, investigations into CC chemokine receptors suggested 
that mRNA for CCR3 could be detected in human monocytes, but not in THP-1 cells.  
However, mRNA for all other CC chemokine receptors was detected in both cell types.  
Both cell types also displayed slightly different purinoceptor expression patterns.  While  
THP-1 cells and human monocytes displayed an overlapping expression pattern for P1 
and P2Y purinoceptors, a slightly different expression pattern for P2X receptors was 
observed.  Interestingly, mRNA for P2X6 was not detected in heterogeneous monocytes, 
but was found in THP-1 cells.  Despite this difference, mRNA for all other P2X receptors 
(except P2X2 and P2X3), were detected in both cell types.  
In summary, the results of this study have provided evidence for the expression of genes 
encoding for monocyte/myeloid cell markers, CC chemokines, CC chemokine receptors 
and purinoceptors in THP-1 cells and human monocytes.  This finding suggests that 
monocytic THP-1 cells represents a suitable alternative to human peripheral blood 
monocytes for studying CC chemokine and purinoceptor biology.   
The next chapter in this thesis (Chapter 4) therefore used THP-1 cells (and human 
PBMCs) as in vitro models to investigate the mechanisms involved in CCL2/CCR2-
mediated signalling and function of monocytes.  As described previously in Chapter 1, the 
research presented in the next chapter looked specifically at the involvement of individual 
signalling components in CCL2/CCR2 activation as measured by intracellular Ca2+ 
release, cell migration, and adhesion to vascular endothelium. 
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Chapter 4: Mechanisms involved in 
CCL2/CCR2-mediated monocyte 
signalling and function 
4.1 Introduction 
The CCR2 receptor is a 7TM GPCR comprising of two almost identical splice variants 
(CCR2A and CCR2B) that differ only in an alternatively spliced carboxyl terminus (Section 
1.6, Chapter 1) (Charo et al., 1994; Yamagami et al., 1994).  CCR2 is activated by the CC 
chemokines CCL2, CCL7, CCL8, CCL11, and CCL13, of which all, except CCL11, 
represent members of the monocyte-chemoattractant protein (MCP) family (Bachelerie et 
al., 2014).  The preferred ligand of CCR2 is CCL2 (monocyte-chemoattractant protein-1) 
which activates CCR2 to initiate an important signalling pathway in immune cells referred 
to as the CCL2/CCR2 axis (Van Coilie et al., 1999; Bachelerie et al., 2014). 
The CCL2/CCR2 axis plays a number of important developmental and immuno-regulatory 
roles in many types of immune cells including monocytes, T-lymphocytes, natural killer 
cells, and dendritic cells (Loetscher et al., 1996; Sozzani et al., 1997; Polentarutti et al., 
1997).  Considered essential for monocyte trafficking (Yoshimura et al., 1989), the 
CCL2/CCR2 axis determines the ability of different monocyte subsets to migrate under 
homeostatic and inflammatory conditions (Weber et al., 2000; Geissmann et al., 2003).  
Studies on mouse classical (Ly6Chigh) monocytes (counterparts of human classical 
(CD14++/CD16-) monocytes), suggest that the CCL2/CCR2 axis is important, if not crucial, 
for monocyte egression from the bone marrow during host defence (Kurihara et al., 1997; 
Serbina and Pamer, 2006; Tsou et al., 2007; Shi et al., 2011). 
Although the CCL2/CCR2 axis is considered a very important signalling pathway, pre-
clinical studies on mouse (Ly6Chigh) monocytes have suggested that CCR2-dependent 
monocyte trafficking underlies many monocyte-associate pathologies including cancer, 
multiple sclerosis, allergic rhinitis, and atherosclerosis (Boring et al., 1998; Gu et al., 1998; 
Izikson et al., 2000; Abbadie et al., 2003; Brϋhl et al., 2004).  For example, Boring et al. 
(1998) and Gu et al. (1998) have shown that mice deficient in CCR2 display a reduced 
formation of atherosclerotic plaques.  Later studies by Tacke et al. (2007) have shown that 
CCR2-dependent mouse (Ly6Chigh) monocyte migration towards arterial walls is 
associated with atherosclerotic plaque formation.  Taken together, these studies have 
emphasised the pleiotropic role played by the CCL2/CCR2 axis that is both beneficial and 
deleterious for organismal homeostasis.   
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However, while these studies indicate that the CCL2/CCR2 axis is important for monocyte 
trafficking under homeostatic and inflammatory conditions, the exact mechanisms by 
which the CCL2/CCR2 axis couples to monocyte signalling and function are not entirely 
clear.  However, despite there being a lot of useful information missing, prior work by 
others has suggested that CCR2 activation involves Gαi/o-type G-proteins coupled to an 
inhibition of adenylate cyclase and an activation of PLC and PI3K (Bizzarri et al., 1995; 
Myers et al., 1995; Turner et al., 1998).  Furthermore, studies by others (Wei et al., 2009) 
have suggested that the intracellular second messenger Ca2+ is also important for cell 
migration.  However, although Ca2+ is thought to be required for CCL2/CCR2-mediated 
monocyte chemotaxis (Olszak et al., 2000; Gouwy et al., 2008), the mechanisms by which 
this important ion directs cellular movement are also unclear. 
4.2 Aims 
THP-1 cells and human PBMCs were employed as in vitro models to elucidate the 
signalling mechanisms involved in CCL2/CCR2-mediated monocyte signalling and 
function.  To address this aim, the involvement of signal transduction components thought 
to be downstream of the CCL2/CCR2 axis were investigated using a number of biological 
and pharmacological tools (Figure 4.1).  The involvement of individual signalling 
components was assessed indirectly by intracellular Ca2+ release, cellular migration, and 
THP-1 cell adhesion to vascular endothelial cells.   
 
Figure 4.1 Signalling pathways investigated in this chapter 
Areas of investigation shown in (red) alongside antagonists and inhibitors used (blue). 
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4.3 Results 
4.3.1 CCL2-evoked Ca2+ responses in THP-1 cells and human PBMCs 
The mobilisation of intracellular Ca2+ upon receptor activation is considered an integral 
component of cellular signalling and activation (Berridge et al., 2000).  Thus, the initial aim 
of this chapter was to determine whether CCL2 would evoke intracellular Ca2+ release 
from THP-1 cells and human PBMCs.  Initial studies set out to test the effects of a range 
of CCL2 concentrations (1-100 ng/ml) on THP-1 cells and the effects of a single 
concentration of CCL2 (50 ng/ml) on human PBMCs. 
As can be seen (Figure 4.2c), CCL2 evoked a concentration-dependent increase in 
intracellular Ca2+ from THP-1 cells.  Maximal Ca2+ %Fmax responses were observed 
between 50 and 100 ng/ml of CCL2 and were 15 ± 2% (n=3) and 18 ± 2% (n=3), 
respectively.  Since 50 ng/ml CCL2 (Figure 4.2a) evoked a maximal response, this 
concentration was used in the majority of studies within this thesis.  Based on this data, 
the estimated EC50, EC20 and EC10 concentrations for CCL2 were 15 ± 3 ng/ml (n=3), 6 ± 
2 ng/ml (n=3), and 4 ± 1 ng/ml (n=3), respectively.  The EC50 in nM for CCL2 was 1.9 nM.  
As shown (Figure 4.2b), human PBMCs were also challenged with 50 ng/ml CCL2 and 
demonstrated a transient intracellular Ca2+ response which was approximately 3-fold less 
than THP-1 cells (5 ± 1%, n=3). 
The results of this study indicated that CCL2 evokes intracellular Ca2+ responses in THP-1 
cells.  These data also suggest that CCL2 evokes similar intracellular Ca2+ responses 
from human CCR2-expressing monocytes. 
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Figure 4.2 CCL2-evoked Ca2+ responses in THP-1 cells and PBMCs 
Representative Ca2+ transients to 50 ng/ml CCL2 challenge in (A) THP-1 cells and (B), 
human PBMCs.  (C) Concentration-response curve showing normalised THP-1 cell 
intracellular Ca2+ responses to CCL2 (1-100 ng/ml).  Responses normalised to Ca2+ 
signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 
replicates.   
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4.3.2 Effect of Ca2+ removal on CCL2-mediated THP-1 cell signalling and function 
In the classical scheme of GPCR activation, PLC drives the formation IP3 which in return, 
acts as second messenger for the release of intracellular Ca2+ from IP3R-expressing 
internal stores such as the ER (Berridge, 1993).  Following a rise in intracellular Ca2+ 
concentrations ([Ca2+]i), a number of OFF mechanisms such as SERCA pumps strive to 
return [Ca2+]i to basal levels (Parekh and Putney, 2005).   
4.3.2.1 Effect Ca2+ removal on CCL2-evoked Ca2+ responses in THP-1 cells 
The previous studies in this chapter (Section 4.3.1) suggest that CCL2 evokes intracellular 
Ca2+ responses from THP-1 cells and human PBMCs.  These data further indicate that 
CCL2 is likely to participate in activating downstream pathways involved in increasing 
[Ca2+]I, either by promoting a release from internal stores, or by allowing Ca
2+ influx.  The 
next studies therefore investigated the requirement of Ca2+ for monocyte signalling and 
function by examining the effects of removing extracellular Ca2+ on THP-1 cell intracellular 
Ca2+ responses evoked by 50 ng/ml CCL2. 
As shown (Figure 4.3), in conditions where extracellular Ca2+ (1.5 mM) was present, CCL2 
evoked an expected intracellular Ca2+ response, where the %Fmax value for CCL2 was 
20 ± 1% (n=5).  In contrast, in conditions where extracellular Ca2+ (1.5 mM) was removed 
and replaced with the Ca2+-chelator EGTA (1 mM), the %Fmax value for CCL2 dropped to 
11 ± 0.4% (n=5), indicating a 48 ± 2% (n=5, p<0.01) reduction.  The decay rates for CCL2 
transients in with Ca2+ (98 ± 12 seconds, n=5) and without Ca2+ conditions (115 ± 14 
seconds, n=5) were compared but were not significantly different (n=5, p=0.49). 
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Figure 4.3 Effect of extracellular Ca2+ removal on CCL2-evoked Ca2+ responses 
in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells in the presence and 
absence of extracellular Ca2+.  (B) Bar chart showing normalised intracellular Ca2+ 
responses to CCL2 (50 ng/ml) in THP-1 cells in the presence and absence of extracellular 
Ca2+.  Responses normalised to Ca2+ signals elicited by 40µM digitonin (%Fmax).  Data 
represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards control (**p<0.01, Students t-test). 
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4.3.2.2 Effect of BAPTA-AM on CCL2-mediated THP-1 cell chemotaxis 
To investigate the requirement for Ca2+ in CCL2-evoked intracellular Ca2+ responses 
further, studies employed the pharmacological tool BAPTA-AM.  As a high-affinity Ca2+-
chelating agent, BAPTA-AM has a Kd value of 0.11 µM (Tsien, 1980).  Because of its 
ability of being able to sequester Ca2+, BAPTA-AM could only be used to investigate the 
requirement of Ca2+ for THP-1 cell chemotaxis towards CCL2 (50 ng/ml). 
As shown (Figure 4.4), THP-1 cells demonstrated a significantly higher chemotactic index 
(n=4, p<0.01) towards CCL2 (6 ± 1, n=4) than towards vehicle (1 ± 0.5, n=4), which 
indicated that CCL2 was chemotactic.  As also shown, BAPTA-AM treatment abolished 
THP-1 cell chemotaxis towards CCL2, where the chemotactic index for BAPTA-AM-
treated cells was 0 ± 0 (n=4, p<0.01) and suggested that Ca2+ was essential not only for 
monocyte chemotaxis towards CCL2, but also for chemokinesis.  While it is possible that 
this result could also be attributed to a loss in THP-1 cell viability, trypan blue and LDH 
studies (Appendix Figure A3 and A5), showed no significant loss in cell viability after a 2.5 
hour exposure of THP-1 cells with BAPTA-AM. 
Taken together, the results of this study indicate that intracellular and extracellular 
sources of Ca2+ contribute to efficient CCL2-mediated THP-1 cell signalling and function.  
The effects of BAPTA-AM further suggest that Ca2+ is essential for cellular migration in 
general.  In an in vivo setting, this would suggest that CCR2-expressing monocytes would 
also require Ca2+ for efficient CCL2-mediated signalling and function. 
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Figure 4.4 Effect of BAPTA-AM on CCL2-mediated THP-1 cell chemotaxis 
(A) Representative images showing the effect of BAPTA-AM (100 µM, 30 minutes) on 
THP-1 cell chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2 hrs).  Scale bar 
represents 10 µm.  (B) Bar chart showing normalised THP-1 cell chemotaxis towards 
vehicle (water) or CCL2 (50 ng/ml, lower chamber, 2hrs) with or without BAPTA-AM (100 
µM; 30 minutes).  Chemotactic index is a ratio of the number of cells that migrated 
towards CCL2 over the number of cells that migrated towards vehicle.  Data represents 
mean ± SEM from n=4 transwells.  Asterisks indicate significant changes towards vehicle 
(**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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4.3.3 Effect of CCR2 antagonism on CCL2-mediated THP-1 cell signalling and 
function 
Experiments designed to elucidate the signalling mechanisms involved in CCL2-mediated 
monocyte signalling and function were next performed with monocytic THP-1 cells. 
As described previously (Section 1.6, Chapter 1), CCL2 is the preferred ligand of the 
CCR2 receptor and forms the CCL2/CCR2 axis, a pathway considered important for 
monocyte trafficking and function (Van Coilie et al., 1999; Bachelerie et al., 2014).  The 
next studies therefore sought to confirm the association between CCL2 and CCR2 and 
understand the requirement of CCR2 for monocyte signalling and function.  To address 
this aim, studies employed BMS-CCR2-22, a pan-CCR2 antagonist reported to be highly 
selective for CCR2 over other CC chemokine receptors.  Studies by Cherney et al. (2008), 
have demonstrated that the IC50 values for BMS-CCR2-22 against CCL2-mediated Ca
2+ 
mobilisation and chemotaxis of human PBMCs are 18 nM and 1 nM, respectively. 
4.3.3.1 Effect of BMS-CCR2-22 on CCL2- and CCL5-evoked Ca2+ responses in THP-1 
cells 
Using THP-1 cells as a model, experiments examined the effects of BMS-CCR2-22 (30 
pM – 100 nM) on intracellular Ca2+ responses evoked by 50 ng/ml CCL2.  As shown 
(Figure 4.5), BMS-CCR2-22 produced a concentration–dependent inhibition of CCL2-
evoked intracellular Ca2+ responses.  Furthermore, it was seen that BMS-CCR2-22 
abolished CCL2-evoked Ca2+ responses at 100 nM (n=3, p<0.01), where the %Fmax 
values for CCL2 in untreated and BMS-CCR2-22-treated cells were 20 ± 1% (n=3) and 0 
± 0% (n=3), respectively.  This result suggests that CCR2 is essential for Ca2+ responses 
evoked by CCL2.  The IC50 concentration of BMS-CCR2-22 was also estimated (IC50 = 2.9 
± 0.3 nM, n=3), and indicated quite interestingly, that BMS-CCR2-22 was more potent 
against CCL2-evoked Ca2+ responses in THP-1 cells than for similar responses in PBMCs 
(Cherney et al., 2008).   
To address whether BMS-CCR2-22 also affected the decay of Ca2+ responses, the 
values were analysed and compared.  Due to a lack of decay, the  values for 30 nM 
and 100 nM BMS-CCR2-22 could not be determined.  The  values of Ca2+ transients for 
all other BMS-CCR2-22 concentrations were analysed, but were not significantly different 
from vehicle.  For example, in paired experiments with 10 nM BMS-CCR2-22, the  values 
of transients in untreated and BMS-CCR2-22-treated cells were 111 ± 8 seconds (n=3) 
and 114 ± 10 seconds (n=3), respectively (n=3, p>0.05). 
It was also necessary to understand the selectivity of BMS-CCR2-22.  Although 
considered selective for CCR2, BMS-CCR2-22 is reported to inhibit CCR3 binding by 37% 
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at 10 µM (Cherney et al., 2008).  While this suggests that the effects of BMS-CCR2-22 in 
the current experiments are attributable to a blockade of CCR3, mRNA transcripts for 
CCR3 were not detected in THP-1 cells (Chapter 3).  Although these data supported the 
use of BMS-CCR2-22, an additional experiment was performed to examine the effects of 
BMS-CCR2-22 (30 and 100 nM) on Ca2+ responses evoked by 50 ng/ml CCL5 in THP-1 
cells.  CCL5 was selected due to its reported activation of CCR1, CCR3, and CCR5 
(Bachelerie et al., 2014). 
As shown (Figure 4.6), the %Fmax values for CCL5 in untreated cells varied between 
paired experiments testing the effects of 30 and 100 nM BMS-CCR2-22.  Despite this, it 
was seen that CCL5-evoked intracellular Ca2+ responses were not significantly attenuated 
by 30 nM BMS-CCR2-22, where the %Fmax values for CCL5 in untreated (7 ± 0.3%, n=3) 
and BMS-CCR2-22-treated cells (8 ± 0%, n=3) were not significantly different (n=3, 
p>0.05).  However, as Figure 4.6 shows, 100 nM BMS-CCR2-22 significantly impaired 
CCL5-evoked Ca2+ responses by 20 ± 5% (n=4, p<0.05), where the %Fmax values for 
CCL5 in untreated and BMS-CCR2-22-treated THP-1 cells were 12 ± 1% (n=4) and 10 ± 
1% (n=4), respectively.  These data indicate that higher concentrations of BMS-CCR2-22 
impair CCL5-evoked intracellular Ca2+ responses.   
A comparison of the decay rates for both sets of treatments did not reveal any significant 
differences.  For example in experiments with 100 nM BMS-CCR2-22, the  values for 
CCL5 in untreated (178 ± 8 seconds, n=4) and BMS-CCR2-22-treated cells (180 ± 16 
seconds, n=4), were not significantly different (n=4, p>0.05).  This data suggests that 
BMS-CCR2-22 does not influence the decay of CCL5 Ca2+ responses in THP-1 cells. 
Taken together, these results suggest that BMS-CCR2-22 attenuates CCL5-evoked 
intracellular Ca2+ responses via a mechanism that is unlikely to involve CCR3. 
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Figure 4.5 Effect of BMS-CCR2-22 on CCL2-evoked Ca2+ responses in THP-1 
cells 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or BMS-CCR2-22 (1-100 nM) for 15 minutes.  (B) Normalised 
concentration-response curve showing the effect of BMS CCR2 22 (30 pM–100 nM, 15 
minutes) on intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells.  Responses 
given as a percentage of CCL2 %Fmax in the absence of BMS-CCR2-22.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± 
SEM from n=3 replicates. 
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Figure 4.6 Effect of BMS-CCR2-22 on CCL5-evoked Ca2+ responses in THP-1 
cells 
Representative Ca2+ transients to CCL5 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or (A) 100 nM or (B) 30 nM BMS-CCR2-22 for 15 minutes.  (C)  Bar chart 
showing normalised intracellular Ca2+ responses to CCL5 (50 ng/ml) in THP-1 cells pre-
treated with vehicle (DMSO) or BMS-CCR2-22 (30-100 nM) for 15 minutes.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± 
SEM from n=3 (30 nM BMS-CCR2-22), or n=4 (100 nM BMS-CCR2-22) replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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4.3.3.2 Effect of BMS-CCR2-22 on CCL2-mediated THP-1 cell chemotaxis and 
adhesion 
BMS-CCR2-22 was also employed to investigate the role of the CCR2 receptor in CCL2-
mediated monocyte trafficking and adhesion.  Experiments first examined the effects of 
BMS-CCR2-22 (100 nM) on THP-1 cell chemotaxis towards 50 ng/ml CCL2.   
As can be seen (Figure 4.7), the chemotactic indexes of THP-1 cells towards vehicle or 
CCL2 were 1 ± 0.2 (n=4) and 14 ± 4 (n=4) respectively, and indicated a significant (n=4, 
p<0.01) increase in cell migration towards CCL2.  As also shown (Figure 4.7), a significant 
inhibition of THP-1 cell chemotaxis was observed with 100 nM BMS-CCR2-22 (91 ± 3%, 
n=4, p<0.05), where the chemotactic index for BMS-CCR2-22-treated THP-1 cells was 1.5 
± 1 (n=4) and thus similar to vehicle-treated cells.  While it is possible that this effect 
reflects a loss in THP-1 cell viability, trypan blue and LDH studies (Appendix Figure A3 
and A5) showed no significant loss in cell viability after a 2.5 hour exposure of THP-1 cells 
with BMS-CCR2-22.  These data therefore suggest that monocyte trafficking towards 
CCL2 requires CCR2 activation. 
The adhesion of monocytes and their subsequent diapedesis into the vascular 
endothelium is an important process in monocyte-driven responses during infection and 
inflammation, and during the development of inflammatory disease (Beekhuizen and van 
Furth, 1993; Woollard and Geissmann, 2010).  Hence, it is important to understand the 
mechanisms involved in driving this process.  To address this aim, the requirement of 
CCR2 for THP-1 cell adhesion to quiescent and TNFα-treated HUVEC monolayers was 
investigated.  An experimental model was set-up where CCL2 primed THP-1 cells were 
incubated with 100 nM BMS-CCR2-22 for 45 minutes and then allowed to adhere to 
vehicle or TNFα-treated (10 ng/ml) HUVEC cell monolayers.  The results of these 
experiments are shown in Figure 4.8a (quiescent) and Figure 4.8b (TNFα-treated). 
As shown (Figure 4.8a), in quiescent HUVEC experiments, vehicle-treated THP-1 cells 
exhibited a % adhesion of 31 ± 9% (n=20, p<0.01).  This result is interesting since it 
suggests that THP-1 cells adhere to HUVEC monolayers under basal conditions.  In 
contrast, a significant increase in % adhesion (100 ± 18%, n=20, p<0.01) was seen when 
THP-1 cells were primed with CCL2, and suggests that CCL2 priming promotes adhesion.  
Interestingly, treatment of CCL2-primed THP-1 cells with 100 nM BMS-CCR2-22 
significantly disrupted CCL2-dependent adhesion by 68 ± 12% (n=5, p<0.01), bringing 
down the % adhesion (32 ± 13%, n=20) to levels almost identical to vehicle-treated cells.   
In experiments with TNFα-treated HUVEC monolayers (Figure 4.8b), the % adhesion of 
vehicle-treated THP-1 cells was 28 ± 12% (n=8).  As also shown, priming of THP-1 cells 
with CCL2 significantly increased the % adhesion to 100 ± 26% (n=8, p<0.05).  This 
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suggests that CCL2-priming also enhances the adhesion of THP-1 cells to TNFα-treated 
HUVECs.  However, it was observed that treatment with 100 nM BMS-CCR2-22 abolished 
adhesion, where the % adhesion of cells was 0 ± 0% (n=8, p<0.01).  This result is 
interesting, and indicates that primary monocyte adhesion to the vascular endothelium 
during inflammation is entirely CCR2-dependent. 
Taken together with the results of Ca2+ studies, these data suggest that CCR2 is likely to 
be critical for CCL2/CCR2-mediated monocyte signalling and function. 
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Figure 4.7 Effect of BMS-CCR2-22 on CCL2-mediated THP-1 cell chemotaxis 
(A) Representative images showing the effect of BMS-CCR2-22 (100 nM) on THP-1 cell 
chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  
(B) Bar chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 
(50 ng/ml, lower chamber, 2hrs) in the presence of BMS-CCR2-22 (100 nM).  
Chemotactic index is a ratio of the number of cells that migrated towards CCL2 over the 
number of cells that migrated towards vehicle.  Data represents mean ± SEM from n=4 
transwells.  Asterisks indicate significant changes towards vehicle (*p<0.05, **p<0.01, 
One-way ANOVA with Bonferroni’s multiple comparison). 
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Figure 4.8 Effect of BMS-CCR2-22 on CCL2-mediated THP-1 cell adhesion to 
quiescent and TNFα-treated HUVEC monolayers 
Bar chart shows normalised adhesion of vehicle-treated or CCL2-primed (50 ng/ml) THP-
1 cells to (A) quiescent and (B) TNFα-treated (10 ng/ml, 5 hours) HUVEC monolayers 
following treatment with vehicle (DMSO) or BMS-CCR2-22 (100 nM, 45 minutes).  
Normalised adhesion represents a percentage of mean adhesion of CCL2-primed THP-1 
cells in the absence of BMS-CCR2-22.  Data represents mean ± SEM from a total of n=20 
replicates from n=4 experiments (quiescent), or a total of n=8 replicates from n=2 
experiments (TNFα-treated).  Asterisks indicate significant changes towards vehicle 
(*p<0.05, **p<0.01, respectively, One-way ANOVA with Bonferroni’s multiple comparison). 
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4.3.4 Effect of Gαi/o inhibition on CCL2/CCR2-mediated THP-1 cell signalling and 
function 
The CCR2 receptor has been shown to activate Gαi/o-type G-proteins in a number of 
studies (Bizzarri et al., 1995; Myers et al., 1995; Turner et al., 1998).  A key study is that 
of Bizzarri et al. (1995), which showed that CCL2-evoked Ca2+ responses in human 
monocytes were almost abolished by Bordetella Pertussis (PTx).  This is a bacterial toxin 
that ribosylates ADP of the Gαi/o subunit thereby preventing the exchange of guanine 
diphosphate (GDP) for guanine triphosphate (GTP), rendering the α subunit unable to 
dissociate from the βγ dimer (Katada and Ui, 1982).  Although PTx has been used 
extensively to show that CCR2 couples to Gαi/o, no prior studies have employed PTx to 
demonstrate an association between Gαi/o, CCL2-evoked Ca
2+ mobilisation, and 
monocyte migration. 
4.3.4.1 Effect of PTx on CCL2-, ATP- and ADP-evoked Ca2+ responses in THP-1 cells 
Using THP-1 cells as a model, studies examined the effects of PTx (100 ng/ml) on 
intracellular Ca2+ responses evoked by CCL2 (50 ng/ml), ATP (30 µM), and ADP (30 µM).  
ATP and ADP were selected as both are known to also activate PTx-insensitive Gαq/11-
type G-proteins (Burnstock, 2012).  
As shown (Figure 4.9), PTx almost completely abolished CCL2-evoked intracellular Ca2+ 
responses in THP-1 cells, demonstrating a % inhibition of 96 ± 1% (n=7, p<0.01).  In 
paired experiments, the %Fmax values for CCL2 in untreated and PTx-treated cells were 
24 ± 1% (n=7) and 1 ± 0.2% (n=7), respectively.  Due to a lack of decay of Ca2+ transients 
in treated cells, the  values were not possible to determine and compare with untreated 
cells.  As can also be seen (Figure 4.9), intracellular Ca2+ responses evoked by ATP and 
ADP were not significantly affected by PTx.  In experiments with ATP, the %Fmax values 
for ATP in untreated and PTx-treated cells were 38 ± 1% (n=11) and 36 ± 2% (n=11), 
respectively (n=11, p>0.05).  In comparison, the %Fmax responses for ADP in untreated 
and PTx-treated THP-1 cells were 26 ± 3% (n=7) and 25 ± 1% (n=7) respectively.  A 
further analysis of the decay rates (, sec) indicated no significant differences in  between 
untreated and PTx-treated cells for either ATP (n=11, p>0.05) or ADP (n=7, p>0.05).  
While the  values for ATP in untreated and PTx-treated cells were 98 ± 5 seconds (n=11) 
and 107 ± 14 seconds (n=11) respectively, for ADP these were 288 ± 27 seconds (n=7) 
and 424 ± 80 seconds (n=7), respectively.  These results suggest that PTx does not affect 
the decay of ATP and ADP Ca2+ transients. 
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Figure 4.9 Effect of PTx on CCL2, ATP, and ADP-evoked Ca2+ responses in THP-
1 cells 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or PTx (100 ng/ml) for 4 hours.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml), ATP (30 µM), or ADP (30 µM) in THP-1 
cells treated with vehicle (water) or PTx (100 ng/ml) for 4 hours.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from 
n=7 (CCL2), n=11 (ATP) and n=3 (ADP) replicates.  Asterisks indicate significant changes 
towards control (**p<0.01, Students t-test). 
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4.3.4.2 Effect of PTx on CCL2-mediated THP-1 cell chemotaxis 
To examine the requirement of Gαi/o for monocyte function, the effects of PTx (100 ng/ml) 
on THP-1 cell migration towards CCL2 were next investigated.  As shown (Figure 4.10), 
untreated THP-1 cells migrated readily towards CCL2, where the chemotactic indexes for 
vehicle and CCL2-challenged cells were 1 ± 0.1 (n=4) and 10 ± 1 (n=4), respectively (n=4, 
p<0.01).  Interestingly, a significant inhibition of THP-1 cell chemotaxis was observed with 
PTx (86 ± 3%, n=4, p<0.01), where the chemotactic index for these cells was 1.5 ± 0.5 
(n=4) and therefore similar to vehicle-treated cells (Figure 4.10).  These results suggest 
that CCR2-dependent monocyte chemotaxis is likely to involve Gαi/o-type G-proteins. 
Taken together, these results suggest that THP-1 cell signalling and function are almost 
completely abolished by the Gαi/o inhibitor, PTx.  These data contribute to the existing 
knowledge that CCR2 signalling involves an activation Gαi/o-type G-proteins in monocytes.  
Interestingly, these data also suggest that ATP and ADP evoke intracellular Ca2+ 
responses in THP-1 cells are PTx-insensitive and are unlikely to be mediated through the 
activation of Gαi/o-type G-proteins. 
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Figure 4.10 Effect of PTx on CCL2-mediated THP-1 cell chemotaxis 
(A) Representative images showing the effect of PTx (100 ng/ml) on THP-1 cell 
chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2 hours).  Scale bar represents 10 
µm.  (B) Bar chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or 
CCL2 (50 ng/ml, lower chamber, 2 hours), with or without PTx (100 ng/ml) pre-treatment.  
Chemotactic index is a ratio of the number of cells that migrated towards CCL2 over the 
number of cells that migrated towards vehicle.  Data represents mean ± SEM from n=4 
transwells.  Asterisks indicate significant changes towards vehicle (**p<0.01, One-way 
ANOVA with Bonferroni’s multiple comparison). 
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4.3.5 Effect of Gβγ inhibition on CCL2-mediated THP-1 cell chemotaxis 
In the classical GPCR signalling paradigm, Gαi/o-type receptors activate PLC through their 
Gβγ dimers (Kadamur and Ross, 2013).  It is possible, therefore, that CCR2 activation in 
monocytes involves an activation of effectors by Gβγ.  Using THP-1 cells as a model, 
studies examined this hypothesis by employing gallein, a βγ-dimer inhibitor reported to 
bind reversibly with a high-affinity (Kd = 400 nM) to the protein-protein interaction “hot 
spot” on the Gβγ subunit, rendering it inactive (Bonacci et al., 2006). 
Initial experiments examined the effects of gallein (100 µM) on CCL2-evoked intracellular 
Ca2+ responses in THP-1 cells.  As shown (Figure 4.11), gallein quenched the fluorescent 
signal through interference with fluo-4 AM.  To overcome this effect, a lower concentration 
of gallein (10 µM) was tested, but was also seen to quench the fluorescent signal.  Further 
Ca2+ experiments with gallein were therefore not undertaken.  On this basis, the next 
experiments focused on testing the effects of gallein (50 µM) on THP-1 cell chemotaxis 
towards CCL2 (50 ng/ml). 
As shown (Figure 4.27), THP-1 cells demonstrated a significantly higher (n=4, p<0.01) 
chemotactic index towards CCL2 (14 ± 2 , n=4), than towards vehicle (1 ± 0.5, n=4).  As 
also shown, gallein produced a significant inhibition of THP-1 cell migration towards CCL2 
(65 ± 2%, n=4, p<0.01), where the chemotactic indexes for vehicle and gallein-treated 
cells were 14 ± 2 (n=4) and 5 ± 0.2 (n=4), respectively. Although a possible explanation 
for this result may be that gallein affected cell viability, trypan blue and LDH studies 
(Appendix Figure A3 and A5) showed no significant loss after a 2.5 hour exposure of 
THP-1 cells with gallein.  These data therefore suggest an association between βγ dimers 
and monocyte chemotaxis towards CCL2. 
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Figure 4.11 Effect of gallein on fluo 4-AM Ca2+ signal detection 
Representative traces showing effect of (A) 100 µM and (B) 10 µM gallein on Ca2+ 
responses in THP-1 cells.  Traces show pre-treatment of THP-1 cells for 15 minutes with 
gallein (10-100 µM) or vehicle (DMSO) prior to challenge with CCL2 (50 ng/ml) and 
application of 40 µM digitonin to achieve %Fmax. 
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4.3.6 Effect of PI3K inhibition on CCL2/CCR2-mediated THP-1 cell signalling and 
function 
Classical GPCR signalling via the Gβγ subunit involves the activation of phospholipase C 
(PLC) (Smrcka, 2008).  In recent years however, it has become apparent that the βγ 
dimer of Gαi/o-type G-proteins, also activates other downstream effectors such as PI3K 
(Krugmann et al., 1999; Brock et al., 2003). 
The studies performed in this chapter suggest a requirement of Gβγ for CCL2/CCR2-
mediated monocyte chemotaxis.  Based on these results, it was hypothesised that CCR2 
activation of Gβγ might lead to an activation of PI3K.  To address this hypothesis, studies 
examined the effects of PI3K inhibition on CCL2/CCR2-mediated THP-1 cell Ca2+ 
responses and chemotaxis.  Studies employed LY-294002, a PI3K inhibitor reported to 
inhibit bovine brain PI3K activity with an IC50 of 1.4 µM (Vlahos et al., 1994).   
4.3.6.1 Effect of LY-294002 on CCL2-evoked Ca2+ responses in THP-1 cells 
Initial experiments tested the effects of LY-294002 (5-50 µM) on intracellular Ca2+ 
responses evoked by 50 ng/ml CCL2.  As shown (Figure 4.12a), application of LY-294002 
to cells caused a small dip in baseline Ca2+ (< 1%Fmax).  A similar dip was also seen 
upon addition of 50 µM LY-294002, but not upon addition of vehicle.  This effect is difficult 
to explain, but suggests a modulation of Ca2+ homeostasis by LY-294002 possibly through 
an inhibition of PI3K.  As also shown (Figure 4.12b and c), LY-294002 attenuated CCL2-
evoked intracellular Ca2+ responses, producing a bell-shaped effect where the greatest 
inhibition was seen with 25 µM LY-294002.  However, with 5 µM LY-294002 CCL2 Ca2+ 
responses were not significantly affected, where the %Fmax values for CCL2 in untreated 
and LY-294002-treated cells were 22 ± 3% (n=3) and 24 ± 2% (n=3), respectively.  In 
comparison, 25 µM and 50 µM LY-294002 attenuated CCL2-evoked intracellular Ca2+ 
responses by 22 ± 2% (n=3, p<0.05) and 12 ± 2% (n=3, p<0.05), respectively.  At 25 µM, 
the %Fmax values for CCL2 in untreated and LY-294002-treated THP-1 cells were 27 ± 
1% (n=3) and 20 ± 1% (n=3), respectively.  For 50 µM LY-294002, these values were 23 ± 
1 (n=3) and 20 ± 1% (n=3), respectively, and suggested that 50 µM LY-294002 impaired 
responses less than 25 µM LY-294002. 
A comparison of the  values suggested no significant differences between untreated and 
LY-294002-treated cells for any of the LY-294002 concentrations tested (n=3, p>0.05).  
For 5 µM LY-294002, the  values for CCL2 in untreated and LY-294002-treated cells 
were 43 ± 3 seconds (n=3) and 44 ± 3 seconds (n=3), respectively, while for 25 µM LY-
294002 these were 62 ± 2 seconds (n=3) and 75 ± 6 seconds (n=3), respectively.  Finally 
for 50 µM LY-294002, the  values for CCL2 in untreated and LY-294002-treated cells 
were 49 ± 5 seconds (n=3) and 57 ± 8 seconds (n=3), respectively.  These results 
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suggest that PI3K inhibition does not influence the decay of CCL2 Ca2+ transients in THP-
1 cells. 
4.3.6.2 Effect of LY-294002 on CCL2-mediated THP-1 cell chemotaxis 
To understand the requirement of PI3K for CCL2/CCR2-mediated monocyte chemotaxis, 
studies tested the effects of LY-294002 (25 µM) on THP-1 cell chemotaxis towards CCL2.  
As shown (Figure 4.27), THP-1 cells demonstrated a significantly higher (n=4, p<0.01) 
chemotactic index towards CCL2 (14 ± 2, n=4) than towards vehicle (1 ± 0.5, n=4).  
Interestingly, treatment with LY-294002 caused a significant inhibition of THP-1 cell 
chemotaxis towards CCL2 (53 ± 4 %, n=4, p<0.05), where the chemotactic index for LY-
294002-treated cells was 7 ± 1 (n=4).  This result suggested a requirement of PI3K for 
THP-1 cell, and possibly, monocyte chemotaxis towards CCL2.  This finding is supported 
by trypan blue and LDH cell viability studies (Appendix Figure A3 and A5), which showed 
no significant loss in THP-1 cell viability after 2.5 hours exposure with 25µM LY-294002. 
Taken together, these results suggest that PI3K is required for efficient CCL2/CCR2-
mediated monocyte signalling and function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
 
 
Figure 4.12 Effect of LY-294002 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of 25 µM LY-294002 on baseline Ca2+.  (B) 
Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or LY-294002 (25 µM) for 15 minutes.  (C) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or LY-294002 (5-50 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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4.3.7 Effect of PLC inhibition on CCL2/CCR2-mediated THP-1 cell signalling and 
function 
One of the main effectors of Gβγ dimers of Gαi/o-type G-proteins are the PLC enzymes, a 
family of soluble enzymes that hydrolyse PIP2 to yield DAG and IP3 (Yang et al., 2013) 
(Chapter 1).  Although the activation of PLC isoenzymes (PLCβ, PLCε and PLCη) by the 
Gβγ dimer has been widely accepted (Boyer et al., 1992; Smrcka et al., 1993; Hains et al., 
2006), studies showing an association between PLC activation and CCR2 are limited, and 
have only been performed in COS-7 cells, (simian fibroblast) (Kuang et al., 1996).  
Moreover, in monocytes, a requirement of PLC for CCL2-mediated monocyte trafficking 
has not yet been shown.   
To address this gap in knowledge, studies examined the requirement of PLC for 
CCL2/CCR2-mediated monocyte signalling and function, employing THP-1 cells as an in 
vitro model.  Studies also employed the pan-PLC inhibitor, U-73122 which has a reported 
IC50 of 1-5 µM against PLC-dependent platelet activation (Bleasdale et al., 1990).  
4.3.7.1 Effect of U-73122 on CCL2-evoked Ca2+ responses in THP-1 cells 
The effects of U-73122 (0.25-5 µM) on intracellular Ca2+ responses evoked by CCL2 (50 
ng/ml) in THP-1 cells were examined in the presence and absence of extracellular Ca2+.  
The purpose of Ca2+-free experiments was to investigate the requirement of PLC 
specifically for store-operated intracellular Ca2+ release. 
As shown (Figure 4.13a), application of U-73122 to cells in the presence of extracellular 
Ca2+ caused a small dip in baseline Ca2+, where the %Fmax responses for dips given by 
0.25 µM and 5 µM U-73122 were -2.7 ± 0.3% (n=3) and -4 ± 0.4% (n=3), respectively.  A 
similar effect was not observed with vehicle or in the absence of extracellular Ca2+, 
suggesting that this effect was attributed to a modulation of Ca2+ homeostasis by U-73122 
connected to its inhibition of PLC.  As also shown (Figure 4.13b and c), U-73122 caused a 
concentration-dependent inhibition of CCL2-evoked intracellular Ca2+ responses, where 
the % inhibition values for 0.25 µM and 5 µM U-73122 were 68 ± 7% (n=3, p<0.05) and 
100 ± 0% (n=4, p<0.01), respectively.  For 0.25 µM, the %Fmax values for CCL2 in 
untreated and U73122-treated THP-1 cells were 26 ± 1% (n=3) and 8 ± 2% (n=3), 
respectively.  In comparison, for experiments with 5 µM U-73122, the %Fmax values for 
CCL2 in untreated and U-73122-treated THP-1 cells were 22 ± 1% (n=4) and 0 ± 0% 
(n=4), respectively.  These data suggest that PLC activation is required for CCL2/CCR2-
mediated THP-1 cell signalling. 
A comparison of the decay kinetics for vehicle and 0.25 µM U-73122-treated cells was 
also made, but did not reveal any significant shifts (n=3, p>0.05) between the  values for 
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untreated (66 ± 2 seconds, n=3) and U-73122-treated THP-1 cells (68 ± 7 seconds, n=3).  
This data suggests that PLC inhibition does not affect the decay of CCL2 Ca2+ transients. 
Experiments performed in SBS from which extracellular Ca2+ (1.5 mM CaCl2) was 
replaced with the calcium chelator EGTA (1 mM) (Chapter 2, Section 2.6.2), showed that 
5 µM U-73122 abolished CCL2-evoked intracellular Ca2+ responses (100 ± 0 %, n=3, 
p<0.05) (Figure 4.13d and e), where the %Fmax responses for CCL2 in untreated and U-
73122-treated cells were 10 ± 2% (n=3) and 0 ± 0% (n=3), respectively.  Due to no Ca2+ 
response in the presence of U-73122, the decay rates (, sec) could not be determined. 
4.3.7.2 Effect of U-73122 on CCL2-mediated THP-1 cell chemotaxis 
Studies next sought to investigate the requirement of PLC for monocyte chemotaxis 
towards CCL2, using THP-1 cells as an in vitro model.  As shown (Figure 4.27), U-73122 
treatment (5 µM) significantly impaired THP-1 cell chemotaxis towards CCL2 by 76 ± 10% 
(n=4, p<0.01), where the chemotactic indexes for untreated and U-73122-treated cells 
were 14 ± 2 (n=4) and 3 ± 1 (n=4), respectively.  Although these data supported a 
possible role for PLC in CCL2/CCR2-mediated monocyte chemotaxis, some caution may 
need to be applied in interpreting these results since LDH release studies showed that 
THP-1 cells exposed for 2.5 hours with 5 µM U-73122 released LDH at % control levels 
(% of Triton-X) above the 20% threshold (36%, n=1) (Appendix Figure A3).  Cell toxicity 
however, was not observed in trypan blue assays (n=3, p>0.05) (Appendix Figure A5), 
where the % viable cells for untreated and treated wells were 100 ± 15% (n=3) and 82 ± 
6% (n=3), respectively.  Given that data obtained in LDH assays reflected a 2.5 hour 
exposure rather than a 2 hour exposure, and are only n=1, firm conclusions about the 
effect of U-73122 on THP-1 cell viability in chemotaxis and intracellular Ca2+ experiments 
may not be drawn.   
Taken together, these results suggest that PLC is required for efficient CCL2/CCR2-
mediated monocyte signalling and function.   
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Figure 4.13 Effect of U-73122 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of 5 µM U-73122 on baseline Ca2+.  (B) 
Representative Ca2+ transients and (C) normalised bar chart showing intracellular Ca2+ 
responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO) or U-73122 
(0.25-5 µM) for 15 minutes.  Experiments performed in the presence of extracellular Ca2+ 
(1.5 mM CaCl2) where data represents mean ± SEM from n=3 (0.25 µM) or n=4 (5µM) 
replicates.  (D) Representative Ca2+ transients and (E) normalised bar chart showing 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or U-73122 (5 µM) for 15 minutes.  Experiments performed in the absence of 
extracellular Ca2+ , where data represents mean ± SEM from n=3 replicates.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Asterisks indicate 
significant changes towards vehicle (**p<0.01, *p<0.05, Students t-test). 
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4.3.8 Effect of IP3R inhibition on CCL2/CCR2-mediated THP-1 cell signalling and 
function 
The release of Ca2+ from the ER into the cellular cytoplasm is a major pathway for the 
supply of intracellular Ca2+ (Clapham, 2007).  The inositol 1,4,5-trisphosphate receptors 
(IP3Rs), ryanodine receptors (RyRs), and Ca
2+ are the primary inducers of Ca2+ release 
from the ER and/or Golgi apparatus (GA) (Chandra et al., 1991; Pinton et al., 1998).  Of 
these, IP3Rs constitute the major mechanism by which GPCRs induce intracellular Ca
2+ 
release (Chapter 1) (Clapham, 2007; Vetter, 2012). 
The IP3Rs are intracellular Ca
2+ channels encoded by three different genes which give rise 
to IP3R1 (splice variants S1, S2 and S3), IP3R2, and IP3R3 (Patel et al., 1999).  Although 
structurally similar, all IP3Rs possess differential binding affinities to IP3 courtesy of 
structural differences in the N-terminal region that acts as a suppressor of IP3 binding (Iwai 
et al., 2007).  Although IP3Rs can be modulated by over 50 different proteins including 
protein kinase A (PKA) and protein kinase C (PKC) (Berridge et al., 2003; Parys and De 
Smedt, 2012), the primary activators of these receptors are the essential co-agonists IP3 
and Ca2+ (Finch et al., 1991; Dupont and Goldbeter, 1993). 
The evidence presented has suggested that CCL2/CCR2 activation is associated with a 
release of intracellular Ca2+ via an activation of PLC.  It is possible, therefore, that 
intracellular Ca2+ released via PLC involves an activation of IP3Rs located on ER and GA.  
To address this hypothesis and assess the requirement of IP3Rs for efficient CCL2/CCR2-
mediated monocyte signalling and function, THP-1 cells were employed as an in vitro 
model along with the pan-IP3R inhibitor Xestospongin-C (XeC).  As a macrocyclic bis-1-
oxaquinolizidine isolated from the Australian sponge, Xestospongia, XeC has a reported 
IC50 against IP3R of 358 nM (Gafni et al., 1997) 
4.3.8.1 Effect of XeC on CCL2-evoked Ca2+ responses in THP-1 cells 
Experiments examined the effects of XeC (5 µM) on 50 ng/ml CCL2-evoked intracellular 
Ca2+ responses in THP-1 cells.  As shown (Figure 4.14a and b), XeC caused a significant 
inhibition of CCL2-evoked intracellular Ca2+ responses (30 ± 3%, n=3, p<0.05), where the 
%Fmax values for CCL2 in untreated and XeC-treated cells were 22 ± 1 % (n=3) and 15 ± 
1% (n=3), respectively.  These data were interesting because they suggested that IP3R 
are required for CCL2 Ca2+ responses in monocytes. 
An analysis of the decay rates of Ca2+ transients showed that XeC significantly increased 
the  value for CCL2 in treated cells by 43 ± 8% (n=3, p<0.05), where  for CCL2 shifted 
from 69 ± 10 seconds (n=3) for untreated cells to 98 ± 15 seconds (n=3) for XeC-treated 
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cells (Figure 4.14c).  These data suggested that IP3R inhibition slowed the decay of CCL2 
Ca2+ transients.   
To examine the requirement for IP3R in CCL2/CCR2 signalling further, experiments were 
designed to test the effects of XeC in the absence of extracellular Ca2+.  However,  pilot 
experiments suggested that THP-1 cells were unable to retain a signal to fluo-4 AM over 
30 minutes as was required for XeC (data not shown). 
4.3.8.2 Effect of XeC on CCL2-mediated THP-1 cell chemotaxis 
To understand the requirement of IP3R for CCL2/CCR2-mediated monocyte chemotaxis, 
studies examined the effects of XeC (5 µM) on THP-1 cell chemotaxis towards 50 ng/ml 
CCL2.  As shown (Figure 4.15), THP-1 cells displayed a significantly higher (n=4, p<0.01) 
chemotactic index towards CCL2 (6 ± 0.7, n=4) than towards vehicle (1 ± 0.3, n=4).  
Interestingly, treatment with XeC significantly attenuated THP-1 cell chemotaxis towards 
CCL2 by 73 ± 10% (n=4, p<0.01), where the chemotactic indexes for untreated and XeC-
treated cells were 6 ± 1 (n=4) and 1.4 ± 0.4 (n=4) respectively.  Although it may be that 
these results are biased due to XeC-mediated cytotoxicity, trypan blue and LDH studies 
were not able to provide any evidence of this (Appendix Figure A3 and A5).  This result 
suggests that XeC attenuates CCL2-mediated THP-1 cell chemotaxis through an 
inhibition of IP3Rs.  
The results of this study suggested that XeC significantly inhibited the magnitude and 
decay of CCL2-evoked intracellular Ca2+ responses in THP-1 cells.  Moreover, it was seen 
that XeC treatment also attenuated THP-1 cell chemotaxis towards CCL2.  Taken 
together, these results suggest that IP3Rs are required for CCL2/CCR2-mediated 
monocyte signalling and function. 
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Figure 4.14 Effect of XeC on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or XeC (5 µM) for 30 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or XeC (5 µM), for 30 minutes.  (C)  Bar chart showing decay rates (, sec) for 
CCL2 (50 ng/ml) Ca2+ transients in THP-1 cells pre-treated with vehicle (DMSO) or XeC (5 
µM), for 30 minutes.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (% 
Fmax).  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant 
changes towards vehicle (*p<0.05, Students t-test). 
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Figure 4.15 Effect of XeC on CCL2-mediated THP-1 cell chemotaxis 
(A) Representative images showing the effect of XeC (5 µ M; 30 minutes) on CCL2-
mediated THP-1 chemotaxis (50 ng/ml, lower chamber, 2 hours).  Scale bar represents 10 
µm.  (B) Bar chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or 
CCL2 (50 ng/ml, lower chamber, 2 hours) following 30 minute pre-treatment of cells with 
vehicle (DMSO), or XeC (5 µM).  Chemotactic index is a ratio of the number of cells that 
migrated towards CCL2 over the number of cells that migrated towards vehicle.  Data 
represents mean ± SEM from n=4 transwells.  Asterisks indicate significant changes 
towards vehicle (**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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4.3.9 Effect of RyR inhibition on CCL2/CCR2-mediated THP-1 cell signalling and 
function 
The ryanodine receptors (RyR) are a family of large (>2.2 MDa) homotetrameric Ca2+ ion 
channels located within the ER membrane (Van Petegem, 2012). Identified by their 
activation by the plant alkaloid ryanodine, the RyR family comprises of three isoforms in 
humans (RyR1, RyR2 and RyR3), with each receptor displaying differential expression 
patterns in cells and tissues (Lanner et al., 2010).  Although RyR activity can be 
modulated by a number of mechanisms including Protein kinase A and L-type Ca2+ 
channels (Lanner et al., 2010; Van Petegem, 2012), the principle agonist is Ca2+, which 
activates RyRs by a mechanism known as Ca2+-induced-Ca2+-release (CICR) (Berridge et 
al., 2000). 
The data presented in this chapter suggests that IP3R activation is required for efficient 
CCL2/CCR2-mediated monocyte signalling and function.  This suggests that RyRs might 
also be involved.  To examine this hypothesis, studies used THP-1 cells as an in vitro 
model to investigate the effects of the RyR inhibitor dantrolene, on CCL2/CCR2-mediated 
intracellular Ca2+ responses and chemotaxis.  As a RyR inhibitor, dantrolene is reported to 
primarily target RyR1 but also has an affinity for RyR3 (Zhao et al., 2001).  Used 
therapeutically as a postsynaptic muscle relaxant, the therapeutic concentration of 
dantrolene is reported to be 10 µM (Flewellen et al., 1983). 
4.3.9.1 Effect of dantrolene on CCL2-evoked Ca2+ responses in THP-1 cells 
To examine the requirement of RyR, studies investigated the effects of dantrolene (20 µM) 
on intracellular Ca2+ responses evoked by 50 and 10 ng/ml CCL2.   
As shown below in Table 4.1, no significant effects of dantrolene were observed on either 
50 ng/ml (n=3, p>0.05), or 10 ng/ml CCL2 (n=3, p>0.05). The  values of 50 ng/ml and 10 
ng/ml CCL2 Ca2+ transients in untreated and dantrolene-treated cells were also not 
significantly different (n=3, p>0.05).  For 50 ng/ml CCL2, the  values for untreated and 
dantrolene-treated cells were 57 ± 2 seconds (n=3) and 58 ± 1 seconds (n=3), while for 10 
ng/ml CCL2 these were 98 ± 7 seconds (n=3), and 99 ± 18 seconds (n=3).  These results 
suggest that the magnitude and decay of CCL2 Ca2+ transients are not significantly 
affected by dantrolene.  Therefore, RyRs are unlikely to be involved in CCL2-mediated 
Ca2+ responses. 
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Table 4.1 Effect of dantrolene on CCL2-evoked Ca2+ responses in THP-1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle 20 µM Dantrolene 
CCL2 50 ng/ml 23 ± 0% 23 ± 0.5 
CCL2 10 ng/ml 5 ± 0.3% 5 ± 0.9% 
Intracellular Ca2+ responses to CCL2 in THP-1 cells pre-treated with vehicle (DMSO) or 
dantrolene for 15 minutes.  Responses normalised to maximum Ca2+ signals elicited by 40 
µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates. 
4.3.9.2 Effect of dantrolene on CCL2-mediated THP-1 cell chemotaxis 
To investigate whether RyRs contributed to monocyte trafficking, transwell experiments 
were designed to test the effects of dantrolene (20 µM) on THP-1 cell chemotaxis towards 
CCL2.  As shown (Figure 4.27), THP-1 cells demonstrated a significantly higher (n=4, 
p<0.01) chemotactic index towards CCL2 (14 ± 2, n=4), than towards vehicle (1 ± 0.5, 
n=4).  As can also be seen, dantrolene significantly attenuated THP-1 cell chemotaxis 
towards CCL2 by 40 ± 4% (n=4, p=<0.05), where the chemotactic indexes shifted from 14 
± 2 (n=4) for untreated cells to 8 ± 1 (n=4) for dantrolene-treated cells.  This data suggests 
that RyRs are required for CCL2/CCR2-mediated monocyte trafficking. 
These results showed that CCL2/CCR2-mediated THP-1 chemotaxis, but not intracellular 
Ca2+ release, was attenated by 20 µM dantrolene.  Based on these data, RyRs are 
unlikely to play a role in CCL2/CCR2-mediated monocyte signalling but may play a role in 
their function. 
4.3.10 Effect of SERCA inhibition on CCL2/CCR2-mediated THP-1 cell signalling 
and function 
The sarco(endo)plasmic reticulum ATPase (SERCA) pump is a high-affinity 110-kDA 
transmembrane Ca2+ transporter located in the ER membrane.  In addition to a role in 
regulating [Ca2+]i levels in the cytoplasm, SERCA is also crucial for replenishing ER stores 
following a depletion caused by agonist activation or leakage (Chapter 1). 
The next aim of this chapter was to investigate the requirement of SERCA activation for 
CCL2/CCR2-mediated monocyte signalling and function.  The evidence presented in this 
chapter has indicated a requirement of the ER for efficient CCL2/CCR2-mediated 
signalling and function.  It was therefore hypothesised that SERCA pumps located on the 
membrane of the ER would replenish the ER following CCL2-mediated depletion.   
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Studies therefore sought to examine this hypothesis using THP-1 cells as a model and the 
pan-SERCA inhibitor thapsigargin; a sesquiterpene lactone derived from the plant Thapsia 
garganica L. (Linnaeus) (Thastrup et al., 1990).  Mechanistically, thapsigargin binds to the 
transmembrane domain of SERCA while it is in a low Ca2+-affinity state (Wuytack et al., 
2002).  The IC50 of thapsigargin varies depending on the test model used as well as the 
conformational state of the receptor, and although it is reported to be between 5-50 nM, it 
can also be as high at 4 µM (Sagara and Inesi, 1991; Treiman et al., 1998).   
4.3.10.1 Effect of thapsigargin on CCL2-evoked Ca2+ responses in THP-1 cells 
Initial experiments investigated the effects of thapsigargin (300 nM and 5 µM) on 50 ng/ml 
CCL2-evoked intracellular Ca2+ responses in THP-1 cells.  As shown (Figure 4.16a), 
thapsigargin produced an intracellular Ca2+ response, where the %Fmax values for 300 
nM and 5 µM thapsigargin were 46 ± 1% (n=3) and 36 ± 3% (n=3), respectively.  This 
effect suggests that SERCA impairment leads to a spontaneous leakage of Ca2+ from the 
ER.  As also shown (Figure 4.16b and c), 300 nM and 5 µM thapsigargin attenuated 
CCL2-evoked intracellular Ca2+ responses with % inhibition values of 73 ± 5% (n=3, 
p<0.05) and 82 ± 2% (n=3, p<0.05), respectively.  For experiments with 300 nM 
thapsigargin, the %Fmax values for CCL2 in untreated and thapsigargin-treated cells were 
28 ± 3% (n=3) and 5 ± 0% (n=3), respectively.  In comparison, in experiments with 5 µM 
thapsigargin, the %Fmax values for CCL2 in untreated and thapsigargin-treated cells were 
19 ± 2% (n=3) and 5 ± 1% (n=3), respectively.  These results suggested that SERCA 
inhibition suppressed the magnitude of CCL2-evoked intracellular Ca2+ responses.  
Although it was also useful to determine whether SERCA impairment affected the 
response decay, the lack of decay of Ca2+ transients in treated cells prevented the  
values from being determined. 
In further experiments performed in the absence of extracellular Ca2+ where 1.5 mM CaCl2 
was omitted from SBS and replaced with 1 mM of the Ca2+ chelator EGTA, it was seen 
that both concentrations (300 nM and 5 µM) of thapsigargin abolished CCL2-evoked 
intracellular Ca2+ responses, giving % inhibition values of 100 ± 0% (n=3, p<0.05) and 100 
± 0% (n=3, p<0.01), respectively (Figure 4.17).  For experiments with 300 nM 
thapsigargin, the %Fmax values for CCL2 in untreated and thapsigargin-treated cells were 
7 ± 1% (n=3) and 0 ± 0% (n=3), respectively, whereas for 5 µM experiments they were 12 
± 0.3% (n=3) and 0 ± 0 (n=3), respectively.  These data support evidence from 
experiments in the presence of extracellular Ca2+, and suggest that SERCA activation is 
essential for intracellular Ca2+ release in the absence of extracellular Ca2+. 
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Figure 4.16 Effect of thapsigargin on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of thapsigargin (300 nM) on baseline Ca2+.  
(B)  Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or thapsigargin (300 nM) for 15 minutes.  (C) Bar chart showing 
normalised intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or thapsigargin (5 µM or 300 nM), for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from 
n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, Students 
t-test). 
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Figure 4.17 Effect of thapsigargin on CCL2-evoked Ca2+ responses in THP-1 cells 
in the absence of extracellular Ca2+ 
(A)  Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or thapsigargin (300 nM) for 15 minutes.  (B) Bar chart showing 
normalised intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or thapsigargin (5 µM or 300 nM), for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from 
n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, **p<0.01 
Students t-test). 
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4.3.10.2 Effect of thapsigargin on CCL2-mediated THP-1 cell chemotaxis 
It was next important to investigate the requirement of SERCA for monocyte function.  
Using THP-1 cells as a model, studies tested the effects of thapsigargin (5 µM) on cellular 
chemotaxis towards 50 ng/ml CCL2.  As shown (Figure 4.18), THP-1 cells demonstrated a 
significantly higher (n=4, p<0.01) chemotactic index towards CCL2 (11 ± 1, n=4) than 
towards vehicle (1 ± 0.2, n=4).  As also shown, treatment of cells with thapsigargin 
attenuated CCL2-mediated chemotaxis by 48 ± 10% (n=4, p<0.01), where the 
chemotactic indexes for untreated and thapsigargin-treated cells were 11 ± 3 (n=3) and 6 
± 1 (n=3), respectively.  Although these results were positive and suggested a 
requirement for SERCA in monocyte function, data from LDH cell viability studies 
suggested that THP-1 cells released LDH (21% of Triton-X, n=1) after 2.5 hours exposure.  
However, this result is only an n=1 and was not supported by the results of trypan blue 
studies which showed that the % of viable cells in vehicle-treated (100 ± 15%, n=3) and 5 
µM thapsigargin-treated wells (88 ± 7%, n=3) were not significantly different (n=3, p>0.05) 
(Appendix Figure A3 and A5).  Thus, further studies are required to confirm this finding. 
In summary, these results suggest that SERCA activity is required for efficient 
CCL2/CCR2-mediated monocyte signalling and function. 
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Figure 4.18 Effect of thapsigargin on CCL2-mediated THP-1 cell chemotaxis 
(A) Representative images showing the effect of thapsigargin (5 µM) on THP-1 cell 
chemotaxis towards CCL2 (50 ng/ml).  Scale bar represents 10 µm.  (B) Bar chart 
showing normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 (50 ng/ml, 
lower chamber, 2 hours), in the presence of vehicle (DMSO) or thapsigargin (5 µM).  
Chemotactic index is a ratio of the number of cells that migrated towards CCL2 over the 
number of cells that migrated towards vehicle.  Data represents mean ± SEM from n=4 
transwells.  Asterisks indicate significant changes towards vehicle (**p<0.01, One-way 
ANOVA with Bonferroni’s multiple comparison). 
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4.3.11 Effect of SOCE inhibition on CCL2/CCR2–associated THP-1 cell signalling 
and function 
Classical GPCR activation involving PLC drives the release of intracellular Ca2+ from 
internal stores such as the ER.  A release of Ca2+ from the ER results in the activation of 
SERCA, an ATPase pump involved in replenishing the ER.  However, this mechanism can 
only prove effective if [Ca2+]i within the cytoplasm is sufficient.  As such, mechanisms such 
as plasma membrane store-operated Ca2+ channels (SOCCs) open following internal 
store depletion in a bid to maintain cellular homeostasis (Parekh and Putney, 2005) 
(Section 1.4.2.1, Chapter 1). 
A number of  SOCCs participating in store-operated Ca2+ entry (SOCE) have been 
identified of which Ca2+-release activated Ca2+ channels (CRAC) are the most well-
characterised (Parekh and Putney, 2005; Feske, 2010).  CRAC regulation is undertaken 
by stromal interaction molecule 1 (STIM1), a protein which acts both as a Ca2+ sensor 
within the ER membrane and as an activator of CRAC channels (Roos et al., 2005; Liou et 
al., 2005).  A second protein, Orai1 (CRACM1) forms the channel-forming subunit of 
CRAC which couples to STIM1 upon ER Ca2+ depletion (Prakriya et al., 2006; Feske et 
al., 2006). 
Hence, it is important to understand the requirement of SOCE for CCL2/CCR2-mediated 
monocyte signalling and function.  Studies therefore examined this hypothesis using THP-
1 cells and the pharmacological tool SKF-96365, an SOCE inhibitor with a reported IC50 of 
10 µM against ICRAC (CRAC-channel current) (Merritt et al., 1990). 
4.3.11.1 Effect of SKF-96365 on CCL2-evoked Ca2+ responses in THP-1 cells 
Studies tested the effects of SKF-96365 (100 µM) on CCL2-evoked intracellular Ca2+ 
responses in THP-1 cells.  Prior to experimentation, the presence of SOCE was verified in 
the absence of extracellular Ca2+ by challenging THP-1 cells with 50 ng/ml CCL2 followed 
by the addition of CaCl2 (1.5 mM) to produce an “add-back” response characteristic of 
SOCE (Figure 4.19a). 
In experiments assessing the requirement of SOCE in the presence of extracellular Ca2+ 
(Figure 4.19b and c), it was seen that treatment of THP-1 cells with SKF-96365 almost 
abolished CCL2-evoked intracellular Ca2+ responses (99 ± 1%, n=3, p<0.01), where the 
%Fmax values for untreated and SKF-96365-treated cells were 24 ± 2% (n=3) and 0.3 ± 
0.3% (n=3), respectively.  These data suggested that CCL2/CCR2-mediated Ca2+ 
responses were almost entirely dependent on SOCE.  Although it was possible that these 
results were due to a reduction in cell viability, trypan blue and LDH assays were unable 
to provide any evidence of this (Appendix Figures A1 and A2).  This suggested that the 
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effects of SKF-96365 were caused by an inhibition of other Ca2+ channels.  Further 
experiments with SKF-96365 were not undertaken as it was discovered that prior work by 
others provided evidence of off-target effects of SKF-96365 (Merritt et al., 1990; Mason et 
al., 1993; Singh et al., 2010),.  Consequently, firm conclusions about the involvement of 
SOCE for efficient CCL2/CCR2 signalling in THP-1 cells may not be drawn. 
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Figure 4.19 Effect of SKF-96365 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing Ca2+ “add-back” response upon addition of 1.5 mM 
CaCl2 after CCL2 (50 ng/ml) challenge.  (B) Representative Ca
2+ transients to CCL2 (50 
ng/ml) in THP-1 cells pre-treated with vehicle (water) or SKF-96365 (100 µM) for 15 
minutes.  (C) Bar chart showing normalised intracellular Ca2+ responses to CCL2 (50 
ng/ml) in THP-1 cells pre-treated with vehicle (water) or SKF-96365 (100 µM) for 15 
minutes.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  
Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle (**p<0.01, Students t-test). 
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4.3.12 Effect of inhibiting DAG metabolism on CCL2/CCR2-mediated THP-1 cell 
signalling and function 
Diacylglycerols (DAG) are multifunctional lipids that serve as signalling molecules and 
precursors for other signalling lipids (Baldanzi, 2014).  DAG typically exerts its function as 
a signalling molecule by binding to the diacylglycerol-binding C1 domain of target proteins 
such as Munc13s, protein kinase D (PKD), Ras guanyl nucleotide-releasing proteins 
(RasGRP), and chimaerins.  However, the prototypical target of DAG is protein kinase C 
(PKC) (Baldanzi, 2014). 
As mentioned previously (Section 1.3.4.2.1, Chapter 1), PLC isoenzymes generate DAG 
and IP3 from the hydrolysis of PIP2 (Yang et al., 2013).  It is possible, therefore, that DAG, 
like IP3, is also important for CCL2/CCR2-mediated monocyte signalling and function.  To 
examine this hypothesis, studies employed inhibitors of diacylglycerol lipase (DAGL) and 
diacylglycerol kinase (DAGK) as these enzymes are involved in DAG metabolism.  
Studies investigated the requirement of these enzymes for CCL2/CCR2-mediated 
monocyte signalling and function using THP-1 cells as a model. 
4.3.12.1 Effect of RHC-80267 on CCL2-evoked Ca2+ responses in THP-1 cells 
The DAGLs are a family of enzymes comprising of two isoenzymes, DAGLα and DAGLβ 
(Bisogno et al., 2003).  Both isoenzymes hydrolyse DAG at the sn-1 fatty acid position to 
yield 2-arachidonolyglycerol (2-AG), an endocannabinoid receptor ligand important for 
neuronal and brain development and function (Harkany et al., 2007).  Within the 
endocannabinoid system, 2-AG signalling is regulated primarily by monoacylglycerol 
lipase (MAGL), an enzyme that hydrolyses 2-AG to yield arachidonic acid (AA), a 
precursor for the synthesis of pro-inflammatory thromboxanes and prostaglandins (Smith 
et al., 1991).   
The requirement for DAGL was investigated using RHC-80267, a dual DAGLα/β inhibitor 
reported to inhibit DAGL in canine and guinea pig platelets (IC50 = 4 µM) (Sutherland and 
Amin, 1982; Canonico et al., 1985). 
In experiments assessing the effects of RHC-80267 (1-50 µM) on CCL2-evoked 
intracellular Ca2+ responses in THP-1 cells, it was seen that RHC-80267 caused a 
concentration-dependent inhibition (Figure 4.20).  While 1 µM RHC-80267 produced no 
significant effects (n=3, p>0.05), it was seen that 50 µM RHC-80267 attenuated CCL2-
evoked intracellular Ca2+ responses by 18 ± 4% (n=5, p<0.01).  In conditions where 50 µM 
RHC-80267 was used, the %Fmax values for CCL2 in untreated and RHC-80267-treated 
THP-1 cells were 20 ± 1% (n=5) and 17 ± 1% (n=5), respectively.  In comparison, in 
experiments with 1 µM RHC-80267, the %Fmax values for CCL2 in untreated and 
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RHC80267-treated cells were 25 ± 2% (n=3) and 23 ± 2% (n=3), respectively.  A further 
analysis of the decay rates showed that  for CCL2 Ca2+ transients in untreated (77 ± 1 
seconds, n=3) and 1µM-RHC-80267-treated cells (76 ± 5 seconds, n=3) remained largely 
unchanged (n=3, p>0.05) (Figure 4.20c).  However, it was seen that 50 µM RHC-80267 
increased  by 15 ± 5% (n=5, p<0.05), where the  values for CCL2 in untreated and 
RHC-80267-treated cells were 60 ± 5 seconds (n=5) and 69 ± 6 seconds (n=5), 
respectively.  These data suggested that RHC-80267, through an impairment of DAGL 
activity, slowed the decay of CCL2 Ca2+ transients.  
To understand the requirement of Ca2+ for DAGL impairment, similar experiments were 
performed in the absence of extracellular Ca2+ with 50 µM RHC-80267, where 1.5 mM 
CaCl2 was omitted from SBS and replaced with 1 mM of the Ca
2+ chelator EGTA.  As 
shown (Figure 4.21), CCL2-evoked intracellular Ca2+ responses were not significantly 
affected by RHC-80267 (n=4, p>0.05), where the %Fmax values for untreated and RHC-
80267-treated cells were 10 ± 0.3% (n=4) and 9 ± 1% (n=4), respectively.  These data 
suggest that the attenuation of DAGL by RHC-80267 is calcium-dependent.  The Ca2+ 
decay rates (, sec) were also analysed and compared for both treatments, but suggested 
that  for untreated (69 ± 7 seconds, n=4) and RHC-80267-treated cells (64 ± 5 seconds, 
n=4), were not significantly different (n=4, p>0.05). 
4.3.12.2 Effect of RHC-80267 on CCL2-mediated THP-1 cell chemotaxis 
In an effort to examine the requirement of DAGL for monocyte function, studies next 
investigated the effects of RHC-80267 (50 µM) on THP-1 cell chemotaxis towards CCL2 
(50 ng/ml).  As shown (Figure 4.27), a significantly higher chemotactic index was 
observed towards CCL2 (14 ± 2, n=4) than towards vehicle (1 ± 0.5, n=4, p<0.01).  As 
also shown treatment of THP-1 cells with RHC-80267 impaired chemotaxis by 49 ± 4% 
(n=4, p<0.01), where the chemotactic indexes for untreated and RHC-80267-treated cells 
decreased from 14 ± 2 (n=4) to 7.2 ± 0.6 (n=4), respectively.  These results were 
interesting and indicated a requirement of DAGL for monocyte function.  However, in LDH 
studies, it was observed that THP-1 cells exposed to RHC-80267 for 2.5 hours released 
LDH at levels close to the 20% threshold (18% of Triton-X, n=1) (Appendix Figure A3), 
suggesting that the effects of RHC-80267 on THP-1 cell signalling and function could also 
be caused by cytotoxicity.  Although this is a possibility, trypan blue assays were unable to 
support the results of LDH studies (Appendix Figure A5).  While this study may have 
indicated that further cell viability tests are required, it nevertheless suggested that DAGL 
is required for monocyte function. 
Taken together, these results suggest that DAGL activity is required for efficient 
CCL2/CCR2-mediated monocyte signalling and function. 
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Figure 4.20 Effect of RHC-80267 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients and (B) bar chart showing normalised intracellular Ca2+ 
responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO) or RHC-
80267 (1 - 50 µM) for 15 minutes.  Responses normalised to Ca2+ signals elicited by 40 
µM digitonin (%Fmax).  (C) Bar chart showing Ca2+ decay rates (, sec) for Ca2+ transients 
to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO) or RHC-80267 (1-50 
µM) for 15 minutes.  Data represents mean ± SEM from n=3 (1 µM) or n=5 (50 µM) 
replicates.  Asterisks indicate significant changes towards vehicle (**p<0.01, *p<0.05, 
Students t-test). 
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Figure 4.21 Effect of RHC-80267 on CCL2-evoked Ca2+ responses in THP-1 cells in 
the absence of extracellular Ca2+ 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or RHC-80267 (50 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or RHC-80267 (50 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from n=4 replicates. 
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4.3.12.3 Effect of R-59-022 on CCL2-evoked Ca2+ responses in THP-1 cells 
The enzyme diacylglycerol kinase (DAGK) is responsible for phosphorylating DAG.  
Although this metabolic pathway is considered a quantitatively minor pathway, it has been 
proposed to be the primary route for maintaining levels of “signalling” DAG (Baldanzi, 
2014).  In mammals, ten DAGKs have been cloned and characterised, and are classified 
into five distinct families (I (α, β, γ), II (δ, η,), III (ε), IV (ζ,), and V (θ)), based primarily on 
differences in their structural motifs (Merida et al., 2008).  All DGKs phosphorylate DAG to 
yield phosphatidic acid (PA), which is mainly generated as a means of regulating DAG 
levels.  However, PA is also accepted as a signalling molecule, and is known to activate a 
number signalling proteins including, atypical PKC, chimaerins, and PLC (Limatola et al., 
1994; Litosch, 2002; Caloca et al., 2003).  PA-specific phosphatases (PAPS) and other 
enzymes responsible for dephosphorylating PA to DAG (Brindley et al., 2009; Baldanzi, 
2014) also interchangeably regulate PA levels. 
Experiments examining the involvement of DAGK in CCL2/CCR2-mediated monocyte 
signalling and function were performed in THP-1 cells.  The pharmacological tool R-59-
022 was also employed as this is an inhibitor of several mammalian DAGKs including type 
I DGKα, type III DGKε, and type V DGKθ (Jiang et al., 2000).  R-59-022 exhibits an IC50 of 
2.8 µM against human DAGK (De Chaffoy De Courcelles et al., 1985). 
Initial experiments tested the effects of R-59-022 (10-30 µM) on CCL2-evoked intracellular 
Ca2+ responses in THP-1 cells.  As shown (Figure 4.22), application of 30 µM R-59-022 to 
cells produced a small increase in baseline Ca2+.  While rises caused by 10 µM R-59-022 
could not be quantified, the %Fmax for 30 µM R-59-022 was 5 ± 1% (n=3).  This 
observation is interesting, and although difficult to explain, reflects the possibility that 
DAGK inhibition alters Ca2+ homeostasis.  As also shown (Figure 4.22), R-59-022 
produced a concentration-dependent inhibition of CCL2-evoked Ca2+ responses, where it 
was observed that 10 µM and 30 µM R-59-022 attenuated CCL2 Ca2+ responses by 38 ± 
7% (n=3, p<0.05) and  81 ± 2% (n=3, p<0.05), respectively.  In paired experiments with 10 
µM R-59-022, the %Fmax values for CCL2 in untreated and R-59-022-treated cells were 
24 ± 1% (n=3) and 15 ± 1% (n=3), whereas in experiments with 30 µM R-59-022 these 
values were 24 ± 2% (n=3) and 5 ± 1% (n=3), respectively.   
To enable a greater understanding of the effects of DAGK inhibition, the decay rates for all 
treatments were analysed and compared.  As shown (Figure 4.22d), 10 µM R-59-022 
significantly slowed the decay of CCL2 Ca2+ transients (n=3, p<0.05), where the  values 
for CCL2 in untreated and R-59-022-treated cells were 77 ± 2 seconds (n=3) and 108 ± 5 
seconds (n=3), respectively.  Interestingly, a significant effect was not observed with 30 
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µM R-59-022 for which the  values for CCL2 in untreated and R-59-022-treated cells 
were 32 ± 10 seconds (n=3) and 59 ± 7 seconds (n=3), respectively (n=3, p>0.05).   
In an effort to understand the requirement of Ca2+ for DAGK inhibition, studies examined 
the effects of 30 µM R-59-022 on CCL2-evoked intracellular Ca2+ responses in the 
absence of extracellular Ca2+ (for method see Chapter 2, Section 2.6.2) (Figure 4.23).  
Although not shown, R-59-022 addition to cells increased baseline Ca2+ by 4 ± 1%Fmax 
(n=3).  This effect suggested that R-59-022 affected Ca2+ mobilisation by releasing Ca2+ 
from internal stores.  As also shown (Figure 4.23), R-59-022 attenuated CCL2-evoked 
intracellular Ca2+ responses by 58 ± 9% (n=3, p<0.01), where the %Fmax values for CCL2 
in untreated and R-59-022-treated cells were 10 ± 1% (n=3) and 4 ± 1% (n=3), 
respectively.  The % inhibition seen under these conditions was less than that observed in 
the presence of intracellular Ca2+ (Figure 4.22), and suggested that the effects of R-59-
022 were partially dependent on extracellular Ca2+.  The decay rates for CCL2 Ca2+ 
transients in untreated (83 ± 16 seconds, n=3) and treated cells (102 ± 21 seconds, n=3) 
suggested that R-59-022 did not significantly affect the decay of Ca2+ transients in the 
absence of extracellular Ca2+ (n=3, p>0.05). 
4.3.12.4 Effect of R-59-022 on UDP-evoked Ca2+ responses in THP-1 cells 
Given the universal role of DAG in PLC-mediated signalling, a brief study was undertaken 
to investigate whether DAGK activity would also be required for THP-1 cell Ca2+ 
responses evoked by the P2Y6/P2Y14 ligand, UDP.  As shown (Figure 4.24), R-59-022 (30 
µM) treatment significantly inhibited UDP-evoked intracellular Ca2+ responses by 70 ± 4% 
(n=3, p<0.01), where the %Fmax values for UDP in untreated and R-59-022-treated cells 
were 25 ± 1% (n=3) and 7 ± 1% (n=3), respectively.  Interestingly, the level of inhibition of 
UDP responses by R-59-022 was comparable to CCL2, and suggested that DAGK 
contributed equally to UDP and CCL2 signalling.  Due to the sustained UDP Ca2+ 
responses in R-59-022-treated cells, the  values of these could not be determined. 
4.3.12.5 Effect of R-59-022 on CCL2-mediated THP-1 cell chemotaxis 
In an effort to assess the requirement of DAGK activity for CCL2/CCR2-mediated 
monocyte function, studies tested the effects of R-59-022 (30 µM) on THP-1 cell 
chemotaxis towards 50 ng/ml CCL2.  As shown (Figure 4.27), R-59-022 significantly 
inhibited THP-1 cell chemotaxis towards CCL2 by 82 ± 3 (n=4, p<0.01), where the 
chemotactic indexes for untreated and R-59-022-treated cells were 14 ± 2 (n=4) and 2.6 ± 
0.4 (n=4), respectively.  Although these data strongly suggested a requirement of DAGK 
for CCL2/CCR2-mediated monocyte chemotaxis, LDH cell viability studies showed that 
THP-1 cells exposed for 2.5 hours to 30 µM R-59-022, released LDH at levels  above the 
20% threshold (31% of Triton-X-100, n=1) (Appendix Figure A3).  However, in trypan blue 
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studies (Appendix Figure A5), the % viable cells in vehicle (100 ± 15%, n=3) and R-59-
022-treated wells (81 ± 7%, n=3) were not significantly different (n=3, p>0.05).  It may be 
the case therefore that further cell viability tests are required.   
Taken together, these data suggest a requirement of DAGK for CCL2/CCR2-mediated 
and UDP-associated monocyte signalling (and function). 
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Figure 4.22 Effect of R-59-022 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of 30 µM R-59-022 on baseline Ca2+.  (B) 
Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or R-59-022 (10 - 30 µM), for 15 minutes.  (C) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or R-59-022 (10 - 30 µM), for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (% Fmax).  (D) Bar chart showing CCL2 (50 ng/ml) Ca2+ decay 
rates (, sec) for THP-1 cells pre-treated with vehicle (DMSO) or R-59-022 (10 - 30 µM) 
for 15 minutes.  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate 
significant changes towards vehicle (*p<0.05, Students t-test). 
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Figure 4.23 Effect of R-59-022 on CCL2-evoked Ca2+ responses in THP-1 cells in 
the absence of extracellular Ca2+ 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or R-59-022 (30 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or R-59-022 (30 µM), for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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Figure 4.24 Effect of R-59-022 on UDP-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to UDP (30 µM) in THP-1 cells pre-treated with vehicle 
(DMSO) or R-59-022 (30 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to UDP (30 µM) in THP-1 cells pre-treated with vehicle 
(DMSO) or R-59-022 (30 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (**p<0.01, Students t-test). 
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4.3.13 Effect of PKC inhibition on CCL2/CCR2-mediated THP-1 cell signalling and 
function 
Protein kinase C (PKC) enzymes drive the phosphorylation of downstream signalling 
proteins.  Comprised of 10 members encoded by 9 genes, the PKC family is split into 
three families of isoenzymes that are grouped according to their sensitivities to specific 
cofactors.  The conventional/classical cPKCs (α, βI, βII, γ) are activated by DAG, phorbol 
esters, and (IP3)-mediated Ca
2+, the novel nPKCs (δ, ε, η, θ) are activated by DAG, 
phorbol esters but not by Ca2+, and the atypical aPKCs (ζ, λ) are activated by anionic 
phospholipids and protein-protein complexes (Suzuki et al., 2001; Yang and Kazanietz, 
2003).  PKC isoenzymes are involved in regulating cellular events including, T-cell 
recognition, cell polarity, migration, and cell cycle progression (Ng et al., 1999; Martin et 
al., 2005; Hayashi and Altman, 2007).   
Given that PKC isoenzymes are important modulators of a wide variety of cellular 
processes, it was important to understand the requirement of PKC isoenzymes for 
CCL2/CCR2-mediated monocyte signalling and function.  To address this aim, studies 
investigates the effects of PKC inhibition on CCL2/CCR2-mediated THP-1 cell intracellular 
Ca2+ responses and chemotaxis.  Studies also employed GF-109203X, a pan-PKC 
inhibitor reported to inhibit isoenzymes from all three classes, but with a mild preference 
for cPKCs and nPKCs.  The IC50 values for GF-109203X range from 8.4 nM for PKCα to 
5.8 µM for PKCζ (Toullec et al., 1991; Martiny-Baron et al., 1993; Gschwendt et al., 1996; 
Anastassiadis et al., 2011). 
4.3.13.1 Effect of GF-109203X on CCL2-evoked Ca2+ responses in THP-1 cells 
In experiments investigating the effects of GF-109203X (1 µM) on (20-50 ng/ml) CCL2-
evoked intracellular Ca2+ responses, it was seen that responses evoked by 50 ng/ml 
CCL2 were not significantly affected by GF-109203X (Figure 4.25), where the %Fmax 
values for CCL2 in untreated and GF-109203X-untreated cells were 25 ± 2% (n=4) and 27 
± 1% (n=4), respectively.  However, it was interesting to observe that Ca2+ responses 
evoked by 20 ng/ml CCL2 were significantly attenuated by GF-109203X (26 ± 3%, n=3, 
p<0.05), where %Fmax values for untreated and GF-109203X-treated cells were 10 ± 0.3 
(n=3), and 8 ± 0.3 (n=3), respectively.   
To further understand the effects of PKC inhibition, the decay rates for all treatments were 
analysed and compared.  As shown (Figure 4.25c), the  values for 20 ng/ml CCL2 (91 ± 
3 seconds, n=3) were higher than 50 ng/ml CCL2 (40 ± 2 seconds, n=3).  These 
differences were interesting, but most likely due to variability between experiments.  As 
also shown, GF-109203X reduced the decay rate of Ca2+ responses evoked by CCL2 20 
ng/ml by 53 ± 8% (n=3, p<0.05), where the  values for CCL2 transients in untreated and 
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treated cells were 91 ± 3 seconds (n=3) and 42 ± 4 seconds (n=3) respectively.  A smaller 
reduction in  was also observed for Ca2+ transients to 50 ng/ml CCL2 (16 ± 3 %, n=3, 
p<0.05), where the  values for CCL2 in untreated and treated cells were 40 ± 2 seconds 
(n=3) and 34 ± 0.3 seconds (n=3), respectively.  These data suggested that GF-109203X, 
through a possible inhibition of PKC, promoted a faster decay of CCL2 Ca2+ transients.  
This is interesting because it suggests that GF-109203X affects the decay, but not the 
magnitude of CCL2 Ca2+ transients. 
To understand whether these effects were Ca2+-dependent, a study was next undertaken 
to test the effects of 1 µM GF-109203X on CCL2 Ca2+ responses in the absence of 
extracellular Ca2+.  As shown (Figure 4.26), CCL2 intracellular Ca2+ responses evoked by 
50 and 20 ng/ml CCL2 were not significantly affected by GF-109203X (n=3, p>0.05).  The 
%Fmax values for 50 ng/ml CCL2 in untreated and GF-109203X-treated cells were 9 ± 
1% (n=3) and 7 ± 1% (n=3), respectively, and for 20 ng/ml CCL2 they were 8 ± 1% (n=3) 
and 9 ± 2% (n=3), respectively.  Interestingly, the decay rates for these treatments 
suggested that GF-109203X promoted a faster decay of CCL2 20 ng/ml and 50 ng/ml 
transients, increasing these by 63 ± 3% (n=3, p<0.01) and 52 ± 6% (n=4, p<0.01), 
respectively.  For 20 ng/ml CCL2, the  values for CCL2 in untreated and GF-109-203X-
treated cells were 98 ± 9 seconds (n=3) and 37 ± 3 seconds (n=3), respectively, whereas 
for 50 ng/ml CCL2, they were 80 ± 6 seconds (n=4) and 37 ± 1 (n=4), respectively.  
Similar to experiments in the presence of extracellular Ca2+, these data suggested that 
PKC inhibition promoted a more rapid decay of Ca2+ transients 
4.3.13.2 Effect of GF-109203X on CCL2-mediated THP-1 cell chemotaxis 
In an effort to examine the requirement of PKC activity for CCL2/CCR2-mediated 
monocyte function, studies investigated the effects of GF-109203X (1 µM) on THP-1 cell 
chemotaxis towards 50 ng/ml CCL2.  As shown (Figure 4.27), THP-1 cell chemotaxis 
towards CCL2 was not significantly affected by GF-109203X, where the chemotactic 
indexes for untreated and GF-109203X-treated cells were 14 ± 2 (n=4) and 13 ± 2 (n=4), 
respectively (n=4, p>0.05).  These data suggest that PKC is not required for CCL2/CCR2-
mediated monocyte chemotaxis.  
Taken together, these data suggest that the PKC inhibitor GF-109203X modulates the 
magnitude and decay of CCL2-evoked intracellular Ca2+ responses.  Furthermore, the 
data provided by chemotaxis studies suggests that PKC is not required for monocyte 
trafficking towards CCL2. 
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Figure 4.25 Effect of GF-109203X on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (20 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or GF-109203X (1 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 and 20 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or GF-109203X (1 µM), for 15 minutes.  (C)  Bar chart showing Ca2+ 
decay rates (, sec) for Ca2+ transients to CCL2 (50 and 20 ng/ml) in THP-1 cells pre-
treated with vehicle (DMSO) or GF-109203X (1 µM), for 15 minutes.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± 
SEM from n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
Students t-test). 
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Figure 4.26 Effect of GF-109203X on CCL2-evoked Ca2+ responses in THP-1 cells 
in the absence of extracellular Ca2+ 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or GF-109203X (1 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 and 20 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or GF-109203X (1 µM), for 15 minutes.  (C)  Bar chart showing Ca2+ 
decay rates (, sec) for Ca2+ transients to CCL2 (50 and 20 ng/ml) in THP-1 cells pre-
treated with vehicle (DMSO) or GF-109203X (1 µM), for 15 minutes.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± 
SEM from n=4 (CCL2 50 ng/ml) and n=3 (CCL2 20 ng/ml) replicates.  Asterisks indicate 
significant changes towards vehicle (*p<0.05, **p<0.01, Students t-test). 
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Figure 4.27 Effect of signalling inhibitors on CCL2-mediated THP-1 cell 
chemotaxis 
(A) Representative images showing the effect of gallein (Gβγ), U-73122 (PLC), LY-
294002 (PI3K), R-59-022 (DAGK), RHC-80267 (DAGL), GF-109203X (PKC), and 
dantrolene (RyR) on THP-1 cell chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2 
hours).  Scale bar represents 10 µm.  (B) Bar chart showing normalised THP-1 cell 
chemotaxis towards vehicle (water) or CCL2 (50 ng/ml, lower chamber, 2 hours) in the 
presence of vehicle (DMSO) or inhibitors at concentrations shown.  Chemotactic index is 
a ratio of the number of cells that migrated towards CCL2 over the number of cells that 
migrated towards vehicle.  Data represents mean ± SEM from n=4 transwells.  Asterisks 
indicate significant changes towards vehicle (**p<0.01, One-way ANOVA with Bonferroni’s 
multiple comparison). 
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4.4 Summary 
This chapter employed monocytic THP-1 cells and human PBMCs as in vitro models in 
order to elucidate the basic signalling mechanisms involved in CCL2/CCR2-mediated 
monocyte signalling and function as measured by intracellular Ca2+ mobilisation, cell 
migration, and adhesion to vascular endothelium.  Using a combination of methodology, a 
number of important findings were made.  Initial observations suggested a role of CCL2 in 
intracellular Ca2+ release and cell migration.  The inhibitory effects of BAPTA-AM and 
other studies in the absence of extracellular Ca2+ suggested that Ca2+ was required for 
efficient CCL2 signalling.  Further studies with BMS-CCR2-22 indicated that CCL2-
mediated monocyte intracellular Ca2+ release, migration and adhesion to vascular 
endothelium required CCR2 activation.  The impairment of CCL2-mediated intracellular 
Ca2+ release and migration by PTx strongly suggested that CCR2 coupled to Gαi/o-type G-
proteins.  Although intracellular Ca2+ experiments using gallein could not be performed, 
the inhibitory effects of this on THP-1 cell chemotaxis suggested that Gβγ activation was 
required for monocyte chemotaxis towards CCL2.  Further experiments with LY-294002 
and U-73122 pointed towards an involvement of PI3K and PLC in CCL2/CCR2-mediated 
monocyte signalling and function.  Studies with XeC supported PLC studies further by 
suggesting that IP3-mediated Ca
2+ release from internal stores was required for 
CCL2/CCR2-mediated monocyte intracellular Ca2+ release and chemotaxis.  Experiments 
using the inhibitor dantrolene however, suggested that RyR activation was required for 
efficient CCL2/CCR2-mediated monocyte function, but not signalling.  The results of 
thapsigargin studies indicated an involvement of SERCA while also indirectly confirming 
an involvement of the ER for efficient CCL2/CCR2-mediated monocyte signalling and 
function.  An involvement of SOCE was tested using the SOCE inhibitor SKF 96365, but 
the results of these studies pointed towards a possible “off-target” effect of this compound.  
In other studies investigating a requirement of DAG, experiments with DAGL (RHC-
80267) and DAGK (R-59-022) inhibitors suggested a requirement of these enzymes for 
efficient CCL2/CCR2-mediated monocyte signalling and function.  Interestingly, the 
inhibitory effect of GF-109203X on low concentrations of CCL2 indicated that PKC was 
needed for CCL2/CCR2 monocyte signalling, but not function.  Interestingly, GF-109203X 
studies also suggested that PKC regulated the decay of CCL2 Ca2+ transients. 
Taken together, these findings suggest that CCL2/CCR2-mediated monocyte signalling 
and function involves an activation of a number of signal transduction components.  These 
findings highlight the importance of understanding the influence of other chemotactic 
pathways on CCL2/CCR2-mediated monocyte signalling and function.  Chapter 5 
therefore addressed this gap in knowledge by examining the requirement of extracellular 
nucleotides and purinoceptors for efficient CCL2/CCR2-mediated monocyte signalling and 
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function using THP-1 cells and human PBMCs as models.  Similarly, to the previous 
chapter, great importance was given to CCL2/CCR2 activation as measured by 
intracellular Ca2+ release, cell migration, and adhesion to vascular endothelium. 
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Chapter 5: Modulation of 
CCL2/CCR2-mediated monocyte 
signalling and function by 
extracellular nucleotides 
5.1 Introduction 
Purinoceptor signalling describes a widespread intercellular system by which purine and 
pyrimidine nucleotides and nucleosides participate in short-term and long-term signalling 
in many cellular processes such as neurotransmission, secretion, cell differentiation, 
proliferation and death (Burnstock, 2012).  The term “purinergic” signalling was initially 
proposed by Burnstock (1971), following studies identifying the role of ATP and ADP in 
non-adrenergic, non-cholinergic (NANC) transmission in the gut (Burnstock et al., 1970).  
The purinoceptor signalling system has since expanded from its humble beginnings and 
now forms an extensive network comprising of nineteen purinoceptors subdivided into 
three distinct families termed P1, P2X and P2Y (Section 1.7.2, Chapter 1) (Khakh et al., 
2001; Abbracchio et al., 2006; Fredholm et al., 2011).   
As discussed in Chapter 1, multiple purinoceptors are expressed by monocytes (Chapter 
1, Table 1.5), suggesting that purinoceptors regulate monocyte signalling and function.  
Early studies by Fischer et al. (1976) first postulated a role for P1 purinoceptors in 
monocyte maturation by showing that adenosine catabolism by ADA prevented their 
maturation to macrophages.  However, it is now known that P1 receptors differentially 
modulate monocyte signalling and function (Haskό et al., 2007; Haskό and Pacher, 2012).  
For example, studies by Takahashi et al. (2007) have shown that while A2A receptors 
promote IL-18-induced monocyte adhesion to the vascular endothelium, other subtypes 
such as A1 and A3 prevent adhesion.  However, in general, P1 receptors play a restorative 
and protective role in monocytes where their activation is known to decrease the 
production of pro-inflammatory mediators such as TNFα, CCL3, and nitric oxide (Le Vraux 
et al., 1993; Haskό et al., 1996; Szabo et al., 1998). 
P2 receptors are also thought to coordinate monocyte signalling and function.  For 
example, studies by Kaufmann et al. (2005), Elliott et al. (2009) and Kronlage et al. (2010) 
have shown that apoptotic, damaged, or infected cells release extracellular nucleotides 
into their environments as “host tissue damage” signals in a bid to recruit monocyte and 
macrophages required for their clearance.  Other groups (Grahames et al., 1999; Warny 
et al., 2001; Cox et al., 2005; Ben Yebdri et al., 2009; Higgins et al., 2014) have also 
shown through their experiments that P2 receptors such as P2Y2, P2Y6, and P2X7 
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regulate the release of the pro-inflammatory mediators TNFα, CCL2, and IL-1β from 
human monocytes and monocytic cells. 
Although the studies described above suggest that purinoceptor signalling is important for 
monocyte signalling and function, it is fast becoming clear that aberrant purinoceptor 
signalling is associated with the onset and progression of an increasing number of 
monocyte-associated pathologies.  For example, studies by Buchheiser et al. (2011) have 
shown that CD73, the enzyme responsible for hydrolysing nucleoside monophosphates 
(Chapter 1, Table 1.6), protects against monocyte recruitment in atherogenesis.  Other 
studies (Seye et al., 2003), have shown that P2Y2 activation promotes monocyte adhesion 
during atherogenesis by inducing the expression of VCAM-1 on arterial smooth muscle 
cells.   
Hence, there seems a strong association between purinoceptor signalling and monocyte-
associated pathologies.  Although purinoceptor signalling represents an attractive 
therapeutic area, the development of novel therapies targeting purinoceptor signalling 
remains at an early stage.  With the obvious exception of anti-thrombotic P2Y12 
antagonists that prevent the formation of platelet-monocyte aggregates (Wijeyeratne and 
Heptinstall, 2011), progress in this area has been relatively slow (Jacobson et al., 2012).  
Considering that other chemoattractants such as chemokines also steer monocyte 
function, the challenges faced within purinoceptor drug discovery may be due to an 
incomplete understanding of the interactions of purinoceptor pathways with other 
established chemotactic pathways.   
5.2 Aims 
THP-1 cells and human PBMCs were used as in vitro models to investigate the signalling 
interactions between purinoceptor and CCL2/CCR2 signalling pathways in monocytes.  
Studies were performed with a view to investigating the modulation of CCL2/CCR2-
mediated monocyte signalling and function by P1 and P2 purinoceptors as measured by 
intracellular Ca2+ release, monocyte migration, and adhesion to vascular endothelial cells.  
Biological and pharmacological tools were employed in order to address each of the 
smaller objectives in this chapter.   
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5.3 Results 
5.3.1 Chemotactic effects of extracellular nucleotides on THP-1 cells 
Recent evidence suggests that apoptotic cells release extracellular nucleotides into their 
microenvironment in order to recruit mononuclear phagocytes (Elliott et al., 2009).  It is 
possible, therefore, that extracellular nucleotides coordinate with chemokines to influence 
the signalling and function of receptor-expressing monocytes.  To enable an examination 
of this hypothesis, a brief study was undertaken to investigate whether extracellular 
nucleotides were chemotactic for monocytes.  To address this hypothesis, studies 
assessed THP-1 cell chemotaxis towards 1 µM ATP, ADP, UTP, and UDP. 
As shown (Figure 5.1), the chemotactic index for THP-1 cells towards vehicle was 1 ± 0.2 
(n=4).  A significant increase in chemotaxis was observed in cells exposed to ATP (4 ± 1, 
n=4, p<0.05) and UTP (6 ± 1, n=4, p<0.01), which suggested that both nucleotides are 
chemotactic.  Although THP-1 cells migrated readily towards ADP (3 ± 0.1, n=4) and UDP 
(3 ± 0.4, n=4), the chemotactic indexes for these were not significantly different from 
vehicle (n=4, p>0.05).  This data suggested that while ATP and UTP were chemotactic for 
THP-1 cells, ADP and UDP were not.  It is possible, however, that higher concentrations 
of ADP and UDP are required to evoke a chemotactic response.   
Taken together, these data suggest that the extracellular nucleotides ATP and UTP are 
chemotactic for THP-1 cells.  It is possible, therefore, that monocytes expressing CCR2 
and specific purinoceptors are responsive to CCL2 as well as ATP and UTP and that this 
influences their signalling and function. 
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Figure 5.1 THP-1 cell migration towards extracellular nucleotides 
(A)  Representative images showing THP-1 cell chemotaxis towards vehicle (water), ATP, 
ADP, UTP or UDP (1 µM, lower chamber, 2 hours).  Scale bar represents 10 µm.  (B) Bar 
chart showing normalised THP-1 cell chemotaxis towards vehicle (water), ATP, ADP, UTP 
or UDP (1 µM, lower chamber, 2hrs).  Chemotactic index is a ratio of the number of cells 
that migrated towards extracellular nucleotides over the number of cells that migrated 
towards vehicle.  Data represents mean ± SEM from n=4 transwells.  Asterisks indicate 
significant changes towards vehicle (**p<0.01, *p<0.05, One-way ANOVA with 
Bonferroni’s multiple comparison). 
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5.3.2 Effect of ecto-nucleotidases on CCL2/CCR2-mediated THP-1 cell and PBMC 
signalling and function 
The ecto-nucleotidases are a family of extracellular enzymes that hydrolyse extracellular 
nucleotides in order to modulate their release and availability at purinoceptors (Chapter 1, 
Section 1.7.6) (Zimmermann et al., 2012).  The ecto-nucleoside triphosphate 
diphosphohydrolases (E-NTPDases) are the major ecto-nucleotidase family involved in 
hydrolysing nucleoside triphosphates (NTP) and diphosphates (NDP) to nucleoside 
monophosphates (NMP) (Robson et al., 2006).  To date, eight E-NTPDase isoenzymes 
(NTPDase1-8) encoded by the genes ENTPD1-8 have been identified (Robson et al., 
2006; Zimmermann et al., 2012).  While NTPDase1, NTPDase2, NTPDase3, and 
NTPDase8 are type II plasma membrane proteins, NTPDase4, NTPDase5, NTPDase6, 
and NTPDase7 are cytosolic and do not hydrolyse nucleotides (Robson et al., 2006).   
The results presented in Figure 5.1 suggest that in an in vivo environment, the capacity of 
monocytes to traffic in response to CCL2 is likely to be influenced by extracellular 
nucleotides.  However, these data also suggest that extracellular nucleotides are far less 
chemotactic for monocytes than CCL2 (Chapter 4) and may therefore play a much smaller 
role than CCL2 as chemoattractants.  While this is possible, it may be that both pathways 
direct monocyte signalling and function downstream of receptor activation through 
signalling crosstalk.  To examine the validity of this hypothesis, studies assessed the 
requirement of extracellular nucleotides for CCL2/CCR2-mediated monocyte signalling 
and function using THP-1 cells and human PBMCs as models.  Studies also employed 
apyrase, an NTPDase1 isolated from potato (S. tuberosum) and described by the 
manufacturers (Sigma-Aldrich, UK) as a mixture of two ATP/ADP specific isoenzymes: 
one with a high ratio of ATPase to ADPase activity (10:1), and one with a low ratio of 
ATPase to ADPase activity (1:1) (Kettlun et al., 1982). 
5.3.2.1 Investigating the selectivity of apyrase 
Prior to conducting experiments, it was first important to perform studies to confirm that 
apyrase was selective for ATP and ADP.  To address this goal, salt-buffered solution 
(SBS) was spiked with 100 µM of ATP, ADP, UTP, or UDP, and vehicle or apyrase (2 
U/ml), and sampled at 0 and 30 minutes.  Levels of NTPs, NDPs, and nucleosides (peak 
height) were detected in samples using ion-pair reverse-phase HPLC. 
As shown (Table 5.1 and Appendix Figures A6-A9), when incubated with vehicle, the peak 
heights (a measure of nucleotide quantity) of all four nucleotides between 0 and 30 
minutes were not significantly different (n=3, p>0.05).  This result suggested that 
nucleotide levels in SBS remained stable over this period.  As also shown, apyrase 
treatment caused a drop in the peak heights of all four nucleotides, where experiments 
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showed that levels of ATP, ADP, and UDP were significantly less in apyrase-treated 
samples than in vehicle-treated 0 minute and 30 minute samples (n=3, p<0.01).  Although 
apyrase also decreased levels of UTP, a significant reduction was only observed between 
vehicle-treated 30 minute samples and apyrase-treated samples (n=3, p<0.05).  In 
experiments involving ATP or ADP (Appendix Figures A6 and A7), a drop in nucleotide 
levels was accompanied by a significant increase in adenosine (n=3, p<0.01, compared to 
vehicle-treated 0 and 30 minutes).  Similarly, a reduction in UTP and UDP by apyrase 
(Table 5.1), resulted in an increase in UMP and uridine (n=3, p<0.01, compared to 
vehicle-treated 0 and 30 minutes) (Appendix Figures A8 and A9).   
Taken together, these data suggest that apyrase hydrolyses purine and pyrimidine NTPs 
and NDPs.  These data also suggest that apyrase exhibits CD73-like activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
177 
 
Table 5.1 Hydrolysis of nucleotides by apyrase  
Nucleotide/ 
Nucleoside 
Peak height (Absorbance 254 nm) 
100 µM ATP Vehicle 0 minutes Vehicle 30 minutes Apyrase 30 minutes 
ATP 38150 ± 4007 37325 ± 4423 471 ± 471** 
ADP 6445 ± 2604 5800 ± 1948 581 ± 47 
AMP 390 ± 194 383 ± 151 1068 ± 1019 
Adenosine 319 ± 319 556 ± 284 65077 ± 17289** 
100 µM ADP Vehicle 0 minutes Vehicle 30 minutes Apyrase 30 minutes 
ATP 1751 ± 137 1299 ± 443 0 ± 0 
ADP 32677 ± 1635 32558 ± 1754 517 ± 64** 
AMP 2743 ± 201 1875 ± 292 853 ± 230 
Adenosine 620 ± 312 1734 ± 220 64701 ± 6518** 
100 µM UTP Vehicle 0 minutes Vehicle 30 minutes Apyrase 30 minutes 
UTP 23045 ± 4521 23689 ± 4307 
3156 ± 95* 
(vehicle 30 minutes) 
UDP 5062 ± 989 4508 ± 674 10 ± 10 
UMP 687 ± 66 646 ± 47 36189 ± 9890** 
Uridine 49 ± 26 32 ± 32 30479 ± 4862** 
100 µM UDP Vehicle 0 minutes Vehicle 30 minutes Apyrase 30 minutes 
UTP 1489 ± 605 1671 ± 675 1326 ± 482 
UDP 39213 ± 3256 37527 ± 2846 0 ± 0** 
UMP 2248 ± 73 2173 ± 60 40600 ± 5145** 
Uridine 87 ± 44 213 ± 50 30432 ± 132** 
Peak height (absorbance at A254nm) for extracellular nucleotides (100 µM) at 0 and 30 
minutes in the presence of vehicle (SBS) and after 30 minutes incubation with apyrase (2 
U/ml).  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant 
changes towards vehicle-treated samples at 0 and 30 minutes unless otherwise stated 
(**p<0.01, *p<0.05, One-way ANOVA with Bonferroni’s multiple comparison). 
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5.3.2.2 Effect of apyrase on CCL2-evoked Ca2+ responses in THP-1 cells and human 
PBMCs 
To determine the requirement of extracellular nucleotides for CCL2/CCR2-mediated 
monocyte signalling, studies examined the effects of apyrase (2 U/ml) on CCL2-evoked 
intracellular Ca2+ responses in THP-1 cells and human PBMCs.  Initial experiments tested 
the effects of apyrase on THP-1 intracellular Ca2+ responses evoked by a range of 
concentrations of CCL2 (1-500 ng/ml). 
As shown (Figure 5.2a), addition of apyrase to THP-1 cells caused a small dip in the 
baseline Ca2+ response (-3% ± 0.3%Fmax, n=3).  A similar effect was not seen with 
vehicle, which indicated the possibility that Ca2+ homeostasis was being modulated by 
apyrase through its ability to scavenge nucleotides.  As also shown (Figure 5.2b and c), 
apyrase attenuated intracellular Ca2+ responses evoked by all concentrations of CCL2, 
causing a rightward parallel shift in the CCL2 concentration-response curve which could 
only be surmounted by increasing the concentration of CCL2.  The EC50 values for CCL2 
in untreated and apyrase-treated THP-1 cells were 15 ± 3 ng/ml (n=3) and 65 ± 8 ng/ml 
(n=3), respectively, and indicated that apyrase reduced the potency of CCL2 by 4-fold.  
For a single concentration of 50 ng/ml CCL2, the %Fmax values of untreated (15 ± 2%, 
n=3) and apyrase-treated (6 ± 0.3%, n=3) cells indicated a % inhibition of 59 ± 5% (n=3 
p<0.01).   
To determine whether apyrase treatment also affected the decay of CCL2 Ca2+ transients, 
the  values for treatments were analysed and compared.  Figure 5.2d shows the decay 
rates (, sec) for Ca2+ transients to CCL2 100, 50, and 30 ng/ml in untreated and apyrase-
treated THP-1 cells.  Although apyrase treatment reduced the  values for all three CCL2 
concentrations, a significant reduction (80 ± 1%, n=3, p<0.01) was only observed for 30 
ng/ml CCL2, where the  values for untreated and apyrase-treated cells were 123 ± 6 
seconds (n=3) and 25 ± 1 seconds (n=3), respectively.  Although apyrase also caused a 
reduction in  for 100 ng/ml CCL2, the values for untreated (82 ± 16 seconds, n=3) and 
apyrase-treated (39 ± 1 seconds, n=3) cells were not significantly different (n=3, p>0.05).  
Similarly, the  values for 50 ng/ml CCL2 in untreated (74 ± 14 seconds, n=3) and 
apyrase-treated (35 ± 1 seconds, n=3) cells were also not significantly different (n=3, 
p>0.05).  Although a significant reduction in  was not seen with higher concentrations of 
CCL2, these data suggest that apyrase promotes a more rapid decay of CCL2 Ca2+ 
transients. 
It is widely accepted that E-NTPDases require Ca2+ or Mg2+ for activity (Kukulski et al., 
2005).  Thus, it was hypothesised that the effects of apyrase would be partially dependent 
on Ca2+.  To examine this hypothesis, the effects of apyrase (2 U/ml) on CCL2 (50 ng/ml)-
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evoked intracellular Ca2+ responses were assessed in the absence of extracellular Ca2+ by 
resuspending cells in an SBS buffer from which Ca2+ was omitted (1.5 mM CaCl2) and 
replaced with the Ca2+ chelator, EGTA (1 mM) (see Chapter 2, Section 2.6.2 for details).  
As shown (Figure 5.3a), apyrase again produced a small dip in the baseline Ca2+ 
response.  Although this effect of apyrase was similar to previous experiments, the 
%Fmax values were <1% and therefore, not possible to quantify.  As also shown (Figure 
5.3b and c), apyrase attenuated CCL2-evoked intracellular Ca2+ responses by 85 ± 7% 
(n=3, p<0.05), where the %Fmax values for untreated and apyrase-treated cells were 10 ± 
2% (n=3) and 1 ± 1% (n=3), respectively.  This result is interesting because it suggests 
that CCL2-evoked Ca2+ responses are more susceptible to apyrase in the absence of 
extracellular Ca2+ than in the presence of extracellular Ca2+, where 50 ng/ml CCL2 
responses were attenuated by 59 ± 5% (n=3 p<0.01).  What is also interesting about 
these data is that they suggest that Mg2+ (1.2 mM) in the experimental buffer may have 
compensated for the lack of Ca2+.  From the data in Figure 5.3, it can also be seen that 
THP-1 cells exhibited an apyrase-resistant component of ~15%Fmax, which may indicate 
a bona-fide activation of CCR2 by CCL2.  Due to the low CCL2 Ca2+ responses in 
apyrase-treated cells, the decay rates for treatments could not be determined. 
The effects of apyrase (2 U/ml) were next examined on CCL2 (50 ng/ml)-evoked 
intracellular Ca2+ responses in human PBMCs.  As shown (Figure 5.4), apyrase 
attenuated CCL2-evoked Ca2+ responses by 47 ± 3% (n=3, p<0.01), where the %Fmax 
values for untreated and apyrase-treated PBMCs were 6 ± 0.3% (n=3) and 3 ± 0.3% 
(n=3), respectively.  These data support THP-1 cell data but also suggest that apyrase 
attenuates CCL2-evoked Ca2+ responses in a mixed cell population likely to contain 
CCR2-expressing monocytes.  The heterogeneous nature of PBMCs may also explain 
why apyrase attenuated CCL2-evoked Ca2+ responses less in PBMCs than in THP-1 
cells.  A further analysis of the decay rates for all treatments showed that the  values for 
untreated (59 ± 29 seconds, n=3) and apyrase-treated cells (39 ± 12 seconds, n=3) were 
not significantly different (n=3, p>0.05).  This data suggests that apyrase does not 
influence the decay of CCL2 Ca2+ transients in PBMCs. 
Taken together, these results suggest that extracellular nucleotides are likely to be 
required for efficient CCL2/CCR2-mediated monocyte signalling. 
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Figure 5.2 Effect of apyrase on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of apyrase (2U /ml) on baseline Ca2+.  (B) 
Representative Ca2+ transients and (C) normalised concentration-response curve showing 
intracellular Ca2+ responses to CCL2 (1-500 ng/ml) in THP-1 cells pre-treated with vehicle 
(water) or apyrase (2 U/ml), for 10 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (% Fmax).  (D) Bar chart showing Ca2+ decay rates (, sec) for 
Ca2+ transients to CCL2 (30-100 ng/ml) in THP-1 cells pre-treated with vehicle (water) or 
apyrase (2 U/ml), for 10 minutes.  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (**p<0.01, Students t-test). 
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Figure 5.3 Effect of apyrase on CCL2-evoked Ca2+ responses in THP-1 cells in 
the absence of extracellular Ca2+ 
(A) Representative trace showing the effect of apyrase (2U /ml) on baseline Ca2+.  (B) 
Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(water) or apyrase (2 U/ml), for 10 minutes.  (C) Bar chart showing normalised intracellular 
Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (water) or 
apyrase (2 U/ml), for 10 minutes.  Responses normalised to Ca2+ signals elicited by 40 µM 
digitonin (% Fmax).  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate 
significant changes towards vehicle (**p<0.01, Students t-test). 
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Figure 5.4 Effect of apyrase on CCL2-evoked Ca2+ responses in human PBMCs 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in PBMCs pre-treated with vehicle 
(water) or apyrase (2 U/ml), for 10 minutes.  (B) Bar chart showing normalised intracellular 
Ca2+ responses to CCL2 (50 ng/ml) in PBMCs pre-treated with vehicle (water) or apyrase 
(2 U/ml), for 10 minutes.  Responses normalised to Ca2+ signals elicited by 40 µM 
digitonin (% Fmax).  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate 
significant changes towards vehicle (**p<0.01, Students t-test). 
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5.3.2.3 Effect of apyrase on CCL2-mediated THP-1 cell chemotaxis and adhesion 
To examine the requirement of extracellular nucleotides for CCL2/CCR2-mediated 
monocyte function, THP-1 cells and PBMCs were employed as models to test the effects 
of apyrase (2 U/ml) on cellular chemotaxis towards CCL2 (50 ng/ml).  As shown (Figures 
5.5 and 5.6), apyrase attenuated THP-1 cell chemotaxis, but enhanced PBMC 
chemotaxis.  In THP-1 cell experiments (Figure 5.5), a significantly higher chemotactic 
index was observed towards CCL2 (7 ± 2, n=5) than towards vehicle (1 ± 0.2, n=5, 
p<0.01).  Interestingly, the chemotactic indexes for untreated (7 ± 2, n=5) and apyrase-
treated cells (2 ± 0.4, n=5) reflected an inhibition of 71 ± 11% (n=5, p<0.05), and 
suggested that apyrase almost abolished CCL2-dependent chemotaxis.  In experiments 
with human PBMCs (Figure 5.6), although a one-way ANOVA analysis suggested that the 
chemotactic index of cells exposed to CCL2 (17 ± 2, n=12) was significantly higher than 
cells migrating towards vehicle (1 ± 0.2, n=12, p<0.01), a Bonferroni’s means comparison 
suggested that these populations were not significantly different (n=12, p>0.05).  Despite 
this, it was seen that apyrase enhanced PBMC migration towards CCL2 by 3.7 ± 1-fold 
(n=12, p<0.01), where the chemotactic indexes for untreated and apyrase-treated PBMCs 
were 17 ± 2 (n=12) and 62 ± 11 (n=12), respectively.  These data are difficult to explain, 
but it might be that apyrase has a chemotactic effect on mixed cell populations.   
Studies by Grϋnewald and Ridley (2010) have shown that the ecto-nucleotidase, CD73 
represses THP-1 cell adhesion to HUVECs by generating adenosine.  In HPLC studies 
(Section 5.3.2.1), incubation of ATP and ADP with apyrase produced adenosine, 
suggesting that apyrase exhibits CD73-like activity.  This suggests that in an in vitro or in 
vivo environment, apyrase would prevent monocyte adhesion to the vascular endothelium.  
Thus, in an effort to examine this hypothesis, studies tested the effects of apyrase (2 
U/ml) on the adhesion of CCL2-primed THP-1 cells to quiescent HUVEC monolayers.   
As shown (Figure 5.7), apyrase treatment caused a 5.9 ± 1-fold (n=16, p<0.01) increase 
in the adhesion of vehicle-treated THP-1 cells, where the %CCL2 control values for 
untreated (vehicle alone) and apyrase/vehicle-treated cells were 19 ± 7% (n=16) and 111 
± 25% (n=16), respectively.  The %CCL2 control values for CCL2-primed untreated and 
apyrase-treated cells were 100 ± 13% (n=16, p<0.05) and 118 ± 26% (n=16, p<0.01), 
respectively.  These data suggested that CCL2-priming and/or apyrase treatment 
promoted THP-1 cell adhesion. 
Taken together, these data suggest that apyrase differentially modulates CCL2/CCR2-
mediated THP-1 cell and PBMC function.  The effects of apyrase in these models would 
need to be considered when performing in vivo studies. 
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Figure 5.5 Effect of apyrase on CCL2-mediated THP-1 cell chemotaxis 
(A)  Representative images showing the effect of apyrase (2 U/ml) on THP-1 cell 
chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  
(B) Bar chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 
(50 ng/ml, lower chamber, 2hrs), in the presence of apyrase (2U/ml).  Chemotactic index 
is a ratio of the number of cells that migrated towards CCL2 over the number of cells that 
migrated towards vehicle.  Data represents mean ± SEM from n=4 transwells.  Asterisks 
indicate significant changes towards vehicle (**p<0.01, One-way ANOVA with Bonferroni’s 
multiple comparison). 
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Figure 5.6 Effect of apyrase on CCL2-mediated human PBMC chemotaxis 
(A)  Representative images showing the effect of apyrase (2 U/ml) on PBMC chemotaxis 
towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  (B) Bar 
chart showing normalised PBMC chemotaxis towards vehicle (water) or CCL2 (50 ng/ml, 
lower chamber, 2hrs), in the presence of apyrase (2U/ml).  Chemotactic index is a ratio of 
the number of cells that migrated towards CCL2 over the number of cells that migrated 
towards vehicle.  Data represents mean ± SEM from a total of n=12 transwells from n=3 
donors.  Asterisks indicate significant changes towards vehicle (**p<0.01, One-way 
ANOVA with Bonferroni’s multiple comparison). 
186 
 
 
 
 
 
 
 
 
 
Figure 5.7 Effect of apyrase on THP-1 cell adhesion to quiescent HUVEC 
monolayers 
Bar chart showing normalised adhesion of vehicle or CCL2-primed (50 ng/ml) THP-1 cells 
to quiescent HUVEC monolayers following treatment with vehicle (water) or apyrase (2 
U/ml, 45 minutes).  Normalised adhesion represented as a percentage of mean adhesion 
of CCL2-primed THP-1 cells in the absence of apyrase.  Data represents mean ± SEM 
from a total of n=16 replicates from n=4 experiments.  Asterisks indicate significant 
changes towards vehicle (*p<0.05, **p<0.01, One-way ANOVA with Bonferroni’s multiple 
comparison). 
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5.3.2.4 Effect of apyrase isoenzymes on CCL2-evoked Ca2+ responses in THP-1 cells 
The data presented has shown that apyrase hydrolyses NTPs, NDPs, and NMPs.  As 
mentioned previously, the manufacturers claim that this apyrase consists of two 
isoenzymes, one with a high ratio (10:1) of ATPase to ADPase activity, and one with a low 
ratio (1:1) of ATPase to ADPase activity.  Thus, for the purpose of this study, these 
isoenzymes were renamed “high NTPase/low NDPase” and “high NTPase/high NDPase”, 
respectively.  The apyrase employed for the studies in thesis will be described in the 
current study as a “high NTPase/high NDPase” apyrase. 
To examine the specific requirement of NTPs and NDPs for CCL2/CCR2-mediated 
monocyte signalling, studies employed a “high NTPase/high NDPase” apyrase (0-4 U/ml), 
and a second NTP-preferring “high NTPase/low NDPase” apyrase (0-4 U/ml).  Studies 
tested the effects of these on THP-1 cell intracellular Ca2+ responses evoked by 50 ng/ml 
CCL2.   
As shown in Figure 5.8a, a small dip in the baseline Ca2+ response was seen upon 
application of the “high NTPase/high NDPase” apyrase to cells (%Fmax 3 ± 0%, n=3), but 
not upon application of the “high NTPase/low NDPase”.  This data suggests that baseline 
Ca2+ responses may be more dependent on NDPs than NTPs.  As also shown, a greater 
inhibition of CCL2-evoked intracellular Ca2+ responses was observed with the “high 
NTPase/high NDPase” apyrase than with the “high NTPase/low NDPase” apyrase.  At the 
highest concentration tested (4 U/ml), the “high NTPase/high NDPase” and “high 
NTPase/low NDPase” apyrases attenuated CCL2-evoked Ca2+ responses by 79 ± 5% 
(n=3, p<0.05) and 44 ± 5% (n=3, p<0.01), respectively.  Although these data suggested 
that the “high NTPase/high NDPase” apyrase attenuated CCL2 Ca2+ responses almost 2-
fold more than the “high NTPase/low NDPase” apyrase, a significant difference between 
these data sets was not found (n=3, p>0.05).  However, at 0.25 U/ml, the “high 
NTPase/high NDPase” apyrase attenuated CCL2 Ca2+ responses (36 ± 4%, n=3, p<0.05) 
significantly more (n=3, p<0.05) than the “high NTPase/low NDPase” apyrase (7 ± 7%, 
n=3, p>0.05).  In paired experiments with 0.25 U/ml of the “high NTPase/high NDPase” 
apyrase, the %Fmax values for CCL2 in untreated and apyrase-treated cells were 18 ± 
1% (n=3) and 10 ± 1% (n=3) respectively.  For 0.25 U/ml of the “high NTPase/low 
NDPase” apyrase, these were 16 ± 2% (n=3) and 13 ± 3% (n=3), respectively.  A 
significantly higher inhibition with the “high NTPase/high NDPase” over the “high 
NTPase/low NDPase”, was also observed at 0.1 U/ml, where the % inhibition values were 
28 ± 4% (n=3, p<0.05) and 5 ± 3% (n=3, p>0.05), respectively.  In these paired 
experiments, for the “high NTPase/high NDPase” apyrase, the %Fmax values for CCL2 in 
untreated and apyrase-treated cells were 18 ± 1% (n=3) and 12 ± 2% (n=3) respectively, 
while for the “high NTPase/low NDPase” apyrase, these were 16 ± 2% (n=3) and 14 ± 3% 
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(n=3), respectively.  In general, these data suggested that at lower concentrations, the 
“high NTPase/high NDPase” apyrase attenuated CCL2 Ca2+ responses far better than the 
“high NTPase/low NDPase” apyrase.  Interestingly, these data also showed that a 10-fold 
higher concentration (0.1 U/ml) of the “high NTPase/low NDPase” apyrase was required 
than the “high NTPase/high NDPase” apyrase to redeem 100% of the control CCL2 Ca2+ 
response.   
To assess whether these isoenzymes differentially affected the decay of CCL2 Ca2+ 
transients, the decay rates (, sec) for all treatments were analysed and compared where 
possible.  A significant difference in  between the apyrases was not observed for any of 
the concentrations examined (4, 2, 1, 0.5, 0.25, 0.1 U/ml) (n=3, p<0.05).  For example, at 
0.25 U/ml, the  values for the “high NTPase/high NDPase” apyrase (46 ± 4 seconds, n=3) 
and “high NTPase/low NDPase” apyrase (69 ± 8 seconds, n=3) were not significantly 
different (n=3, p>0.05). 
Taken together, these data suggest that CCL2-evoked intracellular Ca2+ responses in 
THP-1 cells are more sensitive to inhibition by “high NTPase/high NDPase” apyrase.  This 
suggests that NDPs contribute to CCL2/CCR2-mediated monocyte signalling more than 
NTPs. 
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Figure 5.8 Effect of apyrase isoenzymes on CCL2-evoked Ca2+ responses in 
THP-1 cells 
(A) Representative trace showing the effect of two different apyrases on baseline Ca2+.  
(B) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or apyrases with varying NDPase activity (0-4 U/ml) for 10 minutes.  (C) 
Concentration-response graph showing % CCL2 control values for normalised intracellular 
Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (water) or 
apyrases with varying NDPase activity (0-4 U/ml) for 10 minutes.  Responses given as a 
percentage of normalised intracellular Ca2+ responses to CCL2 (50 ng/ml) in the absence 
of apyrase.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  
Data represents mean ± SEM from n=3 replicates (*p<0.05, Students t-test). 
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5.3.3 Effect of ADA on CCL2-evoked Ca2+ responses in THP-1 cells 
The HPLC results presented in this chapter suggest that apyrase exhibits CD73-like 
activity and produces adenosine from ATP and ADP.  It is possible, therefore, that the 
effects of apyrase on THP-1 cells and PBMCs reflect an activation of P1 purinoceptors by 
adenosine.  In an effort to examine this hypothesis, studies employed adenosine 
deaminase (ADA, EC 3.5.4.4), an enzyme responsible for irreversibly deaminating 
adenosine to inosine (Yegutkin, 2008).  In humans, two isoenzymes of ADA have been 
identified, ADA1 (ADA) and ADA2 which can exist either as intracellular cytosolic 
enzymes, or as ecto-ADAs (Wiginton et al., 1986; Zavialov and Engström, 2005). 
To address the aim of this study, experiments tested the effects of ADA on intracellular 
Ca2+ responses evoked by 50, 20, and 10 ng/ml CCL2.  As shown in Table 5.2, Ca2+ 
responses evoked by all three CCL2 concentrations were not significantly affected by 
ADA (n=3, p>0.05).  For example, in experiments with CCL2 20 ng/ml, the %Fmax values 
for CCL2 in untreated and ADA-treated cells were 22 ± 1% (n=4) and 18 ± 2% (n=4), 
respectively. 
The decay rates (, sec) for Ca2+ transients were also compared for all treatments but 
were not found to be significantly different (n=4, p>0.05, data not shown).  For example, 
for 20 ng/ml CCL2, the  values for untreated and apyrase-treated cells were 79 ± 2 
seconds (n=4) and 77 ± 2 seconds (n=4), respectively. 
Taken together, these data suggest that CCL2/CCR2-mediated monocyte signalling is 
unlikely to involve adenosine. 
Table 5.2 Effect of ADA on CCL2-evoked Ca2+ responses in THP-1 cells 
 Ca2+ response (%Fmax) 
[CCL2] ng/ml Vehicle ADA 2U/ml 
50 29 ± 1 27 ± 1 
20 22 ± 1 18 ± 2 
10 16 ± 1 14 ± 1 
Intracellular Ca2+ responses to CCL2 (50, 20 and 10 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or ADA (2 U/ml), for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from n=3 (CCL2 50 
and 10 ng/ml) and n=4 (CCL2 20 ng/ml) replicates. 
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5.3.4 Effect of endogenous ecto-nucleotidases on CCL2/CCR2-mediated THP-1 
cell signalling 
The ecto-nucleotidases are a family of extracellular plasma membrane enzymes that 
rapidly hydrolyse extracellular nucleotides in order to control their availability at 
purinoceptors (Zimmermann et al., 2012).  Although the E-NTPDases serve as the major 
ecto-nucleotidase family involved in hydrolysing NTPs and NDPs, the ecto-nucleotide 
pyrophosphatase/phosphodiesterases (E-NPPs) and alkaline phosphatases (APs) also 
contribute to NTP and NDP hydrolysis (Zimmermann et al., 2012).   
Given their ubiquitous expression in essentially every tissue and cell (Robson et al., 2006; 
Kukulski et al., 2011), ecto-nucleotidases are likely to be constantly involved in regulating 
extracellular nucleotide availability.  The evidence presented in this chapter has 
suggested that extracellular nucleotides are required for CCL2/CCR2-mediated monocyte 
signalling and function.  It is possible, therefore, that by regulating the availability of 
extracellular nucleotides, endogenous ecto-nucleotidases also regulate CCL2/CCR2 
signalling.  To examine this hypothesis, the next studies tested for the presence of 
endogenous ecto-nucleotidases in monocytic THP-1 cells, and following confirmation of 
their presence, investigated the effects of ecto-nucleotidases inhibitors on CCL2-evoked 
intracellular Ca2+ responses. 
5.3.4.1 Endogenous ecto-nucleotidases in THP-1 cells 
Experiments testing for the presence of endogenously active ecto-nucleotidases involved 
spiking THP-1 cells or SBS with 100 µM ATP, and incubating for 30 minutes at room 
temperature.  Levels of ATP in supernatants (as measured by peak height) were tested 
using HPLC and compared with 0 minute samples. 
As shown (Table 5.3 and Appendix Figure A10), incubation of ATP with THP-1 cells 
significantly reduced the peak height of ATP by 11 ± 2% (n=4, p<0.05).  A reduction in the 
levels of ATP in THP-1 cell supernatants was accompanied by a 1.9 ± 0.05-fold (n=4, 
p<0.01) and 13 ± 0.2-fold (n=4, p<0.01) increase in ADP and AMP, respectively.  
Interestingly, the peak heights of ATP, ADP and AMP were unchanged in experiments 
involving SBS (n=4, p>0.05) (Table 5.3 and Appendix Figure A10).  These data suggested 
that a reduction in ATP levels in the presence of THP-1 cells occurred as a direct result of 
hydrolysis by endogenous ecto-nucleotidases. 
Taken together, these data suggest that endogenous ecto-nucleotidases in THP-1 cells 
are capable of hydrolysing extracellular nucleotides.  
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Table 5.3 Effect of THP-1 cells and SBS on nucleotide and nucleoside levels 
 Peak height (Absorbance 254 nm) 
THP-1 cells 0 minutes 30 minutes 
ATP 50211 ± 1086 (100 µM ATP) 44688 ± 479* 
ADP 2732 ± 215 5052 ± 133** 
AMP 75 ± 44 950 ± 11** 
Adenosine 67 ± 67 154 ± 60 
 Peak height (Absorbance 254 nm) 
SBS 0 minutes 30 minutes 
ATP 44983 ± 522 (100 µM ATP) 45128 ± 178 
ADP 2989 ± 790 2630 ± 814 
AMP 29 ± 29 0 ± 0 
Peak heights for extracellular nucleotides and nucleosides following incubation of ATP 
(100 µM) for 0 or 30 minutes with THP-1 cells or SBS.  Data represents mean ± SEM from 
n=4 experiments.  Asterisks indicate significant changes towards 0 minutes (**p<0.01, 
*p<0.05, Students t-test). 
5.3.4.2 Effect of ecto-nucleotidase inhibitors on CCL2-evoked Ca2+ responses in 
THP-1 cells 
Based on the above data, it was hypothesised that inhibiting endogenous ecto-
nucleotidases would modulate CCL2/CCR2-mediated monocyte signalling.  To examine 
the validity of this hypothesis, studies tested the effects of the E-NTPDase-preferring ecto-
nucleotidase inhibitors ARL-67156 and POM-1 on CCL2-evoked intracellular Ca2+ 
responses in THP-1 cells. 
5.3.4.2.1 ARL-67156 
Initial experiments employed ARL-67156, a structural analogue of ATP reported to weakly 
inhibit NTPDase1, NTPDase3, and E-NPP1 with Ki values of 11, 18, and 12 µM, 
respectively (Lévesque et al., 2007).  To address the above aim, the effects of 100 µM 
ARL-67156 on intracellular Ca2+ responses evoked by 50, 20 and 10 ng/ml CCL2, were 
examined.  As shown (Figure 5.9), treatment of THP-1 cells with ARL-67156 potentiated 
Ca2+ responses evoked by 20 ng/ml CCL2 by 1.2 ± 0.05-fold (n=9, p<0.05), where the 
%Fmax values for CCL2 shifted from 15 ± 2% (n=9) for untreated cells to 17 ± 1% (n=9) 
for ARL-67156-treated cells.  These data suggested that an inhibition of ecto-
nucleotidases potentiated CCL2/CCR2-mediated monocyte signalling.  Interestingly, Ca2+ 
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responses evoked by 50 ng/ml CCL2 (n=4, p>0.05) and 10 ng/ml CCL2 (n=9, p>0.05) 
were not potentiated by ARL-67156.  The %Fmax values for 50 ng/ml CCL2 in untreated 
and ARL-67156-treated cells were 25 ± 4% (n=4) and 25 ± 4% (n=4), respectively, while 
for 10 ng/ml CCL2 these were 20 ± 1% (n=9) and 22 ± 1% (n=9), respectively.  A possible 
explanation for these results may be that the effects of ARL-67156 on these 
concentrations were difficult to detect as 10 ng/ml and 50 ng/ml CCL2 are the near-
minimum and maximum concentrations on the CCL2 concentration-response curve 
(Chapter 4, Figure 4.1).  When analysing the decay rates for all treatments, no significant 
differences between the  values for CCL2 in untreated and treated were observed (n=4-
9, p>0.05).  For example, in paired experiments with 20 ng/ml CCL2, the  values for 
untreated and ARL-67156-treated cells were 102 ± 5 seconds (n=9) and 97 ± 7 seconds 
(n=9), respectively (n=9, p>0.05). 
Members of the E-NTPDase family of ecto-nucleotidases are known to depend on 
millimolar concentrations of Ca2+ (or Mg2+) for activity (Kukulski et al., 2005).  It is possible, 
therefore, that the effects of ARL-67156 on CCL2-evoked intracellular Ca2+ responses 
involve an inhibition of Ca2+ or Mg2+-dependent E-NTPDases.  To investigate the validity 
of this hypothesis, it was necessary to test the effects of ARL-67156 (100 µM) on THP-1 
cell intracellular Ca2+ responses to 50, 20, and 10 ng/ml CCL2 in the absence of at least 
one of these ions, Ca2+.   
As shown (Figure 5.10a and b), no significant differences between the %Fmax values for 
untreated and ARL-67156-treated cells were observed for any of the CCL2 concentrations 
tested (n=3-4, p>0.05).  For example, in experiments with 50 ng/ml CCL2, the %Fmax 
values for untreated (7 ± 1%, n=3) and ARL-67156-treated cells (5 ± 1%, n=3) were not 
significantly different (n=3, p>0.05).  These data are interesting as they suggest that the 
effects of ARL-67156 are Ca2+-dependent.  Furthermore, the results of this study, together 
with apyrase studies, indicate that Ca2+-independent and -dependent E-NTPDases are 
likely to be involved in modulating CCL2-evoked intracellular Ca2+ responses in 
monocytes. 
To assess the effects of ARL-67156 on the decay of CCL2 Ca2+ responses, the  values 
for all treatments were compared.  As shown (Figure 5.10c), ARL-67156 significantly 
reduced  for Ca2+ transients to 20 ng/ml CCL2 by 11 ± 3% (n=4, p<0.05), where the  
values for CCL2 in untreated and ARL-67156-treated cells were 267 ± 51 seconds (n=4), 
and 246 ± 50 seconds (n=4), respectively.  Although these data suggested that ARL-
67156 promoted a faster decay of CCL2 Ca2+ transients, the opposite effect was seen on 
transients evoked by 10 ng/ml CCL2 where ARL-67156 increased  by 10 ± 7-fold (n=3, 
p<0.05).  In these experiments, the  values for CCL2 in untreated and ARL-67156-treated 
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THP-1 cells were 3094 ± 2655 seconds (n=3) and 8184 ± 3683 seconds (n=3), 
respectively.  Collectively, these data suggested that ARL-67156 differentially affected the 
decay of CCL2 Ca2+ transients. 
Taken together, these data suggest that Ca2+-dependent endogenous ecto-nucleotidases 
contribute to modulating CCL2/CCR2-mediated Ca2+ responses. 
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Figure 5.9 Effect of ARL-67156 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (20 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or ARL-67156 (100 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50, 20 and 10 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or ARL-67156 (100 µM) for 15 minutes.  Responses normalised to Ca2+ 
signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from n=4 
(CCL2 50 ng/ml) or n=9 (CCL2 20 and 10 ng/ml) replicates.  Asterisks indicate significant 
changes towards vehicle (*p<0.05, Students t-test). 
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Figure 5.10 Effect of ARL-67156 on CCL2-evoked Ca2+ responses in THP-1 cells in 
the absence of extracellular Ca2+ 
(A) Representative Ca2+ transients and (B) bar chart showing normalised intracellular Ca2+ 
responses to CCL2 (50, 20 and 10 ng/ml) in THP-1 cells pre-treated with vehicle (water) 
or ARL-67156 (100 µM), for 15 minutes.  Responses normalised to Ca2+ signals elicited by 
40 µM digitonin (% Fmax).  (C) Bar chart showing Ca2+ decay rates (, sec) for Ca2+ 
transients to CCL2 (50, 20 and 10 ng/ml) in THP-1 cells pre-treated with vehicle (water) or 
ARL-67156 (100 µM), for 15 minutes.  Data represents mean ± SEM from n=3 (CCL2 50 
and 10 ng/ml) or n=4 (20 ng/ml) replicates.  Asterisks indicate significant changes towards 
vehicle (*p<0.05, Students t-test). 
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5.3.4.2.2 POM-1 
The polyoxymetalate compound POM-1 is an anionic complex comprised of transition 
metal ions bridged together by oxygen atoms.  As an ecto-nucleotidase inhibitor, POM-1 
inhibits NTPDase1, NTPDase2 and NTPDase3 with Ki values of 2.58, 28.8, and 3.26 µM, 
respectively (Mϋller et al., 2006).  This data suggests that POM-1 is 4-times more potent 
than ARL-67156 at inhibiting NTPDase1. 
In an effort to provide further support for the results of ARL-67156 studies, it was 
necessary to test the effects of POM-1 (1 and 100 µM) on THP-1 cell intracellular Ca2+ 
responses evoked by 50, 20, and 10 ng/ml CCL2.  As shown (Figure 5.11a), POM-1 
caused a transient dip (-5 ± 2%Fmax, n=3), in the baseline Ca2+ response.  Although this 
result was interesting and similar to the effect of apyrase on baseline Ca2+, it suggested 
that nucleotide accumulation by POM-1 suppressed baseline Ca2+.   
As also shown (Figure 5.11), 100 µM POM-1 abolished intracellular Ca2+ responses 
evoked by 50 ng/ml (100 ± 0% inhibition, n=3, p<0.01) and 20 ng/ml CCL2 (100 ± 0%, 
n=3, p<0.01), and almost abolished responses to 10 ng/ml CCL2 (96 ± 4%, n=3, p<0.01).  
In these experiments, the %Fmax values for 50 ng/ml CCL2 in untreated and POM-1-
treated cells were 23 ± 1% (n=3) and 0 ± 0% (n=3), respectively.  For 20 ng/ml CCL2 
these were 10 ± 2% (n=3) and 0 ± 0% (n=3), respectively, and for 10 ng/ml CCL2 these 
were (10 ± 3%, n=3) and (0.3 ± 0.3%, n=3), respectively.  From Figure 5.11, it can also be 
seen that intracellular Ca2+ responses evoked by 50, 20, or 10 ng/ml CCL2 were not 
significantly affected by 1 µM POM-1 (n=3, p>0.05).  For example, the %Fmax values for 
50 ng/ml CCL2 in untreated and POM-1-treated cells were 23 ± 1% (n=3) and 21 ± 0.3% 
(n=3), respectively.  These data indicate that 100 µM POM-1 attenuates CCL2/CCR2-
mediated monocyte signalling.   
The decay rates for CCL2 Ca2+ transients for THP-1 cells treated with vehicle or 1 µM 
POM-1 were also compared, but were not significantly different (n=3, p>0.05, data not 
shown).  For example, the  values for 50 ng/ml CCL2 Ca2+ transients from untreated and 
treated cells were 65 ± 3 seconds (n=3) and 64 ± 2 seconds (n=3), respectively (n=3, 
p>0.05).  Together, these data suggest that POM-1 (1 µM) does not affect the decay of 
CCL2 Ca2+ transients. 
While these data indicated that effects of 100 µM POM-1 in experiments might be due to 
cytotoxicity, cell viability studies were unable to demonstrate a significant reduction in 
THP-1 cell viability following a 2.5-hour exposure (Appendix Figure A3 and A4).  It was 
seen that LDH release with POM-1 fell below the 20% threshold (6% of Triton-X-100, 
n=1), while trypan blue studies indicated that the % viable cells in vehicle (100 ± 12%, 
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n=3) and POM-1 treatments (58 ± 9%, n=3), were not significantly different (n=3, p=0.1).  
Thus, the effects of POM-1 were unlikely to be attributed to cytotoxicity. 
In an effort to understand the mechanism of POM-1 further, the effects of POM-1 (100 
µM) on intracellular Ca2+ responses evoked by ATP, ADP, UTP and UDP (30 µM), were 
examined.  As shown (Table 5.4 and Appendix Figures A11 and A12), treatment of THP-1 
cells with POM-1 abolished intracellular Ca2+ responses evoked by the NDPs, ADP and 
UDP by 100 ± 0% (n=3, p<0.05 for both).  However, it was interesting to observe that 
POM-1 only attenuated Ca2+ responses evoked by the NTPs, ATP and UTP by 16 ± 3% 
(n=3, p<0.05) and 17 ± 2% (n=3, p<0.05), respectively.  These data suggested that POM-
1 preferentially abolished Ca2+ responses evoked by NDPs.  Where possible, the decay 
rates (, sec) for Ca2+ transients were also compared, but were not found to be 
significantly different (n=3, p>0.05).  For example, in ATP experiments, the  values for 
untreated (85 ± 1 seconds, n=3) and POM-1-treated cells (86 ± 1 seconds, n=3) were not 
significantly different (n=3, p>0.05). 
Taken together, these data suggest that POM-1 exhibits an off-target effect that is 
preferential for NDPs.  This finding is interesting because it suggests that POM-1 targets 
CCL2- and NDP-evoked intracellular Ca2+ responses through a similar mechanism. 
Table 5.4 Effect of POM-1 on extracellular nucleotide-evoked Ca2+ responses in 
THP-1 cells 
 Ca2+ response (%Fmax) 
Nucleotide Vehicle POM-1 100 µM 
ATP 38 ± 1 32 ± 0.3* 
ADP 26 ± 3 0 ± 0* 
UTP 44 ± 0.3 36 ± 1* 
UDP 18 ± 2 0 ± 0** 
Intracellular Ca2+ responses to nucleotides (30 µM) in THP-1 cells pre-treated with vehicle 
(water) or POM-1 (100 µM) for 15 minutes.  Responses normalised to Ca2+ signals elicited 
by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (**p<0.01, *p<0.05, Students t-test). 
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Figure 5.11 Effect of POM-1 on CCL2-evoked intracellular Ca2+ responses in THP-
1 cells 
(A) Representative trace showing the effect of POM-1 (100 µM) on baseline Ca2+.  (B) 
Representative Ca2+ transients to CCL2 (10 ng/ml) in THP-1 cells pre-treated with vehicle 
(water) or POM-1 (1 or 100 µM) for 15 minutes.  (C) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50, 20 and 10 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or POM-1 (1 or 100 µM) for 15 minutes.  Responses normalised to Ca2+ 
signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 
replicates.  Asterisks indicate significant changes towards vehicle (**p<0.01, One-way 
ANOVA with Bonferroni’s multiple comparison). 
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5.3.5 Effect of P1 receptor antagonism on CCL2-evoked Ca2+ responses in THP-1 
cells 
Although studies with ADA were unable to support an involvement of adenosine in 
CCL2/CCR2-mediated THP-1 cell signalling (Section 5.3.3), the expression mRNA for P1 
purinoceptors in THP-1 cells and human monocytes (Chapter 3, Section 3.3.4) suggests 
that P1 purinoceptors may still be involved.  The next studies therefore examined the 
involvement of P1 purinoceptors using CGS-15943, a triazoloquinazoline derivative 
reported to antagonise all human P1 purinoceptors with a preference for A1 (Ki = 3.5 nM) 
and A2A (Ki = 1.2 nM), over A2B (Ki = 32.4 nM) and A3 (Ki = 35 nM) (Williams et al., 1987; 
Ongini et al., 1999). 
Initial studies examined the effects of CGS-15943 (2.5 µM) on THP-1 cell intracellular 
Ca2+ responses evoked by CCL2 (50, 20 and 10 ng/ml).  As shown (Figure 5.12),  
treatment of cells with CGS-15943 potentiated Ca2+ responses evoked by 10 ng/ml CCL2 
by 1.3 ± 0.1-fold (n=4, p<0.05), where the %Fmax values for CCL2 in untreated and CGS-
15943-treated cells increased from 13 ± 0.4% (n=4) to 16 ± 0.4% (n=4), respectively.  
Interestingly, Ca2+ responses evoked by 50 and 20 ng/ml CCL2 were not significantly 
affected by CGS-15943 (n=4, p>0.05).  For example, the %Fmax values for 20 ng/ml in 
untreated and CGS-15943-treated cells were 19 ± 1% (n=4) and 19 ± 2% (n=4), 
respectively (n=4, p>0.05).  Although these data appeared to support a role for P1 
receptors at low concentrations (10 ng/ml) of CCL2, a comparison of the Ca2+ decay rates 
suggested that CGS-15943 did not significantly affect the decay of CCL2 Ca2+ transients 
(n=4, p>0.05 for all).  For example, the  values for 10 ng/ml CCL2 in untreated and CGS-
15943-treated cells were 185 ± 82 seconds (n=4) and 122 ± 23 seconds (n=4), 
respectively (n=4, p>0.05). 
Given the possible involvement of P1 purinoceptors, it was important to ascertain whether 
CGS-15943 would be able to overcome the inhibitory effects of apyrase on CCL2-evoked 
intracellular Ca2+ responses.  Thus, the effects of CGS-15943 (2.5 µM) on 10 ng/ml CCL2-
evoked Ca2+ responses in apyrase-treated THP-1 cells, were examined.  As shown 
(Figure 5.13), no significant shift in the CCL2 %Fmax response was seen in apyrase-
treated cells co-incubated with CGS-15943 (n=3, p>0.05), where the %Fmax values for 
CCL2 in apyrase-treated and apyrase/CGS-15943-treated cells were 3 ± 0% (n=3) and 3 
± 0.3% (n=3), respectively.  Although these data are negative, it is possible that the effects 
of apyrase masked the effects of CGS-15943.  A further comparison of the decay rates (, 
sec) of CCL2 Ca2+ transients indicated no significant differences between treatments (n=3, 
p>0.05).  In these experiments, the  values for CCL2 in apyrase-treated and 
apyrase/CGS-15943-treated cells were 74 ± 20 seconds (n=3) and 42 ± 5 seconds (n=3), 
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respectively.  This data suggests that CGS-15943 does not affect the decay of CCL2 Ca2+ 
transients. 
Although these data showed that CGS-15943 modulated low-level CCL2/CCR2-mediated 
THP-1 cell signalling, additional studies were unable to confirm these findings.  Taken 
together, these data suggest that further studies may be required to address the 
involvement of P1 purinoceptors in regulating CCL2/CCR2-signalling in monocytes. 
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Figure 5.12 Effect of CGS-15943 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (10 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or CGS-15943 (2.5 µM) for 15 minutes.  (B) Bar chart showing 
normalised intracellular Ca2+ responses to CCL2 (50, 20 and 10 ng/ml) in THP-1 cells pre-
treated with vehicle (DMSO) or CSG-15943 (2.5 µM) for 15 minutes.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± 
SEM from n=4 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
Students t-test). 
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Figure 5.13 Effect of CGS-15943 on CCL2-evoked Ca2+ responses in apyrase-
treated THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (10 ng/ml) in apyrase-treated THP-1 cells pre-
treated with vehicle (DMSO) or CGS-15943 (2.5 µM) for 15 minutes.  (B) Bar chart 
showing normalised intracellular Ca2+ responses to CCL2 (10 ng/ml) in apyrase-treated 
THP-1 cells pre-treated with vehicle (DMSO) or CSG-15943 (2.5 µM) for 15 minutes.  
Responses normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data 
represents mean ± SEM from n=3 paired replicates. 
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5.3.6 Effect of P2 receptor antagonists on CCL2/CCR2-mediated THP-1 cell 
signalling and function 
The results of apyrase studies suggest that scavenging extracellular nucleotides 
attenuates THP-1 cell signalling and function.  It is possible, therefore, that P2 
purinoceptors are required for CCL2/CCR2-mediated monocyte signalling and function.  
To address this hypothesis, experiments were conducted to examine the effects of the P2 
purinoceptor antagonists, suramin and PPADS on CCL2/CCR2-mediated THP-1 cell 
signalling and function. 
5.3.6.1 Suramin 
The polysulfonate compound suramin is a non-competitive and reversible P2 antagonist 
and Gα G-protein inhibitor that displays an IC50 at homomeric human P2X receptors of 1-
10 µM (P2X1, P2X2, P2X3, P2X5), >100 µM (P2X6), and 300 µM (P2X4, P2X7) (Dunn 
and Blakeley, 1988, Khakh et al., 2001).  At P2Y receptors, suramin exhibits KB values of 
0.8-3 µM (P2Y1, P2Y11 and P2Y12) and 50 µM (P2Y2), while also inhibiting P2Y6 by 27% 
and P2Y13 by 80% at 100 µM and 10 µM, respectively (Von Kϋgelgen, 2008).  
To address the aims of this study, experiments were designed to test the effects of 
suramin (100 µM) on CCL2 (50 ng/ml)-evoked intracellular Ca2+ responses in THP-1 cells.  
As shown (Figure 5.14), treatment of cells with suramin abolished CCL2-evoked Ca2+ 
responses (100 ± 0%, n=4, p<0.01), where the %Fmax values for CCL2 in untreated and 
suramin-treated cells were 27 ± 4% (n=4) and 0 ± 0% (n=4), respectively.  These results 
were unexpected and suggested that P2 purinoceptors antagonised by suramin were 
required for CCL2/CCR2-mediated monocyte signalling.  However, while this seemed 
possible, it was discovered that prior work by Yu et al. (2006) showed that suramin bound 
to CCL2, thus preventing its engagement with CCR2.  A second possible explanation for 
these results may be that suramin reduced cell viability.  However, trypan blue studies 
were unable to support this theory (Appendix Figure A4), where the % viable cells for 
THP-1 cells exposed to vehicle (water) and 100µM suramin were 100 ± 12% (n=3) and 82 
± 8% (n=3), respectively.  Also in LDH studies (Appendix Figure A3), levels of LDH fell 
below the 20% threshold (14% of Triton-X-100, n=1). 
Based on the evidence provided by Yu et al. (2006), further experiments with suramin 
were not performed. 
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Figure 5.14 Effect of suramin on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or suramin (100 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(water) or suramin (100 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=4 replicates.  
Asterisks indicate significant changes towards vehicle (**p<0.01, Students t-test). 
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5.3.6.2 PPADS 
The P2 purinoceptor antagonist PPADS (Lambrecht et al., 1992) is a non-competitive 
antagonist at human P2X and P2Y receptors.  At P2X receptors, PPADS exhibits IC50 
values of 1-3 µM (P2X1, P2X2, P2X3), 100-300 µM (P2X4), 200-600 nM (P2X5), and 10-
45 µM (P2X7) (Khakh et al., 2001; Coddou et al., 2011).  At P2Y receptors, PPADS 
exhibits a KB of 4-12 µM at P2Y1, and at 10 µM-100 µM inhibits P2Y13 by 50%, P2Y4 by 
30%, and P2Y6 by 69% (von Kϋgelgen, 2008). 
The effects of PPADS (100 µM) on CCL2 (50 ng/ml)-evoked intracellular Ca2+ responses 
in THP-1 cells were next tested.  As shown (Figure 5.15a), 100 µM PPADS quenched the 
fluo-4 AM signal, therefore preventing the use of this concentration.  In experiments using 
10 µM PPADS (Figure 5.15b and c), no significant inhibition of CCL2-evoked Ca2+ 
responses were observed (n=3, p>0.05), where the %Fmax values for CCL2 in untreated 
and PPADS-treated cells were 26 ± 3% (n=3) and 22 ± 5% (n=3), respectively.  These 
data showed that at 10 µM, PPADS did not modulate CCL2-evoked intracellular Ca2+ 
responses.  This result was interesting because it suggested that P2 purinoceptors 
antagonised by 10 µM PPADS were not required for CCL2/CCR2-mediated monocyte 
signalling.  An analysis of the decay rates (, sec) for untreated (86 ± 6 seconds, n=3) and 
treated cells (75 ± 4 seconds, n=3) suggested that PPADS did not affect the decay of 
CCL2 Ca2+ transients (n=3, p>0.05).  
The effects of 100 µM and 1 mM PPADS on THP-1 cell chemotaxis towards CCL2 were 
next tested to understand the involvement of PPADS-sensitive purinoceptors in 
CCL2/CCR2-mediated monocyte functions.  As shown (Figure 5.16), THP-1 cells 
demonstrated a significantly higher (n=4, p<0.01) chemotactic index towards CCL2 (14 ± 
4, n=4) than towards vehicle (1 ± 0.2, n=4).  As also shown, 100 µM and 1 mM PPADS 
attenuated THP-1 cell chemotaxis towards CCL2 by 78 ± 6% (n=4, p<0.05) and 85 ± 4% 
(n=4, p<0.05), respectively, where the chemotactic indexes for these treatments were 3 ± 
1 (n=4) and 2 ± 1 (n=4), respectively.  Although it is possible that these effects may have 
been attributed to cytotoxicity, 100 µM PPADS exposure for 2.5 hours demonstrated no 
significant loss in THP-1 cell viability in trypan blue assays where the %viable cells for 
cells treated with vehicle and PPADS were 100 ± 12% (n=3) and 71 ± 9% (n=3), 
respectively (n=3, p>0.05).  The LDH release (% Triton-X 100) of cells exposed to 100 µM 
PPADS (4%, n=1) also fell below the 20% threshold (Appendix Figures A3 and A4). 
Taken together, these data suggest that PPADS-sensitive P2 purinoceptors are likely to 
be involved in modulating CCL2/CCR2-mediated monocyte function.    
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Figure 5.15 Effect of PPADS on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of PPADS on Ca2+ signals.  (B) 
Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(water) or PPADS (100 µM) for 15 minutes.  (C) Bar chart showing normalised intracellular 
Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (water) or 
PPADS (100 µM) for 15 minutes.  Responses normalised to Ca2+ signals elicited by 40 µM 
digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates. 
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Figure 5.16 Effect of PPADS on CCL2-mediated THP-1 chemotaxis 
(A)  Representative images showing the effect of PPADS (10 and 100 µM) on THP-1 cell 
chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  
(B) Bar chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 
(50 ng/ml, lower chamber, 2hrs), in the presence of PPADS (10 and 100 µM).  
Chemotactic index is a ratio of the number of cells that migrated towards CCL2 over the 
number of cells that migrated towards vehicle.  Data represents mean ± SEM from n=4 
transwells.  Asterisks indicate significant changes towards vehicle (**p<0.01, *p<0.05, 
One-way ANOVA with Bonferroni’s multiple comparison). 
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5.3.6.3 Effect of P2X receptor antagonists on CCL2/CCR2-mediated THP-1 cell 
signalling and function 
The next studies sought to examine the requirement of individual P2X purinoceptors.  The 
evidence presented in Chapter 3 has suggested that THP-1 cells and human monocytes 
exhibit a similar pattern of mRNA expression for P2X1, P2X4, P2X5, and P2X7.  It is 
possible, therefore, that these PPADS-sensitive purinoceptors are required for 
CCL2/CCR2-mediated monocyte signalling and function.  Thus, in order to examine these 
receptors, the effects of P2X antagonists on CCL2/CCR2-mediated THP-1 cell 
intracellular Ca2+ responses and chemotaxis were examined.  Due to no selective 
antagonists available, the requirement of P2X5 could not be examined. 
5.3.6.3.1 P2X1 
The human P2X1 receptor is encoded by the P2RX1 gene and is located on the short arm 
of chromosome 17 (17p13.3).  The P2X1 subunit shares 40-50% pair-wise identity with 
other P2X receptors (Valera et al., 1994).  P2X1 subunits are able to combine with 
subunits from other P2X receptors (P2X1/2, P2X1/4, and P2X1/5) to form heterotrimers 
(Torres et al., 1998, 1999; Nicke et al., 2005).  As a rapidly desensitising receptor, P2X1 
undergoes rapid internalisation (<1 second) upon ATP exposure (North, 2002).  Of all 
human P2X receptors, P2X1 has the highest affinity for ATP (EC50 = <1 µM) (Evans et al., 
1995). 
Investigations for P2X1 employed Ro-0437626, a benzimidazole-2-carboxamide 
derivative exhibiting 30-fold selectivity at P2X1 over P2X2 and P2X3, and shown to 
attenuate α,β-Methylene-ATP (α,β-meATP) Ca2+ release in P2X1-transfected Chinese 
hamster ovary (CHO) cells (IC50 = 3 µM) (Jaime-Figueroa et al., 2005).  Studies examined 
the effects of Ro-0437626 (10 and/or 100 µM) on Ca2+ responses evoked by 50 ng/ml 
CCL2 and 100 µM α,β-meATP in the presence and/or absence of extracellular Ca2+ 
(Chapter 2, Section 2.6.2 for methodology).  Experiments in the absence of extracellular 
Ca2+ were to confirm that the effects of Ro-0437626 were attributed a blockade of Ca2+ 
influx.  The stable ATP analogue α,β-meATP is reported to be selective for P2X1 and 
P2X3 (EC50 <1 µM) over P2X6 (EC50 >100 µM) and P2X2, P2X4, P2X5, and P2X7 (EC50 
>300 µM) (Valera et al., 1994; Jarvis and Khakh, 2009).   
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Table 5.5 Effect of Ro-0437626 on CCL2- and α,β-meATP-evoked Ca2+ 
responses in THP-1 cells 
 Ca2+ response (%Fmax) 
Condition Ligand Vehicle 
10 µM 
Ro-0437626 
Vehicle 
100 µM 
Ro-0437626 
With Ca2+ CCL2 24 ± 0.3 23 ± 1 24 ± 2 16 ± 1* 
Without Ca2+ CCL2 NT NT 10 ± 1 10 ± 0.3 
With Ca2+ α,β-meATP NT NT 3 ± 0.4 3 ± 0.3 
Intracellular Ca2+ responses to CCL2 (50 ng/ml) and α,β-MeATP (100 µM) in THP-1 cells 
pre-treated with vehicle (DMSO) or Ro-0437626 (10 or 100 µM), for 15 minutes in the 
presence and/or absence of extracellular Ca2+.  Without Ca2+ conditions in the presence of 
1 mM EGTA.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  
NT = not tested.  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate 
significant changes towards vehicle (*p<0.05, Students t-test). 
As shown above in Table 5.6 (and Appendix Figure A13), in the presence of extracellular 
Ca2+, higher concentrations of Ro-0437626 (100 µM) attenuated CCL2-evoked Ca2+ 
responses by 32 ± 2% (n=3, p<0.05).  An analysis of the decay rates showed that the  
values for CCL2 in untreated and Ro-0437626-treated cells were 69 ± 2 seconds (n=3) 
and 70 ± 2 (n=3), respectively and not significantly different (n=3, p>0.05).  For 10 µM Ro-
0437626, the decay rates for untreated (67 ± 3 seconds, n=3) and Ro-0437626-treated 
cells (67 ± 3 seconds, n=3) were also not significantly different (n=3, p>0.05).  Although 
these data suggested an effect attributable to P2X1 antagonism, it was seen in 
experiments that application of 100 µM Ro-0437626 to THP-1 cells produced an erratic 
baseline response following by a sustained increase of ~ 5% Fmax (Appendix Figure 
A13).  A similar result was also observed in the absence of extracellular Ca2+ and might 
be attributed to a release of Ca2+ from internal stores. 
In an attempt to rule out cytotoxicity, THP-1 cells were incubated with 100 µM Ro-
0437626 for 2.5 hours and tested in trypan blue and LDH assays.  The results of trypan 
blue studies indicated no significant differences in %viable cells between vehicle (100% ± 
15%, n=3) and Ro-0437626-treated cells (95 ± 7%, n=3, p>0.05).  Moreover, LDH release 
(% Triton X-100) for Ro-0437626 fell below the 20% threshold (15%, n=1) (Appendix 
Figure A3 and A5).   
From the data in Table 5.6 (and Appendix Figure A13), it is also apparent that CCL2-
evoked Ca2+ responses in the absence of extracellular Ca2+ were not significantly affected 
by 100 µM Ro-0437626 (n=3, p>0.05).  This suggests that Ro-0437626 attenuates CCL2 
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Ca2+ responses by reducing Ca2+ influx.  The decay rates of CCL2 Ca2+ transients in 
untreated (80 ± 6 seconds, n=3) and Ro-0437626-treated cells (81 ± 7 seconds, n=3) 
suggests that Ro-0437626 does not affect the decay of CCL2 Ca2+ transients (n=3, 
p>0.05).  The data in Table 5.6 (and Appendix Figure A14) also show that α,β-meATP-
evoked Ca2+ responses were not significantly affected by 100 µM Ro-0437626 (n=3, 
p>0.05).  Although this result indicates that THP-1 cells might not express protein for 
P2X1 receptors, a rapid desensitisation of P2X1 is also possible.  Although a comparison 
of the decay rates for α,β-meATP between untreated (321 ± 120 seconds, n=3) and 
treated cells (112 ± 15 seconds, n=3) suggested that Ro-0437626 promoted a faster 
decay, these data were not significantly different (n=3, p=0.2). 
To assess the requirement of P2X1 for monocyte function, studies investigated the effects 
of Ro-0437626 (100 µM) on THP-1 cell chemotaxis towards CCL2 (50 ng/ml).  As shown 
(Figure 5.17), THP-1 cells demonstrated a significantly higher (n=4, p<0.01) chemotactic 
index towards CCL2 (11 ± 1, n=4) than towards vehicle (1 ± 0.2, n=4).  Although the 
chemotactic index for Ro-0437626-treated cells (8 ± 3, n=4) indicated that Ro-0437626 
attenuated migration by 25 ± 23% (n=4), these data were not significant (n=4, p>0.05).  In 
general, therefore, these data suggest that THP-1 cell chemotaxis towards CCL2 is 
unaffected by Ro-0437626. 
These data suggest that Ro-0437626 attenuates CCL2-mediated Ca2+ influx via a 
mechanism independent of P2X1.  Furthermore, these effects do not appear to couple to 
THP-cell trafficking.  Taken together, these data suggest that P2X1 activation is not 
required for CCL2/CCR2-mediated monocyte signalling and function. 
5.3.6.3.2 P2X4 
The human P2X4 receptor is encoded by the P2RX4 gene located on the long arm of 
chromosome 12 (12q24.32) and shares 47-55% pair-wise identity with other P2X 
receptors (Garcia-Guzman et al., 1997a).  P2X4 subunits form heterotrimers with P2X1 
(P2X1/4), P2X6 (P2X4/6) and P2X7 (P2X4/7) (Lê et al., 1998; Nicke et al., 2005; Guo et 
al., 2007).  Unlike P2X1, the P2X4 receptor is slow desensitising (>20 seconds), and has 
a lower affinity towards ATP (EC50 = 3-10 µM) (Khakh et al., 2001; Jarvis and Khakh, 
2009).  Nucleotide derivatives such as α,β-meATP are also ligands at P2X4, which, as 
receptors, can also be allosterically modulated by zinc ions (Zn2+) and the antiparasitic 
drug, ivermectin (Coddou et al., 2011). 
Studies for P2X4 employed 5-BDBD, a benzofurodiazepine derivative shown to inhibit 
ATP-evoked Ca2+ responses in human P2X4-expressing CHO cells (IC50 = 0.5 µM) 
(Fischer et al., 2004).  Studies tested the effects of 5-BDBD (1-5 µM) on Ca2+ responses 
evoked by 50 ng/ml CCL2 in the presence and absence of extracellular Ca2+.  The 
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selectivity of 5-BDBD for P2X4 could not be tested as no selective ligands for P2X4 were 
available. 
Table 5.6 Effect of 5-BDBD on CCL2-evoked Ca2+ responses in THP-1 cells 
 Ca2+ response (%Fmax) 
Condition Ligand Vehicle 
1 µM 
5-BDBD 
Vehicle 
5 µM 
5-BDBD 
With Ca2+ CCL2 24 ± 2 22 ± 1 17 ± 0.3 14 ± 0.3* 
Without Ca2+ CCL2 NT NT 10 ± 0.3 9 ± 1 
Intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or 5-BDBD (1 or 5 µM) for 15 minutes.  Without Ca2+ conditions in the presence 
of 1 mM EGTA.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (% 
Fmax).  NT = not tested.  Data represents mean ± SEM from n=3 (with Ca2+) and n=4 
(without Ca2+) replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
Students t-test).   
As shown in Table 5.6 above (and Appendix Figure A15), in the presence of intracellular 
Ca2+, 5 µM 5-BDBD significantly inhibited CCL2-evoked intracellular Ca2+ responses (17 ± 
3%, n=3, p<0.05).  In addition, the decay rates revealed a slower (1.2 ± 0.03-fold, n=3, 
p<0.01) decay of CCL2 Ca2+ transients in cells treated with 5 µM 5-BDBD, where the  
values for untreated and 5-BDBD-treated cells were 66 ± 4 seconds (n=3) and 76 ± 4 
seconds (n=3), respectively.  Although cells treated with 1 µM 5-BDBD were also slowed 
by 1.2 ± 0.05-fold (n=3), the  values for CCL2 in untreated (46 ± 2 seconds, n=3) and 5-
BDBD-treated cells (53 ± 1 seconds, n=3) were not significantly different (n=3, p>0.05).  
These data suggest that 5 µM 5-BDBD attenuates CCL2 Ca2+ responses, and slows their 
decay.  This hypothesis was further supported by cell viability studies which showed no 
significant difference in the %viable cells between vehicle (100% ± 15%, n=3) and 5-
BDBD-treated cells (93 ± 11%, n=3, p>0.05).  Moreover, LDH release (% Triton X-100) for 
5-BDBD fell below 20% (4%, n=1) (Appendix Figure A3 and A5).  However, although 
these data ruled out cytotoxicity, addition of 5 µM 5-BDBD to THP-1 cells in Ca2+ 
experiments resulted in a small increase in baseline Ca2+ (Appendix Figure A15).  This 
was difficult to quantify but was also observed in the absence of extracellular Ca2+ (below) 
and suggested that 5-BDBD modulated intracellular Ca2+ by a mechanism independent of 
Ca2+ influx.  
In experiments in the absence of extracellular Ca2+ (Table 5.6), CCL2-evoked Ca2+ 
responses were not significantly affected by 5 µM 5-BDBD (n=4, p>0.05).  The  values 
for untreated (87 ± 7 seconds, n=4) and 5-BDBD-treated cells (82 ± 9 seconds, n=4) were 
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also not significantly different (n=4, p>0.05).  These data suggest that 5-BDBD does not 
modulate the decay of CCL2 Ca2+ transients in the absence of extracellular Ca2+. 
It was also important to examine the requirement of P2X4 for CCL2/CCR2-mediated 
monocyte function.  Studies on THP-1 cells showed that although THP-1 cell chemotaxis 
towards CCL2 was reduced by 38 ± 10% (n=4), the chemotactic indexes for untreated (11 
± 1, n=4) and 5-BDBD-treated cells (1 ± 0.2, n=4) were not significantly different (n=4, p = 
0.2) (Figure 5.17).  Although these data were interesting, they were unable to confirm a 
requirement of P2X4 for CCL2/CCR2-mediated monocyte chemotaxis.   
Although intracellular Ca2+ experiments suggested a potential requirement of P2X4 for 
CCL2/CCR2-mediated monocyte signalling, secondary observations indicated off-target 
effects of 5-BDBD.  Taken together, these data suggest that P2X4 is not required for 
CCL2/CCR2-mediated monocyte signalling and function. 
5.3.6.3.3 P2X7 
The human P2X7 receptor is encoded by the P2RX7 gene located on the long arm of 
chromosome 12 (12q24.32), and shares the least pair-wise identity (41 to 50%) with other 
P2X receptors (Rassendren et al., 1997; North, 2002).  The P2X7 protein is the longest of 
the P2X receptors due to a longer C-terminus, which is required for determining its 
kinetics, desensitisation, and pore-forming properties (Surprenant et al., 1996).  As 
mentioned previously, P2X7 subunits are able to form heterotrimers with P2X4 subunits 
(P2X4/7) (Guo et al., 2007).  The P2X7 receptor is slow desensitising (>20 seconds), but 
is also the least sensitive purinoceptor to ATP (EC50 >100 µM) (Khakh et al., 2001; North, 
2002; Jarvis and Khakh, 2009).  Due to this characteristic, P2X7 activation is restricted, 
and occurs only in response to prolonged agonist exposure, or ATP release caused by 
cell damage or inflammation (Ferrari et al., 1997; Di Virgilio, 2007).  For this reason, P2X7 
is considered an important therapeutic target (Bartlett et al., 2014).  The gating properties 
of P2X7 also differ from other P2X receptors where a prolonged agonist exposure 
produces a biphasic response that coincides with an increase in pore dilation allowing the 
flow of larger molecules such as the nucleic dye, YO-PRO-1 (Surprenant et al., 1996). 
Studies for P2X7 employed A-438079, a disubstituted tetrazolylmethylpyridine 
characterised as a reversible and competitive blocker of human P2X7.  A-438079 has a 
reported IC50 of ~ 123 nM for BzATP-evoked Ca
2+ release in P2X7-transfected 1321N1 
cells (Nelson et al., 2006).  The current studies first examined the effects of A-438079 (1 
µM and 10 µM) on Ca2+ responses evoked by 50 ng/ml CCL2 and 50 µM of the ribose 
derivative, 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate (BzATP) in the presence 
and/or absence of extracellular Ca2+.  BzATP exhibits a greater potency towards P2X7 
(EC50 ~5 µM) than any other nucleotide, but also activates other P2 receptors including 
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P2Y11 and P2Y13 with similar or greater potency (Bianchi et al., 1999; Donnelly-Roberts et 
al., 2009; Jarvis and Khakh, 2009). 
Table 5.7 Effect of A-438079 on CCL2 and BzATP-evoked Ca2+ responses in 
THP-1 cells 
 Ca2+ response (%Fmax) 
Condition Ligand Vehicle 
1 µM 
A-438079 
Vehicle 
10 µM 
A-438079 
With Ca2+ CCL2 24 ± 2 22 ± 1 17 ± 0.3 14 ± 0.3* 
Without Ca2+ CCL2 NT NT 10 ± 0.3 9 ± 1 
With Ca2+ BzATP NT NT 31 ± 1 32 ± 0.3 
Intracellular Ca2+ responses to CCL2 (50 ng/ml) and BzATP (50 µM) in THP-1 cells pre-
treated with vehicle DMSO) or A-438079 (1 or 10 µM), for 15 minutes.  Without Ca2+ 
conditions in the presence of 1 mM EGTA.  Responses normalised to Ca2+ signals elicited 
by 40 µM digitonin (%Fmax).  NT = not tested.  Data represents mean ± SEM from n=3 
experiments.  Asterisks indicate significant changes towards paired vehicle (*p<0.05, 
Students t-test). 
As shown above in Table 5.7, experiments in the presence of extracellular Ca2+ showed 
that 10 µM A-438079 significantly attenuated CCL2-evoked Ca2+ responses by 10 ± 3% 
(n=3, p<0.05).  In support of these data, cell viability studies (Appendix Figure A3 and A5) 
showed no reduction in cell viability with 10 µM A-438079 (2.5-hour exposure).  
Interestingly, the decay rates of Ca2+ transients suggested that 10 µM A-438079 also 
promoted a 8 ± 1% (n=3, p<0.05) faster decay of CCL2 Ca2+ transients, where the   
values for CCL2 in untreated and A-438079-treated cells were 92 ± 3 seconds (n=3) and 
85 ± 4 seconds (n=3), respectively.  These data suggest that P2X7 antagonism promotes 
a more rapid decay of CCL2 Ca2+ transients.  It was also interesting to observed that in 
experiments performed in the absence of extracellular Ca2+, CCL2-evoked Ca2+ 
responses were not significantly affected by 10 µM A-438079 (n=3, p>0.05).  This 
suggested that the effects of A-438079 on CCL2-evoked Ca2+ responses were attributed 
to a blockade of Ca2+ influx (Table 5.7).  These data were supported by data showing that 
A-438079 did not significantly affect the  values for CCL2 in untreated (57 ± 7 seconds, 
n=3) and A-438079-treated cells (45 ± 3 seconds, n=3, p>0.05). 
In additional experiments examining the selectivity of A-438079, it was seen that Ca2+ 
responses evoked by BzATP were not significantly affected by 10 µM A-438079 (Table 
5.8 and Appendix Figure A16).  While a possible explanation for this result may be that 
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BzATP also activates other P2 receptors, a second explanation may be that P2X7 
receptors are not expressed by THP-1 cells at the post-translational level.   
To determine the requirement of P2X7 receptors for CCL2/CCR2-mediated monocyte 
trafficking, the effects of A-438079 (10 µM) on THP-1 cells trafficking towards CCL2 were 
tested.  As shown (Figure 5.17), CCL2 chemotaxis towards CCL2 was not significantly 
affected by A-438079 (n=4, p<0.05), where the chemotactic indexes for untreated and A-
438079-treated cells were 11 ± 3 (n=4) and 12 ± 4 (n=4), respectively.  In general, 
therefore, these data suggest that P2X7 is not required for CCL2/CCR2-aassociated 
monocyte trafficking. 
These data suggest that A-438079 impairs CCL2-evoked intracellular Ca2+ responses in 
THP-1 cells in the presence of extracellular Ca2+.  However, the results of BzATP Ca2+ 
studies do not support a functional presence of P2X7 in THP-1 cells.  Taken together, the 
findings of this study indicate that P2X7 receptor activation is not required for 
CCL2/CCR2-mediated monocyte signalling and function. 
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Figure 5.17 Effect of P2X antagonists on CCL2-mediated THP-1 cell chemotaxis 
(A) Representative images showing the effect of P2X antagonists Ro-0437626 (P2X1), 5-
BDBD (P2X4) and A-438079 (P2X7) on THP-1 cell chemotaxis towards vehicle CCL2 (50 
ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  (B) Bar chart showing 
normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 (50 ng/ml, lower 
chamber, 2hrs), in the presence of P2X antagonists (concentrations as shown).  
Chemotactic index is a ratio of the number of cells that migrated towards CCL2 over the 
number of cells that migrated towards vehicle.  Data represents mean ± SEM from n=4 
transwells.  Asterisks indicate significant changes towards vehicle (**p<0.01, *p<0.05, 
One-way ANOVA with Bonferroni’s multiple comparison). 
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5.3.6.4 Effect of P2Y receptor antagonism on CCL2/CCR2-mediated THP-1 cell 
signalling and function 
The next principle aim of this chapter was to examine the requirement of individual P2Y 
receptors.  The evidence presented in Chapter 3 has suggested that THP-1 cells and 
human monocytes express mRNA for all P2Y receptors (P2Y1-P2Y14).  Of these 
receptors, P2Y1, P2Y4, P2Y6, and P2Y13 are PPADS-sensitive (von Kϋgelgen, 2008).  It is 
possible, therefore that these and other P2Y receptors are required for CCL2/CCR2-
mediated monocyte signalling and function.  In an effort to examine the requirement of 
these receptors, the effects of P2Y antagonists on CCL2/CCR2-mediated THP-1 cell 
intracellular Ca2+ responses and chemotaxis were examined.  Due to no selective 
antagonists available for P2Y2, P2Y4, and P2Y14, it was not possible to examine the role of 
these receptors.  A requirement of P2Y6 has been addressed in Chapter 6. 
5.3.6.4.1 P2Y1 
The human P2Y1 receptor is encoded by the P2YR1 gene located on the long arm of 
chromosome 3 (3q25.2) and shares 24-46% pair-wise identity with other P2Y receptors 
(Ayyanathan et al., 1996; Janssens et al., 1996; Abbracchio et al., 2006).  P2Y1 is coupled 
to a PTx-insensitive Gαq/11-type G-protein involved in PLC activation (Waldo and Harden, 
2004).  Although the preferred endogenous ligand of P2Y1 is ADP (EC50 ~ 250 nM), ATP 
is also a ligand (EC50 >1 µM) but may also act as an antagonist at low concentrations 
(Schachter and Harden, 1997; Léon et al., 1997).  Studies in platelets and endothelial 
cells have shown that P2Y1 is rapidly desensitised by ADP, an effect prevented by 
NTPDase1 (Enjyoji et al., 1999; Zimmermann et al., 2012). 
Studies involving P2Y1 employed the competitive P2Y1 antagonist MRS-2179, which, at 
100 nM, almost abolishes P2Y1-mediated IP3 formation in P2Y1-transfected 1321N1 
astrocytoma cells (Boyer et al., 1998).  MRS-2179 exhibits a Ki of 84 nM for P2Y1 and 
lacks an effect at P2Y12 and P2Y13 (Waldo et al., 2002).  The current studies tested the 
effects of MRS-2179 (10 µM) on Ca2+ responses evoked by 50 ng/ml CCL2 and 3 µM 
ADP.  Additional studies examined the effects of apyrase (2 U/ml) on Ca2+ responses 
evoked by the P2Y1 agonist, MRS-2365 ((N)-methanocarba-2-methylthio-ADP), which is 
selective for human P2Y1 (EC50 = 1.2 nM) over P2Y12 (inactive) and P2Y13 (EC50 = >1 µM) 
(Chhratriwala et al., 2004). 
As shown below in Table 5.8, CCL2 and ADP-evoked Ca2+ responses were not 
significantly affected by MRS-2179 (n=3, p>0.05 for both experiments).  A comparison of 
the decay rates ( sec) also showed no differences between treatments.  The  values for 
CCL2 in untreated and MRS-2179-treated cells were 115 ± 10 seconds (n=3) and 119 ± 
12 seconds (n=3), respectively (n=3, p>0.05), while for ADP they were 14137 ± 12335 
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seconds (n=3) and 5455 ± 4660 seconds (n=3), respectively (n=3, p>0.05).  These data 
were interesting because they suggested that MRS-2179 did not influence the magnitude 
or the decay of CCL2 and ADP Ca2+ transients.  A possible explanation for a lack of effect 
of MRS-2179 on ADP Ca2+ responses may be that P2Y1 is not expressed by THP-1 cells 
at the post-translational level.  However, other possible reasons include an activation of 
other ADP-sensitive receptors by ADP, or a desensitisation of P2Y1. 
Table 5.8 Effect of MRS-2179 on CCL2- and ADP-evoked Ca2+ responses in THP-
1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle 10 µM MRS-2179 
CCL2 24 ± 0.3 26 ± 0.3 
ADP 9 ± 1 10 ± 1 
Intracellular Ca2+ responses to CCL2 (50 ng/ml) and ADP (3 µM) in THP-1 cells pre-
treated with vehicle (water) or MRS 2179 (10 µM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from 
n=3 replicates.  
In experiments designed to unmask P2Y1-mediated Ca
2+ responses, it was seen that 
apyrase potentiated Ca2+ responses evoked by the P2Y1 agonist MRS-2365 by 2.5 ± 1-
fold (n=3, p<0.05) (Table 5.9 and Appendix Figure A17).  These data suggest that 
apyrase potentiates P2Y1 signalling by limiting receptor desensitisation.  Due to the 
sustained Ca2+ responses seen with MRS-2365, the decay rates for Ca2+ transients could 
not be determined.  While these data were interesting because they supported the 
presence of functional P2Y1 receptors in THP-1 cells, they also indicated that P2Y1 might 
only play a small role in Ca2+ mobilisation in these cells. 
Table 5.9 Effect of apyrase on MRS-2365-evoked Ca2+ responses in THP-1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle Apyrase 2 U/ml 
MRS-2365 2.7 ± 1 5.3 ± 1* 
Intracellular Ca2+ responses to MRS-2365 (100 nM) in THP-1 cells pre-treated with vehicle 
(water) or apyrase (2 U/ml) for 10 minutes.  Responses normalised to Ca2+ signals elicited 
by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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To examine the requirement of P2Y1 for CCL2/CCR2-mediated monocyte chemotaxis, 
experiments tested the effects of MRS-2179 (10 µM) on THP-1 cell chemotaxis towards 
CCL2 (50 ng/ml).  As shown (Figure 5.18), THP-1 cells demonstrated a significantly 
higher (n=4, p<0.01) chemotactic index towards CCL2 (13 ± 1, n=4) than towards vehicle 
(1 ± 0.1, n=4).  As also shown, the chemotactic index of MRS-2179-treated cells (12 ± 2, 
n=4) was not significantly different from untreated cells (n=4, p>0.05).  These data 
suggest that MRS-2179 does not influence THP-1 cell chemotaxis towards CCL2. 
Taken together, these data suggest that P2Y1 activation is not required for CCL2/CCR2-
mediated monocyte signalling and function. 
5.3.6.4.2 P2Y11 
The human P2Y11 receptor is encoded by the P2YR11 gene located on the short arm of 
chromosome 19 (19p13.2), and is the only P2Y receptor containing an intron (1.9Kb) in its 
coding sequence (Communi et al., 1997, 1999).  The P2Y11 receptor shares 21-34% pair-
wise identity with other P2Y receptors (Abbracchio et al., 2006).  Signalling through P2Y11 
involves PTx-insensitive Gαq/11 and Gαs-type G-proteins which activate PLC and to a lower 
extent, adenylate cyclase (Communi et al., 1997, 1999; Qi et al., 2001).  The preferred 
ligand for P2Y11 is ATP (EC50 >8 µM), but ADP is also a weak agonist (EC50 >100 µM) 
(Communi et al., 1997, 1999; Qi et al., 2001).  The role of UTP as a ligand is uncertain, 
where studies by White et al. (2003) suggest that UTP evokes Ca2+ in the absence of IP3 
formation, while more recent studies (Morrow et al., 2014) indicate that UTP is ineffective 
at releasing Ca2+.   
To examine the requirement of P2Y11, studies employed the competitive P2Y11 antagonist 
NF-340 (IC50 = 20-400 nM), a tetrasulfonic-acid suramin analogue shown to inhibit 
ATPγS-evoked Ca2+ release from human P2Y11-transfected 1321N1 astrocytoma cells by 
93% (Meis et al., 2010).  The current studies therefore examined the effects of NF-340 (10 
µM) on THP-1 cell Ca2+ responses evoked by CCL2 (50 ng/ml), ATP (3-30 µM), and the 
P2Y11 ligand, β-nicotinamide adenine dinucleotide hydrate (β-NAD).  Studies reported by 
Moreschi et al. (2006) have shown that 1 mM β-NAD releases intracellular Ca2+ and 
promotes the formation of IP3, cAMP, and cyclic ADP-ribose from human granulocytes 
and human P2Y11-transfected 1321N1 astrocytoma cells. 
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Table 5.10 Effect of NF-340 on CCL2, ATP and β-NAD-evoked Ca2+ responses in 
THP-1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle 10 µM NF-340 
CCL2 30 ± 0.3 31 ± 0.3 
ATP 3 µM 39 ± 1 39 ± 1 
ATP 30 µM 45 ± 1 43 ± 1** 
β-NAD+ 4 ± 0 5 ± 1 
Intracellular Ca2+ responses to CCL2 (50 ng/ml), ATP (3-30 µM), and β-NAD (1 mM) in 
THP-1 cells pre-treated with vehicle (DMSO) or NF-340 (10 µM) for 15 minutes.  
Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data 
represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle (**p<0.01, Students t-test). 
As shown in Table 5.10 above, CCL2 Ca2+ responses were not significantly affected by 
NF-340 (n=3, p>0.05).  A comparison of the  values of Ca2+ transients for treatments also 
showed no significant differences (n=3, p>0.05) between untreated (61 ± 2 seconds, n=3), 
and NF-340-treated cells (60 ± 2 seconds, n=3).  Collectively, these data suggested that 
NF-340 did not affect the magnitude or the decay of CCL2 Ca2+ transients in THP-1 cells.   
In a bid to confirm the functional presence of P2Y11, studies next examined the effects of 
NF-340 on ATP and β-NAD-evoked Ca2+ responses in THP-1 cells.  As shown by Table 
5.10 (and Appendix Figure A18), Ca2+ responses evoked by 3 µM ATP were not 
significantly affected by NF-340 (n=3, p>0.05).  However, it was seen that NF-340 
attenuated Ca2+ responses evoked by 30 µM ATP by 4 ± 0.3% (n=3, p<0.05).  These data 
suggest that NF-340 attenuates Ca2+ responses evoked by 30 µM ATP, but not 3 µM 
ATP.  This is interesting because it ties in with the knowledge that the potency of ATP at 
human P2Y11 is EC50 = >8 µM (Communi et al., 1997, 1999; Qi et al., 2001).  A 
comparison of the decay rates for treatments showed that the  values for 3 µM or 30 µM 
ATP were not significantly affected by NF-340 (n=3, p>0.05, data not shown).  For 
example, the  values for 30 µM ATP in untreated and treated cells were 106 ± 7 seconds 
(n=3) and 111 ± 3 seconds (n=3), respectively (n=3, p>0.05). 
In additional experiments (Table 5.10 and Appendix Figure A18), it was seen that β-NAD 
Ca2+ responses were not significantly affected by NF-340 (n=3, p>0.05).  This is 
interesting and suggests that NF-340 is unable to modulate Ca2+ responses evoked by a 
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more selective P2Y11 ligand.  The sustained responses of β-NAD prevented the decay 
rates of Ca2+ transients from being analysed.   
As with previous experiments, the effects of NF-340 (10 µM) on THP-1 cell chemotaxis 
towards CCL2 (50 ng/ml) were investigated.  As shown (Figure 5.18), THP-1 cell 
chemotaxis towards CCL2 was not significantly affected by NF-340 (n=4, p>0.05), 
although the chemotactic indexes of untreated (13 ± 1, n=4) and NF-340-treated cells (7 ± 
2, n=4) suggested that trafficking was attenuated by 40 ± 21% (n=4).  These data hinted 
at the possibility that NF-340 attenuated THP-1 cell chemotaxis towards CCL2, but also 
suggested that further work was needed. 
In summary, these results indicate that P2Y11 is not required for CCL2/CCR2-mediated 
monocyte signalling and function. 
5.3.6.4.3 P2Y12 
The human P2Y12 receptor is encoded by the P2YR12 gene located on the long arm of 
chromosome 3 (3q24-q25) (Zhang et al., 2001; Bodor et al., 2003).  In general, P2Y12 
shares 22-48 % pair-wise identity with other P2Y receptors (Abbracchio et al., 2006).  The 
preferred ligand is ADP which has a reported Ki of 5.9-6.3 in P2Y12-transfected CHO cells 
and human platelets (Hollopeter et al., 2001; Savi et al., 2001).  P2Y12 is also activated by 
ATP which is much weaker (Ki = 5.2-6.1) (Savi et al., 2001).  Unlike most other P2Y 
purinoceptors, P2Y12 signals via PTx-sensitive Gαi/o-type G-proteins coupled to the 
inhibition of adenylate cyclase (Hollopeter et al., 2001; Jantzen et al., 2001).  Activation of 
PI3K by the Gβγ dimer of P2Y12 is considered important for the completion ADP-mediated 
platelet aggregation (Reséndiz et al., 2003).  For this reason, P2Y12 is considered an 
important therapeutic target (Wijeyeratne and Heptinstall, 2011).  The role of P2Y12 in 
Ca2+ mobilisation however, is less clear.   
To examine the requirement of P2Y12, studies employed the P2Y12 antagonist, AR-C-
66096, a difluoromethylene ATP analogue shown to impair ADP-mediated human platelet 
aggregation with an IC50 of 11 nM (Humphries et al., 1994).  The current studies 
investigated the effects of AR-C-66096 (1 µM) on THP-1 cell Ca2+ responses evoked by 
CCL2 (50 ng/ml) and ADP (30 µM). 
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Table 5.11 Effect of AR-C-66096 on CCL2 and ADP-evoked Ca2+ responses in 
THP-1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle 1 µM AR-C-66066 
CCL2 23 ± 3 25 ± 1 
ADP 32 ± 2 33 ± 1 
Intracellular Ca2+ responses to CCL2 (50 ng/ml) and ADP (30 µM) in THP-1 cells pre-
treated with vehicle (water) or AR-C-66096 (1 µM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from 
n=3 replicates.  
As shown by Table 5.11 above, CCL2 Ca2+ responses were not significantly affected by 
AR-C-66096 (n=3, p>0.05).  These data suggest that CCL2/CCR2-mediated intracellular 
Ca2+ responses in THP-1 cells are unlikely to require P2Y12.  A comparison of the decay 
rates for untreated (90 ± 1 seconds, n=3) and ARC-66096-treated cells (93 ± 3 seconds, 
n=3) were also not significantly different (n=3, p>0.05), suggesting that AR-C-66096 did 
not affect the decay of CCL2 Ca2+ transients.  As also shown, similar experiments with 
ADP showed that Ca2+ responses were also not significantly affected by AR-C-66096 
(n=3, p>0.05).  The  values for ADP in untreated (197 ± 16 seconds, n=3) and AR-C-
66096-treated cells (210 ± 4 seconds, n=3) were also not significantly different (n=3, 
p>0.05).  Collectively, these results suggested that neither the magnitude nor the decay of 
CCL2 and ADP Ca2+ transients were affected by AR-C-66096.  A possible reason for 
these results might be that P2Y12 receptors may not couple to intracellular Ca
2+ release in 
THP-1 cells and monocytes. 
The requirement of the P2Y12 receptor for CCL2/CCR2-mediated monocyte function was 
examined by testing the effects of AR-C-66096 on THP-1 cell chemotaxis towards CCL2 
(50 ng/ml).  As shown (Figure 5.18), although the chemotactic indexes between untreated 
(13 ± 1, n=4) and AR-C-66096-treated THP-1 cells (10 ± 2, n=4) suggested that AR-C-
66096 attenuated chemotaxis by 17 ± 19% (n=4), these data were not statistically 
significant (n=4, p>0.05).  In general, therefore, these data suggest that AR-C-66096 does 
not modulate THP-1 cell migration towards CCL2. 
Taken together, these data do not support a requirement of P2Y12 receptors for efficient 
CCL2/CCR2-mediated monocyte signalling and function.  Furthermore, these data 
support the hypothesis that P2Y12 does not couple to intracellular Ca
2+ signalling. 
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5.3.6.4.4 P2Y13 
The next studies in this chapter examined the requirement of the human P2Y13 receptor 
for CCL2/CCR2-mediated monocyte signalling and function.  The P2Y13 receptor is 
encoded by the P2YR13 gene located on the long arm of chromosome 3 (3q24) 
(Communi et al., 2001; Zhang et al., 2002).  Structurally, P2Y13 is most similar to P2Y12 
and P2Y14, and in general, shares 21-48 % pair-wise identity with other P2Y receptors 
(Abbracchio et al., 2006).  Although the preferred ligand for P2Y13 is ADP (pIC50 = 6.5), 
ATP is also a ligand (pIC50 = 5.4) (Marteau et al., 2003).  P2Y13 drives adenylate cyclase 
inhibition through a PTx-sensitive Gαi/o-type G-protein (Communi et al., 2001).  Studies by 
Marteau et al. (2003) suggest that high concentrations of ADP enable P2Y13 to dually 
couple to PTx-insensitive Gαs-type G-proteins.  Communi et al. (2001) and Marteau et al. 
(2003) have additionally shown that P2Y13 activation leads to an accumulation of IP3, 
thereby suggesting a possible involvement in Ca2+ release.  Further support for this 
hypothesis has come from studies using dual P2Y12/P2Y13 antagonists and the P2Y13 
antagonist, MRS-2211 (Bianco et al., 2005; Ceruti et al., 2008; Carrasquero et al., 2009). 
To examine the requirement of P2Y13, studies employed the competitive P2Y13 antagonist, 
MRS-2211.  Described as a 2-chloro-5-nitro analogue of PPADS, MRS-2211 exhibits an 
pIC50 of 5.97 against ADP-mediated IP3 formation in human P2Y13-1321N1 astrocytoma 
cells (Kim et al., 2005).  The current studies first examined the effects of MRS-2211 (10 
µM) on THP-1 cell Ca2+ responses evoked by CCL2 (50 ng/ml) and ADP (3 µM). 
Table 5.12 Effect of MRS-2211 on CCL2- and ADP-evoked Ca2+ responses in THP-
1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle 10 µM MRS-2211 
CCL2 23 ± 3 25 ± 1 
ADP 9 ± 1 4 ± 1** 
Intracellular Ca2+ responses to CCL2 (50 ng/ml) and ADP (3 µM) in THP-1 cells pre-
treated with vehicle (water) or MRS 2211 (10 µM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from 
n=3 experiments.  Asterisks indicate significant changes towards vehicle (**p<0.01, 
Students t-test). 
As shown in Appendix Figure A19a, MRS-2211 caused a mild quenching of the 
fluorescent signal, dropping the %Fmax signal by ~ -3%.  As also shown by Table 5.12 
above and Appendix Figure A19, CCL2 Ca2+ responses were not significantly affected by 
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MRS-2211 (n=3, p>0.05).  These data suggest that P2Y13 is not required for CCL2-Ca
2+ 
responses.  A comparison of the decay rates for CCL2 Ca2+ transients in untreated (78 ± 4 
seconds, n=3) and MRS-2211-treated cells (78 ± 3 seconds, n=3), showed that these 
were also not significantly affected by MRS-2211 (n=3, p>0.05).  While CCL2 Ca2+ 
responses appeared not to be affected by MRS-2211, it was interesting to observe that 
MRS-2211 significantly attenuated ADP-evoked Ca2+ responses by 51 ± 3% (n=3, p<0.01) 
(Table 5.12 and Appendix Figure A19).  These data suggest that Ca2+ responses evoked 
by ADP are MRS-2211-sensitive.  Due to a lack of decay of ADP Ca2+ transients in MRS-
2211-treated cells, the  values could not be determined.   
To rule out cytotoxicity, cell viability studies tested the effects of 10 µM MRS-2211 on 
THP-1 cell viability over 2.5 hours.  Trypan blue studies indicated that the %viable cells for 
untreated (100 ± 12%, n=3) and MRS-2211-treated cells (115 ± 9%, n=3) were not 
significantly different (Appendix Figure A4).  Likewise, LDH release for 10 µM MRS-2211 
fell below the 20% toxic threshold (5% of Triton-X-100, n=1) (Appendix Figure A3).  In 
general, therefore, it seems that THP-1 cells exposed to MRS-2211 for 2.5 hours remain 
viable. 
In chemotaxis experiments with THP-1 cells, it was seen that although 10 µM MRS-2211 
reduced migration by 27 ± 24% (n=4), the chemotactic indexes for untreated (13 ± 1, n=4) 
and MRS-2211-treated cells (9 ± 2, n=4) were not significantly different (n=4, p>0.05).  
These data were therefore in agreement with CCL2 Ca2+ studies but also suggested that 
MRS-2211 was unable to significantly modulate CCL2/CCR2-mediated THP-1 cell 
migration. 
Taken together, these data suggest that CCL2/CCR2-mediated monocyte signalling and 
function does not require an activation of P2Y13.   
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Figure 5.18 Effect of P2Y antagonists on CCL2-mediated THP-1 chemotaxis 
(A) Representative images showing the effect of P2Y antagonists for P2Y1 (MRS-2179), 
P2Y11 (NF-340), P2Y12 (AR-C-66096), or P2Y13 (MRS-2211) on THP-1 cell chemotaxis 
towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  (B) Bar 
chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 (50 
ng/ml, lower chamber, 2hrs), in the presence of P2Y antagonists (concentrations as 
shown).  Chemotactic index is a ratio of the number of cells that migrated towards CCL2 
over the number of cells that migrated towards vehicle.  Data represents mean ± SEM 
from n=4 transwells.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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5.4 Summary 
This chapter employed monocytic THP-1 cells and human PBMCs as in vitro models to 
investigate the requirement of extracellular nucleotides for CCL2/CCR2-mediated 
monocyte signalling and function.  A number of methodology and pharmacological tools 
were employed to assess nucleotide hydrolysis, Ca2+ mobilisation, cell migration, and cell 
adhesion to vascular endothelium.  Using these tools, several important findings were 
made.  Initial observations suggested that extracellular nucleotides were chemotactic.  
Further experiments with apyrase indicated that extracellular nucleotides were required for 
CCL2/CCR2-mediated monocyte intracellular Ca2+ release and cell migration.  However, 
an enhancement of human PBMC chemotaxis by apyrase conflicted with these findings, 
but also suggested that these differences might reflect the heterogeneous nature of these 
cells.  Additional studies with different apyrases pointed towards a greater requirement of 
NDPs than NTPs.  In THP-1 cells, a potentiation of CCL2 Ca2+ responses was seen with 
ARL-67156, and suggested that extracellular nucleotides were required for CCL2/CCR2 
signalling.  In further investigations assessing the requirement of individual purinoceptors, 
it was seen that while studies with ADA were unable to identify a role for adenosine, 
studies with CGS-15943 indicated a requirement of P1 receptors at low CCL2 
concentrations.  While suramin could not be used due to its ability to bind to CCL2, THP-1 
cell chemotaxis experiments with the P2 antagonist PPADS indicated that P2X1, P2X4, 
P2X5, P2X7, P2Y1, P2Y4, P2Y6, and P2Y13 were candidate purinoceptors for modulating 
CCL2/CCR2-mediated monocyte chemotaxis.  Further THP-1 cell experiments with the 
P2X antagonists Ro-0436726, 5-BDBD, and A-438079 and the P2Y antagonists MRS-
2179, NF-340, AR-C-66096 and MRS-2211, were unable to show that P2X1, P2X4, P2X7, 
P2Y1, P2Y11, P2Y12 or P2Y13 receptors modulated CCL2/CCR2-mediated monocyte 
signalling and function. 
Taken together, the findings of this study suggest that extracellular nucleotides are 
required for efficient CCL2/CCR2-mediated monocyte signalling and function.  The 
findings of this study also indicate that P1, P2X1, P2X4, P2X7, P2Y1, P2Y11, P2Y12 and 
P2Y13 purinoceptors are unlikely to be involved in modulating CCL2/CCR2-mediated 
monocyte signalling and function.  It is possible, therefore, that other purinoceptors are 
required.  Although a number of purinoceptors such as P2X5, P2Y2, P2Y4, P2Y6 and 
P2Y14 still remain candidates, commercially available antagonists are only available for 
P2Y6.  The focus of the next chapter (Chapter 6) was therefore to investigate the 
requirement of P2Y6 for CCL2/CCR2-mediated monocyte signalling and function using 
THP-1 cells and human PBMCs as in vitro models.  The research presented in this 
chapter gives importance to CCL2/CCR2 activation as measured by intracellular Ca2+ 
release, cell migration, and cell adhesion to vascular endothelium. 
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Chapter 6: Investigating the 
requirement of the P2Y6 receptor for 
CCL2/CCR2-mediated monocyte 
signalling and function 
6.1 Introduction 
The P2Y6 purinoceptor was first cloned and characterised by Chang and colleagues from 
rat aortic smooth muscle cells in 1995 (Chang et al., 1995).  The human P2Y6 receptor 
was later cloned from human placenta and human T-cells by Communi et al. (1996) and 
Southey et al. (1996), respectively.  It is now known that P2Y6 has 328 amino acids and is 
encoded by the P2RY6 gene located on the long arm of chromosome 11 (11q13.5) which 
lies adjacent to the P2RY2 gene for P2Y2 (11q13.5-q14.1) (Communi et al., 1996; 
Pidlaoan et al., 1997; Somers et al., 1997).  The human P2Y6 receptor is 23-46% 
homologous to other human P2Y receptors and shares most pair-wise identity with P2Y1 
(46%), P2Y2 (41%) and P2Y4 (43%) (Communi et al., 1996; Abbracchio et al., 2006).  RT-
PCR studies on human osteoblastic MG-63 cells have identified three isoforms (1, 2, and 
3) of the human P2RY6 gene (Maier et al., 1997).  Isoform 1 is encoded by seven splice 
variants (1, 2, 3, 5, 6, 7, and 8) that differ only in their 5' UTR (untranslated region).  
Isoform 2, which is encoded by splice variant 9, has a longer N-terminus compared to 
other variants and contains a 5' UTR and 5' coding region that differs from splice variant 1.  
Finally, isoform 3 appears to be a pseudogene that has a coding region containing an 
extra base that causes a frame shift resulting in a truncation of the translated protein 
thereby rendering it non-functional (Maier et al., 1997). 
The human P2Y6 receptor is involved in the activation of PLC through a PTx-insensitive 
Gαq/11-type G-protein (Communi et al., 1996).  Other studies (Nishida et al., 2008) suggest 
that P2Y6 can also couple to Gα12/13-type G-proteins in rat cardiomyocytes, where 
activation increases the expression of TGF-β (transforming growth factor-β), periostin, 
connective tissue growth factor, and ACE (angiotensin-converting enzyme).   
The preferred natural ligand of the human P2Y6 receptor is UDP, which exhibits an EC50 in 
P2Y6-transfected 1321N1 astrocytoma cells of 300 nM and 11 nM for IP3 formation and 
intracellular Ca2+ release, respectively (Communi et al., 1996; Cox et al., 2005).  Other 
natural ligands are UTP (EC50 6 µM), ADP (EC50 30 µM), and ATP (EC50 >3 mM) 
(Communi et al., 1996).  As a slow-desensitising receptor, P2Y6 exhibits a slow and 
sustained response upon activation.  Robaye et al. (1996) first noticed this characteristic 
in studies looking at IP3 formation in human P2Y6-transfected 1321N1 cells challenged 
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with UDP or ADP.  In their studies, the authors noted that IP3 levels peaked after 15-30 
minutes post-challenge and remained sustained for over 60 minutes.  Brinson and Harden 
(2001) later discovered that the possession of a single threonine in the carboxyl-terminal 
domain and the lack of the serine residues Ser-333 and Ser-334 were responsible for the 
slow desensitisation of P2Y6.  Truncation of these residues in P2Y4-transfected 1321N1 
cells prevented UTP-mediated phosphorylation, desensitisation, and internalisation of 
P2Y4 receptors. 
Transcripts of the human P2Y6 receptor have been found in a variety of tissues including 
heart, placenta, brain, spleen, and thymus (Communi et al., 1996; Moore et al., 2001; 
Wihlborg et al., 2006).  Transcripts for P2Y6 are also detected in a variety of cells including 
epithelial cells, endothelial cells, and leukocytes (Communi et al., 1996; Wong et al., 2009; 
Riegel et al., 2011).  In leukocytes, P2YR6 expression is evident in neutrophils, 
monocytes, macrophages, dendritic cells, and T lymphocytes (Jin et al., 1998; Berchtold 
et al., 1999; Moore et al., 2001; Wang et al., 2004). 
Physiological and pharmacological studies on the P2Y6 receptor in both human and 
animal models have identified a number of possible roles.  For example, studies in human 
omental and cerebral arteries (Malmsjö et al., 2003) and separate P2Y6-knockout (KO) 
mice (Bar et al., 2008) have shown that P2Y6 is capable of eliciting arterial smooth muscle 
contraction.  Other authors including Wihlborg et al. (2006), Wong et al. (2008), and 
Bernier et al. (2013) have also reported an involvement of P2Y6 in ion channel regulation.  
For example, activation of P2Y6 in LPS-treated (lipopolysaccharide) microglia reduces 
P2X4 Ca2+ entry and impairs ATP-dependent migration (Bernier et al., 2013).   
More recently, attention has focussed on the role of P2Y6 in regulating innate immunity 
and inflammation.  Somers et al. (1997) first speculated a role by showing a UDP-
mediated upregulation of P2RY6 expression and intracellular Ca2+ release in activated T-
cells, but not in resting T-cells.  Since these early observations, other groups (Warny et al, 
2001; Cox et al., 2005) have demonstrated P2Y6-dependent release of pro-inflammatory 
cytokines such as TNF-α and IL-8 from monocytic THP-1 cells and U937 cells.  An 
enhanced expression and release of CCL2 and CCL3 from microglia and astrocytes 
following P2Y6 activation has also been reported (Kim et al., 2011; Morioka et al., 2013).  
Of greater interest however, are studies placing a direct link between P2Y6 and 
inflammation.  For example, Viera et al. (2011) have associated P2Y6 activation with 
cytokine release from epithelial cells in airway inflammation.  Other studies also link P2Y6 
with vascular inflammation and atherosclerosis.  Riegel et al. (2011) have shown that 
chemokine expression, adhesion molecule expression, and vascular leakage in LPS-
induced inflammation, is impaired in P2Y6-deficient mice, or, in wild-type mice treated with 
the P2Y6 antagonist MRS-2578.  Similarly, Guns et al (2010) observed an increase in 
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P2Y6 expression in aortic segments from atherosclerotic mice, an effect attributed to an 
increased infiltration of macrophages into aortic segments.  More recently, Stachon et al. 
(2014) have reported a correlation between P2Y6 and leukocyte adhesion to the vessel 
wall.  In their studies the authors reported seeing a greater expression of P2Y6 in 
atherosclerotic aortas from apolipoprotein E-deficient/P2Y6
+/+ mice than from mice 
exhibiting an apolipoprotein E-deficient/P2Y6
-/- phenotype, the latter of which also 
exhibited smaller atherosclerotic lesions than their apolipoprotein E-deficient/P2Y6
+/+ 
counterparts.   
Together, these studies provide important insights into the P2Y6 receptor and its proposed 
involvement in innate immunity and inflammation.  Based on the evidence provided by 
these studies, it seems plausible that P2Y6 may engage in crosstalk with chemokine 
pathways involved in steering monocyte function. 
6.2 Aims 
The aim of this chapter was to investigate the requirement of the human P2Y6 receptor for 
CCL2/CCR2-mediated monocyte signalling and function using monocytic THP-1 cells and 
human PBMCs as in vitro models.  CCL2/CCR2-mediated signalling and function were 
indirectly measured by intracellular Ca2+ release, cell migration, and adhesion to 
endothelial cells.  Studies employed pharmacological and molecular tools for this purpose.  
The research presented in this chapter also looks at the involvement of the CCL2/CCR2 
axis in extracellular nucleotide release from THP-1 cells. 
6.3 Results 
6.3.1 Effect of P2Y6 antagonism on CCL2/CCR2-mediated THP-1 cell and human 
PBMC signalling and function 
The initial aim of this chapter was to examine the requirement of the P2Y6 receptor for 
CCL2/CCR2-mediated monocyte signalling and function.  To address this aim, studies 
employed MRS-2578, a non-competitive and insurmountable P2Y6 antagonist exhibiting 
an IC50 of 37 ± 16 nM against UDP-mediated IP3 formation in human P2Y6-transfected 
1321N1 astrocytoma cells (Mamedova et al., 2004).  MRS-2578 (10 µM) has been shown 
to demonstrate little or no antagonist activity against other P2Y receptors (P2Y1, P2Y2, 
P2Y4 and P2Y11) (Mamedova et al., 2004). 
6.3.1.1 Effect of MRS-2578 on CCL2-evoked Ca2+ responses in THP-1 cells 
To investigate the requirement of P2Y6 for CCL2/CCR2-mediated monocyte signalling, 
studies first examined the effects of a range of MRS-2578 concentrations (10 nM – 10 µM) 
on intracellular Ca2+ responses evoked by CCL2 (50 ng/ml) in THP-1 cells.  As shown in 
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Figure 6.1a, following the addition of 1 µM MRS-2578 to cells, a small and sustained rise 
in the baseline Ca2+ response was seen (4.3 ± 1%Fmax, n=3).  A similar increase was 
also seen upon addition of 100 nM, 300 nM, and 10 µM MRS-2578, but not upon addition 
of vehicle.  This effect is difficult to explain, but suggests a modulation of Ca2+ 
homeostasis by MRS-2578 that might be related to its antagonism of P2Y6.  As also 
shown (Figure 6.1b and c), MRS-2578 produced a concentration-dependent inhibition of 
CCL2-evoked intracellular Ca2+ responses.  Under these conditions, the estimated IC50 for 
MRS-2578 was 418 ± 68 nM (n=3).  At the higher concentrations of MRS-2578 tested, 1 
and 10 µM, CCL2-evoked intracellular Ca2+ responses were impaired by 73 ± 7% (n=3, 
p<0.01) and 79 ± 1% (n=3, p< 0.01), respectively.  In paired experiments with 1 µM MRS-
2578, the %Fmax values for CCL2 in untreated and MRS-2578-treated cells were 25 ± 
1% (n=3), and 7 ± 2% (n=3), respectively.  Similarly, for experiments with 10 µM MRS-
2578, the %Fmax values for untreated and MRS2578-treated cells were 25 ± 1% (n=3) 
and 5 ± 0.3% (n=3), respectively.  Together, these data show a significant reduction of 
CCL2-evoked intracellular Ca2+ responses by MRS-2578.   
The decay rates of Ca2+ transients for all treatments were also compared, but were not 
significantly different (p<0.05).  For example, in paired experiments with 1 µM MRS-2578, 
the  values for CCL2 in untreated and treated cells were 90 ± 11 seconds (n=3) and 80 ± 
14 seconds (n=3), respectively (n=3, p>0.05). 
To rule out the possibility of cytotoxicity, THP-1 cells were exposed to MRS-2578 (1 and 
10 µM) for 2.5 hours prior to viability testing in trypan blue and LDH assays (Appendix 
Figures A3 and A5).  The results of trypan blue assays suggested a possible cytotoxic 
effect with 10 µM, but not 1 µM-MRS 2578.  The % viable cells for vehicle, 10 µM and 1 
µM MRS-2578 were 100 ± 15% (n=3), 49 ± 4% (n=3), and 85 ± 4% (n=3, p>0.05), 
respectively.  While a significant difference between vehicle and 10 µM MRS-2578 was 
not evident using a paired t-test (n=3, p>0.05), a one-way ANOVA with Bonferroni’s 
multiple comparison suggested that 10 µM MRS-2578 reduced cell viability (n=3, p<0.01).  
THP-1 cells treated with 1 µM MRS-2578 however, did not cause a reduction in cell 
viability with either statistical test (n=3, p>0.05).  In the LDH assay, the % control values 
(% of Triton-X) for 1 µM (13%, n=1) and 10 µM MRS-2578 (14%, n=1) fell below the 20% 
toxic threshold.  Since these experiments were performed at 2.5 hours and in the case of 
LDH were only an n=1 replicate, firm conclusions about the effect of MRS-2578 on THP-1 
cell viability in intracellular Ca2+ experiments may not be drawn.   
To understand the requirement of P2Y6 further, the effects of 1 µM MRS-2578 were 
examined in the absence of extracellular Ca2+ (see Chapter 2, Section 2.6.2 for 
methodology).  As shown (Figure 6.2a), 1 µM MRS-2578 produced a small elevation in 
baseline Ca2+.  The response was less than that seen in experiments with extracellular 
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Ca2+ and thus, was difficult to quantify.  As also shown (Figure 6.2b and c), MRS-2578 
significantly impaired CCL2-evoked intracellular Ca2+ responses by 42 ± 2% (n=3, 
p<0.05), where the %Fmax values for CCL2 in untreated and MRS-2578-treated cells 
were 9 ± 1% (n=3) and 5 ± 1% (n=3), respectively.  These data indicate that MRS-2578 
impairs CCL2-evoked intracellular Ca2+ responses in the absence of extracellular Ca2+.  
This is interesting because it suggests that MRS-2578 impairs GPCR-mediated 
intracellular Ca2+ release.  What is also interesting about these data is that the % inhibition 
of CCL2-evoked intracellular Ca2+ responses under these conditions is almost 2-fold less 
than that seen in the presence of intracellular Ca2+ (73 ± 7%, n=3, p<0.01).  This suggests 
that the level of inhibition by MRS-2578 depends almost equally on GPCR-mediated 
intracellular Ca2+ release and Ca2+ influx. 
The decay rates for both treatments were also interesting as they suggested that MRS-
2578 promoted a 32 ± 1% (n=3, p<0.01) faster decay of Ca2+ transients in the absence of 
extracellular Ca2+ (Figure 6.2d).  The values for untreated and MRS-2578-treated THP-1 
cells were 146 ± 5 seconds (n=3) and 99 ± 3 seconds (n=3), respectively.  Since a similar 
effect is not evident with MRS-2578 in the presence of extracellular Ca2+, it seems 
possible that the effects seen here support an impairment of GPCR-mediated intracellular 
Ca2+ release by MRS-2578. 
Together, these data suggest that the P2Y6 antagonist MRS-2578 attenuates CCL2-
evoked intracellular Ca2+ responses in THP-1 cells.  These data suggest a possible 
requirement of P2Y6 for CCL2/CCR2-mediated intracellular Ca
2+ signalling in monocytes. 
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Figure 6.1 Effect of MRS-2578 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of 1 µM MRS-2578 on baseline intracellular 
Ca2+.  (B) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated 
with vehicle (DMSO) or MRS-2578 (10 nM-10 µM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  (C) Normalised concentration-
response curve showing the effect of MRS-2578 (10 nM-10 µM, 15 minutes), on 
intracellular Ca2+ responses to 50 ng/ml CCL2.  Responses given as a percentage of 
CCL2 %Fmax in the absence of MRS-2578.  Data represents mean ± SEM from n=3 
replicates. 
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Figure 6.2 Effect of MRS-2578 on CCL2-evoked Ca2+ responses in THP-1 cells in 
the absence of extracellular Ca2+ 
(A) Representative trace showing the effect of 1 µM MRS-2578 on baseline intracellular 
Ca2+.  (B) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated 
with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  (C) Bar chart showing 
normalised intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  Responses normalised to Ca2+ 
signals elicited by 40 µM digitonin (% Fmax).  (D) Bar chart showing Ca2+ decay rates (, 
sec) for Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(DMSO) or MRS-2578 (1 µM) for 15 minutes.  Data represents mean ± SEM from n=3 
replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, **p<0.01, 
Students t-test). 
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6.3.1.2 Effect of MRS-2578 on CCL2-evoked Ca2+ responses in human PBMCs 
The next experiments sought to examine the effects of 1 µM MRS-2578 on (50 ng/ml) 
CCL2-evoked intracellular Ca2+ responses in human PBMCs.  The rationale behind these 
studies was to understand the requirement of P2Y6 for CCL2/CCR2-mediated signalling in 
monocytes using primary human cells comprising of a mixed cell population.  As shown 
(Figure 6.3a), a small increase in the baseline Ca2+ response was observed upon addition 
of 1 µM MRS-2578.  Although this effect was difficult to quantify, it mirrored the effects of 
MRS-2578 on baseline Ca2+ in THP-1 cells.  As also shown (Figure 6.3b and c), MRS-
2578 attenuated CCL2-evoked intracellular Ca2+ responses in PBMCs by 34 ± 9% (n=3, 
p<0.05), where the %Fmax values for untreated and MRS2578-treated cells were 5 ± 1% 
(n=3) and 3 ± 1% (n=3), respectively.  Interestingly, the % inhibition in PBMCs with MRS-
2578 was ~2-fold less than that observed in THP-1 cells (73 ± 7%, n=3, p<0.01).  This 
result may reflect the fact that PBMCs are heterogeneous and comprise of several cell 
types in addition to monocytes.  Although the magnitude of responses were affected by 
MRS-2578, a comparison of the decay rates for treatments did not reveal a significant 
difference (n=3, p>0.05) between untreated (36 ± 8 seconds, n=3) and MRS-2578-treated 
cells (46 ± 5 seconds, n=3).  This data suggests that MRS-2578 does not influence the 
decay of CCL2 Ca2+ transients in PBMCs. 
These results suggest that MRS-2578 impairs CCL2-evoked intracellular Ca2+ responses 
in human PBMCs, of which a subset are monocytes.  Taken together, these data suggest 
that P2Y6 is required for CCL2/CCR2-mediated signalling in human PBMCs. 
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Figure 6.3 Effect of MRS-2578 on CCL2-evoked Ca2+ responses in human PBMCs 
(A) Representative trace showing the effect of 1 µM MRS-2578 on baseline intracellular 
Ca2+.  (B) Representative Ca2+ transients to CCL2 (50 ng/ml) in PBMCs pre-treated with 
vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  (C) Bar chart showing normalised 
intracellular Ca2+ responses to CCL2 (50 ng/ml) in PBMCs pre-treated with vehicle 
(DMSO) or MRS-2578 (1 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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6.3.1.3 Effect of dual P2Y6/CCR2 antagonism on CCL2-evoked Ca
2+ responses in 
THP-1 cells 
Previous studies conducted by Mamedova et al. (2004) have shown that 1 µM MRS-2578 
abolishes agonist-induced P2Y6 activation.  In THP-1 cell experiments presented earlier in 
this chapter (Section 6.3.1.2), it was seen that 1 µM MRS-2578 impaired CCL2-evoked 
Ca2+ responses by 73 ± 7% (n=3, p<0.01).  Hence, it could conceivably be hypothesised 
that 73% of the CCL2-evoked intracellular Ca2+ response is attributable to P2Y6, and 27% 
to bona-fide CCR2.  Thus, it was important to test the effects of dual P2Y6/CCR2 
antagonism on CCL2-evoked intracellular Ca2+ responses in THP-1 cells.  To this end, 
cells were pre-treated with either vehicle, 1 µM MRS-2578, or 1 µM MRS-2578 plus 100 
nM of the CCR2 antagonist, BMS-CCR2-22 prior to CCL2 (50 ng/ml) challenge.  
A small increase in baseline Ca2+ was observed following the addition of 1 µM MRS-2578 
to THP-1 cells.  This was also seen in experiments where MRS-2578 and BMS-CCR2-22 
were co-applied (Figure 6.4a).  As also shown (Figure 6.4b and c), 1 µM MRS-2578 
inhibited CCL2-evoked intracellular Ca2+ responses to a similar degree as seen previously 
(64 ± 6%, n=3, p<0.01), where the %Fmax values for CCL2 in untreated and MRS-2578-
treated cells were 25 ± 1% (n=3) and 9 ± 2% (n=3), respectively.  The residual CCL2 Ca2+ 
response was abolished (100 ± 0% inhibition, n=3, p<0.01), by pre-treatment of cells with 
1 µM MRS-2578 and 100 nM BMS-CCR2-22, where the %Fmax value for CCL2 was 0 ± 
0% (n=3).  This result suggests that 36% of the CCL2-evoked intracellular Ca2+ response 
in THP-1 cells is attributable to bona-fide CCR2 activation.   
An examination of the decay rates (, sec) for untreated (89 ± 1 seconds, n=3) and 1µM 
MRS-2578-treated THP-1 cells (108 ± 12 seconds, n=3) showed that these were not 
significantly different (n=3, p>0.05), therefore supporting previous results (Section 
6.3.1.2).  As Ca2+ transients for CCL2 were abolished by a co-application of 1 µM MRS-
2578 and 100 nM BMS-CCR2-22, the  values for these transients could not be analysed. 
Taken together, these data suggest that CCL2-evoked intracellular Ca2+ responses in 
monocytes involve an activation of CCR2 and P2Y6. 
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Figure 6.4 Effect of MRS-2578 and BMS-CCR2-22 on CCL2-evoked Ca2+ 
responses in THP-1 cells 
(A) Representative trace showing the effect of 1 µM MRS-2578 on baseline intracellular 
Ca2+.  (B) Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated 
with vehicle (DMSO), MRS-2578 (1 µM), or MRS-2578 (1 µM) plus BMS-CCR2-22 (100 
nM) for 15 minutes.  (C) Bar chart showing normalised intracellular Ca2+ responses to 
CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO), MRS-2578 (1 µM), or 
MRS-2578 (1 µM) plus BMS-CCR2-22 (100 nM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from 
n=3 replicates.  Asterisks indicate significant changes towards vehicle (**p<0.01, One-way 
ANOVA with Bonferroni’s multiple comparison). 
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6.3.1.4 Effect of MRS-2578 on CCL2-mediated THP-1 cell and PBMC chemotaxis 
To determine the requirement of P2Y6 for CCL2/CCR2-mediated monocyte function, 
studies examined the effects of MRS-2578 on THP-1 cell/PBMC migration towards CCL2, 
and THP-1 cell adhesion to quiescent and TNFα-treated HUVEC monolayers. 
The effects of 1 µM MRS-2578 on THP-1 cell migration towards CCL2 (50 ng/ml) were 
first tested.  As shown in Figure 6.5, the chemotactic indexes of THP-1 cells towards 
vehicle (1 ± 1, n=4) and CCL2 (7 ± 2, n=4) indicated a significant increase in cell migration 
towards CCL2 (n=4, p<0.01).  As also shown, 1 µM MRS-2578 significantly attenuated 
THP-1 cell chemotaxis towards CCL2 by 82 ± 2% (n=4, p<0.01), where the chemotactic 
index for MRS-2578-treated cells was 1 ± 0.2 (n=4) and therefore similar to vehicle.  In 
general, therefore, these results suggest a significant impairment of THP-1 cell 
chemotaxis towards CCL2 by MRS-2578.  While it is possible that this effect could be 
attributed to MRS-2578 cytotoxicity, trypan blue and LDH studies (Appendix Figures A3 
and A5) showed no significant loss in cell viability after a 2.5 hour exposure of THP-1 cells 
with 1 µM MRS-2578. 
A similar experiment with 1 µM MRS-2578 was conducted in human PBMCs.  As shown 
(Figure 6.6), THP-1 cells demonstrated a significantly (n=12, p<0.01) higher chemotactic 
index towards CCL2 (25 ± 4, n=12) than towards vehicle (1 ± 0.5, n=12).  From this data it 
is also noticable that PBMCs displayed a higher chemotactic index towards CCL2 than 
THP-1 cells.  This is interesting and may reflect less chemokinesis by PBMCs.  As also 
shown, treatment of cells with MRS-2578 significantly attenuated PBMC chemotaxis 
towards CCL2 by 82 ± 5% (n=12, p<0.01), where a chemotactic index of 6 ± 2 (n=12) was 
seen.  Interestingly, the % inhibition observed in PBMCs was similar to that of THP-1 
cells, and may reflect the level of P2Y6 involvement in CCL2/CCR2-mediated migration. 
In summary, these data suggests that MRS-2578 significantly impairs THP-1 cell and 
human PBMC migration towards CCL2.  This suggests that P2Y6 is required for 
CCL2/CCR2-mediated monocyte chemotaxis.  
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Figure 6.5 Effect of MRS-2578 on CCL2-mediated THP-1 cell chemotaxis 
(A)  Representative images showing the effect of MRS-2578 (1 µM) on THP-1 cell 
chemotaxis towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  
(B) Bar chart showing normalised THP-1 cell chemotaxis towards vehicle (water) or CCL2 
(50 ng/ml, lower chamber, 2hrs) with or without MRS-2578 (1 µM).  Chemotactic index is a 
ratio of the number of cells that migrated towards CCL2 over the number of cells that 
migrated towards vehicle.  Data represents mean ± SEM from n=4 transwells.  Asterisks 
indicate significant changes towards vehicle (**p<0.01, One-way ANOVA with Bonferroni’s 
multiple comparison). 
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Figure 6.6 Effect of MRS-2578 on CCL2-mediated human PBMC chemotaxis 
(A)  Representative images showing the effect of MRS-2578 (1 µM) on PBMC chemotaxis 
towards CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 10 µm.  (B) Bar 
chart showing normalised PBMC chemotaxis towards vehicle (water) or CCL2 (50 ng/ml, 
lower chamber, 2hrs), with or without MRS-2578 (1 µM).  Chemotactic index is a ratio of 
the number of cells that migrated towards CCL2 over the number of cells that migrated 
towards vehicle.  Data represents mean ± SEM from a total of n=12 transwells from n=3 
donors.  Asterisks indicate significant changes towards vehicle (**p<0.01, One-way 
ANOVA with Bonferroni’s multiple comparison). 
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6.3.1.5 Effect of MRS-2578 on CCL2-mediated THP-1 cell adhesion 
Several studies thus far have linked P2Y6 with vascular inflammation (Bar et al., 2008; 
Guns et al., 2010; Riegel et al., 2011; Stachon et al., 2014).  One of these studies by 
Riegel et al. (2011), demonstrated a selective induction of P2RY6 expression in human 
microvascular endothelial cells following treatment with TNFα.  In follow-on experiments in 
a mouse model of endotoxinemia, the authors noticed that knockout of P2Y6 reduced 
cytokine and adhesion molecule expression, and reduced LPS-dependent vascular 
leakage.  Other studies by Guns et al. (2010) and Stachon et al. (2014) discovered a 
correlation between P2RY6 expression and an increased infiltration of macrophages and 
other leukocytes towards vessel walls in aortic segments from atherosclerotic mice.  As 
described previously in this thesis, a number of studies have also suggested a similar 
involvement of CCR2 in vascular inflammation (Boring et al., 1998; Gu et al., 1998; Weber 
et al., 1999).  It is possible, therefore, that monocyte adhesion to the vascular endothelium 
involves crosstalk between P2Y6 and CCR2.   
To examine the above hypothesis, studies employed MRS-2578 to investigate the 
requirement of P2Y6 for adhesion of CCL2-primed THP-1 cells to quiescent and TNFα-
treated HUVEC monolayers.  For experiments, CCL2-primed THP-1 cells were incubated 
with 1 µM MRS-2578 for 45 minutes and then allowed to adhere to vehicle or TNFα-
treated (10 ng/ml) HUVEC cell monolayers.   
In quiescent HUVEC experiments (Figure 6.7a), vehicle-treated THP-1 cells exhibited a % 
adhesion of 31 ± 10% (n=12).  This result is interesting since it suggests that THP-1 cells 
adhere to HUVECs in the absence of stimulus.  A significant increase in % adhesion (100 
± 11%, n=12, p<0.01) was seen with CCL2-primed THP-1 cells and suggested that CCL2 
priming facilitated adhesion.  As also shown (Figure 6.7a), treatment of CCL2-primed 
THP-1 cells with MRS-2578 significantly attenuated adhesion by 70 ± 9% (n=12, p<0.01), 
bringing the % adhesion down a level comparable to vehicle-treated cells (30 ± 9%, 
n=12). 
A similar effect with 1 µM MRS-2578 was observed in experiments with TNFα-treated 
HUVEC monolayers (Figure 6.7b).  The % adhesion of vehicle-treated THP-1 cells was 28 
± 12% (n=12) and therefore similar to adhesion of these cells to quiescent HUVECs.  As 
also shown, CCL2-priming significantly increased the % adhesion of THP-1 cells to TNFα-
treated HUVEC monolayers by 100 ± 26% (n=12, p<0.05), therefore supporting quiescent 
HUVEC experiments.  As also shown (Figure 6.7b), treatment of CCL2-primed THP-1 
cells with 1 µM MRS-2578 attenuated adhesion by 78 ± 15% (n=12, p<0.05), with cells 
displaying a % adhesion comparable to vehicle-treated cells (22 ± 15%, n=12). 
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Taken together, these data indicate that MRS-2578 significantly impairs adhesion of 
CCL2-primed THP-1 cells to quiescent and TNFα-treated HUVEC monolayers.  Based on 
this evidence, a requirement of P2Y6 for CCL2/CCR2-mediated monocyte adhesion to the 
vascular endothelium seems plausible. 
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Figure 6.7 Effect of MRS-2578 on CCL2-mediated THP-1 cell adhesion to 
quiescent and TNFα-treated HUVEC monolayers 
Bar chart showing normalised adhesion of vehicle or CCL2-primed (50 ng/ml) THP-1 cells 
to (A) quiescent and (B) TNFα-treated (10 ng/ml, 5 hours) HUVEC monolayers after 
treatment with vehicle (DMSO) or MRS-2578 (1 µM, 45 minutes).  Normalised adhesion 
represented as a percentage of mean adhesion of CCL2-primed THP-1 cells in the 
absence of MRS-2578.  Data represents mean ± SEM from a total of n=12 replicates from 
n=3 experiments.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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6.3.2 Characterisation of P2Y6-stable and parental 1321N1 astrocytoma cells 
6.3.2.1 Extracellular nucleotide-evoked Ca2+ responses in P2Y6-stable 1321N1 cells 
The human P2Y6 receptor has been shown in human P2Y6-transfected 1321N1 
astrocytoma cells to be activated by UDP, UTP, ADP and ATP with EC50 values of 300 
nM, 6 µM, 30 µM, and >3 mM, respectively (Communi et al., 1996).  It is possible 
therefore, that one or more of these ligands are involved in activating P2Y6 upon activation 
of CCR2.  Thus, in an effort to examine this hypothesis, the human P2Y6 receptor was 
pharmacologically characterised by examining intracellular Ca2+ responses evoked by 
ATP, ADP, UTP, and UDP in human P2Y6-stable and parental 1321N1 cells (gift from 
Professor Jens George Leipziger). 
Table 6.1 Nucleotide Ca2+ responses in P2Y6-stable 1321N1 cells 
Ligand EC50 
F-Ratio at highest 
concentration 
Concentration at which minimum 
response detected and F-Ratio 
ATP >100µM 0.3 ± 0.1 (100 µM) 300 nM (0.01 ± 0.01) 
ADP 3.4 ± 0.2 µM 0.9 ± 0.06 (100 µM). 300 nM (0.004 ± 0.002) 
UTP 887 ± 113 nM 1 ± 0.1 (100 µM) 10 nM (0.0004 ± 0.0004) 
UDP 23 ± 2.6 nM 0.7 ± 0.06 (10 µM) 10 nM (0.14 ± 0.04) 
EC50 values represent mean ± SEM from n=3 estimations.  F-Ratio is a change in 
intracellular Ca2+ following subtraction of the baseline response.  F-ratio represents mean 
± SEM from a total of n=9 replicates from n=3 experiments. 
As shown above in Table 6.1 (and Appendix Figures A20 and A21), all of the nucleotides 
tested (ATP, ADP, UTP, and UDP) evoked concentration-dependent increases in 
intracellular Ca2+ in P2Y6-stable 1321N1 cells.  Of the ligands tested, the weakest ligand 
was ATP with an EC50 of >100µM, and the most potent ligand was UDP with an estimated 
EC50 of 23 ± 2.6 nM (n=3).   
Together, these data suggest an order of potency of UDP > UTP > ADP > ATP that is 
consistent with the order of potency proposed by Communi et al. (1996).  The EC50 values 
estimated in the current study suggest a greater potency of these ligands in driving 
intracellular Ca2+ release than IP3 formation. 
6.3.2.2 Extracellular nucleotide-evoked Ca2+ responses in parental 1321N1 cells 
Studies reported by Communi et al. (1996) and Cox et al. (2005) have demonstrated that 
parental 1321N1 cells and pcDNA3-transfected 1321N1 cells do not respond to classical 
extracellular nucleotides.  If correct, then it is reasonable to suggest that ATP, ADP, UTP, 
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and UDP are ligands of the human P2Y6 purinoceptor.  Thus, to confirm the findings of 
Communi et al. (1996) and Cox et al. (2005), ATP-, ADP-, UTP-, and UDP-evoked 
intracellular Ca2+ responses in parental 1321N1 cells were tested.   
Table 6.2 Nucleotide Ca2+ responses in parental 1321N1 cells 
 Ca2+ response 
Ligand F-Ratio at 100 µM F-Ratio at 10 µM 
Vehicle 0.13 ± 0.02 
ATP 0.15 ± 0.01 0.14 ± 0.01 
ADP 0.17 ± 0.01 0.16 ± 0.009 
UTP 0.15 ± 0.01 0.15 ± 0.01 
UDP 0.18 ± 0.01 0.15 ± 0.009 
The F-Ratio is a change in intracellular calcium following subtraction of the baseline 
response.  Data represents mean ± SEM from a total of n=9 replicates from n=3 
experiments. 
As shown above in Table 6.2 (and Appendix Figure A22), no significant changes in the F-
Ratio were observed with any of the nucleotides tested when compared with vehicle (n=9, 
p>0.05 for all treatments).  These results suggest that parental 1321N1 cells do not 
respond to the extracellular nucleotides ATP, ADP, UTP, or UDP.  It can therefore be 
assumed that intracellular Ca2+ responses evoked by these ligands in P2Y6-1321N1 cells, 
involves a selective activation of the human P2Y6 purinoceptor. 
6.3.2.3 Effect of MRS-2578 on ADP and UDP-evoked Ca2+ responses in P2Y6-stable 
1321N1 cells 
The P2Y6-stable 1321N1 cells were next employed to examine the effects of MRS-2578 
on ADP- and UDP-evoked intracellular Ca2+ responses.  The aim of this study was to 
understand the effects of P2Y6 antagonism on P2Y6-specific Ca
2+ responses.  To address 
this aim, cells were pre-treated with MRS-2578 (0.1 pM – 1 µM) prior to challenge with 
EC50 concentrations of ADP (3.4 µM) or UDP (23 nM).   
As shown in Figure 6.8 and Figure 6.9, MRS-2578 produced a concentration-dependent 
inhibition of ADP- and UDP-evoked intracellular Ca2+ responses.  In experiments involving 
ADP, the % control values in cells treated with vehicle or 1 µM MRS-2578 were 100 ± 5% 
(n=9) and 70 ± 6% (n=9), respectively and although not statistically significant (n=9, 
p=0.7), suggested an inhibition of 29 ± 6% (n=9).  A possible explanation for the variability 
of this data may be the poor solubility of MRS-2578.  In experiments with UDP, the % 
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control values for untreated and MRS-2578-treated cells were 100 ± 4% (n=9) and 62 ± 
6% (n=9), respectively and were indicative of a 36 ± 6% inhibition (n=9, p<0.05).  UDP 
Ca2+ responses were also significantly attenuated by 1 pM (23 ± 5%, n=9, p<0.05), 10 pM 
(24 ± 4%, n=9, p<0.05), 10 nM (22 ± 6%, n=9, p<0.01) and 100 nM MRS-2578 (35 ± 4%, 
n=9, p<0.01). 
An examination of the decay rates of Ca2+ transients showed that 1µM MRS-2578 
facilitated a 14 ± 6% (n=9, p<0.05) faster decay of ADP Ca2+ transients, where the  
values of untreated and MRS-2578-treated cells were 33 ± 2 seconds (n=9) and 28 ± 1 
seconds (n=9), respectively (Figure 6.8c).  UDP Ca2+ transients for untreated (40 ± 2 
seconds, n=9) and 1 µM MRS-2578-treated cells (40 ± 2 seconds, n=9) were not 
significantly different (n=9, p>0.05). 
Taken together, these data suggest that MRS-2578 attenuates UDP-evoked Ca2+ 
responses in P2Y6-stable 1321N1 cells.  This may reflect a preferential activation of P2Y6 
by UDP. 
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Figure 6.8 Effect of MRS-2578 on ADP-evoked Ca2+ responses in P2Y6-stable 
1321N1 cells 
(A) Representative Ca2+ transients to ADP (3.4 µM) in P2Y6-transfected 1321N1 cells pre-
treated with vehicle (DMSO) or MRS-2578 (1 µM), for 30 minutes.  (B) Concentration-
response curve showing the effect of MRS-2578 (0.1 pM – 1 µM, 30 minutes) on 
normalised intracellular Ca2+ responses to ADP (3.4 µM) in P2Y6-transfected 1321N1 
cells.  Responses given as a percentage of normalised peak Ca2+ responses to ADP in 
the absence of MRS-2578.  (C)  Bar chart showing Ca2+ decay rates (, sec) for Ca2+ 
transients to ADP (3.4 µM) in P2Y6-transfected 1321N1 cells pre-treated with vehicle 
(DMSO) or MRS-2578 (1 µM) for 30 minutes.  Data represents mean ± SEM from at total 
of n=9 replicates from n=3 experiments.  Asterisks indicate significant changes towards 
vehicle (*p<0.05, Students t-test). 
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Figure 6.9 Effect of MRS-2578 on UDP-evoked Ca2+ responses in P2Y6-stable  
1321N1 cells 
(A) Representative Ca2+ transients to UDP (23 nM) in P2Y6-transfected 1321N1 cells pre-
treated with vehicle (DMSO) or MRS-2578 (1 µM), for 30 minutes.  (B) Concentration-
response curve showing the effect of MRS-2578 (0.1 pM – 1 µM, 30 minutes) on 
normalised intracellular Ca2+ responses to UDP (23 nM) in P2Y6-transfected 1321N1 cells.  
Responses given as a percentage of normalised peak Ca2+ responses to UDP in the 
absence of MRS-2578.  Data represents mean ± SEM from a total of n=9 replicates from 
n=3 experiments. 
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6.3.3 Effect of P2Y6 antagonism on extracellular nucleotide-evoked Ca
2+ 
responses in THP-1 cells 
The results presented in this chapter suggest a requirement of P2Y6 for efficient 
CCL2/CCR2-mediated monocyte signalling and function.  These data also suggest that 
ATP, ADP, UTP, and UDP activate P2Y6.  It is possible, therefore, that one or more of 
these ligands participate in P2Y6 activation after CCR2 is activated.  It may also be that 
MRS-2578 blocks P2Y6 activation by these ligands.  The next studies therefore tested the 
effects of 1 µM MRS-2578 on intracellular Ca2+ responses evoked by 1 µM ATP, ADP, 
UTP, and UDP-evoked in monocytic THP-1 cells. 
Table 6.3 Effect of MRS-2578 on extracellular nucleotide-evoked Ca2+ responses 
in THP-1 cells 
 Ca2+ response (%Fmax) 
Ligand Vehicle 1 µM MRS-2578 
ATP 29 ± 1 20 ± 0.3** 
ADP 6 ± 0.3 3 ± 0.3* 
UTP 38 ± 1 26 ± 2** 
UDP 6 ± 0.3 5 ± 0.3* 
Intracellular Ca2+ responses to ATP, ADP, UTP, and UDP (all 1 µM) in THP-1 cells pre-
treated with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from 
n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, **p<0.01, 
Students t-test). 
As shown in Table 6.3 (and Appendix Figures A23 and A24), MRS-2578 significantly 
inhibited intracellular Ca2+ responses evoked by all four extracellular nucleotides.  The % 
inhibition values for ATP (31 ± 1%, n=3, p<0.01), ADP (41 ± 5%, n=3, p<0.05), UTP (32 ± 
5%, n=3, p<0.01) and UDP (26 ± 5%, n=3, p<0.05) suggested that intracellular Ca2+ 
responses evoked by ATP and ADP were more sensitive than UTP or UDP to attenuation 
by MRS-2578.  Interestingly, the  values for ADP and UDP Ca2+ transients were not 
possible to determine, and may have indicated a preferential activation of P2Y6, which is a 
slow-desensitising receptor (Robaye et al., 1996).  In experiments involving ATP, the 
decay rates for Ca2+ transients for untreated (129 ± 4 seconds, n=3) and MRS-2578-
treated cells (156 ± 5 seconds, n=3) were not significantly different (n=3, p=0.06), but 
indicated that MRS-2578 slowed the decay of ATP Ca2+ transients by 1.2 ± 0.1 fold (n=3).  
In experiments involving UTP however, MRS-2578 increased the decay of Ca2+ transients 
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by 1.3 ± 0.1-fold (n=3, p<0.05), where the  values for ADP in untreated and MRS-2578-
treated cells were 108 ± 3 seconds (n=3) and 142 ± 8 seconds (n=3), respectively.  These 
data are interesting because they suggest that MRS-2578 preferentially slows the decay 
of NTP-evoked Ca2+ transients.  
Taken together, these data suggest that MRS-2578 attenuates intracellular Ca2+ 
responses evoked by 1 µM ATP, ADP, UTP and UDP with a rank order of 
ADP>UTP>ATP>UDP.  This finding suggests that ADP is likely to play a bigger role than 
other extracellular nucleotides in engaging with P2Y6 upon CCR2 activation in monocytes. 
6.3.4 The functional presence of P2Y14 in THP-1 cells 
The human P2Y14 receptor was first cloned by Nomura et al. (1994) from human myeloid 
KG-1 cells and is encoded by the P2YR14 gene located on the long arm of chromosome 3 
(3q24-q25.1).  P2Y14 shares most pair-wise identity with P2Y12 and P2Y13 (47%)  (Nomura 
et al., 1994; Chambers, 2000; Abbracchio et al., 2006).  Although P2Y14 signalling is 
primarily through PTx-sensitive Gαi/o-type G-proteins coupled to adenylate cyclase 
inhibition, PLC activation has also been reported, and is likely to involve a dual coupling of 
P2Y14 to Gαi/o and Gαq/11 (Chambers, 2000; Skelton et al., 2003; Mϋller et al., 2005). 
The human P2Y14 purinoceptor is activated by several UDP-sugars, including UDP-
glucose, UDP-N-acetyl glucosamine, and UDP-glucuronic acid (Fricks et al., 2009).  In 
humans, the preferred ligands of P2Y14 are UDP and UDP-galactose (Fricks et al., 2009; 
Carter et al., 2009).  Although studies by Fricks et al. (2009) initially suggested that UDP 
blocked P2Y14, the same group later reported that UDP acted as an agonist of P2Y14 
(EC50 29-74 nM), and that earlier experiments were inaccurate as they were performed 
using test models expressing low levels of P2Y14 and non-cognate Gα15/16 G-proteins 
(Carter et al., 2009). 
The experiments presented in this chapter have shown that 1 µM MRS-2578 attenuates 
UDP-evoked Ca2+ responses in THP-1 cells by 26 ± 5% (n=3, p<0.05) (Section 6.3.3).  
This result suggests that 74% of the UDP response is resistant to MRS-2578.  Since UDP 
is also a ligand of P2Y14, it is possible that the MRS-2578-resistant component is 
attributed to P2Y14.  An experiment to assess this hypothesis would have ideally involved 
the use of a P2Y14-selective antagonist, but due to none being commercially available, this 
experiment could not be performed.  Instead, the current study sought to provide 
functional evidence for P2Y14 in THP-1 cells by testing Ca
2+ responses to 30 µM UDP-
glucose, a P2Y14 ligand exhibiting an EC50 of 72-323 nM in cAMP inhibition assays in 
human P2Y14-transfected HEK 293, CHO and rat C6-glioma cells (Carter et al., 2009). 
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As shown (Figure 6.10), UDP-glucose caused a transient intracellular Ca2+ response in 
THP-1 cells, where the %Fmax responses for cells challenged with vehicle or UDP-
glucose (30 µM) were 0.7 ± 0.3% (n=3) and 4.7 ± 0.3% (n=3), respectively (n=3, p<0.05).  
These data suggest that functional P2Y14 purinoceptors are expressed in THP-1 cells.  
Furthermore, since no studies in literature have tested the effects of UDP-glucose or other 
UDP sugars on P2Y6 activation, these data also indicate that UDP-glucose-evoked 
intracellular Ca2+ responses in THP-1 cells do not involve P2Y6.   
Taken together and in combination with the previous results presented in Section 6.3.3, 
these data suggest that UDP-evoked intracellular Ca2+ responses in THP-1 cells and 
monocytes involve the UDP-sensitive receptors, P2Y6 and P2Y14. 
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Figure 6.10 UDP-glucose-evoked Ca2+ responses in THP-1 cells 
 (A) Representative Ca2+ transient in THP-1 cells to UDP-glucose (30 µM).  (B) Bar chart 
showing normalised intracellular Ca2+ responses to vehicle (water) or UDP-glucose (30 
µM) in THP-1 cells.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (% 
Fmax).  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant 
changes towards vehicle (**p<0.01, Students t-test). 
 
 
253 
 
6.3.5 Investigating CCR2 and P2Y6 crosstalk in THP-1 cells 
The evidence presented thus far suggests that CCL2/CCR2-mediated monocyte signalling 
and function involves crosstalk between CCR2 and P2Y6.  Indeed, crosstalk of 
purinoceptors with other signalling pathways is not a novel phenomenon and was first 
seen by Ralevic and Burnstock (1990) in studies which identified ATP as a synergistic co-
transmitter with noradrenaline in sympathetic nerves.  Other groups have since identified 
crosstalk between purinoceptors and a number of other signalling pathways, including 
those driven by N-formyl-Met-Leu-Phe (fMLP) (Chen et al., 2006), thromboxanes 
(Oestreich et al., 2013), and cysteinyl leukotrienes (Mellor et al., 2001). 
Crosstalk between different GPCR pathways can also result in an amplification of 
intracellular Ca2+ responses through the activation of different G-proteins (Gerwins and 
Fredholm, 1992; Werry et al., 2003).  Purinoceptors have also been reported to engage in 
crosstalk with other GPCRs via common isoforms of PLC.  For example, Roach et al. 
(2008) discovered that Ca2+ responses in RAW264-7 macrophage cells and mouse bone 
marrow-derived macrophages involved synergism between UDP and complement 5a 
through the activation of PLCβ3.   
6.3.5.1 Effect of CCL2/UDP co-application on Ca2+ responses in THP-1 cells 
Given the possibility that monocyte signalling and function involves crosstalk between 
CCR2 and P2Y6, it is possible that the ligands of these receptors, CCL2 and UDP, act 
synergistically.  To examine this hypothesis, intracellular Ca2+ responses in THP-1 cells 
were tested following challenge with either CCL2 alone (50 ng/ml), UDP alone (30 µM), or 
a combination of both (CCL2/UDP). 
As shown (Figure 6.11), the %Fmax responses for THP-1 cells challenged with CCL2 (25 
± 1%, n=4) and UDP (11 ± 2%, n=4) were significantly different (n=4, p<0.01).  In THP-1 
cells challenged with CCL2/UDP, a %Fmax of 30 ± 1% (n=4) was seen and gave a 
significantly higher response than UDP alone (n=4, p<0.05) (Figure 6.11).  The %Fmax 
response for CCL2/UDP was not significantly higher than cells challenged with CCL2 
alone (n=4, p=0.055), but suggested a 1.4 ± 0.2 fold (n=4) increase.  Although not 
statistically significant, this result suggests that further experiments may show that a co-
application of CCL2 and UDP amplifies CCL2-evoked intracellular Ca2+ responses in THP-
1 cells.  A further analysis of the decay rates showed that the  values for CCL2 (114 ± 6 
seconds, n=4) and UDP (291 ± 73 seconds, n=4) were significantly different (n=4, 
p<0.05), with UDP Ca2+ transients exhibiting a slower decay, possibly from P2Y6 
activation (Figure 6.11c).  In comparison, cells challenged with CCL2/UDP exhibited a  
value of 94 ± 8 seconds (n=4), which indicated a significantly faster decay than UDP alone 
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(n=4, p<0.05), but no faster or slower than CCL2 (n=4, p>0.05).  This result suggests that 
the rate of decay of Ca2+ transients for CCL2 and CCL2/UDP are similar. 
Taken together, these data suggest that a co-application of CCL2 and UDP to THP-1 cells 
does not amplify CCL2 intracellular Ca2+ responses.  However, as data hinted at a 
possible amplification, it may be that further studies are required to confirm this. 
6.3.5.2 Effect of BMS-CCR2-22 on UDP-evoked Ca2+ responses in THP-1 cells 
To examine further for crosstalk between CCR2 and P2Y6, the next studies investigated 
the effects of the CCR2 antagonist, BMS-CCR2-22 (100 nM) on UDP (30 µM)-evoked 
intracellular Ca2+ responses in THP-1 cells.  As shown (Figure 6.12), UDP-evoked Ca2+ 
responses were not significantly affected by BMS-CCR2-22, where the %Fmax responses 
for UDP in untreated (11 ± 0.3, n=3) and BMS-CCR2-22-treated cells (12 ± 0.3, n=3) were 
not statistically different (n=3, p>0.05).  A further comparison of the decay rates for UDP 
Ca2+ transients in untreated (235 ± 46 seconds, n=3) and BMS-CCR2-22-treated cells 
(218 ± 48 seconds, n=3) also revealed no significant differences between the two 
treatments (n=3, p>0.05).   
Taken together, these data suggest that BMS-CCR2-22 does not impair UDP-evoked 
intracellular Ca2+ responses in monocytes.  This suggests that crosstalk between CCR2 
and P2Y6 may be unidirectional. 
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Figure 6.11 Effect of CCL2/UDP co-application on Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to CCL2 (50 ng/ml), UDP (30 µM) and CCL2/UDP (50 
ng/ml + 30 µM).  (B) Bar chart showing normalised intracellular Ca2+ responses to CCL2 
(50 ng/ml), UDP (30 µM) and CCL2/UDP (50 ng/ml + 30 µM) in THP-1 cells.  (C)  Bar 
chart showing decay rates (, sec) for Ca2+ transients to CCL2 (50 ng/ml), UDP (30 µM) 
and CCL2/UDP (50 ng/ml + 30 µM) in THP-1 cells.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates 
(*p<0.05, *p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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Figure 6.12 Effect of BMS-CCR2-22 on UDP-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to UDP (30 µM) in THP-1 cells pre-treated with BMS-
CCR2-22 (100 nM) for 15 minutes.  (B)  Bar chart showing normalised intracellular Ca2+ 
responses to UDP (30 µM) in THP-1 cells pre-treated with BMS-CCR2-22 (100 nM) for 15 
minutes.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  
Data represents mean ± SEM from n=3 replicates. 
 
257 
 
6.3.6 Investigating crosstalk between P2Y6 and FPRs in THP-1 cells 
The chemoattractant N-formyl-Methionyl-Leucyl-Phenylamine (fMLP) is a product derived 
from degraded bacterial or mitochondrial peptides (Showell et al., 1976).  It is now 
considered a potent chemoattractant and lysoenzyme inducer for a variety of leukocytes, 
and in particular, for neutrophils (Carp, 1982).  fMLP signalling occurs through PTx-
sensitive Gαi/o-coupled formyl peptide receptors (FPR), a group of PRRs comprising of 
three family members (FPR1, FPR2 and FPR3) in humans that are expressed by cells of 
both non-myeloid (e.g.platelets, endothelial cells) and myeloid origin (monocytes, 
neutrophils) (Ye et al., 2009).  In monocytes, FPR activation induces intracellular Ca2+ 
release, cytokine and superoxide anion release, and also chemotaxis (Yasaka et al., 
1982; Ohura et al., 1987; Godfrey et al., 1988; Gouwy et al., 2009). 
The evidence presented in this chapter has suggested that P2Y6 is required for monocyte 
signalling and function mediated by the chemotactic peptide, CCL2.  However, while these 
data suggest a novel association between P2Y6 and CCR2, the requirement of P2Y6 for 
monocyte signalling and function may also extend to other chemotactic peptides.  To 
examine the validity of this hypothesis, the effects of apyrase and MRS-2578 on fMLP-
mediated THP-1 cell intracellular Ca2+ responses and chemotaxis were examined,   
6.3.6.1 Effect of apyrase and MRS-2578 on fMLP-evoked Ca2+ responses in THP-1 
cells 
Initial studies examined the ability of fMLP to evoke intracellular Ca2+ responses in THP-1 
cells.  Cells were therefore challenged with 0.01, 0.1, 1 and 10 µM fMLP.  As shown 
(Figure 6.13a), fMLP elicited a concentration-dependent intracellular Ca2+ response.  
Using the results from this study, a median concentration of 1 µM fMLP was used in 
further assays.   
In further experiments, it was seen that apyrase (2 U/ml) significantly attenuated fMLP-
evoked intracellular Ca2+ responses in THP-1 cells by 61 ± 6% (n=3, p<0.05), where it 
was seen that the %Fmax responses for fMLP in untreated and apyrase-treated cells 
were 3 ± 0.3% (n=3) and 1 ± 0% (n=3), respectively (Figure 6.13).  This result was 
unexpected, and suggests that extracellular nucleotide scavenging impairs fMLP-FPR 
monocyte signalling.  Due to a lack of decay of CCL2 Ca2+ transients in apyrase-treated 
cells, the  values could not be determined. 
In experiments investigating the requirement of P2Y6 for fMLP-FPR signalling, it was seen 
that THP-1 cell intracellular Ca2+ responses to fMLP were insensitive to 1 µM MRS-2578 
(n=3, p>0.05), where no change in the % Fmax values for fMLP in untreated (2 ± 0, n=3), 
and MRS-2578-treated cells (2 ± 0, n=3) was seen (Figure 6.14).  The decay rates for 
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fMLP Ca2+ transients for untreated (78 ± 25 seconds, n=3) and MRS-2578-treated cells 
(42 ± 3 seconds, n=3) were compared, and although the data suggested that MRS-2578 
promoted a faster decay of Ca2+ transients, these data were not significantly different 
(n=3, p=0.2). 
These data have shown that fMLP-evoked intracellular Ca2+ responses in THP-1 cells are 
sensitive to inhibition by apyrase, but not by MRS-2578.  Taken together, these data 
suggest a requirement of extracellular nucleotides for fMLP-FPR-associated signalling, 
but exclude a role for P2Y6. 
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Figure 6.13 Effect of apyrase on fMLP-evoked Ca2+ responses in THP-1 cells 
(A)  Representative Ca2+ transients in THP-1 cells following challenge with fMLP (0.01 - 
10 µM).  (B) Representative Ca2+ transients to fMLP (1 µM) in THP-1 cells pre-treated with 
apyrase (2 U/ml) for 10 minutes.  (C) Bar chart showing normalised intracellular Ca2+ 
responses to fMLP (1 µM) in THP-1 cells pre-treated with apyrase (2 U/ml) for 10 minutes.  
Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data 
represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle (no apyrase) (*p<0.05, Students t-test). 
 
 
260 
 
 
 
Figure 6.14 Effect of MRS-2578 on fMLP-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to fMLP (1 µM) in THP-1 cells pre-treated with MRS-
2578 (1 µM) for 15 minutes.  (B) Bar chart showing normalised intracellular Ca2+ 
responses to fMLP (1 µM) in THP-1 cells pre-treated with MRS-2578 (1 µM) for 15 
minutes.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  
Data represents mean ± SEM from n=3 replicates.   
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6.3.6.2 Effect of apyrase and MRS-2578 on fMLP-mediated THP-1 cell chemotaxis 
To examine the requirement of extracellular nucleotides and P2Y6 for fMLP-mediated 
chemotaxis, experiments next tested the effects of apyrase (2 U/ml) and MRS-2578 (1 
µM) on THP-1 cell chemotaxis towards 1 µM fMLP.  As shown (Figure 6.15), THP-1 cells 
demonstrated a significantly higher (n=4, p<0.01) chemotactic index towards fMLP (4.3 ± 
0.4, n=4), than towards vehicle (1 ± 0.12, n=4).  This result supports the hypothesis that 
fMLP is a chemoattractant for monocytes.  As also shown, apyrase significantly inhibited 
chemotaxis of THP-1 cells towards fMLP by 77 ± 6% (n=4, p<0.01), where cells displayed 
a chemotactic index that was comparable to vehicle (1 ± 0.3, n=4).  Interestingly, no 
significant reduction in the chemotactic index for THP-1 cells treated with MRS-2578 was 
seen, where the chemotactic indexes of untreated (4.3 ± 0.4, n=4) and MRS-2578-treated 
cells (3.5 ± 0.3, n=4) were not significantly different (n=4, p>0.05). 
Taken together, these data suggest a requirement of extracellular nucleotides for fMLP-
FPR-associated monocyte signalling and function but do not support a requirement of the 
P2Y6 purinoceptor.  It is possible, therefore, that fMLP-FPR-associated monocyte 
signalling and function involves crosstalk between FPRs and other purinoceptors. 
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Figure 6.15 Effect of apyrase and MRS-2578 on fMLP-mediated THP-1 cell 
chemotaxis 
(A)  Representative images showing the effect of apyrase (2 U/ml) and MRS-2578 (1 µM) 
on THP-1 cell chemotaxis towards fMLP (1 µM, lower chamber, 2hrs).  Scale bar 
represents 10 µm.  (B) Bar chart showing normalised THP-1 cell chemotaxis towards 
vehicle (water) or fMLP (1 µM, lower chamber, 2hrs), with or without apyrase (2 U/ml) or 
MRS-2578 (1 µM).  Chemotactic index is a ratio of the number of cells that migrated 
towards fMLP over the number of cells that migrated towards vehicle.  Data represents 
mean ± SEM from n=4 transwells.  Asterisks indicate significant changes towards vehicle 
(**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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6.3.7 Effect of P2Y6 desensitisation on CCL2-evoked Ca
2+ responses in THP-1 cells 
The P2Y6 receptor is a slow-desensitising receptor that displays a slow and sustained 
response upon agonist activation (Abbracchio et al., 2006).  Studies have previously 
shown that challenging P2Y6-transfected 1321N1 cells with UDP or ADP evokes a cellular 
response (IP3 formation) that declines after 60 minutes, but remains detectable for up to 3 
hours post-challenge (Robaye et al., 1996).  Furthermore, P2Y6 responses can be fully 
restored at 45 minutes post-first-challenge Robaye et al. (1996). 
In order to provide further evidence for a requirement of P2Y6 for CCL2/CCR2-mediated 
monocyte signalling and function, studies next examined the effects of P2Y6 
desensitisation on CCL2-evoked intracellular Ca2+ responses in THP-1 cells.  However, in 
order to justify these experiments, it was first important to examine whether the P2Y6 
ligands, ADP and UDP desensitised P2Y6-mediated intracellular Ca
2+ responses. 
6.3.7.1 Effect of repeat ADP or UDP challenge on Ca2+ responses in THP-1 cells 
To determine whether ADP or UDP desensitised P2Y6-mediated intracellular Ca
2+ 
responses, THP-1 cells were challenged with ADP or UDP (3 µM) twice, once at 0 
minutes (1st challenge) and another at 10 minutes (2nd challenge).  A concentration of 3 
µM of ADP and UDP was chosen as this is shown to elicit a reasonable intracellular Ca2+ 
response in P2Y6-stable 1321N1 cells (Section 6.3.2).   
As shown (Figure 6.16a and b), the %Fmax responses for 1st and 2nd ADP challenges 
were 8 ± 0.3% (n=3) and 5 ± 1% (n=3), respectively, and indicated a reduction of 40 ± 8% 
(n=3, p<0.05), consistent with a slow desensitisation of P2Y6.  The Ca
2+ transient decay 
rates for ADP were also different.  Although the  values for ADP at 0 minutes (1st) could 
not be accurately determined due to the sustained responses, the  value for ADP at 10 
minutes (2nd) was 34604 ± 12244 seconds (n=3) and suggested a faster decay due to 
P2Y6 desensitisation.  As also shown (Figure 6.16c and d), intracellular Ca
2+ responses to 
3 µM UDP were attenuated by 68 ± 10 % (n=3, p<0.05), where the %Fmax values for 1st 
and 2nd UDP challenges were 9 ± 0.3% (n=3) and 3 ± 1% (n=3), respectively.  Due to the 
sustained intracellular Ca2+ responses, the decay rates for UDP could not be accurately 
determined. 
Taken together, these data suggest that prior activation of P2Y6 with ADP or UDP 
desensitises P2Y6 to further challenge by ADP or UDP.  A greater impairment of UDP 
Ca2+ responses may reflect its greater potency at P2Y6.   
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Figure 6.16 Effect of repeat ADP- or UDP-challenge on Ca2+ responses in THP-1 
cells 
Representative Ca2+ transients to (A) ADP (3 µM) or (C) UDP (3 µM) in THP-1 cells at 0 
minutes (1st challenge), and 10 minutes (2nd challenge).  Bar chart showing normalised 
intracellular Ca2+ responses to (B) ADP (3 µM) or (D) UDP (3 µM) in THP-1 cells at 0 
minutes (1st application), and 10 minutes (2nd application).  Responses normalised to Ca2+ 
signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± SEM from n=3 
replicates.  Asterisks indicate significant changes towards 1st challenge (*p<0.05, Students 
t-test) 
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6.3.7.2 Effect of ADP and UDP challenge on CCL2-evoked Ca2+ responses in THP-1 
cells 
A similar experimental design was applied to examine the effects of ADP and UDP on 
CCL2-evoked intracellular Ca2+ responses.  To this end, THP-1 cells were challenged with 
vehicle, ADP (3 µM) or UDP (3 µM) at 0 minutes, and then challenged with CCL2 (50 
ng/ml) 10 minutes later.  As shown (Figure 6.17a and b), prior challenge of THP-1 cells 
with ADP resulted in a 27 ± 5% reduction (n=3, p<0.05) in the CCL2-evoked Ca2+ 
response, where the %Fmax responses for CCL2 in cells challenged with vehicle and 3 
µM ADP were 26 ± 1% (n=3) and 19 ± 1% (n=3), respectively.  This result suggests that 
prior activation of P2Y6 by ADP impairs CCL2-evoked intracellular Ca
2+ responses.  A 
comparison of the  values for CCL2 across treatments was also made, but did not reveal 
any significant differences (n=3, p>0.05) between vehicle (89 ± 1 seconds, n=3) and ADP-
challenged THP-1 cells (94 ± 4 seconds, n=3). 
A similar impairment (28 ± 4%, n=5, p<0.01) of CCL2-evoked intracellular Ca2+ responses 
was observed in cells challenged with 3 µM UDP (Figure 6.17c and d).  As shown, the 
%Fmax responses for CCL2 in vehicle and UDP-challenged cells were 22 ± 1% (n=5), 
and 16 ± 0.3% (n=5), respectively.  These data supported the results of ADP experiments 
and suggested a similar impairment of CCL2-evoked intracellular Ca2+ responses 
following nucleotide challenge.  Interestingly, a significant reduction (14 ± 4%, n=5, 
p<0.05) in the decay rates between vehicle (79 ± 5 seconds, n=5) and UDP-challenged 
cells (67 ± 4 seconds, n=5) was observed (Figure 6.17e), indicating a faster decay of 
CCL2 Ca2+ transients following UDP challenge. 
In summary, these results suggest that prior challenge of THP-1 cells with ADP or UDP 
attenuates CCL2-evoked intracellular Ca2+ responses.  This indicates that P2Y6 activation 
cross-desensitises CCL2/CCR2-mediated signalling in monocytes. 
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Figure 6.17 Effect of ADP or UDP challenge on CCL2-evoked Ca2+ responses in 
THP-1 cells 
Representative Ca2+ transients to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle 
(water) or (A) ADP (3 µM) or (C) UDP (3 µM) for 10 minutes.  Bar chart showing 
normalised intracellular Ca2+ responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with 
vehicle (water) or (B) ADP (3 µM) or (D) UDP (3 µM) for 10 minutes.  (E)  Bar chart 
showing Ca2+ decay rates (, sec) for CCL2 Ca2+ transients in THP-1 cells pre-treated with 
vehicle (water) or UDP (3 µM) for 10 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 (ADP), or 
n=5 (UDP) replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
**p<0.01, Students t-test). 
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6.3.8 Generation and evaluation of P2RY6-KD THP-1 cells  
To provide further evidence for crosstalk between CCR2 and P2Y6, it was important to 
employ a molecular-based approach to silence the P2RY6 gene.  The methodology 
employed involved the use of a lentiviral vector (pLKO.1) to deliver a short hairpin RNA 
(shRNA) sequence for P2RY6 into THP-1 cells to enable a stable and long-term gene 
knockdown (Section 2.5, Chapter 2).  P2RY6-KD lines were generated using two 
methods, either by generating pLKO.1-puro shRNA-encoding lentivirus in-house, or by 
purchasing lentiviral particles incorporating pLKO.1-puro P2RY6-shRNA sequences.  Both 
studies also involved the use of pLKO.1-puro non-target-shRNA lentiviral particles to 
generate a “scrambled” THP-1 cell line that acted as a negative control. 
6.3.8.1 Generation of P2RY6-KD THP-1 cells with in-house P2RY6-shRNA lentivirus 
6.3.8.1.1 UDP-evoked Ca2+ responses 
P2RY6-KD THP-1 cell lines were generated using in-house lentiviral particles encoding 
the P2RY6-shRNA sequences 14073 and 14075, as identified by the RNA interference 
(RNAi) consortium (TRC) (Table 2.11, Chapter 2).  Sequence 14075 was identified from 
studies conducted by Ben Yebdri et al. (2009).   
Following the generation of cell lines, the first approach taken was to triage P2RY6-KD 
THP-1 cells based on the functional efficacies of their shRNA sequences.  This was done 
by comparing UDP (30 µM)-evoked intracellular Ca2+ responses between scrambled and 
P2RY6-KD cell lines (14073 and 14075). 
Table 6.4 UDP-evoked Ca2+ responses in scrambled and P2RY6-KD cell lines 
Ca2+ response (% Fmax) 
Scrambled 14073 Scrambled 14075 
10 ± 1 10 ± 2 10 ± 1 17 ± 1** 
Decay rate (, sec) 
Scrambled 14073 Scrambled 14075 
242 ± 24 227 ± 69 s 109 ± 18 124 ± 7 
Intracellular Ca2+ responses and decay rates (, sec) for UDP (30 µM) in THP-1 cells 
transduced with non-target (scrambled) or P2YR6-shRNA sequences 14073 and 14075.  
Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data 
represents mean ± SEM from n=3 (14073) or n=4 (14075) replicates.  Asterisks indicate 
significant changes towards scrambled (**p<0.01, Students t-test). 
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As shown above in Table 6.4, no significant changes in the %Fmax values for UDP were 
detected between scrambled and 14073-cells (n=3, p>0.05).  The decay rates (, sec) of 
scrambled and 14073-cells were also not significantly different (n=3, p>0.05).  These data 
suggest that 14073-cells do not exhibit a functional impairment of P2Y6.  In similar 
experiments with 14075 cells, a 1.6 ± 0.3-fold increase in UDP Ca2+ responses over 
scrambled cells was seen (n=4, p<0.01).  These data were interesting because they 
suggested that shRNA 14075 enhanced P2Y6 function.  However, it was interesting to 
observe that the decay rates of UDP Ca2+ transients for scrambled and 14075 cells were 
not significantly different (n=4, p>0.05), suggesting that shRNA 14075 did not affect the 
decay of UDP Ca2+ transients.   
6.3.8.1.2 qRT-PCR analysis of P2RY6 expression 
A pilot qRT-PCR (quantitative real-time-polymerase chain reaction) study was next 
conducted using primers detailed in Chapter 2 to assess for P2RY6 expression in 
scrambled and 14075 cells lines.  14073 cells were excluded from this study as these 
showed no functional P2Y6 knockdown.  Table 6.5 lists the relative quantitation (RQ) and 
fold-shift values for P2RY6 in scrambled and 14075 cells.  As described previously 
(Chapter 2), the RQ value represents the fold-change in gene expression relative to 
scrambled cells.   
Table 6.5 Relative quantitation and fold-shift values for scrambled and P2RY6-
KD 14075 THP-1 cells 
shRNA Gene RQ Fold-shift 
Scrambled P2YR6 1.0 1.0 
14075 P2YR6 1.1 0.9 
Data represent n=1 replicate.  Relative quantification (RQ) values were normalised to β-
actin and then further normalised to scrambled cells according to the 2-∆∆Ct method (Livat 
and Schmittgen, 2001).  An RQ value of 0.5 (2-fold shift) was considered significant. 
As shown (Table 6.5), a 0.9 fold-(10%) increase in P2RY6 expression was seen in 14075 
cells (n=1).  Although this data is interesting and may explain the increased UDP-evoked 
Ca2+ responses seen in these cells (Table 6.4), these data are only an n=1 replicate and 
below the reliable detection limits of qRT-PCR which is unable to reliably detect less than 
a 2-fold change (1 PCR cycle) in gene expression (Karlen et al., 2007). 
Taken together, these data suggest that the shRNA sequences 14073 and 14075 do not 
encode for P2YR6 knockdown in THP-1 cells.   
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6.3.8.2 Generation of P2RY6-KD THP-1 cells using MISSION® P2RY6-shRNA 
lentivirus 
Due to difficulties with shRNA sequences 14073 and 14075, it was decided that the most 
convenient and rapid method for generating P2RY6-KD THP-1 cells was to use Sigma 
MISSION® lentivirus particles.  To enable generation of P2RY6-KD THP-1 cells, five 
shRNA sequences including 14075, were selected (Table 2.12, Chapter 2).  P2RY6-KD 
and scrambled THP-1 lines were generated as described in Section 2.5.5 (Chapter 2).  
Cell lines were triaged in terms of shRNA functional efficacies as measured by UDP- and 
CCL2-evoked intracellular Ca2+ responses. 
6.3.8.2.1 UDP-evoked Ca2+ responses 
The functional efficacies of shRNA sequences were examined by comparing (30 µM) 
UDP-evoked intracellular Ca2+ responses for all P2RY6-KD cell lines with scrambled cells.   
Table 6.6 UDP-evoked Ca2+ responses in scrambled and P2RY6-KD cell lines 
Ca2+ response (% Fmax) 
Scrambled 14075 14076 14077 357968 358038 
15 ± 1 17 ± 0.3 10 ± 0.3** 11 ± 1** 9 ± 1** 8 ± 1** 
Decay rate (, sec) 
Scrambled 14075 14076 14077 357968 358038 
88 ± 2 90 ± 6 63 ± 2 161 ± 26* 51 ± 10 85 ± 3 
Intracellular Ca2+ responses and decay rates (, sec) for UDP (30 µM) in THP-1 cells 
transduced with non-target (scrambled) or P2YR6-shRNA sequences.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± 
SEM from n=3 replicates.  Asterisks indicate significant changes towards scrambled 
(*p<0.05, **p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
As shown above in Table 6.6 (and Appendix Figure A25), a significant impairment of 
UDP-evoked intracellular Ca2+ responses was seen with the majority of P2RY6 shRNA 
sequences, with the greatest impairment seen in cells transduced with 358038 (50 ± 5%, 
n=3, p<0.01).  UDP %Fmax responses were also attenuated in THP-1 cells transduced 
with 14076 (37 ± 4%, n=3, p<0.01), 14077 (30 ± 1%, n=3, p<0.01) and 357968 (39 ± 3%, 
n=3, p<0.01).  As also shown by Table 6.6 (and Appendix Figure A25), THP-1 cells 
transduced with 14075 were not significantly different from scrambled cells (n=3, p>0.05).  
Interestingly, an assessment of the decay rates for scrambled and P2RY6-KD THP-1 cell 
lines showed that only 14077 cells exhibited a significant 1.8 ± 0.3 fold (n=3, p<0.05) 
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increase in  over scrambled cells (Table 6.6 and Appendix Figure A25).  This result 
therefore suggested that UDP Ca2+ transients in cells transduced with 14077 decayed ~2-
fold slower than scrambled cells.  This data is difficult to explain but suggests a greater 
effect of this shRNA on P2Y6 desensitisation.  In contrast, the  values for all other P2RY6 
shRNA sequences were not significantly different from scrambled cells (n=3, p>0.05 for 
all). 
Taken together, these data suggest that THP-1 cells transduced with shRNA sequences 
14076, 14077, 357968, and 358038, display reduced intracellular Ca2+ responses to UDP.  
From these data, it also apparent that 358038 is the best-performing shRNA, while 14075 
is the worst-performing shRNA. 
6.3.8.2.2 CCL2-evoked Ca2+ responses 
The results above have suggest that THP-1 cells transduced with the P2RY6 shRNA 
sequences 14076, 14077, 357968, and 358038 show reduced Ca2+ responses to UDP.  It 
is possible, therefore, that these also display a reduced intracellular Ca2+ response to 
CCL2.  To examine this hypothesis, CCL2-evoked intracellular Ca2+ responses in 
scrambled and P2RY6-KD THP-1 lines were compared. 
Table 6.7 CCL2-evoked Ca2+ responses in scrambled and P2RY6-KD cell lines 
Ca2+ response (%Fmax) 
Scrambled 14075 14076 14077 357968 358038 
26 ± 0.3 29 ± 1 24 ± 1 24 ± 1 24 ± 1 21 ± 0** 
Decay rate (, sec) 
Scrambled 14075 14076 14077 357968 358038 
104 ± 1 91 ± 1** 76 ± 2** 85 ± 1** 84 ± 3** 84 ± 2** 
Intracellular Ca2+ responses and decay rates (, sec) for CCL2 (50 ng/ml) in THP-1 cells 
transduced with non-target (scrambled) or P2YR6-shRNA sequences.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± 
SEM from n=3 replicates.  Asterisks indicate significant changes towards scrambled 
(**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
As shown above in Table 6.7 (and Appendix Figure A26), CCL2-evoked intracellular Ca2+ 
responses were significantly impaired by 20 ± 1% (n=3, p<0.01) in THP-1 cells transduced 
with shRNA 358038.  In comparison, no significant reduction in CCL2 Ca2+ responses was 
seen in cells transduced with 14075, 14076, 14077, or 357968 (all n=3, p>0.05).  These 
results are interesting because the results of UDP Ca2+ experiments identified that 358038 
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was the best-performing P2YR6-shRNA (Table 6.6).  It may be the case therefore, that 
P2YR6-shRNA functional efficacy correlates with CCR2 function. 
A further comparison of the decay rates revealed that the CCL2 Ca2+ transients of all 
P2RY6-KD cell lines decayed significantly faster than scrambled cells (Table 6.7 and 
Appendix Figure A26).  The % reduction for 14075 (12 ± 1%, n=3, p<0.01), 14076 (26 ± 
1%, n=3, p<0.01), 14077 (18 ± 1%, n=3, p<0.01), 357968 (19 ± 3%, n=3, p<0.01) and 
358038 (19 ± 1%, n=3, p<0.01) suggested that this might be a general characteristic of 
P2RY6-shRNA. 
In summary, these results suggest that THP-1 cells transduced with P2RY6-shRNA 
358038 show an attenuated Ca2+ response to CCL2.  This finding supports the hypothesis 
that P2Y6 is required for CCL2/CCR2-mediated monocyte signalling. 
6.3.8.2.3 qRT-PCR analysis of P2RY6 and CCR2 expression 
THP-1 cells transduced with shRNA 358038 (positive) and 14075 (negative) and non-
target (scrambled) shRNA were tested for CCR2 and P2RY6 expression using qRT-PCR.  
As previously described, cells were examined for P2RY6 expression in order to assess for 
gene knockdown.  Cells were also tested for CCR2 expression, which served as a control.  
Primers used for qRT-PCR are listed in Table 2.7 and 2.10 (Chapter 2).  Table 6.8 shows 
the relative expression values (RQ) and fold-shifts for CCR2 and P2YR6 in scrambled, 
358038 and 14075 cells. 
Table 6.8 Relative quantitation and fold-shift values for scrambled and P2RY6-
KD cells 
shRNA Gene RQ ±SEM Fold-shift in gene expression 
Scrambled CCR2 1.0 ± 0 1.0 ± 0 
14075 CCR2 0.8 ± 0.1 1.3 ± 0.2 
358038 CCR2 0.8 ± 0.1 1.3 ± 0.2 
Scrambled P2RY6 1.0 ± 0 1.0 ± 0 
14075 P2RY6 1.0 ± 0.1 1.1 ± 0.1 
358038 P2RY6 0.5 ± 0.1 2.0 ± 0.3 
Data represent n=3 replicates.  Relative quantification (RQ) values were normalised to β-
actin and then further normalised to scrambled cells according to the 2-∆∆Ct method (Livat 
and Schmittgen, 2001).  An RQ value of 0.5 (2-fold reduction) or 2.0 (2-fold increase) was 
considered significant. 
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As shown (Table 6.8), all three shRNA exhibited a similar RQ value for CCR2 mRNA.  
Although the fold-shift values for CCR2 in 14075 and 358038 cells indicated a 1.3 ± 0.2-
fold reduction (n=3), these data were considered unreliable as they were below the 
reliable detection limit of qRT-PCR (Karlen et al., 2007).  As Table 6.8 shows, cells 
transduced with 358038 exhibited a 2.0 ± 0.3 (n=3) fold-reduction in P2RY6 expression.  
This result was within the reliable detection limit of qRT-PCR and indicated that these 
cells were knocked down for P2RY6.  This result accords with earlier observations, which 
showed a 50 ± 5% (n=3, p<0.01) attenuation of UDP Ca2+ responses. 
Taken together, these data suggest that shRNA 358038 produces a 2-fold knockdown 
(KD) in P2RY6 expression in THP-1 cells.  These data also suggest that CCR2 
expression is not knocked down. 
6.3.9 CCL2/CCR2-mediated function of P2Y6-KD cells 
The next aim of this chapter was to examine the requirement of P2Y6 for CCL2/CCR2-
mediated monocyte function using THP-1 cells transduced with shRNA 358038 (“P2Y6-
KD” cells). 
Experiments first tested the ability of scrambled and P2Y6-KD cells to migrate towards 
CCL2 (50 ng/ml).  As shown (Figure 6.18), scrambled cells demonstrated a significantly 
higher (n=4, p<0.01) chemotactic index towards CCL2 (13 ± 1, n=4) than towards vehicle 
(1 ± 0.1, n=4).  Although P2Y6-KD cells also demonstrated a significantly higher (n=4, 
p<0.01) chemotactic index towards CCL2 (5 ± 1, n=4) than towards vehicle (1 ± 0.1, n=4), 
their migration towards CCL2 was 59 ± 5% (n=4) less than scrambled cells (n=4, p<0.01).  
This suggests that P2Y6-KD cells have a reduced capacity to chemotax towards CCL2. 
To understand the effects of P2Y6-KD on other monocyte functions, experiments tested 
the adhesion of scrambled and P2Y6-KD cells to quiescent and TNF-α-treated HUVEC 
monolayers.  Cells were CCL2-primed (50 ng/ml) or vehicle-treated prior to co-incubation 
with HUVEC monolayers treated with vehicle or TNFα (10 ng/ml).  As shown in Figure 
6.19a, the adhesion values (% scrambled CCL2 control) of vehicle-treated scrambled and 
P2Y6-KD cells to quiescent HUVECs were 21 ± 9% (n=12) and 42 ± 19% (n=12), 
respectively.  However, although these data suggested that P2Y6-KD cells adhered to 
quiescent HUVECs better than scrambled cells, it was observed that the capacity of both 
cell types to adhere differed slightly following CCL2-priming.  While the % scrambled 
CCL2 control value for scrambled cells (100 ± 19%, n=12, p<0.05) indicated a significant 
5 ± 1-fold (n=12, p<0.05) increase in adhesion, the % scrambled CCL2 control value for 
P2Y6-KD cells (109 ± 27%, n=12) was not significantly different from vehicle-treated cells 
(n=12, p=0.1).  A possible explanation for these results may be that P2Y6-KD cells 
adhered variably to THP-1 cells to quiescent HUVEC monolayers. 
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As shown in Figure 6.19b, the adhesion values (% scrambled CCL2 control) of vehicle-
treated scrambled and P2Y6-KD cells to TNFα-treated HUVECs were 6 ± 6% (n=8) and 12 
± 9% (n=8), respectively.  CCL2-priming of scrambled cells resulted in a significant 16 ± 6-
fold increase (n=8) in adhesion, where the % scrambled CCL2 control value was 100 ± 
37% (n=8, p<0.05).  Interestingly, this increase was greater than that seen in quiescent 
HUVECs experiments, and may indicate an enhancement of CCL2-mediated cellular 
adhesion by TNFα.  However, the most interesting result to emerge from this experiment 
was the lack of adhesion of CCL2-primed P2Y6-KD THP-1 cells, which exhibited a % 
scrambled CCL2 control value that was comparable to vehicle-treated P2Y6-KD cells (14 ± 
10%, n=8, p>0.05).  These data suggest that P2Y6-KD attenuates monocyte adhesion 
under inflammatory conditions. 
Collectively, these data suggest that P2Y6-KD attenuates CCL2-mediated THP-1 cell 
adhesion to TNFα-treated HUVECs.  In the wider context, these findings suggest that a 
blockade of P2Y6 attenuates CCL2/CCR2-mediated monocyte adhesion to the vascular 
endothelium under inflammatory conditions. 
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Figure 6.18 CCL2-mediated scrambled and P2Y6-KD cell chemotaxis 
(A)  Representative images showing scrambled and P2Y6-KD THP-1 cell migration 
towards vehicle (water) or CCL2 (50 ng/ml, lower chamber, 2hrs).  Scale bar represents 
10 µm.  (B) Bar chart showing normalised scrambled and P2Y6-KD THP-1 cell chemotaxis 
towards vehicle (water) or CCL2 (50 ng/ml, lower chamber, 2hrs).  Chemotactic index is a 
ratio of the number of cells that migrated towards CCL2 over the number of cells that 
migrated towards vehicle.  Data represents mean ± SEM from n=4 transwells.  Asterisks 
indicate significant changes towards paired vehicle (**p<0.01, One-way ANOVA with 
Bonferroni’s multiple comparison). 
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Figure 6.19 CCL2-mediated adhesion of scrambled and P2Y6-KD cells to 
quiescent and TNFα-treated HUVEC monolayers 
Bar chart showing normalised adhesion (1 hour) of scrambled and P2Y6-KD THP-1 cells 
to (A) quiescent and (B) TNFα-treated (10 ng/ml, 5 hours) HUVEC monolayers following 
priming of THP-1 cells with CCL2 (50 ng/ml) or vehicle (water) (45 minutes).  Normalised 
adhesion represented as a percentage of mean adhesion of CCL2-primed scrambled 
THP-1 cells.  Data represents mean ± SEM from a total of n=12 replicates from n=3 
experiments (quiescent HUVECs), or a total of n=8 replicates from n=2 experiments 
(TNFα-treated).  Asterisks indicate significant changes towards vehicle-treated scrambled 
cells (*p<0.05, One-way ANOVA with Bonferroni’s multiple comparison). 
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6.3.10 CCL2-mediated extracellular nucleotide release in THP-1 cells 
6.3.10.1 Detecting CCL2-mediated extracellular nucleotide release 
While the evidence from the studies in this thesis suggest that P2Y6 is required for 
CCL2/CCR2-mediated monocyte signalling and function, the mechanism(s) by which 
CCR2 and P2Y6 crosstalk remains an unresolved question.  However, recent studies by 
Chen et al. (2006) and Sumi et al. (2010) have given important insights into the possible 
mechanisms by which purinoceptors and non-purinoceptors crosstalk.  For example, 
Chen et al. (2006) have shown that in neutrophils, activation of FPR receptors by fMLP 
releases ATP and guides neutrophil chemotaxis via a co-activation of P2Y2 and A3 
purinoceptors.  The same group (Sumi et al., 2010) have recently shown that adrenergic 
α1 receptors activation on mice aortic rings drives tissue contraction and ATP release, an 
effect weakened by apyrase or P2Y2-knockout.  Together, these studies suggest 
purinoceptor crosstalk with other GPCRs involves a release of ATP.  It is possible, 
therefore, that CCR2 and P2Y6 also crosstalk through a release of extracellular 
nucleotides.   
Hence, it was important to investigate this hypothesis.  Experiments were therefore 
performed to investigate if CCL2-challenged THP-1 cells would release P2Y6 ligands 
(ATP, ADP, UTP, and UDP) into cell supernatants.  THP-1 cells were challenged with 
vehicle or CCL2 (50 ng/ml) and sampled immediately (0 minutes/t=0 min) and at 2 
minutes (t=2 min).  Clarified samples were analysed for extracellular nucleotides using 
ion-pair reverse-phase HPLC, a technique able to detect a minimum nucleotide 
concentration of 1 µM (Section 2.9, Chapter 2).   
Interestingly, ATP was the only nucleotide consistently detected within samples (n=5).  
Other nucleotides (ADP, UTP, and UDP) were also detected, but not consistently in every 
experiment.  Figure 6.20 shows a representative experiment for ATP.  As shown, CCL2 
challenge produced a time-dependent increase in ATP absorbance (n=5).  These data 
suggest that an activation of the CCL2/CCR2 axis in monocytes evokes a release of ATP.  
However, since these data were not quantitative, it was not possible to determine whether 
ATP released by THP-1 cells in response to CCL2 activated P2Y6.  Therefore, in order to 
quantify the amount of ATP released by cells, a commercial luciferin-luciferase ATP assay 
was employed to quantify ATP release over time.  In these experiments, THP-1 cells were 
challenged with vehicle or CCL2 (50 ng/ml) and sampled every two minutes for 14 
minutes.  The concentration of ATP ([ATP]) in samples was then determined. 
As shown (Figure 6.21a), CCL2-challenge resulted in a transient rise in [ATP] in THP-1 
cell supernatants.  At its highest level at 8 minutes, the [ATP] in cell supernatants was 
1013 ± 108 nM (n=7) and was significantly higher than all other time-points (n=7, p<0.01).  
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The average [ATP] of all other time-points was 228 ± 37 nM (n=36).  Figure 6.21b shows 
the [ATP] at 8 minutes in supernatants from THP-1 cells challenged with vehicle or CCL2.  
As shown, a significantly higher [ATP] was detected in supernatants from THP-1 cells 
challenged with CCL2 (1013 ± 108 nM, n=7) than from cells challenged with vehicle (217 
± 38 nM, n=7, p<0.01).  These data suggest that CCL2 challenge increases the [ATP] in 
THP-1 cell supernatants by 4.7-fold.   
Taken together, these data indicate that CCL2 challenge liberates ~ 1 µM ATP from THP-
1 cells.  Although HPLC experiments were not always able to detect ADP in these 
experiments, as a metabolic product of ATP, a release of ADP following CCL2 challenge 
seems plausible. 
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Figure 6.20 Detection of CCL2-mediated ATP release in THP-1 cells by ion-pair 
reverse-phase HPLC 
Representative experiment showing absorbance (A254nm) of ATP liberated from THP-1 
cells challenged with vehicle (water) or CCL2 (50 ng/ml).  Sampling performed at 0 
minutes (t=0 min), or 2 minutes (t=2 min) post-CCL2 challenge, or at 0 minutes post-
vehicle challenge.  ATP standard (1 µM) serves as a reference. 
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Figure 6.21 Detection of CCL2-mediated ATP release in THP-1 cells by luciferase-
luciferin 
(A) Trace showing amount of ATP in THP-1 cell supernatants following challenge with 
CCL2 (50 ng/ml) at 6 minutes (shown by arrow).  (B)  Bar chart showing ATP 
concentration (nM) at 8 minutes in supernatants from THP-1 cells challenged with vehicle 
(water) or  CCL2 (50 ng/ml).  Data represents mean ± SEM from n=7 replicates.  Asterisks 
indicate significant changes towards other time-points (A), or vehicle (B) (**p<0.01, One-
way ANOVA with Bonferroni’s multiple comparison (A), or Students t-test (B)). 
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6.3.10.2 Investigating THP-1 cell lysosomes as a source of ATP 
The release of ATP from THP-1 cells following CCL2 challenge represents a novel finding 
but at the same time, raises some important questions about the mechanisms involved in 
coupling CCR2 activation to ATP release, and the subsequent coupling of P2Y6 activation 
to the CCL2/CCR2 axis.  In an effort to understand how ATP release occurs, the source of 
ATP in THP-1 cells was investigated.  Given the amount of evidence linking ATP release 
with lysosomes and secretory vesicles (Chen et al., 2006; Eltzschig et al., 2006; 
Sivaramakrishnan et al., 2012), it was important to investigate whether CCL2 caused ATP 
release from lysosomes containing the enzyme β-hexosaminidase.  To this end, THP-1 
cells were incubated with Triton X-100 (positive control), vehicle (SBS or DMSO), CCL2 
(50 or 100 ng/ml), or GPN (0.2 mM) and tested for β-hexosaminidase release as 
described in Section 2.10 (Chapter 2).   
Table 6.9 β-hexosaminidase in THP-1 cell supernatants 
Treatment β-hexosaminidase (% Triton X-100) 
Triton X-100 (1%) 100 ± 7 (p<0.01 versus SBS) 
SBS 0.7 ± 0.3 
DMSO (2%) 0.0 ± 0.3 
GPN (0.2 mM) 28 ± 3 (p<0.01 versus DMSO) 
CCL2 50 ng/ml 0.7 ± 0.3 
CCL2 100 ng/ml 0.4 ± 0.1 
Data represents mean ± SEM from a total of n=6 replicates from n=3 experiments.  
Statistical tests performed using one-way ANOVA with Bonferroni’s multiple comparison. 
As shown in Table 6.9, Triton X-100 caused a significant release of β-hexosaminidase 
from THP-1 cells over SBS (n=6, p<0.01), therefore supporting the presence of lysosomes 
in THP-1 cells.  A significant increase in β-hexosaminidase was also seen in cells treated 
with GPN (n=6, p<0.01).  This result supported prior work by Sivaramakrishnan et al. 
(2012).  Interestingly, no significant increase in β-hexosaminidase release over SBS was 
seen with either 50 ng/ml CCL2 (n=6, p>0.05) or 100 ng/ml CCL2 (n=6, p>0.05).  These 
data suggest that CCL2 does not evoke β-hexosaminidase release from THP-1 cells. 
Taken together, these data suggest that CCL2 does not cause β-hexosaminidase release 
from THP-1 cells.  These results also suggest that ATP release may not be from 
lysosomes containing β-hexosaminidase. 
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5.4 Summary 
This chapter set out to investigate the requirement of the P2Y6 purinoceptor for 
CCL2/CCR2-mediated monocyte signalling and function using monocytic THP-1 cells and 
where possible, human PBMCs as models.  A number of methodology combined with 
molecular and pharmacological tools were employed to examine intracellular Ca2+ 
mobilisation, cell migration, adhesion, and ATP release.  A number of important findings 
were made.  Initial experiments in THP-1 cells with the P2Y6 antagonist, MRS-2578 
revealed a requirement for P2Y6 in CCL2/CCR2-mediated Ca
2+ signalling, cellular 
migration, and adhesion to HUVECs.  Additional studies in human PBMCs supported 
these findings.  Further studies in THP-1 cells led to the identification that 64-70% of the 
CCL2 Ca2+ response was attributed to P2Y6, and the remaining to a bona-fide activation of 
CCR2.  Intracellular Ca2+ studies in P2Y6-stable 1321N1 cells indicated that P2Y6 could be 
activated by the extracellular nucleotides ATP, ADP, UTP, and UDP, at concentrations 
≤300 nM.  The most potent of these ligands, UDP, evoked Ca2+ responses that were 
attenuated by MRS-2578, but not abolished.  Further data indicated that THP-1 cells 
expressed functional P2Y14, a receptor activated by UDP.  Additional studies in THP-1 
cells with MRS-2578 supported 1321N1 experiments in that they suggested that ATP, 
ADP, UTP and UDP activated P2Y6.  While the results of co-application studies pointed 
towards a lack of synergy between CCL2 and UDP, they also indicated the need for 
additional studies.  The results of fMLP-FPR studies ruled out a requirement of P2Y6, but 
indicated that other purinoceptors were likely to involved in regulating FPR signalling.  
Interestingly, desensitisation studies suggested that CCR2 receptors could be cross-
desensitised by P2Y6.  Further support for these data came from experiments with P2Y6-
KD cells, which showed that knockdown of P2RY6 attenuated THP-1 cell Ca2+ responses 
to UDP and CCL2, and also reduced cellular chemotaxis and adherence to TNFα-treated 
HUVEC monolayers.  ATP release studies indicated that THP-1 cells challenged with 
CCL2 released ATP into supernatants.  However, additional experiments suggested that 
this did not involve secretory vesicles containing β-hexosaminidase. 
Taken together, these findings suggest that CCL2/CCR2 signalling in monocytes involves 
crosstalk with the P2Y6 purinoceptor.  Furthermore, activation of P2Y6 upon CCR2 
engagement involves a concomitant release of ATP. 
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Chapter 7: Discussion 
7.1 Overview 
The CCL2/CCR2 axis is important for orchestrating monocyte function under physiological 
conditions, but is also associated with a growing number of monocyte-associated 
pathologies.  Although this has led to several CCR2 antagonists being developed, a lack 
of efficacy of these in clinical trials has meant that none are therapeutically useful.  The 
lack of progress made in this area indicates a need to better understand in vivo models, 
the contributions of other CCR2 ligands, as well as the influence of other chemotactic 
pathways (such as purinoceptor signalling).  Indeed, a considerable amount of evidence 
has been published on the involvement of purinoceptors in monocyte function and CCL2 
release (Cox et al., 2005; Stokes and Surprenant, 2007; Morioka et al., 2013; Garcia et 
al., 2014; Higgins et al., 2014; Shieh et al., 2014).  It is possible, therefore, that monocyte 
signalling and function involves crosstalk between purinoceptors and CCR2.  This 
hypothesis was therefore investigated in this thesis using human monocytic THP-1 cells 
and human PBMCs as in vitro models.  Areas studied in this thesis included: 
(i) The expression of mRNA transcripts for monocyte/myeloid cell markers, CC 
chemokines, CC chemokine receptors, and purinoceptors in THP-1 cells and 
human monocytes (Chapter 3). 
(ii) The mechanisms involved in CCL2/CCR2-mediated monocyte signalling and 
function (Chapter 4). 
(iii) The requirement of extracellular nucleotides and purinoceptors for 
CCL2/CCR2-mediated monocyte signalling and function (Chapter 5) 
(iv) The requirement of P2Y6 for CCL2/CCR2-mediated monocyte signalling and 
function (Chapter 6). 
(v) The involvement of the CCL2/CCR2 axis in extracellular nucleotide release 
(Chapter 6). 
7.2 Concluding Remarks 
In conclusion, this study has characterised in some depth, the CCL2/CCR2 axis, and its 
involvement in monocyte signalling and function.  This research has supported some of 
the established pathways involved in CCL2/CCR2 signalling, while indicating the 
requirement of novel and less well-established pathways (Figure 7.1).  Investigating the 
individual contributions of these complex pathways further may enhance our 
understanding of monocyte-associated pathologies and drive future research towards 
novel therapies. 
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The findings of this study have also suggested a novel requirement of the P2Y6 
purinoceptor for CCL2/CCR2-mediated monocyte signalling and function (Figure 7.1).  
The data presented has indicated for the first time that ATP released by monocytes upon 
CCR2 activation under homeostatic and inflammatory conditions is important for 
deciphering chemical cues in the microenvironment.  Although it is likely that other 
chemotactic signals also influence monocyte function in vivo, it is evident from the findings 
presented here that crosstalk between CCR2 and P2Y6 is crucial for CCL2/CCR2-
mediated monocyte trafficking and adhesion.  Thus, the association between CCR2 and 
P2Y6 identified by this research will serve as a base for future studies directed towards 
developing novel therapies targeting monocyte-associated pathologies.   
 
Figure 7.1 CCR2 and P2Y6 crosstalk in monocytes 
Diagram showing some of the main signalling pathways proposed by this work.  Thick 
arrows represent established pathways investigated in this thesis, or pathways that are 
widely known to occur.  Thinner arrows represent less-established pathways that have 
been suggested by this work.  Dashed arrows represent novel pathways that have been 
suggested by this work.  Diagram does not show the possible involvement of non-ER Ca2+ 
stores.  Further studies are required to confirm these findings and to better understand the 
involvement of these signalling cascades in monocyte signalling and function. 
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7.3 Key Findings 
mRNA transcripts for monocyte and myeloid markers are expressed by THP-1 cells 
and human monocytes 
The monocytic leukaemia cell line THP-1 was employed as an in vitro model for this work.  
However, prior to performing experiments it was important to understand if these cells 
represented a suitable model for studying monocyte signalling and function.  This was 
done initially by comparing the expression of mRNA for the monocyte and myeloid 
markers, CD14, CD16, CD33, and CD93, between THP-1 cells and human peripheral 
blood monocytes.   
RT-PCR results suggested that THP-1 cells expressed mRNA for CD14, CD33, and 
CD93, while monocytes expressed mRNA for CD14, CD16, CD33, and CD93.  This 
finding supports the hypothesis that both cells types are of myeloid origin (Pilling et al., 
2009).  A second interesting finding from this study was that mRNA for CD16 was not 
detected in THP-1 cells.  Although it is possible that levels may have fallen below the 
limits of detection by RT-PCR, it could also be that THP-1 cells genuinely lack CD16 
which would agree with post-translational studies (Auwerx, 1991; Fleit and Kobasiuk, 
1991).  In this study, it was found that THP-1 cells expressed mRNA for CD14.  This is 
interesting because other groups suggest that THP-1 cells either express low levels of 
mRNA or protein for CD14 (Daigneault et al., 2010; Bruckmeier et al., 2012), or only 
express this upon differentiation to macrophages (Kohro et al., 2004; Aldo et al., 2013).  
Given that THP-1 cells have a natural tendency to differentiate into macrophages when 
cultured at high densities (above 1e6/ml), expression of CD14 may be density-dependent.  
However, while this might be why CD14 mRNA was detected in THP-1 cells, this is 
unlikely because cells were always cultured below 7e5/ml (Chapter 2). 
The results of this study suggested that human monocytes expressed mRNA for CD14 
and CD16.  This result was expected, and suggests that samples comprised of multiple 
monocyte subtypes.  The expression of mRNA for these markers agrees with the findings 
of mRNA and post-translational studies performed on human monocyte populations 
(Passlick et al., 1989; Auwerx, 1991; Geissmann et al., 2003).  However, while the results 
of this study are interesting, it is important to bear in mind that the monocyte isolation 
methodology employed may not have provided a pure monocyte population, resulting in 
the detection of CD14 and CD16 on other myeloid cells (Pilling et al., 2009).  Further 
studies with purified monocyte populations are therefore recommended. 
The findings of this study, while preliminary, suggest that THP-1 cells and peripheral-
blood monocytes express a similar pattern of mRNA transcripts for monocyte and myeloid 
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markers.  These findings may help us to understand the suitability of THP-1 cells as a 
model for investigating monocyte signalling and function. 
mRNA transcripts for CC chemokines and their receptors are expressed by THP-1 
cells and human monocytes 
Monocyte-associated inflammatory diseases are often associated with an up-regulated 
expression of CC chemokines and their receptors (Bruegel et al., 2006; Kaminsky et al., 
2008; Selvaraj et al., 2012).  Therefore, assessing any alterations in expression would 
provide an effective biomarker for inflammatory diseases.  To understand the suitability of 
THP-1 cells as a model for investigating CC chemokine signalling, studies compared the 
expression of mRNA transcripts for CC chemokines and their receptors between THP-1 
cells and human monocytes.   
RT-PCR results suggested that both cell types expressed mRNA for all of the CC 
chemokines tested (CCL2, CCL3, CCL4, and CCL5).  This finding suggests that these 
chemokines would serve as useful biomarkers.  The results of further mRNA studies 
suggested that THP-1 cells expressed all CC chemokine receptors, except mRNA for 
CCR3.  In comparison, mRNA transcripts for all CC chemokine receptors including CCR3 
were detected in human monocytes.  These results agree with prior work showing that 
THP-1 cells express CCR1, CCR2, CCR5, and CCR9 and human monocytes express 
CCR1, CCR2, CCR3, CCR5, and CCRL2 (Neote et al., 1993; Yamagami et al., 1994; 
Combadiere et al., 1996; Weber et al., 2000; Migeotte et al., 2002; Kim et al., 2004; 
Apostolakis et al., 2010; Schmutz et al., 2010).  However, the expression of other 
receptors is a novel finding.  The lack of mRNA for CCR3 in THP-1 cells is also 
interesting.  Although this result differs from the findings of post-translational studies 
(Martinelli et al., 2001), it may be that levels of mRNA fell below the limits of RT-PCR 
detection. 
A second important finding was that mRNA for CCR2A and CCR2B were detected in 
THP-1 cells and human monocytes.  The expression of mRNA for both variants in THP-1 
cells supports post-translational studies by Campwala et al. (2014).  The detection of 
mRNA for CCR2A and CCR2B in monocytes is also interesting because CCR2B is known 
to be more readily expressed on the cell surface and activated than CCR2A (Wong et al., 
1997; Sanders et al., 2000).  Thus, identifying which of these participate in monocyte 
function would be interesting.  However, in general, the finding that monocytes express 
mRNA for CCR2 agrees with prior studies (Weber et al., 2000; Tacke et al., 2007).  This 
suggests that monitoring CCR2 mRNA expression would be useful as it would enable a 
greater understanding of pathologies where monocytes differentiate to macrophages, 
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which results in a loss of CCR2 expression (Fantuzzi et al., 1999; Kaufmann et al., 2001; 
Phillips et al., 2005). 
The findings of this study suggest that THP-1 cells and human monocytes express a 
similar pattern of expression of CC chemokines and their receptors.  The expression of 
novel CC chemokine receptors may help enhance our understanding of the role played by 
these receptors in monocyte function. 
mRNA transcripts for purinoceptors are expressed by THP-1 cells and human 
monocytes 
RT-PCR results suggested that THP-1 cells and human monocytes expressed mRNA for 
all P1 purinoceptors.  While the expression of these in monocytes is consistent with prior 
reports (Merrill et al., 1997; Broussas et al., 1999; Thiele et al., 2004), only A2A and A2B 
receptors have been previously detected in THP-1 cells (Munro et al., 1998; Khoa et al., 
2001; Bshesh et al., 2002).  The expression of A1 and A3 in THP-1 cells therefore 
represents a novel finding and may enhance our understanding of the involvement of 
these receptors in monocyte-associated pathologies.  Although further studies at the post-
translational level are required, the current findings are important because they suggest 
that THP-1 cells and human monocytes express all P1 purinoceptors. 
Studies of P2X purinoceptors suggested that THP-1 cells express mRNA for all P2X 
receptors except P2X2 and P2X3, while human monocytes express all P2X receptors 
except P2X2, P2X3, and P2X6.  The expression of P2X1, P2X4, and P2X7 in both cell 
types is consistent with prior reports (Humphreys and Dubyak, 1998; Into et al., 2002; 
Wang et al., 2004; Kaufmann et al., 2005; Li and Fountain, 2012), but suggests that the 
expression of P2X5 and P2X6 in THP-1 cells, and P2X5 in human monocytes, represent 
novel findings.  The detection of mRNA for P2X5 in both cell types is interesting but could 
not be compared with previous studies as the results from these are not in agreement (Lê 
et al., 1997; Kaufmann et al., 2005).  Thus, our own studies at the post-translational level 
are recommended.  Although these results also suggested that THP-1 cells expressed 
mRNA for P2X6, a functional role of this receptor is unlikely as it is unable to establish 
functional homotrimers (Barrera et al., 2005).  The findings of this study also suggested 
that both cell types lack mRNA for P2X2 and P2X3 which may reflect the fact that both 
receptors are mainly found in sensory neurones (Burnstock and Knight, 2004).  What is 
also interesting about P2X2 and P2X3 is that mRNA transcripts for these purinoceptors 
could not be detected in human brain.  While the lack of P2X3 mRNA transcripts in human 
brain fits well with prior work published by Garcia-Guzman et al. (1997b), it is interesting 
that the lack of P2X2 mRNA in human brain differs from the findings of Lynch et al. (1999) 
whose cloning work on the human P2X2 receptor from the pituitary gland showed that 
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mRNA transcripts for P2X2 splice variants could be detected in amygdala and brain 
tissue.  It may be the case therefore, that the brain RNA samples used within the current 
study represent a section of the human brain which poorly expresses P2X2. 
RT-PCR results suggested that THP-1 cells and human monocytes expressed mRNA for 
P2Y purinoceptors.  However, while this suggested that both cell types exhibited a similar 
pattern of expression, these results could not be compared with prior work due to 
inconsistencies in these earlier studies.  For example, quantitative studies on THP-1 cells 
suggest that these express mRNA for P2Y2, but not P2Y1 or P2Y4 (Moore et al., 2001), 
while non-quantitative studies detect P2Y1, P2Y2, P2Y6, and P2Y11 (Ben Yebdri et al., 
2009).  Similarly, non-quantitative studies on monocytes (Kaufmann et al., 2005) suggest 
that they express P2Y2, P2Y11, and P2Y13, while quantitative studies report mRNA for all 
P2Y purinoceptors except P2Y14, which was not tested (Wang et al., 2004).  It may be the 
case, therefore, that these inconsistencies between studies are due to differences in the 
methodologies and samples used.  The results of this study also indicated that both cell 
types expressed mRNA for P2Y14.  Although the involvement of P2Y14 in immune cells is 
unclear (Burnstock and Boeynaems, 2014), the expression of this receptor in both cell 
types represents a novel finding. 
CCL2-evokes intracellular Ca2+ release from THP-1 cells and human PBMCs 
The mobilisation of intracellular Ca2+ upon receptor activation is considered an integral 
component of cellular signalling and activation (Berridge et al., 2000).  From studies in 
literature, it is clear that CC chemokines such as CCL2 induce Ca2+ release from 
intracellular Ca2+ stores in monocytes, THP-1 cells, and human PBMCs upon receptor 
activation (Sozzani et al., 1993; Bizzarri et al., 1995; Kim et al., 2004; Cherney et al., 
2008). 
Intracellular Ca2+ studies using THP-1 cells and human PBMCs showed that application of 
CCL2 to cells induced a transient release of Ca2+.  This finding is considered significant 
since it supports prior work in THP-1 cells and human PBMCs (Kim et al., 2004; Cherney 
et al., 2008) and suggests that CCL2 drives intracellular Ca2+ release in monocytes.  
Additional studies of THP-1 cells indicated that CCL2 exhibited an EC50 of 1.9 nM for 
intracellular Ca2+ release.  This is interesting because it compares well with EC50 values 
for CCL2 (0.7–10 nM) previously published through work performed on human monocytes 
and CCR2-transfected cell lines (Charo et al., 1994; Myers et al., 1995; Combadiere et al., 
1995; Sozzani et al., 1995; Wong et al., 1997).  However, while the present study 
suggested an involvement of CCR2 in CCL2-mediated Ca2+ mobilisation, it was unable to 
identify which CCR2 variant (CCR2A or CCR2B) was involved in initiating these 
responses.  Identifying which variant is involved in intracellular Ca2+ release would 
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therefore be useful to address given that CCR2A and CCR2B are known to differentially 
regulate Ca2+ release and chemotaxis of Jurkat T-cells (Sanders et al., 2000).   
Removal of extracellular Ca2+ attenuates CCL2-mediated THP-1 cell signalling and 
function 
The association between CCL2-evoked intracellular Ca2+ release and monocyte function is 
not completely understood.  Although previous work by others has suggested that Ca2+ 
release is chemotactic for human monocytes (Olszak et al., 2000; Gouwy et al., 2008), the   
signalling events that couple intracellular Ca2+ release to monocyte trafficking have not 
been fully established.  Therefore, to address this gap in knowledge, studies examined the 
requirement of extracellular Ca2+ for CCL2-mediated THP-1 intracellular Ca2+ release and 
chemotaxis. 
The results from intracellular Ca2+ studies suggested that CCL2-evoked intracellular Ca2+ 
responses in monocytes were partially dependent on Ca2+ influx.  This finding is 
interesting, and directly supports prior work by Bizzarri et al. (1995) whose studies 
showed a similar attenuation of CCL2-evoked Ca2+ responses in single monocytes 
following a removal of extracellular Ca2+.  Interestingly, earlier studies by the same group 
on heterogeneous monocytes (Sozzani et al., 1993), suggested that CCL2-induced Ca2+ 
responses were entirely dependent on Ca2+ influx, therefore contradicting the findings of 
Bizzarri et al. (1995).  It is possible, therefore, that the results presented by Sozzani et al. 
(1993) could be attributed to errors in their methodology.   
THP-1 cell chemotaxis studies suggested that the Ca2+ chelator BAPTA-AM abolished 
CCL2-mediated and CCL2-independent cellular chemotaxis.  This finding is important 
since it suggests that THP-1 cell chemotaxis and chemokinesis are fully dependent on the 
availability of intracellular Ca2+.  A lack of cytotoxicity of BAPTA-AM in cell viability studies 
supported these results.  While previous studies have not dealt with the effects of 
sequestering Ca2+ on CCL2-mediated monocyte chemotaxis, it is interesting that Moyano 
Cardaba et al. (2012) proposed that THP-1 cell chemotaxis towards the CC chemokine 
CCL3 occurs independently of intracellular Ca2+ release.  Although this implies that 
individual chemokines differ in their Ca2+ requirements for chemotaxis, it is interesting that 
other groups (Wei et al., 2009; Tsai et al., 2014), have discovered that “calcium flickers” at 
the leading edge of migrating cells are required for directed cell migration and adhesion.  
This supports the hypothesis that intracellular Ca2+ is required for CCL2-mediated and 
CCL2-independent cellular chemotaxis.  Given the importance of these findings, other 
Ca2+ chelators (e.g. EGTA) should be used to provide further support of a requirement of 
Ca2+ for monocyte chemotaxis. 
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CCR2 antagonism attenuates CCL2-mediated THP-1 cell signalling and function 
Although the association between CCL2 and its cognate receptor CCR2 is well-
recognised (Bachelerie et al., 2014), CCL2 is also known to bind to other chemokine 
receptors including ACKR1, ACKR2, CCR3, and CCR5 (Daugherty et al., 1996; Blanpain 
et al., 1999; Bachelerie et al., 2014).  Thus, CCL2-mediated signalling and function of 
monocytes may not be entirely driven by CCR2.  To investigate this hypothesis, studies 
employed the CCR2A/CCR2B antagonist BMS-CCR2-22. 
The results of intracellular Ca2+ experiments showed that BMS-CCR2-22 attenuated 
CCL2-evoked intracellular Ca2+ responses in a concentration-dependent manner, 
exhibiting an IC50 of 2.9 nM.  At higher concentrations (100 nM), BMS-CCR2-22 abolished 
CCL2 Ca2+ signals, suggesting that CCL2-mediated signalling depended entirely on 
CCR2.  This finding supports the expression of mRNA for CCR2 as shown by the work in 
this thesis, but also stands in agreement with other published studies showing that CCL2 
signals primarily through CCR2 (Charo et al., 1994; Yamagami et al., 1994; Myers et al., 
1995).  In further intracellular Ca2+ studies, it was interesting to observe that human 
PBMCs were less sensitive than THP-1 cells to the effects of BMS-CCR2-22.  Although 
this result is difficult to explain, it may be that PBMCs express lower levels of CCR2 at the 
post-translational level.  Although the findings of this study suggested that BMS-CCR2-22 
selectively targets CCR2, the results of additional experiments showed that CCL5-evoked 
Ca2+ responses were also attenuated by BMS-CCR2-22, suggesting a possible 
antagonism of receptors activated by this ligand (CCR1, CCR3 and CCR5) (Bachelerie et 
al., 2014).  This seems possible given that Cherney et al. (2008) have shown that high 
concentrations of BMS-CCR2-22 (10 µM) inhibit CCR3 binding (Cherney et al., 2008).  
However, while it is possible that the concentrations of BMS-CCR2-22 used in the current 
study could have also targeted CCR3, it is important to bear in mind that mRNA for CCR3 
could not be detected in THP-1 cells.  Furthermore, the CCL5 used for these studies was 
only 95% pure and may have contained contaminants.  Thus, further work with CCL5 of a 
greater purity, or studies with CCR3-transfected cells, are required. 
In migration experiments, it was seen that BMS-CCR2-22 abolished THP-1 cell 
chemotaxis towards CCL2, effectively bringing cell migration down to chemokinesis levels.  
This result was quite striking, and suggests that monocyte trafficking and signalling in 
response to CCL2 in vivo would be entirely dependent on CCR2.  Moreover, these results 
suggested that constitutive CCL2 signalling does not control chemokinesis.  The effects of 
BMS-CCR2-22 on CCL2-mediated cellular trafficking is in agreement with prior work in 
PBMCs (Cherney et al., 2008), showing that BMS-CCR2-22 impairs PBMC chemotaxis 
towards CCL2 more readily than intracellular Ca2+ responses.  This is interesting, and 
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suggests that in an in vivo setting, monocyte trafficking towards excessive CCL2 gradients 
would be more sensitive to CCR2-blockade than to intracellular Ca2+ signalling. 
The results of studies investigating the requirement of CCR2 for monocyte adhesion 
showed that BMS-CCR2-22 nearly abolished CCL2-dependent adhesion to quiescent 
HUVEC monolayers, but completely abolished CCL2-dependent and independent 
adhesion to TNFα-treated monolayers.  These findings support prior work showing that 
CCR2 is required for monocyte adherence to the vascular endothelium (Shyy et al., 1993; 
Kuziel et al., 1997; Gerszten et al., 1999), but also suggest that monocyte adhesion under 
inflammatory conditions is fully-dependent on CCL2/CCR2.  This seems plausible given 
that treatment of HUVEC monolayers with IL-1β or TNFα upregulates CCR2 surface 
expression and CCL2 release (Weber et al., 1999).  This may also help to explain why 
inflammatory pathologies involving monocyte adhesion and infiltration are significantly 
attenuated by CCL2/CCR2-blockade (Boring et al., 1998; Gu et al., 1998).   
The findings of this study are therefore important as they help us to understand the 
involvement of the CCL2/CCR2 axis in monocyte signalling and function under 
physiological and inflammatory conditions.  However, a key area for further research is the 
involvement of adhesion molecules in these interactions and the release of CCL2 by 
TNFα-treated HUVECs. 
Inhibition of Gαi-G-proteins and Gβγ dimers attenuates CCL2/CCR2-mediated THP-1 
cell signalling and/or function 
In the literature, it is widely accepted that CCR2 signals through Gαi-type G-proteins 
coupled to an inhibition of adenylate cyclase (Bachelerie et al., 2014).  The current study 
therefore set out to provide confirmation of this by examining the effects of PTx on 
CCL2/CCR2-mediated THP-1 cell intracellular Ca2+ mobilisation and chemotaxis. 
The results of Ca2+ experiments showed that CCL2-evoked Ca2+ responses were almost 
abolished by PTx.  However, while these results agree with prior work showing that 
CCL2/CCR2 intracellular Ca2+ signalling involves an activation of Gαi (Bizzarri et al., 1995; 
Myers et al., 1995; Kuang et al., 1996), they also indicated that CCL2/CCR2 signalling 
might not entirely involve Gαi.  Interestingly, Bizzarri et al. (1995) and Myers et al. (1995) 
were unable to fully abolish CCL2/CCR2 Ca2+ responses with PTx.  Although this 
suggests that other G-proteins might be involved, it may just be that a longer incubation 
with PTx (> 6-hours) is required to abolish Ca2+ responses.  Interestingly, the results of 
chemotaxis studies showed that PTx abolished CCL2-dependent migration.  Although 
these results differed from Ca2+ experiments, they suggested that CCL2-mediated 
monocyte trafficking in vivo would be entirely through Gαi.  These findings are consistent 
with studies by Sozzani et al. (1994) which demonstrated a complete block of CCL2-
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mediated PBMC chemotaxis by PTx.  In general, therefore, it seems that CCL2-mediated 
monocyte signalling and function primarily involves Gαi. 
In Ca2+ experiments, quenching of the fluorescent signal prevented the use of gallein.  
Given that gallein has a high affinity (400 nM) for Gβγ (Bonacci et al., 2006), a possible 
way to prevent quenching in future studies is to use a lower concentration of gallein.  
However, in chemotaxis experiments, gallein treatment attenuated CCL2-mediated THP-1 
cell chemotaxis.  These results support prior work in lymphocytic cells showing that Gβγ 
activation drives CCL2-dependent trafficking (Arai et al., 1997).  A wider implication of 
these findings is that Gβγ inhibitors selectively blocking CCR2 would be able to attenuate 
excessive monocyte trafficking towards CCL2.  Although these findings suggested a very 
important discovery, an arguable weakness with this study is that gallein was used at a 
high concentration (100 µM).  Future studies should therefore re-test gallein at lower 
concentrations or use molecular approaches such as the overexpression of Gα-transducin 
to inactivate free Gβγ dimers (Lustig et al., 1993).  While this study may have identified 
that further work is required, it nevertheless enhanced our understanding of the signalling 
cascades downstream of CCR2 activation in monocytes. 
Inhibition of PI3K attenuates CCL2/CCR2-mediated THP-1 cell signalling and 
function 
The classical scheme of GPCR signalling implies that Gβγ dimers regulate PI3-kinase 
(Krugmann et al., 1999; Brock et al., 2003).  It is possible, therefore, that PI3K is required 
for CCL2/CCR2-mediated monocyte signalling and function.  To this end, studies 
examined the effects of the PI3K inhibitor, LY-294002 (Vlahos et al., 1994) on CCL2-
mediated THP-1 cell intracellular Ca2+ responses and chemotaxis. 
The results of Ca2+ studies showed that LY-294002 induced a transient dip in the baseline 
Ca2+ response while also significantly attenuating CCL2-evoked intracellular Ca2+ 
responses.  These results suggest that PI3K participates in Ca2+ homeostasis and 
CCL2/CCR2 signalling.  An involvement of PI3K in Ca2+ homeostasis is supported by prior 
work showing that PI3K isoenzymes activate L-type Ca2+ channels and PLC, but attenuate 
CRAC channels (Rameh et al., 1998; Suzuki et al., 2010; Carnevale and Lembo, 2012).  It 
is possible, therefore, that the effects seen here with LY-294002 reflect a modulation of 
Ca2+ homeostasis by one of these routes.  Interestingly, studies reported by Turner et al. 
(1998) have also shown that CCL2/CCR2 signalling in THP-1 cells activates PI3K (p110γ 
and C2α).  This suggests that CCL2/CCR2 signalling is coupled to PI3K activation, which 
could be required for downstream signalling events in monocytes.  However, although the 
findings of the current study are interesting, a particular weakness in these data is that LY-
294002 is not exclusively selective for PI3K and can inhibit other targets such as NFκB 
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and mTOR, which may have influenced the results (Gharbi et al., 2007; Avni et al., 2012).  
Thus, these findings may need to be interpreted with caution and further supported by 
other approaches. 
In chemotaxis experiments, it was discovered that LY-294002 attenuated CCL2-mediated 
THP-1 cell chemotaxis, thus suggesting a requirement of PI3K for CCL2/CCR2-mediated 
monocyte chemotaxis.  Although the selectivity of LY-294002 may have been an issue, 
the present findings support prior THP-1 chemotaxis studies showing a similar result with 
LY-294002 (Turner et al., 1998).  However, other more recent studies (Volpe et al., 2010) 
suggest that PI3K activation is not essential for THP-1 cell chemotaxis towards CCL2.  A 
wider implication of this is that CCL2-mediated leukocyte trafficking in vivo, would not 
require PI3K activation.  While firm evidence for a requirement of PI3K for CCL2-mediated 
monocyte trafficking may yet be required, it is apparent from the literature that PI3K 
activation at the leading edge of other cell types such as neutrophils, is essential for cell 
polarisation and chemotaxis (Wang et al., 2002).  Moreover, studies in apoE-/- mice have 
demonstrated that deleting PI3K in macrophages attenuates atherosclerotic plaque 
formation (Chang et al., 2007).  This finding indicates that PI3K activation could be up-
regulated in monocytes under inflammatory conditions such as atherosclerosis. 
Inhibition of PLC attenuates CCL2/CCR2-mediated THP-1 cell signalling and 
function 
It is generally accepted that classical GPCR signalling also involves an activation of the 
PLC isoenzymes PLCβ, PLCε, and PLCη by the Gβγ dimer (Blank et al., 1992; Boyer et 
al., 1992; Smrcka et al., 1993).  Although it is accepted that CCR2 activation in monocytes 
leads to an accumulation of IP3 and a release of Ca
2+, only studies by Kuang et al. (1996), 
suggest that these events involve PLC.  Moreover, in monocytes, a requirement of PLC 
for CCL2-mediated monocyte trafficking has not yet been shown.  Studies therefore 
sought to address this gap in knowledge using the PLC inhibitor U-73122. 
The results of Ca2+ mobilisation studies showed that U-73122 produced a concentration-
dependent inhibition of CCL2-evoked Ca2+ responses in THP-1 cells, where it was seen 
that high concentrations of U-73122 abolished responses.  This result is interesting 
because it suggests that PLC is essential for CCL2-mediated monocyte signalling.  
Although studies by Kuang et al. (1996) have shown that CCR2 activation in monkey 
fibroblast COS-7 cells leads to an activation of PLCβ3, no prior studies have reported a 
similar association in monocytic cells or monocytes.  The findings of the present study are 
therefore both novel and important since they indicate an involvement of PLC in 
CCL2/CCR2-mediated monocyte signalling.  A second important finding from this study 
was the modulation (dip) in baseline Ca2+ by U-73122.  This result supported the widely-
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accepted notion that PLC activation is required for generating IP3 for Ca
2+ release 
(Kadamur and Ross, 2013).  It may be the case therefore that constitutive PLC activation 
is necessary for Ca2+ homeostasis.  Moreover, these results also indirectly support the 
involvement of PI3K in PLC activation (Rameh et al., 1998), since application of LY-
294002 to THP-1 cells also resulted in a similar dip in baseline Ca2+. 
In chemotaxis experiments, it was seen that U-73122 almost abolished CCL2-mediated 
THP-1 cell chemotaxis.  These findings match those observed in Ca2+ studies and 
suggest that PLC activation is necessary for CCL2-mediated monocyte signalling and 
trafficking.  It is also encouraging to compare this finding with that of Lee et al. (2009) who 
discovered that CCL2-mediated chemotaxis of human eosinophilic leukaemia EoL-1 cells 
involved PLC.  More recently, Moyano Cardaba et al. (2012) have shown that PLC 
activation is necessary for THP-1 cell chemotaxis towards CCL3.  The evidence in 
literature therefore points towards a requirement of PLC for CC chemokine-mediated 
monocyte chemotaxis.  However, although these findings represent a very important 
discovery, it is important to bear in mind that further investigations suggested that 
prolonged U-73122 exposure led to a loss in THP-1 cell viability.  While this suggests that 
U-73122 could have attenuated THP-1 cell migration independent of PLC, it is well-known 
that all PLC inhibitors are generally cytotoxic (Powis et al., 1982).  A second issue which 
might also have influenced the interpretation of these results is that U-73122, at the 
concentrations tested, may have inhibited other targets including PTx-sensitive G-proteins 
and lipid kinases (Horowitz et al., 2005).  A further study with a more selective inhibitor, 
such as edelfosine (Powis et al. 1982), or a molecular-based approach is therefore 
recommended.  Although the findings of the present study may need to be interpreted with 
caution, they nevertheless indicated that PLC activation is required for CCL2/CCR2-
mediated monocyte signalling and function, which is a novel finding. 
Inhibition of IP3 and RyR receptors attenuates CCL2/CCR2-mediated THP-1 cell 
signalling and/or function 
From the literature, it is clear that in the classical paradigm of GPCR signalling, IP3 is 
formed from the hydrolysis of PIP2 by PLC.  Furthermore, it is recognised that IP3 and 
Ca2+ are essential co-activators of IP3Rs (Clapham, 2007; Vetter, 2012).  Thus, in an effort 
to examine the requirement of IP3R for CCL2/CCR2-mediated monocyte signalling and 
function, studies employed the IP3R antagonist Xestospongin-C (XeC). 
Analysis of results from THP-1 Ca2+ mobilisation studies showed that XeC attenuated the 
magnitude and slowed the decay of CCL2-evoked intracellular Ca2+ responses.  
Furthermore, chemotaxis experiments showed that XeC nearly abolished CCL2-
dependent THP-1 cell chemotaxis.  These results are interesting because they suggest 
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that CCL2-mediated Ca2+ responses and monocyte trafficking requires a release of Ca2+ 
from the ER and GA.  Although, these results conflict with those of Sozzani et al. (1993) 
whose studies reported that monocyte CCL2/CCR2-mediated Ca2+ responses did not 
involve intracellular Ca2+ stores, they are consistent with later findings of the same group 
(Bizzarri et al., 1995) which showed that intracellular stores and plasma membrane 
channels equally contributed to CCL2-mediated Ca2+ responses in monocytes.  The 
results of the present study also indirectly support additional studies showing that CCR2 
activation in monocytes leads to an accumulation of IP3 (Wong et al., 1997).  However, 
although the findings of this study indicate a very important discovery, they also need to 
be interpreted with caution because XeC is known to inhibit SERCA at concentrations 
similar to those used in this study (De Smet et al., 1999).  Although more recent studies 
(Saleem et al., 2014) do not agree with the findings of De Smet et al. (1999), they suggest 
that XeC is a poor inhibitor of IP3R inhibitor compared to its counterpart, heparin.  Thus, 
performing similar experiments with heparin are recommended. 
To determine the involvement of other Ca2+-release mechanisms in CCL2/CCR2-
mediated monocyte signalling and function, studies investigated the effects of the RyR 
inhibitor, dantrolene.  The results of Ca2+ and chemotaxis studies suggested that RyR 
activation was not required for CCL2-mediated intracellular Ca2+ release, but was required 
for chemotaxis.  The findings of this study are significant and suggest that RyRs 
participate in CCL2-mediated monocyte chemotaxis.  Although further research should be 
done to confirm these results, it is interesting that the findings of this study support Clark 
and Petty (2005) whose experiments showed that RyRs localise at the leading-edge of 
cells where F-actin-rich protrusions and uropods for cell polarity and chemotaxis are 
formed.  Moreover, Matyash et al. (2002) have shown that macrophages fail to migrate 
towards chemotactic agents following RyR disruption.  Thus, RyRs may yet be important 
for monocyte signalling and trafficking. 
Inhibition of SERCA attenuates CCL2/CCR2-mediated THP-1 cell signalling and 
function 
The high-affinity SERCA pump is important for sequestering excess levels of cytosolic 
Ca2+ and replenishing the ER following agonist-mediated Ca2+ depletion (Berridge et al., 
2000; Clapham, 2007).  Although SERCA serves an important role in maintaining Ca2+ 
homeostasis, only studies reported by Bizzarri et al. (1995) have investigated the 
requirement of SERCA for efficient CCL2/CCR2-mediated monocyte signalling and 
function.  Studies therefore sought to confirm these findings using the SERCA1/3 inhibitor 
thapsigargin. 
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The results of intracellular Ca2+ studies showed that thapsigargin attenuated CCL2-evoked 
intracellular Ca2+ responses in the presence of extracellular Ca2+ and abolished responses 
in the absence of extracellular Ca2+.  These results suggest that SERCA activation is 
necessary for replenishing the ER during CCL2/CCR2-mediated intracellular Ca2+ 
responses.  This finding directly contradicts early reports by Sozzani et al. (1993) but 
supports those of Bizzarri et al. (1995) whose studies with thapsigargin showed that 
internal Ca2+ stores and Ca2+ influx mechanisms contributed to CCL2-mediated Ca2+ 
responses in monocytes.  Taken together with other data presented in this thesis, these 
present findings suggest that CCL2/CCR2-mediated intracellular Ca2+ responses in 
monocytes involves an IP3R-mediated release of Ca
2+ from the ER (and possibly the GA), 
coupled to a restorative action by SERCA.  This hypothesis is also indirectly supported by 
the fact that addition of thapsigargin to cells increased baseline Ca2+.  This suggests that 
thapsigargin renders SERCA unable to maintain ER Ca2+ thus leading to a leakage and a 
corresponding Ca2+ influx (Treiman et al., 1998).  However, although the findings of this 
study indicate a very important discovery, it is important to bear in mind that the results of 
LDH studies suggested that thapsigargin reduced cell viability, which may have affected 
the interpretation of the experimental results.  Although this finding is disappointing, it 
agrees with the general hypothesis that cytotoxicity would be expected with thapsigargin, 
since an impairment of SERCA would render it unable to sequester cytotoxic levels of 
cytosolic Ca2+ (Periasamy and Kalyanasundaram, 2007).  These latter findings are 
therefore also very important as they provide an additional depth of understanding of the 
mechanisms by which intracellular Ca2+ is maintained by cells. 
Inhibition of DAGL attenuates CCL2/CCR2-mediated THP-1 cell signalling and 
function 
The classical GPCR signalling paradigm predicts that PIP2 hydrolysis by PLC yields IP3 
and the second messenger, DAG.  Although DAG is important for the activation of 
downstream signalling proteins involved in GPCR signalling (Baldanzi, 2014), no previous 
studies have investigated the requirement of DAG for CCL2/CCR2-mediated monocyte 
signalling and function.  Studies therefore sought to address this gap in knowledge by 
examining the requirement of DAG through inhibitors of the DAG-metabolising enzymes, 
DAGL (RHC-80267) and DAGK (R-59-022). 
The results of Ca2+ studies showed that the DAGL inhibitor RHC-80267 attenuated CCL2-
evoked intracellular Ca2+ responses in the presence of extracellular Ca2+, but not in the 
absence of extracellular Ca2+.  These results suggest a requirement of DAGL for 
CCL2/CCR2-mediated monocyte signalling, but also indicate that the effects of RHC-
80267 are Ca2+-dependent.  Interestingly, the results of chemotaxis experiments showed 
that RHC-80267 attenuated THP-1 cell chemotaxis towards CCL2.  These data therefore 
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suggest that DAGL facilitates CCL2/CCR2-mediated monocyte signalling and function, 
either by limiting DAG availability, or by generating other second messengers.  While less 
is known about DAG, the involvement of DAGL-derived second messengers in 
CCL2/CCR2-signalling has been well-studied.  For example, Kishimoto et al. (2004), have 
shown that monocytes release CCL2 in response to 2-arachidonolyglycerol (2-AG), a 
product of DAGL.  It is possible; therefore, that 2-AG-mediated CCL2 release amplifies 
CCR2-generated signals.  It is also widely accepted that CCL2/CCR2 activation drives 
monocytes to generate arachidonic acid (AA), a product formed from the hydrolysis of 2-
AG by monoacylglycerol lipase (MAGL) (Locati et al., 1994).  Given that AA is a precursor 
for the synthesis of pro-inflammatory thromboxanes and prostaglandins (Smith et al., 
1991), pathways downstream of AA might feed into the CCL2/CCR2-axis thereby 
exacerbating inflammation.  However, although these findings indicate a very important 
discovery, a release of LDH by THP-1 cells exposed to RHC-80267 suggests that this 
may have resulted in a biased interpretation of these data.  An additional note of caution is 
due here since RHC-80267, at concentrations used for this study, has been shown to 
inhibit other serine hydrolases such as MAGL, platelet activating factor (PAF) and 
acetylcholine esterase (AchE) (Hoover et al., 2008).  Thus, further experiments with other 
DAGL inhibitors are required.  Despite its exploratory nature, this study offers some 
insights into the interplay between DAGL and the CCL2/CCR2 axis in monocytes, which 
might be an important area for future research. 
Inhibition of DAGK attenuates CCL2/CCR2- and P2Y6-associated THP-1 cell 
signalling and/or function 
The results of Ca2+ experiments assessing the requirement of DAG through DAGK 
showed that CCL2-evoked Ca2+ responses were almost abolished by R-59-022 in the 
presence of extracellular Ca2+, and significantly attenuated in the absence of extracellular 
Ca2+.  These results, indicate a novel requirement of DAGK for CCL2/CCR2-mediated 
monocyte signalling, but also suggest that the effects of R-59-022 are partially-dependent 
on Ca2+.  The findings of this study are also consistent with DAGL studies and point 
towards the possibility that DAG accumulation attenuates CCL2-evoked Ca2+ responses.  
A second interesting observation was that application of R-59-022 transiently increased 
the baseline Ca2+ response.  A possible explanation for this might be that DAG increased 
Ca2+ influx by directly activating TRPC channels (Hofmann et al., 1999).   
The results of THP-1 cell chemotaxis studies showed that DAGK inhibition by R-59-022 
significantly attenuated CCL2-mediated chemotaxis, where the degree of inhibition with R-
59-022 mirrored that seen in Ca2+ assays.  These results are interesting, and suggest that 
DAGK is required for CCL2/CCR2-mediated monocyte function.  However, as with Ca2+ 
studies, an alternative explanation for these results might be that DAGK inhibitors 
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accumulate DAG, which leads to an attenuation of monocyte chemotaxis towards CCL2.  
Although similar studies have not been performed by others, it is interesting that 
phosphatidic acid (PA), which is formed by DAGK, and activates PLC (Limatola et al., 
1994; Litosch, 2002), has been shown to be secreted by monocytic cells in response to 
CCL2 (Turner et al., 1996).  It is possible, therefore, that PA generated by DAGK amplifies 
CCL2/CCR2-mediated monocyte signalling and function through PLC.  This hypothesis 
seems plausible given that PA also induces monocyte migration (Zhou et al., 1995).  A 
wider implication to this finding is that CCL2/CCR2-mediated monocyte/macrophage 
pathologies would be exacerbated by DAGK.  However, this hypothesis is disputed by 
studies showing that DAGK expression is lost upon monocytic cell differentiation to 
macrophages (Yamada et al., 2003).   
It was next hypothesised that DAGK might also be required for P2Y6-associated monocyte 
signalling.  The results of THP-1 cell Ca2+ experiments with R-59-022 suggested that 
DAGK was also required for P2Y6-associated monocyte signalling.  This indirectly 
corroborates the ideas of Scott et al. (2013) who found that UDP-activation of P2Y6-
transfected 1321N1 cells led to a DAGKζ- and phospholipase D (PLD)-mediated release 
of PA.  This result indicates an involvement of DAGK in P2Y6- and CCR2-mediated 
monocyte signalling and function.  While this is interesting and identifies a point at which 
P2Y6 and CCR2 might converge, it may also be that DAGK plays a general role in 
signalling of all GPCRs.  Thus, future studies should seek to examine other chemotactic 
GPCR-signalling pathways before firm conclusions are drawn. 
While the results of this study indicate an important role for DAGK for CCL2/CCR2-
mediated monocyte signalling and function, it is important that these results are 
interpreted with caution since cell viability studies suggested that THP-1 cells exposed to 
R-59-022 for prolonged periods, released high levels of LDH.  A further note of caution is 
due here since R-59-022 is known to inhibit a number of other kinases (Fedorov et al., 
2007), thus further work with better DAGK inhibitors are needed.   
Inhibition of PKC attenuates CCL2/CCR2-mediated THP-1 cell signalling 
The classical (cPKC) and novel (nPKC) families of PKC are preferentially activated by 
DAG (Yang and Kazanietz, 2003).  It is possible, therefore, that the inhibitory effects of 
DAGL and DAGK inhibitors on CCL2/CCR2-mediated monocyte signalling and function 
reflect an activation of PKC by DAG.  The validity of this hypothesis was examined using 
the PKC inhibitor, GF-109203X. 
The results of THP-1 cell Ca2+ experiments showed that GF-109203X attenuated CCL2-
evoked Ca2+ responses to low concentrations of CCL2, but not to maximal concentrations 
of CCL2.  These findings suggest that activation of PKC is necessary for low-level 
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CCL2/CCR2 signalling, but not for higher-level signalling.  A possible explanation for this 
might be that a greater level of CCR2 activation promotes a greater turnover of DAG, 
thereby limiting PKC activation.  However, while this hypothesis seems plausible, it is 
interesting that the present findings differ from Carnevale and Cathcart (2003) whose 
studies suggested that CCL2-mediated Ca2+ responses in human monocytes involved 
PKCβ.  These studies are also interesting because the authors suggest that PKC is 
indirectly involved in CCL2/CCR2 signalling and is only important for signal-transduction 
downstream of the immediate calcium signal.  This is interesting because, in the present 
study, PKC inhibition was found to accelerate the decay of CCL2 Ca2+ transients, which 
suggests that PKC plays a negative role in replenishment of the ER.  In support of this, 
studies by Venkatachalam et al. (2003) and Kawasaki et al. (2010) have shown that PKC 
inhibits the SOCE channels TRPC and CRAC, thereby preventing replenishment of the 
ER.  The findings of this study are therefore important as they help us gain a clearer 
picture of the mechanisms involved in PKC signalling in monocytes.   
In experiments addressing the requirement of PKC for CCL2/CCR2-mediated monocyte 
chemotaxis, it was seen that CCL2-mediated THP-1 cell chemotaxis was unaffected by 
GF-109203X.  This finding contradicts the findings of Carnevale and Cathcart (2003), 
whose studies showed that GF-109203X or PKCβ-silencing attenuated CCL2-mediated 
monocyte chemotaxis.  In agreement with Carnevale and Cathcart (2003), other studies 
have also shown an involvement of PKC isoenzymes in cell polarity and migration (Ng et 
al., 1999; Larsson, 2006).  It may be the case therefore, that the findings of Carnevale and 
Cathcart (2003) differ from the present study because of differences in the methodologies 
applied.  For example, Carnevale and Cathcart (2003) pre-incubated cells with GF-
109203X for 1 hour prior to chemotaxis assays, while the present study did not pre-
incubate.  Thus, further studies involving a pre-incubation of GF-109203X may be 
necessary.   
While this study may have failed to confirm a requirement of PKC for CCL2/CCR2-
mediated monocyte chemotaxis, it nevertheless suggested that monocyte signalling in 
response to CCL2 is influenced by PKC. 
Extracellular nucleotides are required for CCL2/CCR2-mediated THP-1 cell and 
human PBMC signalling and function 
A considerable amount of the literature has been published on the involvement of 
purinoceptors in CCL2 release from monocytic cells and monocyte progeny (Cox et al., 
2005; Stokes and Surprenant, 2007; Morioka et al., 2013; Garcia et al., 2014; Higgins et 
al., 2014; Shieh et al., 2014).  Although these studies suggest that purinoceptor signalling 
plays a role in modulating CCL2/CCR2-mediated monocyte signalling and function, the 
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exact mechanisms by which these pathways crosstalk is still an open question.  The 
present studies therefore sought to address this question using the ecto-nucleotidase, 
apyrase, which dephosphorylate nucleotides to render them inactive. 
The results of Ca2+ mobilisation experiments showed that apyrase significantly attenuated 
CCL2-mediated intracellular Ca2+ responses in THP-1 cells and human PBMCs.  These 
findings are novel and suggest that extracellular nucleotides are required for efficient 
CCL2/CCR2-mediated monocyte and PBMC signalling.  Interestingly, the results of further 
experiments investigating the requirement for NTPs and NDPs showed that CCL2-
mediated Ca2+ responses were attenuated less by an apyrase isoenzymes with reduced 
NDPase activity/velocity.  This suggests that NDPs are more likely to be required for 
efficient CCL2-mediated Ca2+ responses.  A second important observation made in these 
studies was that apyrase caused a dip in the baseline Ca2+ response.  The fact that this 
effect was less evident in the absence of extracellular Ca2+ and almost absent in 
experiments with a lower NDPase apyrase, suggests that NDPs maintain background 
Ca2+ homeostasis by releasing intracellular Ca2+.  This hypothesis differs from prior work 
reported by this group (Sivaramakrishnan et al., 2012), where the experimental results 
suggested that ATP played a role in maintaining Ca2+ homeostasis.  A possible 
explanation for these differences might be that Sivaramakrishnan et al. (2012) did not 
examine the involvement of NDPs on baseline Ca2+. 
Experiments next examined the requirement of extracellular nucleotides for CCL2/CCR2-
mediated monocyte function.  The results of chemotaxis experiments showed that 
apyrase almost abolished CCL2-dependent THP-1 cell chemotaxis but interestingly, 
potentiated PBMC chemotaxis.  A potentiation of PBMC chemotaxis by apyrase was 
unexpected and may have reflected the heterogeneous nature of PBMCs and the 
chemotactic effects of nucleotides and nucleosides on different cell types (Chen et al., 
2006; Zhang et al., 2006; Myrtek and Idzko, 2007; Kronlage et al., 2010).  Although these 
findings suggest that additional experiments with purified CCR2-expressing monocytes 
are required, the inhibition of CCL2-mediated THP-1 cell chemotaxis by apyrase is 
encouraging, because it supports the hypothesis that extracellular nucleotides are 
required for CCL2/CCR2-mediated monocyte signalling and function.  A wider implication 
of these findings is that ecto-nucleotidases such as NTPDase1 would be therapeutically 
beneficial for pathologies associated with an excessive trafficking of monocytes towards 
CCL2, a theory indirectly supported by studies showing that NTPDase1 produces anti-
inflammatory and anti-thrombotic effects in cells such as neutrophils and platelets (Enjyoji 
et al., 1999; Hyman et al., 2009; Reutershan et al., 2009).  The anti-inflammatory effects 
of ecto-nucleotidases have also been brought to the fore by APT102, an engineered ADP-
selective NTPDase3 that has been shown to prevent thrombus formation and reduce 
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infarction size in animal models (Moeckel et al., 2014).  Using APT102 as a research tool 
would be therefore be interesting as this would allow enhance our understanding of the 
involvement of ADP in CCL2/CCR2-mediated monocyte signalling and function. 
The results of adhesion experiments showed that apyrase enhanced CCL2-mediated 
THP-1 cell adhesion to HUVECs.  These results conflicted with the findings of chemotaxis 
and Ca2+ studies, and suggested that extracellular nucleotide scavenging increased 
CCL2-mediated monocyte adhesion.  Although this finding is disappointing, an alternative 
explanation for these results may be that apyrase accumulates adenosine, which may 
facilitate cellular adhesion.  However, although this is a possibility and could be tested 
indirectly with ADA, prior work has shown that ATP and UTP increase monocyte adhesion 
to endothelial cells by up-regulating VCAM-1 expression (Seye et al., 2003), while 
adenosine typically inhibits adhesion by down-regulating ICAM-1, VCAM-1 and E-selectin 
(Takahashi et al., 2007; Hassanian et al., 2014).  This suggests that THP-1 cells are likely 
to respond differently to extracellular nucleotides and nucleosides, and that further studies 
examining the effects of these on monocyte adhesion are important to conduct before firm 
conclusions about the findings of this experiment are drawn. 
Inhibition of ecto-nucleotidases potentiates CCL2/CCR2-mediated THP-1 cell 
signalling 
Studies next sought to address whether endogenously active ecto-nucleotidases 
modulated CCL2/CCR2-mediated monocyte signalling.  To address this aim, studies 
employed the ecto-nucleotidase inhibitors ARL-67156 and POM-1 and tested the effects 
of these on CCL2-evoked intracellular Ca2+ responses in THP-1 cells. 
The results of Ca2+ studies showed that ARL-67156 potentiated intracellular Ca2+ 
responses evoked by near-EC50 concentrations of CCL2 in the presence of extracellular 
Ca2+, but not in the absence of extracellular Ca2+.  These findings are interesting because 
they suggest that Ca2+-sensitive ecto-nucleotidases are involved in modulating 
CCL2/CCR2-mediated Ca2+ responses in monocytes.  An implication of this is the 
possibility that monocyte sensing of CCL2 is enhanced in environments where ecto-
nucleotidase activity is inadequate.  However, this hypothesis conflicts with studies 
showing that monocytes from ENTPD1 (NTPDase1)-null mice are unable to efficiently 
transmigrate towards CCL2 and extracellular nucleotides (Goepfert et al., 2001).  This 
suggests that ecto-nucleotidases are needed for monocyte trafficking towards CCL2.  It 
may be the case therefore, that ecto-nucleotidases are required for CCL2/CCR2 
signalling, but must be fine-tuned.  This is would also support the hypothesis that NDPs 
are preferentially required for CCL2/CCR2-mediated monocyte signalling. 
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The results of further Ca2+ studies with POM-1 showed that high concentrations of this 
ecto-nucleotidase inhibitor abolished CCL2-evoked Ca2+ responses.  These results were 
unexpected, and suggested that ecto-nucleotidase inhibition attenuated CCL2/CCR2-
mediated monocyte signalling.  Additional studies showed that POM-1 abolished Ca2+ 
responses evoked by ADP and UDP, and impaired Ca2+ responses evoked by ATP and 
UTP, therefore indicating similarities between the effects of POM-1 on NDP- and CCL2-
evoked intracellular Ca2+ responses.  While a possible explanation for these findings could 
be that POM-1 activity leads to a desensitisation/internalisation of NDP and CCL2-
sensitive receptors, other studies (Wall et al., 2008) suggest that POM-1 attenuates 
synaptic transmission independent of its ecto-nucleotidase inhibition.  It may be the case; 
therefore, that POM-1 attenuates CCL2 and NDP Ca2+ responses through ecto-
nucleotidase-independent off-target effects.  Given these drawbacks, future studies 
should use alternative ecto-nucleotidase inhibitors, such as the recently identified 
NTPDase1 inhibitor, ticlodipine (Lecka et al., 2014). 
P1 purinoceptor antagonism does not modulate CCL2/CCR2-mediated THP-1 cell 
signalling 
To gain a better understanding of the requirement of purinoceptor signalling for 
CCL2/CCR2-mediated monocyte signalling and function, studies examined the 
contributions of P1, P2X, and P2Y purinoceptors.  Initial studies focused on P1 
purinoceptors using the P1 antagonist, CGS-15943. 
The results of THP-1 cell Ca2+ mobilisation experiments showed that CGS-15943 
potentiated intracellular Ca2+ responses evoked by near-EC20 concentrations of CCL2.  
These data suggest that P1 purinoceptors negatively regulate CCL2/CCR2-mediated 
monocyte signalling.  However, in additional experiments, it was seen that CGS-15943 
was unable to recover CCL2-evoked Ca2+ responses in THP-1 cells treated with apyrase.  
Furthermore, experimental results showed no modulation of CCL2-evoked intracellular 
Ca2+ responses by ADA.  These latter findings therefore suggest that P1 purinoceptors 
are not negative regulators of CCL2/CCR2-mediated monocyte signalling.  Although the 
results of initial experiments suggest that P1 purinoceptors were involved, it may be that 
CCL2- Ca2+ responses are potentiated by CGS-15943 through its off-target inhibition of 
PI3K, which would increase Ca2+ influx through CRAC channels (Edling et al., 2014).  
However, a second possible explanation for these results might be that CGS-15943 is 
unable to distinguish between individual P1 receptors which can produce differential 
effects in monocytes (Haskό et al., 2007).  Future studies should therefore investigate this 
possibility by using selective P1 antagonists.  While this investigation may have failed to 
suggest an involvement of P1 purinoceptors in CCL2/CCR2-mediated monocyte 
signalling, it nevertheless demonstrated the importance of P1 purinoceptors. 
302 
 
P2X1, P2X4 and P2X7 antagonism does not modulate CCL2/CCR2-mediated THP-1 
cell signalling and function 
Studies next examined the requirement of P2X purinoceptors by testing the effects of 
antagonists for P2X1 (Ro-0437626), P2X4 (5-BDBD) and P2X7 (A-438079) on THP-1 cell 
CCL2/CCR2-mediated intracellular Ca2+ responses and chemotaxis. 
The results of Ca2+ experiments showed that the P2X1 antagonist Ro-0437626 produced 
a concentration-dependent inhibition of CCL2-evoked intracellular responses in THP-1 
cells, but was unable to modulate CCL2-mediated chemotaxis.  These results suggested 
an involvement of P2X1 in CCL2/CCR2-mediated monocyte signalling, but not in function.  
However, while this indicated a very important discovery, the results of additional 
selectivity experiments showed that Ro-0437626 was unable to modulate Ca2+ responses 
evoked the P2X1 ligand α,β-meATP, suggesting the possibility that P2X1 was either 
rapidly desensitised (Torres et al., 1998), or not expressed by THP-1 cells at the post-
translational level.  A further reason for interpreting these data with caution is that Ro-
0437626 was used at a concentration which is over 30-fold higher than the reported IC50 
(Jaime-Figueroa et al., 2005) which may have resulted in off-target effects.  Moreover, the 
results of Ca2+ experiments suggested that Ro-0437626 increased the baseline Ca2+ 
response through a Ca2+ release from internal stores.  Although interpreting these data 
are difficult as a similar result has not been previously demonstrated, it may be that high 
concentrations of Ro-0437626 produce an off-target effect or that P2X1 receptors 
negatively couple to Ca2+ release from internal stores.  Although these results are 
interesting, they have been unable to firmly suggest an association between P2X1 and the 
CCL2/CCR2 axis in monocytes. 
In experiments examining a requirement for P2X4, the results of Ca2+ experiments showed 
that the P2X4 antagonist 5-BDBD caused a Ca2+-dependent inhibition of CCL2-evoked 
Ca2+ responses and slowed their decay.  These results suggest that P2X4 receptors are 
required for CCL2/CCR2-mediated monocyte signalling.  However, in cell migration 
experiments, it was seen that CCL2-mediated THP-1 cell migration was unaffected by 5-
BDBD, suggesting that the effects of 5-BDBD on CCL2 Ca2+ responses did not couple to 
functional responses.  Moreover, in Ca2+ experiments, it was seen that 5-BDBD increased 
baseline Ca2+ levels in the absence of extracellular Ca2+.  Although a similar result has not 
been previously demonstrated, it may that a high concentration of 5-BDBD leads to a 
P2X4-dependent release of Ca2+ from internal stores.  Since no selective P2X4 ligands 
were available, this hypothesis could not be tested.  These studies were therefore unable 
to confirm a requirement of P2X4 receptors for CCL2/CCR2-mediated monocyte signalling 
and function, but indicated that the use of more selective approaches to study P2X4 would 
be an interesting area for future research.  Another reason for undertaking this research is 
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that CCR2 activation is known to increase P2X4 expression and cell-surface trafficking in 
microglia during neuropathic pain (Toyomitsu et al., 2012), suggesting that both receptors 
could also engage in similar crosstalk in monocytes. 
Although the P2X7 receptor is well-known for its involvement in the release of pro-
inflammatory mediators such as IL-1β and IL-18 (Ferrari et al., 1997), its requirement for 
CCL2/CCR2-mediated monocyte signalling and function has yet to be investigated.  Thus, 
the final studies on P2X purinoceptors examined the requirement of the P2X7 receptor 
using the P2X7 antagonist, A-438079.  The results of THP-1 cell Ca2+ experiments 
showed that A-438079 produced a small inhibition of CCL2-evoked intracellular Ca2+ 
responses in the presence of extracellular Ca2+.  This result was considered significant 
since it supported a requirement of P2X7 for CCL2/CCR2-mediated monocyte signalling.  
However, the results of chemotaxis experiments showed that THP-1 cell migration 
towards CCL2 was unaffected by A-438079, suggesting that P2X7 was not required for 
monocyte migration.  Further experiments examining the selectivity of A-438079 for P2X7 
showed that BzATP-evoked Ca2+ responses in THP-1 cells were also unaffected by A-
438079.  A possible reason for this might be that the effects of A-438079 on BzATP Ca2+ 
responses were difficult to detect because P2X1, P2X4, P2X7, P2Y11, and P2Y13 
receptors would have also been activated by BzATP (Bianchi et al., 1999; Jarvis and 
Khakh, 2009).  However, although this is a possibility, Nelson et al. (2006) have 
demonstrated in their studies that a similar concentration of A-438079 attenuates BzATP-
induced IL-1β release and YoPro-1 uptake in THP-1 cells.  Interestingly, P2X7-mediated 
Ca2+ influx was not tested by this study, which suggests that it may not be easily detected.  
Thus, additional studies addressing these issues are recommended.  A second reason for 
pursuing P2X7 receptors further is that P2X7 has been shown to promote CCL2 release in 
microglia (Shieh et al., 2014), which may suggest an involvement of P2X7 and CCR2 in 
microglia-associated inflammatory pathologies. 
P2Y1, P2Y11, P2Y12, and P2Y13 antagonism does not modulate CCL2/CCR2-mediated 
THP-1 cell signalling and function 
Studies next examined the requirement of P2Y purinoceptors for CCL2/CCR2-mediated 
monocyte signalling and function.  To address this aim, studies examined the effects of 
antagonists for P2Y1 (MRS-2179), P2Y11 (NF-340), P2Y12 (AR-C-66096), and P2Y13 
(MRS-2211) on CCL2/CCR2-mediated THP-1 cell Ca2+ responses and chemotaxis. 
The results of experiments showed that CCL2/CCR2-mediated THP-1 cell Ca2+ responses 
and chemotaxis were not significantly affected by MRS-2179, NF-340, AR-C-66096, and 
MRS-2211.  These results suggested that P2Y1, P2Y11, P2Y12, and P2Y13 purinoceptors 
were not required for CCL2/CCR2-mediated monocyte signalling and function.  This 
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finding is important since it suggests that the inhibitory effects of PPADS and apyrase on 
THP-1 cell CCL2-mediated intracellular Ca2+ responses and chemotaxis are not through 
an impairment of these receptors.  In order to provide additional support for these findings, 
studies sought evidence that each P2Y antagonist attenuated intracellular Ca2+ responses 
evoked by preferred ligands.   
In experiments for P2Y1, ADP-evoked Ca
2+ responses were not significantly inhibited by 
the P2Y1 antagonist, MRS-2179.  Although it is difficult to explain this result, it is possible 
that P2Y1 receptors are rapidly desensitised by ADP, making functional responses difficult 
to detect (Enjyoji et al., 1999).  Although further Ca2+ studies showed that the P2Y1-
selective ligand MRS-2365 evoked intracellular Ca2+ responses in THP-1 cells, and that 
these were potentiated by apyrase, the small magnitude of these responses suggested 
that P2Y1 receptors were either rapidly desensitised, or poorly coupled to intracellular Ca
2+ 
release in THP-1 cells.  As no prior work has shown an involvement of P2Y1 receptors in 
intracellular Ca2+ release from monocytes or monocytic cells, either of these situations are 
possible.  Although this study may have been unable to identify an involvement of P2Y1 in 
CCL2/CCR2-mediated monocyte signalling and function, it nevertheless demonstrated a 
functional presence of P2Y1 in THP-1 cells, which is a novel finding.  Further studies at the 
post-translational level are therefore recommended to confirm these findings. 
The results of Ca2+ experiments for P2Y11 showed that the P2Y11 antagonist NF-340, 
attenuated intracellular Ca2+ responses evoked by ATP in THP-1 cells.  Although this 
result indirectly supported a lack of involvement of P2Y11 in CCL2/CCR2-mediated 
monocyte signalling and function, additional experiments showed that NF-340 was unable 
to modulate Ca2+ responses evoked by the P2Y1/P2Y11 ligand, β-NAD.  This result was 
unexpected and suggests that β-NAD evokesCa2+ release through P2Y1 rather than 
P2Y11.  However, another possible explanation for this result might be that β-NAD only 
activates P2Y11 under inflammatory conditions.  This hypothesis supports previous work 
showing that monocytes only respond to β-NAD following exposure to lipopolysaccharide 
(Klein et al., 2009).  It may be the case, therefore, that P2Y11 is not readily activated in 
monocytes.  Examining the requirement of P2Y11 for CCL2/CCR2-mediated monocyte 
signalling and function under inflammatory conditions would thus be an interesting area 
for future research. 
The results of Ca2+ experiments for P2Y12 showed that ADP-evoked Ca
2+ responses were 
not significantly affected by the P2Y12 antagonist, AR-C-66096.  Although these results 
were negative, they tied in with the knowledge that P2Y12 purinoceptors couple to AC 
inhibition via Gαi/o (Hollopeter et al., 2001, Savi et al., 2001).  However, it is interesting that 
more recent studies (Bianco et al., 2005; Ceruti et al., 2008) suggest that P2Y12 receptors 
couple to intracellular Ca2+ release in microglia.  However, a weakness of these studies is 
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that the results reported by these authors were based on data provided by dual 
P2Y12/P2Y13 antagonists (AR-C69931MX and Cangrelor), which may have influenced the 
interpretation of the experimental results.  This would potentially explain why no other 
studies have associated P2Y12 with intracellular Ca
2+ release.  Further research should 
therefore be done to investigate the effects of AR-C-66096 on ADP-mediated Ca2+ 
mobilisation in P2Y12-transfected cells.  While the present study may have failed to 
demonstrate a requirement of P2Y12 for CCL2/CCR2-mediated monocyte signalling and 
function, it nevertheless provided some insight into P2Y12 signalling in monocytic cells. 
In experiments for P2Y13, it was discovered that the P2Y13 antagonist, MRS-2211 
attenuated Ca2+ responses evoked by ADP.  These results tie in with the knowledge that 
P2Y13 receptors couple to intracellular Ca
2+ release (Communi et al., 2001; Marteau et al., 
2003), but also support the hypothesis that P2Y13 receptors are not required for 
CCL2/CCR2-mediated monocyte signalling or function.  The results of this study also 
support the functional presence of P2Y13 in THP-1 cells, which has not previously been 
reported.  Although other studies have shown that P2Y13 drives intracellular Ca
2+ release 
through PLC in microglia (Zeng et al., 2014), similar studies in monocytes and monocytic 
cells have not been performed.  The discovery that THP-1 cells express functional P2Y13 
receptors suggests that these cells may serve as a useful model for investigating P2Y13-
mediated reverse-cholesterol transport in macrophages (Boeynaems et al., 2010) 
P2Y6 antagonism attenuates CCL2/CCR2-mediated THP-1 cell and human PBMC 
signalling 
The final chapter in this thesis investigated the requirement of the P2Y6 purinoceptor for 
CCL2/CCR2-mediated monocyte signalling and function.  Initial studies employed the 
P2Y6 antagonist, MRS-2578 and tested its effects on CCL2-evoked intracellular Ca
2+ 
responses in THP-1 cells and human PBMCs. 
The results of these experiments showed that MRS-2578 caused a concentration-
dependent inhibition of CCL2-evoked Ca2+ responses in THP-1 cells and significantly 
attenuated CCL2-evoked Ca2+ responses in human PBMCs.  These findings supported 
the results of experiments with apyrase and PPADS, but also importantly indicated a 
requirement of P2Y6 for efficient CCL2/CCR2-mediated monocyte signalling.  A wider 
implication of this is that P2Y6 antagonism in vivo would attenuate excessive monocyte 
trafficking towards CCL2 chemotactic gradients.  However, while this indicated a novel 
and important discovery, the results of experiments showed that MRS-2578 inhibited Ca2+ 
responses less in PBMCs than in THP-1 cells.  Although this is difficult to explain, it may 
be that P2Y6 expression varies between different PBMCs.  This seems possible given that 
prior work has shown that 1 µM MRS-2578 abolishes UDP-mediated IP3 accumulation in 
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P2Y6-transfected 1321N1 cells, but only halves UDP-evoked Ca
2+ responses in a mixed 
population of human monocytes (Mamedova et al., 2004; Woszczek et al., 2010).  
Although this study has been successful in demonstrating crosstalk between P2Y6 and 
CCR2, it is important to note that a weakness of this study was that 10 µM MRS-2578 
may have antagonised P2Y1 receptors (Mamedova et al., 2004).  Although this may have 
influenced the interpretation of experimental results, earlier experiments in this thesis 
were unable to provide firm evidence that THP-1 cells expressed functional P2Y1 
receptors.   
Another important finding was that application of MRS-2578 to both cell types increased 
baseline Ca2+.  Additional studies in the absence of extracellular Ca2+ indicated that the 
effects of MRS-2578 on baseline Ca2+ involved Ca2+ influx and a mobilisation from internal 
stores.  This finding is interesting because it suggests that P2Y6 could be involved in 
maintaining Ca2+ homeostasis.  Although a similar result has not previously been reported, 
Bernier et al. (2013) have shown through their studies on microglia that P2Y6 attenuates 
P2X4-mediated Ca2+ influx, meaning that P2Y6 could also play a similar role in monocytes.  
Although this is a possibility, this hypothesis conflicts with data showing a similar elevation 
of baseline Ca2+ in the absence of extracellular Ca2+.  Thus, further work to address the 
mechanism behind this effect is required.   
Dual P2Y6 and CCR2 antagonism abolishes CCL2/CCR2-mediated THP-1 cell 
signalling 
Having investigated the requirement of P2Y6 for CCL2/CCR2-mediated monocyte 
signalling, this study next asked whether CCL2-evoked intracellular Ca2+ responses in 
monocytes involved a co-activation of P2Y6 and CCR2.  The results showed that a co-
treatment of THP-1 cells with MRS-2578 and BMS-CCR2-22 abolished CCL2-evoked 
intracellular Ca2+ responses.  This suggests that CCL2-evoked intracellular Ca2+ 
responses in monocytes involves both receptors, but also indicates that dual antagonists 
of CCR2 and P2Y6 may be therapeutically beneficial.  However, an arguable weakness 
with this study is that data generated previously in this thesis showed that BMS-CCR2-22 
abolished CCL2-evoked intracellular Ca2+ responses.  This essentially means that CCR2 
antagonists would be able to regulate monocyte trafficking towards CCL2 without the 
need for P2Y6 antagonists.  However, as shown by others (Cox et al., 2005; Kim et al., 
2011; Zhang et al., 2011), P2Y6 activation in immune cells and astrocytes is often 
associated with a release of CCL2, thus highlighting the possibility that CCR2-mediated 
pathologies are exacerbated by P2Y6.  This might explain why CCR2 antagonists have 
lacked clinical efficacy (Bachelerie et al., 2014). 
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P2Y6 antagonism attenuates CCL2/CCR2-mediated THP-1 cell and human PBMC 
function 
The findings above suggest that P2Y6 crosstalk with CCR2 regulates monocyte signalling.  
It was therefore important to understand the involvement of P2Y6 in CCL2/CCR2-
mediated monocyte function.  Studies addressed this aim by testing the effects of MRS-
2578 on THP-1 cell and human PBMC chemotaxis, and THP-1 cell adhesion to vascular 
endothelial cells. 
The results of chemotaxis experiments showed that MRS-2578 nearly abolished CCL2-
mediated THP-1 cell and PBMC chemotaxis.  These results suggest that crosstalk 
between P2Y6 and CCR2 is essential for efficient monocyte and PBMC chemotaxis.  
Although this finding is novel, studies by Zhang et al. (2011), have demonstrated that 
P2Y6 activation promotes the chemotaxis of RAW264.7-macrophages by inducing the 
release of CCL2.  Cox et al. (2005) have also demonstrated the release of CCL2 by U937 
monocytic cells in response to UDP.  Although these studies differ from the present study, 
they support the hypothesis that crosstalk between P2Y6 and CCR2 is important for the 
signalling and function of monocytes and their progeny.  Determining whether CCR2-
expressing monocytes release CCL2 in response to P2Y6 activation would thus represent 
an interesting research area, as it would enable a greater understanding of how P2Y6 and 
CCR2 crosstalk modulates monocyte function. 
A second important finding from chemotaxis studies was that the level of inhibition with 
MRS-2578 mirrored apyrase and PPADS, suggesting that all three compounds attenuated 
CCL2-mediated cellular chemotaxis through a common pathway.  Although these results 
supported the study hypothesis, the effects of MRS-2578 on PBMCs were unexpected 
since studies in this thesis showed that apyrase enhanced chemotaxis.  These differences 
are difficult to explain, but might be related to the two different mechanisms by which 
apyrase and MRS-2578 act (Cohn and Meek, 1957; Mamedova et al., 2004).  Further 
studies to examine the mechanisms by which apyrase and MRS-2578 differentially 
modulate monocyte chemotaxis are therefore recommended.  Despite these 
discrepancies, the findings of this study indicate that P2Y6 activation is required for 
CCL2/CCR2-mediated monocyte signalling and chemotaxis. 
The results of adhesion experiments showed that MRS-2578 abolished CCL2/CCR2-
mediated THP-1 cell adhesion to both quiescent and TNFα-treated HUVEC monolayers.  
These findings suggest that P2Y6 is important for CCL2-mediated monocyte adhesion to 
the vascular endothelium under homeostatic and inflammatory conditions.  Although these 
findings are novel, it is interesting that other groups also implicate a role for P2Y6 in 
vascular inflammation (Bar et al., 2008; Guns et al., 2010; Riegel et al., 2011; Kim et al., 
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2011; Stachon et al., 2014; Garcia et al., 2014).  A key study is that of Riegel et al. (2011), 
in which LPS- or TNFα-challenge of the vascular endothelium led to a selective 
upregulation of P2Y6, VCAM-1 and ICAM-1 expression, and IL-8 release, all of which were 
markedly attenuated by MRS-2578.  More recently, Stachon et al. (2014) and Garcia et al. 
(2014) have demonstrated that P2Y6-deficient mice exhibit smaller atherosclerotic lesions 
due to a reduced ability of leukocytes to roll and adhere to vasculature.  Garcia et al. 
(2014) have even gone further by showing that P2Y6-deficient macrophages secrete less 
CCL2.  In general, therefore, it seems that monocyte chemotaxis and adherence are 
functions coordinated by P2Y6 and CCR2.  One of the issues that emerge from this is that 
dual targeting of these receptors may be a more therapeutically efficacious strategy than 
targeting either receptor alone.   
P2Y6 antagonism attenuates extracellular nucleotide-mediated THP-1 cell signalling 
In an effort to understand the involvement of individual extracellular nucleotides in P2Y6 
activation in monocytes, studies sought to characterise P2Y6-mediated Ca
2+ responses 
using P2Y6-stable 1321N1 astrocytoma cells.  The results of these experiments suggested 
that the rank order of potency of extracellular nucleotides (UDP>UTP>ADP>ATP) 
matched the findings of Communi et al. (1996).  Moreover, the results of this study 
suggested that purine and pyrimidine nucleotides were required for P2Y6 activation in 
monocytes.   
In additional THP-1 cell Ca2+ experiments, it was discovered that MRS-2578 inhibited Ca2+ 
responses evoked by these ligands with a rank order of ADP>UTP>ATP>UDP.  Although 
this suggests that MRS-2578 favours other ligands over UDP, it may be that nucleotide 
purity, which fluctuated between 95% for ADP, to 99% for ATP, influenced these results.  
A second possible explanation might be that Ca2+ responses evoked by UDP in THP-1 
cells involved an activation of P2Y14 and the orphan GPCR, GPR17 (Ciana et al., 2006; 
Carter et al., 2009; Hamel et al., 2011).  Interestingly, further Ca2+ experiments testing this 
hypothesis showed that the P2Y14/GPR17 ligand UDP-glucose (Ciana et al., 2006; Carter 
et al., 2009), induced Ca2+ release from THP-1 cells thereby supporting the hypothesis 
that these receptors contributed to UDP-evoked Ca2+ responses in THP-1 cells.  This 
result also supports a functional presence of the P2Y14 receptor in THP-1 cells, which is a 
novel finding. 
Although this study has been unable to demonstrate that MRS-2578 preferentially impairs 
UDP-evoked Ca2+ responses in THP-1 cells, it has demonstrated that purine and 
pyrimidine extracellular nucleotides are required for P2Y6 activation in monocytes. 
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CCL2 and UDP co-application influences THP-1 cell intracellular Ca2+ responses 
The next study in this thesis set out with the aim of assessing the mechanisms involved in 
P2Y6 and CCR2 crosstalk.  To address this aim, studies investigated the effects of CCL2 
and UDP co-application on THP-1 cell Ca2+ responses. 
The results of this experiment suggested that Ca2+ responses evoked by UDP/CCL2 were 
not significantly higher than Ca2+ responses evoked by CCL2 alone.  While this indicated 
that UDP and CCL2 did not synergistically amplify CCL2 Ca2+ responses, a slightly higher 
Ca2+ response with UDP/CCL2 suggested that additional experiments with a lower 
concentration of CCL2 were required.  In additional Ca2+ studies examining for crosstalk 
between P2Y6 and CCR2, it was seen that the CCR2 antagonist BMS-CCR2-22 did not 
significantly affect UDP-evoked Ca2+ responses in THP-1 cells.  This finding is important 
because it suggests that crosstalk between P2Y6 and CCR2 is unidirectional.  A wider 
implication of this is that antagonists and antibodies targeting CCR2 would be ineffective 
in modulating monocyte trafficking towards extracellular nucleotides.  This is interesting 
because it provides a possible explanation as to why clinical trials on CCR2 antagonists 
have proved unsatisfactory (Bachelerie et al., 2014) 
Although the findings of this study suggest that further work is required, they also indicate 
that the relationship between P2Y6 and CCR2 is unidirectional.  This finding may help us 
to understand how drugs targeting P2Y6 and CCR2 can be fine-tuned to become effective 
therapies. 
Ecto-nucleotidases attenuate fMLP-FPR-associated THP-1 signalling and function  
The next objective was to examine whether other chemotactic pathways involved in 
orchestrating monocyte signalling and function required P2Y6.  To this end, studies tested 
the effects of apyrase and MRS-2578 on fMLP-FPR-associated THP-1 cell signalling and 
chemotaxis. 
The results of Ca2+ studies showed that fMLP-FRP-associated Ca2+ responses were 
attenuated significantly by apyrase, but not by MRS-2578.  Chemotaxis studies mirrored 
these results, and suggested that P2Y6 receptors did not modulate monocyte signalling 
and function by engaging in crosstalk with FPRs.  This is important since it suggests that 
P2Y6 and CCR2 may form an exclusive pairing.  However, the inhibition of fMLP-FPR-
associated THP-1 cell signalling and function by apyrase is an interesting finding, and 
suggests an involvement of other purinoceptors.  While further experiments are required 
to establish this, it is interesting that Chen et al. (2006) suggest that A3 and P2Y2 
purinoceptors guide neutrophil chemotaxis towards fMLP.  It is possible; therefore, that A3 
and P2Y2 play a similar role in monocytes.  While these and other purinoceptors are 
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possible candidates, a lack of involvement of P2Y6 purinoceptors raises intriguing 
questions regarding the mechanisms involved in determining its requirement for CCR2 
signalling, but not for FPR signalling.  Although the reasons for this are unclear, it may be 
that FPR-mediated extracellular nucleotide release sites are located physically far from 
P2Y6, while CCR2-mediated extracellular nucleotide release sites are in close proximity.  
However, a second possible explanation for this might be that P2Y6 and CCR2 form 
heterodimers.  While this is an interesting and novel concept, further work is required to 
establish this. 
Although the findings of these studies indicate that P2Y6 receptors are not required for 
fMLP-FPR-associated monocyte signalling and function, they indicate that other 
purinoceptors may be involved.  Understanding whether other purinoceptors crosstalk with 
FPRs to modulate monocyte signalling and function would thus represent an interesting 
research area. 
P2Y6 cross-desensitisation of CCR2 attenuates CCL2/CCR2-mediated THP-1 cell 
signalling 
The findings of this thesis suggest that CCR2-expressing monocytes rely on crosstalk 
between P2Y6 and CCR2 for proper guidance towards chemotactic signals transmitted by 
CCL2.  However, as the evidence presented has shown, the relationship between P2Y6 
and CCR2 is unidirectional, indicating that P2Y6 may functionally regulate CCR2 through 
the process of cross-(heterologous) desensitisation.  Homologous and heterologous 
desensitisation studies therefore sought to examine this hypothesis by using the P2Y6 
ligands, ADP and UDP. 
The results of homologous P2Y6 desensitisation studies showed that after pre-challenge 
of THP-1 cells with ADP or UDP, both nucleotides failed to induce a similar Ca2+ 
response.  This result suggests that P2Y6 can be desensitised by its ligands ADP and 
UDP.  In cross-desensitisation studies, it was seen that pre-challenge of THP-1 cells with 
ADP or UDP suppressed subsequent CCL2-evoked Ca2+ responses.  These findings are 
consistent with MRS-2578 studies, but also suggest that activation of P2Y6 cross-
desensitises CCR2.  A wider implication of this is that, in an in vivo setting, the capacity of 
monocytes to traffic in response to CCL2 would be regulated by P2Y6, which may serve 
as an important regulatory mechanism.  However, while the findings of this study indicate 
a very important and novel discovery, they also suggest that reverse agonist studies are 
required to develop a better understanding of the mechanisms involved in crosstalk 
between P2Y6 and CCR2. 
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P2Y6 knockdown attenuates CCL2/CCR2-mediated THP-1 cell signalling and 
function 
To provide further evidence for crosstalk between P2Y6 and CCR2, studies employed 
molecular approaches (shRNA) to generate P2RY6-KD THP-1 cell lines.  Of the five 
P2RY6-KD cell lines generated, four were significantly less responsive to UDP than 
scrambled THP-1 cells in Ca2+ studies.  However, additional Ca2+ studies suggested that 
only the best-performing shRNA from these (358038) displayed an attenuated Ca2+ 
response to CCL2.  Although it was disappointing that only one P2RY6-KD cell line could 
be taken forward for further studies, qRT-PCR studies were encouraging since they 
indicated that 358038 cells displayed a 2-fold knockdown in P2RY6 mRNA expression, 
but no knockdown in CCR2 mRNA expression.  The results of this study are important 
because they support the hypothesis that P2Y6 is required for CCL2/CCR2 monocyte 
signalling. 
The results of experiments examining the effects of P2Y6-KD on CCL2/CCR2-mediated 
monocyte chemotaxis showed that 2-fold less P2Y6-KD cells migrated towards CCL2 than 
scrambled cells.  This finding agrees with prior observations made in apyrase and MRS-
2578 experiments, and is considered important since it suggests that fine-tuning P2Y6 
activation in vivo would be therapeutically beneficial as this would attenuate excessive 
monocyte trafficking towards CCL2. 
The results of HUVEC adhesion experiments suggested that CCL2-primed P2Y6-KD and 
scrambled THP-1 cells differed in their capacity to adhere to TNFα-treated HUVEC 
monolayers.  Although both cell types adhered similarly to quiescent HUVECs, it was 
seen that CCL2-primed P2Y6-KD cells adhered significantly less than scrambled cells to 
TNFα-treated HUVEC monolayers.  These findings differed from earlier results showing 
that MRS-2578 abolished CCL2-mediated THP-1 cell adhesion to quiescent and TNFα-
treated HUVEC monolayers.  These differences may lie in the fact that MRS-2578 and 
P2RY6 shRNA attenuate P2Y6 by different mechanisms.  While 1 µM MRS-2578 
completely antagonises P2Y6 responses (Mamedova et al., 2004), P2RY6 shRNA only 
partially silences P2Y6.  This suggests that MRS-2578-treated THP-1 cells would be 
unable to adhere, but P2Y6-KD cells would express enough P2Y6 to allow some adhesion.   
While the results of quiescent experiments suggested that P2Y6-KD cells adhered to 
HUVEC monolayers similarly to scrambled cells, it was interesting that in further 
experiments, P2Y6-KD cells were unable to adhere to TNFα-treated HUVEC monolayers.  
It may be that, under these conditions, an upregulation of CCR2 and P2Y6 expression on 
the endothelium (Weber et al., 1999; Riegel et al., 2011) means that a greater demand is 
placed on these receptors.  This would potentially explain why P2Y6-KD cells were unable 
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to adhere, and why the CCR2 antagonist BMS-CCR2-22 abolished CCL2- and non-CCL2-
dependent THP-1 cell adhesion to TNFα-treated HUVEC monolayers.  Although several 
questions remain unanswered at present, it is apparent from the findings of this study that 
P2Y6 antagonists or dual CCR2/P2Y6 antagonists may be therapeutically beneficial. 
THP-1 cells challenged with CCL2 release ATP 
The release of ATP is an important mechanism by which cells send danger signals during 
stress, damage, infection, or hypoxia (Boeynaems, and Communi, 2006; Bours et al., 
2006).  Many cell types such as immune cells release ATP into their microenvironment in 
a bid to adjust their functional responses to non-purinoceptor chemoattractants (Junger, 
2011).  For example, neutrophils self-regulate their responses to fMLP via autocrine 
purinoceptor signalling (Chen et al., 2006; Sumi et al., 2010).  Studies therefore examined 
whether CCR2 and P2Y6 crosstalk involved a release of extracellular nucleotides.   
The results of non-quantitative (HPLC) experiments showed that CCL2 challenge of THP-
1 cells resulted in a robust detection of ATP in cell supernatants, while other extracellular 
nucleotides were difficult to detect.  These results, although a little disappointing, suggest 
that monocytes release ATP upon CCR2 activation, which is a novel finding.  
Furthermore, these results also support an involvement of ATP in P2Y6 activation.  Given 
that, ecto-nucleotidases rapidly hydrolyse ATP to ADP (Zimmermann et al., 2012); it may 
be that ADP also activates P2Y6, which would also support the results of apyrase 
isoenzyme studies showing a greater involvement of NDPs in CCL2 Ca2+ responses. 
The results of quantitative studies suggested that THP-1 cells released 1 µM ATP into 
supernatants following CCL2 challenge.  This finding accords with earlier observations, 
but more importantly, supports prior work (Cox et al., 2005) and data generated in P2Y6-
stable 1321N1 cells showing that P2Y6 can be activated by <300 nM ATP.  As 
experiments with P2Y6-stable 1321N1 cells also suggested that P2Y6 could be activated 
by <300 nM ADP, it may be that ATP release leads to the generation of sufficient levels of 
ADP for P2Y6 activation. 
Although this finding suggests that monocytes release high amounts of ATP in response 
to stimuli, it is interesting that other phagocytes such as neutrophils, release higher levels 
of ATP (3 µM) in response to fMLP (Chen et al., 2006).  The reason for this is not clear but 
it might be that neutrophils, which make up the majority of circulating leukocytes, require 
higher levels of ATP for autocrine and paracrine purinoceptor signalling (Junger, 2011).  
However, an alternative explanation may be that the bulk-phase measurements 
undertaken during this study underestimated the true ATP concentration near the plasma 
membrane (Praetorius and Leipziger, 2009).  This applies not only to ATP, but also to 
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other extracellular nucleotides.  A further study focussing on the concentration of 
extracellular nucleotides at the plasma membrane is therefore suggested. 
THP-1 cells challenged with CCL2 do not release lysosomal enzymes 
Prior work by others has shown that ATP can be stored and released from secretory 
lysosomes (Zhang et al., 2007; Sivaramakrishnan et al., 2012; Hiasa et al., 2014).  
However, no previous studies have investigated the source of ATP from monocytes 
following CCL2 challenge.  This study therefore set out to investigate this hypothesis by 
examining the release of the lysosomal enzyme, β-hexosaminidase in response to CCL2. 
The results of experiments showed that THP-1 cells challenged with CCL2 did not release 
β-hexosaminidase into supernatants.  These results were disappointing, but suggested 
that the levels of β-hexosaminidase released by cells might not have been easily detected 
using the methodology used.  Although these data indicate that monocytes challenged 
with CCL2 do not release ATP from secretory vesicles containing β-hexosaminidase, it is 
interesting that microglial cells, which are essentially tissue-resident macrophages, do 
release β-hexosaminidase in response to CCL2 (Toyomitsu et al., 2012).  It is difficult to 
explain why these differences exist, but it may be that monocytes generally contain less 
secretory vesicles than macrophages (Cohn and Benson, 1965).  However, while this is a 
valid point, the results of the present study showed that GPN caused a significant release 
of β-hexosaminidase in THP-1 cells.  Sivaramakrishnan et al. (2012) have also reported a 
similar result, but unlike this study, the present study has been unable to demonstrate that 
β-hexosaminidase release coincides with ATP release.  A possible explanation for this 
may be that ATP and β-hexosaminidase reside in different secretory vesicles, but that the 
general lysosomotropic and cytotoxic mechanism of GPN (Jadot et al., 1990) led 
Sivaramakrishnan et al. (2012) to believe that ATP and β-hexosaminidase were co-
released from the same location.  A further study with more focus on the mechanisms 
involved in ATP secretion is therefore recommended. 
7.4 Future Directions 
The investigations conducted in this thesis have focussed on deciphering the CCL2/CCR2 
axis in monocytes and investigating its modulation by extracellular nucleotides.  While 
several novel hypotheses have been put forward by this research, further work to 
establish their relevance is required.  However, several questions remain unanswered and 
should be addressed in future investigations in order to understand the mechanisms 
proposed by this study. 
It has been proposed by this research that THP-1 cells and human monocytes exhibit an 
overlapping expression pattern of mRNA for a number of monocyte markers, CC 
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chemokines, CC chemokine receptors, and purinoceptors.  This study has also assumed 
that both cell types express mRNA for the enzymes and targets investigated in this study.  
Determining the expression of these at the post-translational level is therefore required 
since it would allow a better understanding of the contributions of individual pathways. 
The present investigation was unable to investigate the individual contributions of all 
purinoceptors in CCL2/CCR2 signalling due to a lack of antagonist availability.  
Addressing the involvement of these receptors in future studies would be useful for 
determining whether other purinoceptors are involved. 
The results of fMLP-FPR studies suggest that other purinoceptors might be involved.  
Furthermore, a requirement of P2Y6 for CCL2/CCR2 indicates that other chemotactic 
pathways may also require P2Y6.  Understanding the contribution of P2Y6 and other 
purinoceptors in other chemotactic pathways would thus represent an interesting area for 
future research. 
It seems clear from this work that the involvement of P2Y6 in CCL2 release should be 
investigated further.  Experiments addressing this would provide valuable information 
about the mechanisms involved in P2Y6 and CCR2 crosstalk.  Furthermore, future studies 
should also investigate the involvement of downstream components such as DAG and 
PLC in crosstalk studies. 
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Appendix : Supplementary Data 
 
 
 
 
 
 
Figure A1 Detection of adenine nucleotides and nucleosides by ion-pair reverse-
phase HPLC 
Representative traces showing absorbance (A254nm) and retention times of 100 µM (A) 
ATP, (B) ADP, (C) AMP and, (D) adenosine in salt-buffered solution (SBS).  Sampling 
performed immediately after nucleotide and nucleoside addition. 
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Figure A2 Detection of uridine nucleotides and nucleoside by ion-pair reverse-
phase HPLC 
Representative traces showing absorbance (A254nm) and retention times of 100 µM (A) 
UTP, (B) UDP, (C) UMP and, (D) uridine in salt-buffered solution (SBS).  Sampling 
performed immediately after nucleotide and nucleoside addition. 
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Figure A3 Effect of compounds on LDH release from THP-1 cells 
Bar chart showing normalised THP-1 cell viability following incubation (2.5 hours) with 
vehicle (SBS or 1% DMSO) or inhibitors and antagonists at concentrations shown.  Loss 
in cell viability given as a percentage of 0.1% Triton X-100.  Acceptable threshold set to 
20%.  Data represents mean ± SEM from n=1 replicate. 
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Figure A4 Effect of water-soluble compounds on THP-1 cell viablity  
Bar chart showing normalised THP-1 cell viability following incubation (2.5 hours) with 
vehicle (water) or inhibitors and antagonists at concentrations shown.  Cell viability given 
as a percentage of vehicle.  Data represents mean ± SEM from n=3 replicates  
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Figure A5 Effect of DMSO-soluble compounds on THP-1 cell viablity  
Bar chart showing normalised THP-1 cell viability following incubation (2.5 hours) with 
vehicle (DMSO) or inhibitors and antagonists at concentrations shown.  Cell viability given 
as a percentage of vehicle.  Data represents mean ± SEM from n=3 replicates (**p<0.01, 
One-way ANOVA with Bonferroni’s multiple comparison). 
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Figure A6 Effect of apyrase on ATP 
Representative traces showing absorbance (A254nm) and retention time for ATP (100 µM) 
at (A) 0 minutes in the presence of vehicle (SBS), and (B) following a 30 minute 
incubation with apyrase (2U/ml).  (C) Bar chart showing peak height (absorbance at 
A254nm) of 100 µM ATP and related nucleotides and nucleosides at 0 minutes in the 
presence of vehicle, and following a 30 minute incubation with vehicle or apyrase (2U/ml).  
Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle at 0 minutes (**p<0.01, One-way ANOVA with Bonferroni’s multiple 
comparison). 
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Figure A7 Effect of apyrase on ADP 
Representative traces showing absorbance (A254nm) and retention time for ADP (100 µM) 
at (A) 0 minutes in the presence of vehicle (SBS), and (B) following a 30 minute 
incubation with apyrase (2U/ml).  (C) Bar chart showing peak height (absorbance at 
A254nm) of 100 µM ADP and related nucleotides and nucleosides at 0 minutes in the 
presence of vehicle, and following a 30 minute incubation with vehicle or apyrase (2U/ml).  
Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle at 0 minutes (**p<0.01, One-way ANOVA with Bonferroni’s multiple 
comparison). 
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Figure A8 Effect of apyrase on UTP 
Apyrase treatment reduced levels of UTP in SBS buffer.  Representative traces showing 
absorbance (A254nm) and retention time for UTP (100 µM) at (A) 0 minutes in the presence 
of vehicle (SBS), and (B) following a 30 minute incubation with apyrase (2U/ml).  (C) Bar 
chart showing peak height (absorbance at A254nm) of 100 µM UTP and related nucleotides 
and nucleosides at 0 minutes in the presence of vehicle, and following a 30 minute 
incubation with vehicle or apyrase (2U/ml).  Data represents mean ± SEM from n=3 
replicates.  Asterisks indicate significant changes towards vehicle at 0 minutes (**p<0.01, 
*p<0.05, One-way ANOVA with Bonferroni’s multiple comparison). 
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Figure A9 Effect of apyrase on UDP 
Representative traces showing absorbance (A254nm) and retention time for UDP (100 µM) 
at (A) 0 minutes in the presence of vehicle (SBS), and (B) following a 30 minute 
incubation with apyrase (2U/ml).  (C) Bar chart showing peak height (absorbance at 
A254nm) of 100 µM UDP and related nucleotides and nucleosides at 0 minutes in the 
presence of vehicle, and following a 30 minute incubation with vehicle or apyrase (2U/ml).  
Data represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle at 0 minutes (**p<0.01, One-way ANOVA with Bonferroni’s multiple 
comparison). 
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Figure A10 Hydrolysis of ATP by SBS and THP-1 cells 
Incubation of ATP with THP-1 cells resulted in a reduction in levels of ATP and increase in 
levels of ADP and AMP.  Representative HPLC traces showing ATP and ADP peaks at 
(A) 0 minutes in SBS and (B), 30 minutes in the presence of THP-1 cells.  (C)  Bar chart 
showing mean peak heights for ATP, ADP, AMP and adenosine following incubation of 
ATP (100 µM) for 0 or 30 minutes with THP-1 cells.  (D)  Bar chart showing mean peak 
heights for ATP, ADP, AMP and adenosine following incubation of ATP (100 µM) for 0 or 
30 minutes in the absence of THP-1 cells.  Mean peak heights represent mean ± SEM for 
n=4 experiments.  Asterisks indicate significant changes towards vehicle at 0 minutes 
(*p<0.05, **p<0.01, Students t-test). 
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Figure A11 Effect of POM-1 on ATP- and ADP-evoked Ca2+ responses in THP-1 
cells 
(A) Representative Ca2+ transients and (B) bar chart showing normalised intracellular Ca2+ 
responses to ATP (30 µM) in THP-1 cells pre-treated with vehicle (water) or POM-1 (100 
µM) for 15 minutes.  (C) Representative Ca2+ transients and (D) bar chart showing 
normalised intracellular Ca2+ responses to ADP (30 µM) in THP-1 cells pre-treated with 
vehicle (water) or POM-1 (100 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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Figure A12 Effect of POM-1 on UTP- and UDP-evoked Ca2+ responses in THP-1 
cells 
(A) Representative Ca2+ transients and (B) bar chart showing normalised intracellular Ca2+ 
responses to UTP (30 µM) in THP-1 cells pre-treated with vehicle (water) or POM-1 (100 
µM) for 15 minutes.  (C) Representative Ca2+ transients and (D) bar chart showing 
normalised intracellular Ca2+ responses to UDP (30 µM) in THP-1 cells pre-treated with 
vehicle (water) or POM-1 (100 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, **p<0.01, Students t-test). 
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Figure A13 Effect of Ro-0437626 on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of 100 µM Ro 0437626 on baseline Ca2+.  (B) 
Representative Ca2+ transients and (C) bar chart showing normalised intracellular Ca2+ 
responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO) or Ro-
0437626 (10 or 100 µM), for 15 minutes in the presence of extracellular Ca2+.  (D) 
Representative Ca2+ transients and (E) bar chart showing normalised intracellular Ca2+ 
responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO) or Ro 
0437626 (100 µM), for 15 minutes in the absence of extracellular Ca2+.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± 
SEM from n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
Students t-test). 
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Figure A14 Effect of Ro-0437626 on α,β-MeATP-evoked Ca2+ responses in THP-1 
cells 
(A) Representative Ca2+ transients to α,β-MeATP (100 µM) in THP-1 cells pre-treated with 
vehicle (DMSO) or Ro 0437626 (100 µM) for 15 minutes.  (B) Bar chart showing 
normalised intracellular Ca2+ responses to α,β-MeATP (100 µM) in THP-1 cells pre-treated 
with vehicle (DMSO) or Ro 0437626 (100 µM) for 15 minutes.  Responses normalised to 
Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 
replicates. 
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Figure A15 Effect of 5-BDBD on CCL2-evoked Ca2+ responses in THP-1 cells 
(A) Representative trace showing the effect of 5 µM 5-BDBD on baseline Ca2+.  (B) 
Representative Ca2+ transients and (C) bar chart showing normalised intracellular Ca2+ 
responses to CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle DMSO) or 5-BDBD 
(1 or 5 µM), for 15 minutes.  Responses normalised to Ca2+ signals elicited by 40 µM 
digitonin (% Fmax).  (D) Bar chart showing Ca2+ decay rates (, sec) for Ca2+ transients to 
CCL2 (50 ng/ml) in THP-1 cells pre-treated with vehicle (DMSO) or 5-BDBD (1 or 5 µM), 
for 15 minutes.  Data represents mean ± SEM from n=3 replicates.  Asterisks indicate 
significant changes towards vehicle (**p<0.01, *p<0.05, Students t-test). 
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Figure A16 Effect of A 438079 on BzATP-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to BzATP (50 µM) in THP-1 cells pre-treated with 
vehicle (DMSO) or A 438079 (10 µM) for 15 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to BzATP (50 µM) in THP-1 cells pre-treated with vehicle 
(DMSO) or A 438079 (10 µM) for 15 minutes.  Responses normalised to Ca2+ signals 
elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
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Figure A17 Effect of apyrase on MRS 2365-evoked Ca2+ responses in THP-1 cells 
(A) Representative Ca2+ transients to MRS 2365 (100 nM) in THP-1 cells pre-treated with 
vehicle (water) or apyrase (2 U/ml) for 10 minutes.  (B) Bar chart showing normalised 
intracellular Ca2+ responses to MRS 2365 (100 nM) in THP-1 cells pre-treated with vehicle 
(water) or apyrase (2 U/ml) for 10 minutes.  Responses normalised to Ca2+ signals elicited 
by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from n=3 replicates.  
Asterisks indicate significant changes towards vehicle (*p<0.05, Students t-test). 
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Figure A18 Effect of NF-340 on ATP- and βNAD-evoked Ca2+ responses in THP-1 
cells 
Representative Ca2+ transients to (A) ATP (30 µM) and (C) β-NAD (1 mM) in THP-1 cells 
pre-treated with vehicle (DMSO) or NF-340 (10 µM) for 15 minutes.  Bar chart showing 
normalised intracellular Ca2+ responses to (B) ATP (3 and 30 µM) and (D) β-NAD (1 mM) 
in THP-1 cells pre-treated with vehicle (DMSO) or NF 340 (10 µM) for 15 minutes.  
Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data 
represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle (**p<0.01, Students t-test). 
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Figure A19 Effect of MRS-2211 on CCL2- and ADP-evoked Ca2+ responses in THP-
1 cells 
(A) Representative trace showing the effect of MRS-2211 on baseline Ca2+.  
Representative Ca2+ transients to (B) CCL2 (50 ng/ml) and (D) ADP (3 µM) in THP-1 cells 
pre-treated with vehicle (water) or MRS 2211 (10 µM) for 15 minutes.  Bar chart showing 
normalised intracellular Ca2+ responses to (C) CCL2 (50 ng/ml) and (E) ADP (3 µM) in 
THP-1 cells pre-treated with vehicle (water) or MRS 2211 (10 µM) for 15 minutes.  
Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data 
represents mean ± SEM from n=3 replicates.  Asterisks indicate significant changes 
towards vehicle (**p<0.01, Students t-test). 
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Figure A20 ATP-and ADP-evoked Ca2+ responses in P2Y6-stable 1321N1 cells 
ATP- and ADP-evoked intracellular Ca2+ responses in P2Y6-stable 1321N1 cells.  
Representative Ca2+ transients to (A) ATP (100 µM, 1 µM and 0.01 µM) and (C) ADP (100 
µM, 1 µM and 0.01 µM) in P2Y6-stable 1321N1 cells.  Concentration-response curve 
showing normalised intracellular Ca2+ responses to (B) ATP (10 nM – 100 µM) and (D) 
ADP (10 nM – 100 µM) in P2Y6-transfected 1321N1 cells.  Responses normalised to peak 
Ca2+ response by subtracting F Ratios for vehicle (SBS) treated cells from F Ratios for 
ATP- or ADP-treated cells.  Data represents mean ± SEM from a total of n=9 replicates 
from n=3 experiments. 
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Figure A21 UTP- and UDP-evoked Ca2+ responses in P2Y6-stable 1321N1 cells 
UTP- and UDP-evoked intracellular Ca2+ responses in P2Y6-stable 1321N1 cells.  
Representative Ca2+ transients to (A) UTP (100 µM, 1 µM and 0.01 µM) and (C) UDP (10 
µM, 100 nM, and 1 nM) in P2Y6-stable 1321N1 cells.  Concentration-response curve 
showing normalised intracellular Ca2+ responses to (B) UTP (10 nM – 100 µM) and (D) 
UDP (1 nM – 10 µM) in P2Y6-transfected 1321N1 cells.  Responses normalised to peak 
Ca2+ response by subtracting F Ratios for vehicle (SBS) treated cells from F Ratios for 
UTP- or UDP-treated cells.  Data represents mean ± SEM from a total of n=9 replicates 
from n=3 experiments. 
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Figure A22 Extracellular nucleotide-evoked Ca2+ responses in parental 1321N1 
cells 
Extracellular nucleotides (ATP, ADP, UTP and UDP) were unable to evoke intracellular 
Ca2+ responses in parental 1321N1 cells.  Bar chart showing peak intracellular Ca2+ 
responses (F Ratio) in 1321N1 cells challenged with vehicle (SBS) or ATP, ADP, UTP and 
UDP (10 and 100 µM).  Data represents mean ± SEM from a total of n=9 replicates from 
n=3 experiments. p>0.05 for all treatments 
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Figure A23 Effect of MRS-2578 on ATP- and ADP-evoked Ca2+ responses in THP-1 
cells 
Representative Ca2+ transients to (A) ATP (1 µM) and (C) ADP (1µM) in THP-1 cells pre-
treated with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  Bar chart showing 
normalised intracellular Ca2+ responses to (B) ATP (1 µM) and (D) ADP (1 µM)  in THP-1 
cells pre-treated with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± 
SEM from n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, 
**p<0.01, Students t-test). 
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Figure A24 Effect of MRS-2578 on UTP and UDP-evoked Ca2+ responses in THP-1 
cells 
Representative Ca2+ transients to (A) UTP (1 µM) and (D) UDP (1µM) in THP-1 cells pre-
treated with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  Bar chart showing 
normalised intracellular Ca2+ responses to (B) UTP (1 µM) and (E) UDP (1 µM) in THP-1 
cells pre-treated with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  (C) Bar chart 
showing Ca2+ decay rates (, sec) for Ca2+ transients to UTP (1 µM) in THP-1 cells pre-
treated with vehicle (DMSO) or MRS-2578 (1 µM) for 15 minutes.  Responses normalised 
to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  Data represents mean ± SEM from 
n=3 replicates.  Asterisks indicate significant changes towards vehicle (*p<0.05, **p<0.01, 
Students t-test). 
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Figure A25 UDP-evoked Ca2+ responses in scrambled and P2RY6-KD THP-1 cells 
(A) Representative UDP (30 µM) Ca2+ transients in scrambled and 358038 THP-1 cells.  
(B) Bar chart showing normalised (30 µM) UDP-evoked intracellular Ca2+ responses in 
THP-1 cells transduced with non-target (scrambled) or P2YR6-shRNA sequences 14075, 
14076, 14077, 357968 and 358038.  (C)  Bar chart showing decay rates (, sec) for UDP 
(30 µM) Ca2+ transients in THP-1 cells transduced with non-target or P2YR6-shRNA 
sequences.  Responses normalised to Ca2+ signals elicited by 40 µM digitonin (%Fmax).  
Data represents mean ± SEM from n=3 paired replicates.  Asterisks indicate significant 
changes towards scrambled (*p<0.05, **p<0.01, One-way ANOVA with Bonferroni’s 
multiple comparison). 
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Figure A26 CCL2-evoked Ca2+ responses in scrambled and P2RY6-KD THP-1 cells 
(A) Representative CCL2 (50 ng/ml) Ca2+ transients in THP-1 cells transduced with non-
target (scrambled) shRNA and P2RY6-shRNA 358038.  (B) Bar chart showing normalised 
(50 ng/ml) CCL2-evoked intracellular Ca2+ responses in THP-1 cells transduced with non-
target (scrambled) or P2RY6-shRNA sequences 14075, 14076, 14077, 357968 and 
358038.  (C) Bar chart showing decay rates (, sec) for CCL2 (50 ng/ml) Ca2+ transients in 
THP-1 cells transduced with non-target or P2RY6-shRNA sequences.  Responses 
normalised to Ca2+ signals elicited by 40 µM digitonin (% Fmax).  Data represents mean ± 
SEM from n=3 replicates.  Asterisks indicate significant changes towards scrambled 
(**p<0.01, One-way ANOVA with Bonferroni’s multiple comparison). 
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